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ABSTRACT
Background: Natural immunity to S. pneumoniae is thought to rely on antigen-specific T and 
B memory that can be rapidly mobilised to mediate microbial clearance at the mucosal 
surface as well as interrupt multiplication following invasion. HIV infection however 
increases the risk of invasive pneumococcal disease (IPD) and pneumococcal colonisation, 
suggesting that natural-acquired pneumococcal immunity is compromised in HIV infection. 
The aim of this research project was to investigate the effect of underlying HIV infection on 
naturally-acquired pneumococcal immunity in Malawian adults and the impact of 
antiretroviral therapy on this immunity. Additionally, the study evaluated the effect of HIV 
infection on immune memory mounted in response to vaccine protein antigens.
Methods: Peripheral blood mononuclear cells obtained from HIV-uninfected and infected 
Malawian adults were stimulated with pneumococcal concentrated culture supernatants 
derived from a standard strain D39 wild-type, isogenic mutant strain lacking pneumolysin 
(Ply-) and diphtheria toxoid. In vitro immune responses to these antigens were assessed by 
CFSE proliferation, T and B ELISpot, surface expression of CD 154 and cytokine production 
by intracellular cytokine staining and bio-plex cytokine assays. Additionally, the proportion 
of T and B cell subsets including naive, memory, senescent and regulatory cells were 
determined using flow cytometry.
Results: Circulating central memory (Tcm) and naive (Tn) CD4+ T cells were preferentially 
lost in asymptomatic HIV infection. There was also an over representation of senescent and 
regulatory T cells in HIV-infected adults. Pneumococcal-specific immune responses were 
either compromised (IFN-y effector responses, proliferative and CD 154 expression) or 
altered (IFN-y/IL-10) in asymptomatic HIV infection. HIV infection also increased the 
prevalence of nasopharyngeal colonisation in adults with advanced disease. There was some 
regeneration of pneumococcal specific CD4+ T cell responses including effector memory 
responses, proliferative capacity, CD 154 pathway and ability to produce simultaneously 
multiple cytokines following initiation of ART. However, there was no regeneration of 
antigen-specific memory B cell responses. T and memory B cell responses to protein vaccine 
antigen (diphtheria toxoid) were compromised and appeared short-lived in HIV-infected 
persons well-established on ART,
I!
ABSTRACT
Conclusion: The data from this research project showed that HIV infection compromises 
systemic naturally-acquired pneumococcal immunity and that there is some regeneration of 
this immunity following initiation of ART. It is not known however whether the re­
constituted immunity is long-term and protective. The data also suggests that immune 
memory to vaccine protein antigens is compromised in HIV-infected adults and possibly 
short-lived even in individuals stable on ART. These findings have important implications 
for clinical care of HIV-mfected persons on ART and future studies on pneumococcal 
immunity in the context of HIV infection and therapy.
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CHAPTER 1 Introduction
1.1 Streptococcus pneumoniae
Streptococcus pneumoniae - the pneumococcus- is a Gram positive, encapsulated bacterial 
commensal that colonises the upper respiratory tract (nasopharyngeal cavity). It is believed 
that pneumococcal colonisation is mostly asymptomatic (Bogaert, De Groot et al. 2004), 
although recent data indicate that respiratory tract symptoms may occur (Sleeman, Daniels et 
al. 2005). Pneumococcal colonisation however can progress to respiratory or even systemic 
disease [Figure 1.1]. Pneumococcal disease will not occur without preceding nasopharyngeal 
colonisation with the homologous strain (Bogaert, De Groot et al. 2004). Pneumococcus 
causes life-threatening diseases such as pneumonia, septicaemia and meningitis (Cartwright 
2002). In addition, it causes less serious but very prevalent diseases such as otitis media and 
sinusitis. Infection rates are high mainly in young children, the elderly, and individuals with 
immunocompromising conditions such as asplenia, cancer, chronic illness and HIV/AIDS 
(Jedrzejas 2001).
1.2 Pneumococcal Carriage and Risk factors
The upper respiratory tract is sterile prior to birth. The nasopharyngeal flora however is 
established within the first months of life (Bogaert, De Groot et al. 2004). In addition to 
bacteria that typically do not cause disease, a wide range of Gram-positive and Gram­
negative bacteria that also have the potential to cause disease, such as S. pneumoniae, H 
influenzae, N. meningitidis and M. catarrhalis can colonise the nasopharynx, albeit at various 
times throughout the host lifetime (Caugant, Hoiby et al. 1994; Adegbola, Mulholland et al. 
1998; Harrison, Moms et al. 1999). Every person is likely to be colonised with these 
pathogens at least once during life and an individual bacterial strain can be carried for weeks 
to months before it is eventual cleared.
1
CHAPTER 1 INTRODUCTION
I
Prte uTn-ococd
I
Aspiration <-
Alveoli
Hasopharyngeal
colonisation
v y v 
aiaod
Bacteraemia
Local spread
y
N^ninges
Meningitis
Incidence Severity
Figure 1.1 | Diseases caused by Streptococcus pneumoniae. Pneumococci colonise the 
nasopharynx, evade host immunity and spread to the middle ear, sinus, lower respiratory tract, 
blood and meninges. Pneumococci cause otitis media in the middle ear, sinusitis in the sinus, 
pneumonia in the lower respiratory tract, bacteraemia in blood and meningitis in the meninges. 
The incidences of different types of pneumococcal infection are inversely related to the severity 
of disease: otitis media is the most common but the least severe. (Jambo, Sepako etal. 2010)
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With the pneumococcus, nasopharyngeal carriage prevalence is influenced by the age of 
individuals and the presence of pneumococcal earners in the immediate environment 
(O’Brien, Dagan et al. 2008). Worldwide, carriage rates are highest among children under 2 
years of age (Leino, Auranen et al. 2001; Regev-Yochay, Raz et al. 2004). Similarly, the 
prevalence of pneumococcal carnage in sub-Saharan Africa, is very high in early life (-70- 
90% of children aged <5 years) and continues well into adulthood (Hill, Akisanya et al. 
2006).
Fifty to ninety percent of the children are colonised within months after birth (Hill, Akisanya 
et al. 2006; Granat, Mia et al. 2007; Rudan, Boschi-Pinto et al. 2008) and the cumulative 
frequency of colonisation in this group is almost 100% (Hill, Akisanya et al. 2006). For 
example, in the Gambia, the pneumococcus was acquired within the first months of life 
(93% < 1 month and 96% < 3 months) with the mean and median age at first acquisition of 
carriage noted as 33 days (95% confidence interval, 29-36 days) and 24 days, respectively 
(Rudan, Boschi-Pinto et al. 2008). In Malawi, the rate of pneumococcal colonisation was 
observed to be 84% among children less than 5 years of age, 65% of which occurred in 
children less than the age of 3 months (Feikin, Davis et al. 2003). Carnage rates however 
decrease significantly with increasing age (Hill, Akisanya et al. 2006). In the Gambia, the 
prevalence of pneumococcal carriage decreased to 51% among subjects > 40 years from 97% 
among children aged < 1 year (p<0.001). A similar situation was observed in Kenya, where 
among 0-4, 5-9 and 10-85 year old, pneumococcal carriage rate was 57%, 41% and 6.4% 
respectively (Abdullahi, Nyiro et al. 2008).
Data from this thesis (section 4.3.1) and other studies (French N, unpublished data) show that 
the prevalence of nasopharyngeal carriage among healthy Malawian adults (Blantyre district) 
is around 15%. Colonisation is generally followed by horizontal spread of .S', pneumoniae to 
individuals hi the immediate surroundings resulting in the spread of the pathogen within the 
community. Horizontal dissemination of pneumococcal strains is associated with risk factors 
such as overcrowding which is often seen in hospitals, day care centres, prisons and 
orphanages (Bogaert, De Groot et al. 2004). In a study in The Netherlands, there was a 1.6 
fold relative risk of pneumococcal nasopharyngeal colonisation in children attending day care 
centres compared with children cared for at home (Bogaert, Engelen et al. 2001).
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Similarly, a colonisation rate of up to 82% was reported in infants living in an orphanage in 
Paris, France ( - a region of the world where carriage rates are generally lower) (Raymond, 
Le Thomas et al. 2000). In both The Netherlands and French studies, there was an increased 
genetic clustering of pneumococcal isolates, suggesting an increased and/or frequent 
horizontal spread of pneumococcal strains in crowded areas (Bogaeit, De Groot et al. 2004).
1.3 Pneumococcal Disease in Africa
Childhood pneumonia is the leading cause of mortality in children less than five years of age 
in the world (Rudan, Tomaskovic et al. 2004; Rudan, Boschi-Pinto et al. 2008) and S. 
pneumoniae is one of the main pathogens associated with clinical pneumonia. In prospective 
microbiology-based studies, the pathogen was identified in 30-50% of pneumonia cases 
(Juven, Mertsola et al. 2000; Rudan, Tomaskovic et al. 2004). Berkley et al (Berkley, Lowe 
et al. 2005) noted that pneumococcus causes 25% of all preventable deaths in children less 
than 5 years of age and several other studies have shown that 60-90% of lower respiratory 
tract infections are caused by the pneumococcus (Cutts, Zaman et al. 2005; Levine, O'Brien 
et al. 2006).
The incidence esthnate for children less than five years of age for developing countries is 
0.29 episodes per child-year, which equates to 151 million episodes each year (Table 1.1) 
(Rudan, Tomaskovic et al. 2004; Rudan, Boschi-Pinto et al. 2008). Of all the new cases, 11- 
20 million (7-13%) cases are severe enough to require hospitalisation. An estimate of clinical 
pneumonia incidence for Africa is 0.33 episodes per child-year, translating into 35.33 million 
new cases per year (Table 1.1) (Rudan, Tomaskovic et al. 2004; Rudan, Boschi-Pinto et al. 
2008). Africa has by and large, the highest burden of childhood mortality in the world and the 
continent accounts for 50% of worldwide deaths from pneumonia in children less than five 
years of age (WHO 2007).
There are no population-based data on the incidence of pneumococcal disease in adults in 
developing countries including those in Africa. A study of migrant workers in South Africa 
gold mines (high-risk group) in the 1970s revealed that one miner in eleven developed 
pneumococcal disease each year (Fedson and Scott 1999).
Fedson et al. estimated that approximately one in every 12-18 medical admissions in East and 
Southern Africa is caused by pneumococcal pneumonia (Fedson and Scott 1999). In a study
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done in Soweto, South Africa, the annual incidence estimates for invasive pneumococcal 
disease for HIV-seronegative adults 18-40 and >65 years in age were 24 per 100,000 and 64 
per 100 000 respectively (Jones, Huehner et al. 1998).
Table 1.1 | Estimates of incidence and number of new cases per year of clinical 
pneumonia in children aged less than 5 years, by WHO region3 (Rudan T et al. 2008)
WHO region Total population 
aged 0-4 years 
(millions)
Estimated 
Incidence (e/cy)
Estimated no. of 
new cases per year 
(millions)
African 105.62 0.33 35.13
Americas 75.78 0.1 7.84
Eastern Mediterranean 69.77 0.28 19.67
European 51.96 0.06 3.03
South-East Asia 168.74 0.36 60.95
Western Pacific 133.05 0.22 29.07
Total (developing countries) 523.31 0.29 151.76
Total (developed countries) 81.61 0.05 4.08
Total 604.93 0.26 155.84
e/cy, episodes per child-year.
a Up to 10% of all new cases may progress to severe episodes and require hospitalization.
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1.4 HIV Epidemiology
Human immunodeficiency virus (HIV) and its associated syndrome, acquired 
immunodeficiency syndrome (AIDS) remains a major global health problem with millions of 
people especially in Africa either infected or affected by HIV/AIDS. Sub-Saharan Africa is 
the most affected region with an estimated 22.4 million [20.8 - 24.1 million] people living 
with HIV or 67% of the global total (UNAIDS, 2009) (Figure 1.2). HIV seroprevalence in 
many sub-Saharan African countries exceeds 10% overall, rising to over 30% in pregnant 
women.
Western & “Eastern Europe
STCentralAsia
-North America
1.4 million
[1.2-1.6 million]
Caribbean
240 000
[220 000 - 260 000]
Central Europe
850 000 1.5 million
[710000-970 000] l1 4" 17 miir,onl
Middle East & North Africa
310 000
[250000 - 380 000]
EastAsia
850 000
[700000-1.0 million]
-V
Latin America
2.0 million
[1.8-2.2 million]
Sub-Saharan Africa
22.4 million
[20.8-24.1 million]
MB
South & South-EastAsia
 3.8 mi
[3.4-4.3 million] 
Oceania
59 000
[51 000 - 68 000]
Total: 33.4 million (31.1 - 35.8 million)
Figure 1.2 | Adults and children estimated to be living with HIV, 2008 (UNAIDS, Aids epidemic 
update. 2009 [www.unaids.org])
Increased carriage and susceptibility to disease by bacteria that normally colonise the upper 
respiratory tract (URT) is one of the earliest manifestations of HIV infection in both 
industrialised and non-industrialised countries (Manfredi, Nanetti et al. 2000; Pan, Diep et al. 
2005).
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1.5 Pneumococcal Carriage in the context of HIV
Data on pneumococcal nasopharyngeal carriage in HIV-infected persons suggests that 
carriage rates may be higher in HIV-infected individuals, than in uninfected persons 
(Rodriguez-Barradas, Tharapel et al. 1997; Madhi, Adrian et al. 2007; Gill, Mwanakasale et 
al. 2008). Patients with low CD4+ counts were more likely to be persistent pneumococcal 
carriers (Rodriguez-Barradas, Tharapel et al. 1997), and HIV-infected children were observed 
to have a higher prevalence of pneumococcal colonisation than HIV-negative children 
(Madhi, Adrian et al. 2007). More recently, a study in Zambian mothers demonstrated that 
HIV infection increased the risk of colonisation, (risk ratio [RR], 1.9; 95% confidence 
interval [Cl], 1.3-2.8) and repeat colonisation (RR, 2.4; 95% Cl, 1.1-5.3), and reduced the 
time to new colonisation (P = .01)(Gill, Mwanakasale et al. 2008),
1.6 Pneumococcal Disease and HIV Infection
The emergence of HIV infection has dramatically changed the epidemiology of 
pneumococcal disease in both adults and children. The HIV pandemic has resulted in a large 
increase in the incidence and severity of childhood pneumonia in developing countries (Zar 
2004). Data from a number of studies indicate that the incidence of hospitalisation for lower 
respiratory tract infection (LRTI) is higher in HIV-infected children than in their HIV 
uninfected counterparts (Mofenson, Yogev et al. 1998; Madhi, Petersen et al. 2000; Madhi, 
Kuwanda et al. 2005). The incidence of hospitalisation among children not vaccinated with a 
polysaccharide conjugate vaccine (PCV) in South Africa was almost 6.6 fold higher among 
HIV-infected children (16.7 cases for every 100 children per year ) than in their HIV 
uninfected counterparts (2.6 cases for every 100 children per year ) (Madhi, Petersen et al. 
2000). In the United States, the incidence of pneumonia in HIV-infected children was found 
to be seven fold higher than the historical incidence rates of 3 to 4.2 cases for every 100 
children per year (Foy, Cooney et al. 1973; Klugman 2008; Madhi and Pelton 2008). In some 
sub-Saharan African countries, approximately 45% of children hospitalized for pneumonia 
are HIV-infected (Madhi, Petersen et al. 2000).
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HIV-infected individuals (adults and children) are 20 to 100 times more likely to suffer 
invasive pneumococcal disease (IPD) than their age-matched HIV negative persons 
(McEllistrem, Mendelsohn et al. 2002; Klugman 2008). Though highly active antiretroviral 
therapy (HAART) has been associated with a 60% reduction in IPD, the risk of disease in 
HIV positive persons is 30 times greater compared to uninfected individuals (Heffernan, 
Barrett et al 2005). The burden of pneumococcal disease is HIV infected children in Africa 
is 40-fold higher than in developed countries (Klugman 2008). In South Africa, the rates of 
IPD in HIV-infected children under 2 years of age was found to be 42-fold (95% confidence 
interval 27-66) greater than that in HIV negative children (Klugman, Madhi et al. 2007) 
whereas in the USA the burden of the disease was 9-13 fold greater in HIV positive children 
pre-HAART era (Klugman, Madhi et al. 2007).
It is estimated that HIV accounts for at least 50% of all serious pneumococcal infections and 
pneumonia cases in adults in Africa (French 2003; Klugman, Madhi et al. 2007; Klugman 
2008). A survey (case series) of 167 patients with IPD in Blantyre, Malawi, identified HIV 
infection as the most common risk factor for IPD (Gordon, Chaponda et al. 2002). Ninety- 
five percent of the patients suffering IPD were HIV-infected. Similar high rates of 
pneumococcal bacteraemia were recorded in the USA in the pre-HAART era (1094/ 100 000 
in 1995/6) (Heffernan, Barrett et al. 2005; Klugman, Madhi et al. 2007).
1.7 Morphology, Cultivation and Identification of S. pneumoniae
Streptococcus pneumoniae cells are capsulated, gram positive, lancet-shaped cocci (one end 
is broad or rounded and the other is pointed). It was fust isolated by George M. Sternberg and 
Louis Pasteur in 1880 (Austrian 1999). They usually occur in pairs (diplococci) with the 
rounded ends juxtaposed and the long axis of the coccus parallel to the line joining the pair 
(Paniker 2006). Pneumococci are characteristically small measuring about 1 pm in diameter.
Streptococcus pneumoniae is a fastidious bacterium, growing best in 5% carbon dioxide 
(microaerophilic cultivation). Nearly 20% of fresh clinical isolates require frilly anaerobic 
conditions. S. pneumoniae is usually cultured in media that contain blood as growth requires 
a source of catalase (e.g. blood) to neutralize the large amount of hydrogen peroxide 
produced by the bacteria. In complex media containing blood, at 37°C, the bacterium 
doubles every 20-30 minutes (Howden 1976; Hansen 2000).
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On blood agar, pneumococci grow as glistening colonies of about 1 mm in diameter. The 
colonies normally produce a zone of alpha (green) haemolysis (a greenish discoloration of the 
blood agar surrounding a bacterial colony or the darkening of the agar under the colony), 
which differentiates S. pneumoniae from the group A (beta haemolytic) streptococcus, but not 
from commensal alpha haemolytic (viridans) streptococci which are co-inhabitants of the 
nasopharyngeal cavity (Ryan 2004; Paniker 2006). Special tests therefore have to be carried 
out to differentiate the pneumococcus from Streptococcus viridans (Table 1.2).
In the laboratory, pneumococci are identified by sensitivity or susceptibility to optochin and 
to lysis by bile salts (deoxycholate) (Table 1.2). S. pneumoniae is sensitive or susceptible to 
optochin reagent while Streptococcus viridians is resistant (O'Brien and Nohynek 2003; 
HPA(UK) 2004; Paniker 2006). Additionally, S. pneumoniae produces a self-lysing enzyme 
(autolysin). Autolysin causes the organism, when grown in high density to undergo a 
characteristic autolysis that kills the entire culture. The presence of bile salt (deoxycholate) 
accelerates this process. A positive test appears as clearing of the culture's turbidity.
Table 1.2 | Differentiation between Streptococcus pneumoniae and Streptococcus viridans
S. pneumoniae S. viridans
Morphology Lancet-shaped
Capsulated
Oval or round cells 
Non-capsulated
Optochin Sensitivity Test Sensitive Resistant
Blood -agar plates Inhibition of growth
Bile Solubility Test
Broth culture
Blood-agar plates
'Soluble'
Clearing of the culture's turbidity
Colony 'disappearance'
Green zone of a-hemolysis unaffected
Insoluble
Inulin Fermentation Not Ferment Ferment
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1.8 Pneumococcal Virulence factors 
1.8.1 Polysaccharide Capsule
Streptococcus pneumoniae virulence is multi-faceted. Essential pneumococcal virulence 
factors include: the capsule, cytoplasmic and cell-surface proteins (Figure 1.3). Nearly all 
strains of the pneumococcus have a polysaccharide capsule, which is the basis for serotyping 
(Lynch and Zhanel 2010). The capsule is the outermost layer of S. pneumoniae and except for 
serotype 3, it is covalently attached to the outer surface of the cell-wall peptidoglycan 
(Kadioglu, Weiser et al. 2008) . It is considered the most virulent part of the pneumococcus 
(Bergmami and Hammerschmidt 2006). Moreover, the virulence of the pneumococcus is 
related to the thickness of the capsule in a particular strain and serotype (Mac and Kraus 
1950; Kadioglu, Weiser et al. 2008).
Over 90 distinct serotypes have been identified to date (Lynch and Zhanel 2010). However, a 
limited number of these serotypes (~20 serotypes) are responsible for over 80% of the global 
invasive pneumococcal disease burden (Lynch and Zhanel 2009). The most common disease- 
causing serotypes being 1,3,4,6A, 6B, 7F,8,9V,14,18C,19F and 23F. In young children, 
serotypes 6,14,18,19 and 23F predominate. Serotypes 1 and 5 are common in developing 
countries but are less common in industrialized countries reflecting differences in serotype 
distribution among geographic regions.
The capsule inhibits opsonisation of the underlying bacterial surface components and 
subsequent phagocytosis during invasion (Kadioglu, Weiser et al. 2008; Weiser 2009) and 
facilitates the organism’s transit from the luminal mucus to the epithelial surface where stable 
colonisation occurs.
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Figure 1.3 | Schematic diagram of pneumococcal virulence factors. Streptococcus pneumpniae 
synthesises several factors that are thought to have a role in pneumococcal disease process. 
These include the polysaccharide capsule, cytoplasmic and cell-surface proteins. PavA - 
pneumococcal adhesion and virulence A; Eno -enolase; PspA -pneumococcal surface proteins A;, 
CbpA - choline-binding protein A; PiuA - Pneumococcal iron uptake; PiaA - Pneumococcal iron 
acquisition and PsaA - Pneumococcal surface Adhesion A 
*lmage ofS. pneumoniae from the Sanger Institute (www.sanger.ac.uk)
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1.8.2 Protein Virulence factors 
1.8.2.1 Pneumolysin (cytoplasmic protein)
Streptococcus pneumoniae produces a single toxin, which is a member of the large 
cholesterol binding cytolysin expressed by gram-positive bacteria (Weiser 2009). 
Pneumolysin has a cytolytic and a noncytolytic activity (Preston and Dockrell 2008). The 
cytolytic activity is mediated by pore-formation and the noncytolytic activity is mediated 
arguably by complement activation and Toll-like receptor 4 binding (Preston and Dockrell 
2008). Site-directed mutagenesis has shown that distinct parts of the toxin molecule are 
responsible for the two activities (Boulnois, Paton et al. 1991; Mitchell, Andrew et al. 1991).
Pneumolysin is cytotoxic to all cells with cholesterol in the membrane and as such interacts 
with the outer membrane of all eukaryotic cells (Cockeran, Anderson et al. 2002). The toxin 
alters and/or impairs both the function and viability of host cells even those required for 
clearing the pathogen (Weiser 2009). The cell-modulatory activities of pneumolysin are 
summarized in Table 1.3. By altering normal functioning of the immune cells pneumolysin 
may enhance persistence and invasiveness of the pneumococcus. In the case of alveolar 
epithelial cells and pulmonary endothelial cells for example, the toxin impairs the alveolar 
capillary barrier, triggering alveolar flooding and influx of nutrients for pneumococcal 
growth and facilitating penetration through respiratory epithelium into the blood stream 
(Cockeran, Anderson et al. 2002). The cell-modulatory activities of pneumolysin, somewhat 
paradoxically, may contribute to elimination of the S. pneumoniae by host defences. In a 
mouse model of pneumococcal colonisation it was observed that the interaction of 
pneumolysin and neutrophil promoted delivery and release of pneumococcal specific 
antigens to the nasal associated lymphoid tissues, enhancing adaptive immune responses 
against S. pneumoniae (Matthias, Roche et al. 2008; Jambo, Sepako et al. 2010).
Pneumolysin also activates the complement classical pathway. This appears to involve 
antibody binding (via Fc), by a region of pneumolysin homologous to C-reactive protein (a 
human acute-phase protein also capable of activating the classical pathway (Mitchell, 
Andrew et al. 1991). The interaction of pneumolysin with the classical pathway results in 
reduced C3 deposition on the pneumococcus, limiting opsonisation of pneumococci by the 
classical pathway (Yuste, Botto et al. 2005).
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Animal studies show that pneumolysin is required for the development of pneumonia and 
bacteraemia. Data suggests that S. pneumoniae requires pneumolysin to successfully survive 
in both the upper and lower respiratory tracts (Berry, Ogunniyi et al. 1999; Orihuela, Gao et 
al. 2004; Kadioglu, Weiser et al. 2008) and as stated earlier pneumolysin is essential for the 
pneumococcus to translocate from the lungs to the bloodstream (Benton, Everson et al. 1995; 
Berry, Ogunniyi et al. 1999; Orihuela, Gao et al. 2004; Kadioglu, Weiser et al. 2008). It is 
also required for bacterial survival in blood. If a host is infected by a pneumolysin-expressing 
pneumococci not only are high numbers of bacteria detectable in blood but the host is rapidly 
overwhelmed by the infection (Benton, Everson et al. 1995; Berry, Ogunniyi et al. 1999). 
Conversely, in the case of pneumolysin negative pneumococci the animals have been shown 
to tolerate pneumococci with no obvious disease symptoms resulting in chronic bacteraemia 
(Benton, Everson et al. 1995; Kadioglu, Weiser et al. 2008).
Table 1.3 | Cell-modulatory activities of pneumolysin
Action Cell-modulatory activity References
Apoptosis Induction of apoptosis in a number of cell types including 
neutrophils, macrophages & neuronal cells- related to 
influx of extracellular calcium into toxin-treated cells 
probably enhancing 5. pneumoniae persistence and 
invasiveness
(Zysk, Bejo et al. 2000; 
Dockrell, Lee et al. 2001; 
Braun, Sublett et al.
2002)
Phagocytic
function
Inhibition of the phagocytic functions of immune cells such 
as human neutrophil and monocyte respiratory burst
(Nandoskar, Ferrante et 
al. 1986).
Chemotaxis Stimulation CD4 T cell chemotaxis and recruitment of 
neutrophils to inflammatory lesion. Pneumolysin's
complement-activating activity important for the 
recruitment of T cells while the toxin's cytolytic activity 
influences neutrophil recruitment
(Jounblat, Kadioglu et al. 
2003; Hirst, Kadioglu et 
al. 2004)
Pro­
inflammation
Induction of proinflammatory reaction in immune cells
• production of 11-13,TNF-a & NO by macrophages. 
The response involves signalling through Toll-like 
receptor 4
• Production of superoxide, prostaglandin E2, 
leukotriene B4 & elastase by neutrophils
(Cockeran, Anderson et 
al. 2002)
13
CHAPTER 1 INTRODUCTION
1.8.2.2 Cell-Surface Proteins
The surface of the pneumococcus is decorated with proteins that are covalently and non- 
covalently attached to the cell wall. Based on genomic analysis these proteins fall into at least 
three classes: the choline-binding protein (CBP) family, the lipoprotems and proteins that are 
covalently anchored in the cell wall by a LPxTG motif ( a carboxy (c)-terminal sortase) 
(Kadioglu, Weiser et al. 2008). In addition to the three classes named above, there is a group 
of surface proteins (often referred to as non-classical proteins) that lacks a classical leader 
peptide and membrane anchoring motifs (Figure 1.3). Surface proteins either interact directly 
with the host tissues or are involved in masking the bacterial surface from the host defence 
mechanisms (Table 1.4).
1.8.2.2a Choline-Binding Proteins (CBPs)
The CBPs are a family of surface proteins non-covalently bound to the phosphorylcholine 
moiety of the cell wall ofS. pneumoniae by a conserved choline binding domain consisting of 
1 to 10 repeats of a 20-amino-acid sequence. Pneumococci can produce 13 to 16 different 
CBPs (Bergmami and Hammerschmidt 2006). Chief among the CBPs are pneumococcal 
surface protein A and C (PspA & PspC [CbpA]).
Pneumococcal surface protein A (PspA- protective antigen)
PspA (-92.5 kDa) is one of the most studied pneumococcal surface protems because of its 
significant immune protective potential. It is relatively variable at the DNA and protein 
sequence levels and is expressed by almost all clinical serotypes (Briles, Hollingshead et al. 
2000; Kadioglu, Weiser et al. 2008). PspA is known to play a key role in the pneumococcal 
virulence (Table 1.4). It inhibits complement deposition on the pneumococcal surface and 
thus prevents complement-mediated opsonisation of .S', pneumoniae (Ren, Szalai et al. 2003; 
Yuste, Botto et al. 2005). In the absence of PspA function, pneumococcal virulence is 
attenuated and there is an increase in complement receptor- mediated clearance of 
pneumococci (Ren, Szalai et al. 2004).
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PspA also binds the human iron transporter lactoferrin (van Rossum, Lysenko et al. 2005). 
The iron depleted form, apolactoferrin kills S. pneumoniae and as such the lactoferrin binding 
property of PspA may protect the pneumococcus from the bactericidal effects of 
apolactoferrin. In fact, Shaper et al. showed that PspA protects S. pneumoniae from killing 
by apolactoferrin (Shaper, Hollingshead et al. 2004). An additional property of PspA is its 
ability to inhibit the clearance of pneumococci from the bloodstream (Briles, Tart et al. 
1998).
PspA has been shown to elicit an antibody response in children and adults over 50 years of 
age with pneumococcal disease (Rapola, Jantti et al. 2000; Samukawa, Yamanaka et al. 2000; 
Virolainen, Russell et al. 2000; Baril, Briles et al. 2004). During the course of the invasive 
disease, antibodies to PspA peak at the convalescent phase. PspA can also elicit T cell 
immune response in adults suffering invasive disease (Baril, Dietemann et al. 2006) and in 
such individuals both interleukin (IL)-10 and interferon (IFN)- production increased during 
convalescence suggesting that these cytokines may be involved in modulating antibody-based 
immunity to pneumococcal disease. In a mouse model, immunisation with PspA was highly 
immunogenic, eliciting IgG antibody in serum which correlated inversely with susceptibility 
to carriage (Quin, Moore et al. 2007).
Pneumococcal surface protein C (PspC [CbpA])
The pneumococcal surface protein C (PspC; also known as SpsA or CbpA ~ 75 kDa) is the 
largest and most abundant of the CBPs and is found in almost 70% of all pneumococcal 
strains. It is a multifunctional protein hence its several names. PspC is thought to facilitate 
the translocation of pneumococci across nasopharyngeal epithelial layer by binding the 
polymeric immunoglobulin receptor that normally transports secretory IgA (Zhang, Mostov 
et al. 2000). Furthermore, it interferes with the innate immune system by interacting with the 
complement factor FI preventing C3b activation and complement-mediated 
opsonophagocytosis of pneumococci (Jarva, Hellwage et al. 2004).
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Table 1.4 | Clusters of pneumococcal surface proteins and their role in pathogenesis
Cluster Proteins Role Ref
Choline- Pneumococcal surface Binds iron transporter lactoferrin and (Ren, Szalai et al. 2003;
binding protein A (PspA) inhibits complement deposition on the Shaper, Hollingshead et al.
proteins pneumococcal surface 2004; Yuste, Botto et al.
(CBP) Pneumococcal surface Promotes uptake of pneumococci into
2005)
protein (PspC) epithelial cells. Interferes with the innate (Zhang, Mostov et al. 2000;
immune response against pneumococcus Jarva, Hellwage et al. 2004)
Lipoproteins Pneumococcal surface Substrate-binding lipoprotein of ABC-type (Kadioglu, Weiser et al.
(Metal
binding
proteins)
Adhesion A (PsaA) manganese-transport system - a system 
which is involved in resistance to oxidative
2008)
stress. Suspected to be an adhesin 
molecule
(Kadioglu, Weiser et al.
Pneumococcal iron Iron-uptake ABC transporters. ABC 2008)
acquisition (PiaA) & transport system is involved in resistance
Pneumococcal iron
uptake (PiuA)
to oxidative stress
LPxTG - NanA Assist adherence by revealing host (Burnaugh, Frantz et al.
anchored receptors and changes the surfaces of 2008; Weiser 2009)
protein competing bacteria within the niche
Non-Classical Pneumococcal
adherence & virulence 
factor A (PavA)
Fibronectin adhesion (Pracht, Elm et al. 2005)
IgA protease, Phosphorylcholine (Chop) and Autolysin
Human immunoglobulin A1 (IgAl), which is the predominant form of the IgA in the upper 
respiratory tract, classically works by blocking adhesive interactions of microbes with host 
tissues (Weiser, Bae et al. 2003). Streptococcus pneumoniae however expresses an IgAl 
protease, an enzyme that cleaves human IgAl. Cleaved IgAl enhances bacterial attachment 
to host cell (Weiser, Bae et al. 2003). Studies suggest that the cleavage of IgA results in 
formation of Fab fragments whose cationic charge neutralises the negative charge of 
pneumococcal capsule and enhances bacterial attachment to host cells (Weiser, Bae et al. 
2003; Preston and Dockrell 2008).
16
CHAPTER 1 INTRODUCTION
Additionally, the interaction between IgA and IgA protease exposes phosphorylcholine 
(Chop), which mediates bacterial adherence to the epithelial cells via the platelet activating 
factor receptor (PAFr) and activate host cell signalling through this receptor (Kadioglu, 
Weiser et al. 2008; Preston and Dockrell 2008). Phosphorycholine (Chop) is a component of 
both cell-wall-associated acids and lipoteichoic acids and is present in many other microbes 
especially those that colonise the upper respiratory tract such as Haemophilus influenzae. It 
also anchors choline-binding binding proteins to the bacterial cell wall (Kadioglu, Weiser et 
al. 2008).
Autolysm is an enzyme that is capable of degrading the bacterial cell wall of an organism 
within which it is produced. The major autolysin of pneumococci is an amidase called LytA. 
This enzyme cleaves the N-acetyl muramoyl-L-alanine bond of pneumococcal peptidoglycan 
(Kadioglu, Weiser et al. 2008). It is thought that autolysin contributes to the virulence of S. 
pneumoniae, by mediating the release of pneumolysin from the pneumococcal cytoplasm 
during infection (Lock, Hansman et al. 1992). S. pneumoniae mutants lacking LytA, have 
been shown to have reduced virulence in mouse models of bacteraemia and pneumonia 
(Kadioglu, Weiser et al. 2008).
1.8.2.2b Lipoproteins
Pneumococcal lipoproteins play a major role in substrate transport and bacterial fitness. The 
pneumococcal surface adhesin A (PsaA~37 kDa) is common to all pneumococcal serotypes. 
It is the substrate-binding lipoprotein of an ABC-type manganese-transport system 
(Bergmami and Hammersclnnidt 2006). It has been suggested that PsaA is an adhesin 
molecule because it has sequences that are also found in adhesin molecules from other 
streptococci (Kadioglu, Weiser et al. 2008). Mutations in PsaA cause pleiotropic effects 
(multiple effects from a single gene) including reduced adherence of pneumococci to host 
cells, attenuation in a mouse infection model, and hypersensitivity to oxidative stress (Mann, 
Lawson et al. 2002; Tseng, McEwan et al. 2002). Since PsaA mutants need manganese for 
normal growth, the pleiotropic effect may be a result of a deficient manganese transport 
system which in turn affect expression of other genes including adhesin (Kadioglu, Weiser et 
al. 2008).
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Interestingly, anti-PsaA antibodies inhibit pneumococcal adherence to human nasopharyngeal 
epithelial cells and subcutaneous immunisation of mice with PsaA inhibits pneumococcal 
carriage (Johnson, Dykes et al. 2002; Romero-Steiner, Pilishvili et al. 2003). PsaA elicits 
antibody responses in children and adults over 50 years of age with pneumococcal disease 
(Rapola, Jantti et al. 2000; Samukawa, Yamanaka et al. 2000). In these studies, children at 
ages 6, 12, 18 and 24 produced antibodies to PsaA and the antibody concentration increased 
with age. In adults over 50 years, antibody concentration rose significantly during the course 
of the invasive disease.
Pneumococcal iron acquisition (PiaA) and Pneumococcal iron uptake (PiuA) are iron-uptake 
ABC transporter lipoprotems, and have been shown to be required for full pneumococcal 
virulence. A single mutation hi either of the proteins have been shown to reduce virulence in 
models of pneumonia and bacteraemia while for a double mutant the attenuation was much 
more pronounced (Brown, Gilliland et al. 2002). Immunisation with PiaA and PiuA elicits 
protective antibodies that not only recognize these proteins but promote opsonophagocytosis 
of S. pneumoniae (Jomaa, Yuste et al. 2005).
1.8.2.2c Neuraminidase- LPXTG-anchored proteins
Neuraminidase (Nan) also known as sialidase is another virulence factor of S. pneumoniae 
that is present in all strams of pneumococci. The enzyme sequentially cleaves terminal sugars 
(sialic acid residues) common to many human glycoconjugates such as glycoproteins 
(Kadioglu, Weiser et al. 2008). The pneumococcus encodes at least three neuraminidase 
genes; nanA, nanB and nanC (Jedrzejas 2001), whereby most strains encode NanA and NanB 
and only 50% of the strams encode NanC.
The exact role of neurammidase in pneumococcal pathogenesis is incompletely determined. 
However, in a murine model of acute pneumonia, NanA and B were shown to be essential for 
pneumococcal survival in the bloodstream and respiratory tract (Manco, Hemon et al. 2006). 
Others have shown that NanA removes sialic acid of human airway components (lactoferrin, 
secretory component, and IgA) that bind to the bacterial surface and possibly mediate 
bacterial clearance (King, Hippe et al. 2004). This effect may facilitate bacterial persistence 
in the respiratory tract (King, Hippe et al. 2004).
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NanB is necessary for infection of lower and upper respiratory tract (Berry, Lock et al. 1996), 
and in the deglycosylation of host glycoconjugates, which S. pneumoniae utilises as a sole 
source of carbon to sustain growth (Burnaugh, Frantz et al. 2008). In a nutshell, 
deglycosylation of human glycoconjugates, may expose receptors on the cell-surface, prevent 
mechanisms of clearance that require these molecules or provide nutrients for bacterial 
growth (Weiser 2009). NanC is thought to have a tissue-specific role and was more conunon 
in isolates from cerebrospinal fluid than in carriage isolates (Pettigrew, Fennie et al. 2006).
1.8.2.2d Non-classical Proteins
There are a number of proteins that appear on the surface of S. pneumoniae but do not 
possess classical features of bacterial surface proteins. Pneumococcal adherence and 
virulence factor A (PavA) is one such protein. Studies suggest that PavA acts as a fibronectin 
adhesin and modulates vital but yet-to be determined virulence determinants (Pracht, Elm et 
al. 2005).
1.9 HIV Infection and Pathogenesis
Co-receptors and HIV pathogenesis
HIV infection of cells begins when the envelope glycoprotein (Env) of a viral particle binds 
to both CD4 and a coreceptor that is a member of the chemokine receptor family. In almost 
all cases, HIV uses chemokine receptors CCR5 and CXC4 as these co-receptors (Deng, Liu et 
al. 1996; Feng, Broder et al. 1996). CCR5 is expressed on a small fraction of memory CD4+ 
T cells, while the expression of CXCR4 is high on na'ive T cells and decreases with 
differentiation and activation (Bleul, Wu et al. 1997; Gorry and Ancuta 2011). CCR5-using 
viruses (R5 viruses) are transmitted from person to person and are dominant in the early and 
chronic phases of HIV-1 infection (Keele, Giorgi et al. 2008). However, in roughly 40% to 
50% of infected individuals, progression to late stages of infection is preceded by a switch in 
co-receptor usage, to viral variants able to use CXCR4 (X4 viruses) or both CCR5 and 
CXCR4 (R5X4 vimses) (Gorry and Ancuta 2011). The broadened cell tropism of X4 and 
R5X4 viruses, in part, contributes to more rapid disease progression in individuals who have 
a co-receptor switch. Nonetheless, most HIV-infected persons progress to the late stages of 
infection whilst exclusively harbouring R5 vimses.
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Studies suggest that this R5 predominance is due to enhanced macrophage (M)-tropism, 
increased fitness, ability to scavenge low levels CD4 and CCR5 and resistance of CCR5 
antagonist (Gony and Ancuta 2011).
Role of DC in HIV infection
Dendritic cells (DCs) provide a highly specialised mechanism (through then- antigen 
sampling and migratory capacities), whereby an antigen encountered in the peripheral tissues, 
notably skin and mucosal membranes, can be brought together with the T cells and in the 
process initiate adaptive immune responses against the antigen (Reis e Sousa 2006). HIV 
exploits this specialised mechanism to gain access to T cells in the lymph nodes, and 
establish a persistent infection of CD4+ T cells (Rowland-Jones 1999; Wu and KewalRamani
2006) . At the mucosal surfaces, HIV infects or associates with immature dendritic cells 
(Burleigh, Lozach et al. 2006), but only the very early stages of viral replication occur in 
these cells. The maturing DCs then migrate to the lymphoid tissues that are enriched in CD4+ 
T cells. In these tissues, HIV infection of activated CD4+ T cells occurs, facilitating HIV 
dissemination (McDonald, Wu et al. 2003; Wiley and Gummuluru 2006; Wu and 
KewalRamani 2006).
The Course of HIV Infection
HIV infection is characterised by three phases namely the primary infection phase, the 
asymptomatic or chronic phase and the symptomatic phase or AIDS [Figure 1.4] (Centlivre, 
Sala et al. 2007; Douek 2007). The primary infection phase is associated with a substantial 
increase in plasma viral load and may be accompanied by a transient illness similar to 
glandular fever, with malaise, muscle pains, swollen lymph nodes, sore throat and rash (Roitt, 
Brostoff et al. 2001). However, the interaction between the virus and the host’s immune 
system leads to a decrease of the viral load to a primary infection viral set point (Figure 1.4) 
(Douek 2007). Based on measurements in peripheral blood, during the primary infection 
phase there is a transient and often unimpressive decrease in CD4+ T cell count (Centlivre, 
Sala et al. 2007). During this phase there is also a dramatic and a preferential depletion of 
CD4+ memory T cells in mucosa especially in the gut-associated lymphoid tissue (GALT) 
which houses up to 80% of CD4+ T cells in the body (Centlivre, Sala et al. 2007; Douek
2007) . This is mamtamed throughout the chronic phase.
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Figure 1.4 | Schematic diagram of a typical course of HIV-1 infection showing 
changes in plasma viral load, peripheral blood CD4 T -cell counts and whole body 
reservoirs of CD4+ T cells.
The GALT CD4+ T cells are depleted within 2 weeks of HIV infection (Sheth, Chege et al. 
2008). The depletion of gastrointestinal CD4 T cells is associated with high frequencies of 
infected CD4 T cells (Brenchley and Douek 2008). Pulmonary mucosal site represented by 
BAL however appears to evade the massive CD4 T-cell depletion characteristic ot the 
gastrointestinal tract.
The asymptomatic phase is characterised by a steady increase in viral load from the primary 
infection viral set point and a decrease in the number of CD4" T lymphocytes in peripheral 
blood (Figure 1.4) (Douek 2007). Symptomatic Phase or AIDS is associated with a terminal 
failure of the immune system (Douek 2007). The CD4+ T cell numbers continue to fall and 
the viral load keeps rising (Figure 1.4). Additionally, non-specific constitutional symptoms 
such as fevers, night sweats and diarrhoea occur (Roitt, Brostoff et al. 2001). A variety of 
conditions that affect the mucous membranes and the skin such as oral candidiasis, shingles, 
and recurrent anogenital herpes simplex occur as well. These conditions are often a sign of 
the development of serious opportunistic infections and tumours such as Pneumocystis 
carinii, Mycobacterium tuberculosis and Kaposi's sarcoma (Roitt, Brostoff et al. 2001). 
These opportunistic infections usually constitute AIDS when the CD4 T cell count falls 
below 200 cells per micro litre.
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HIV Infection and Immune Dysfunction
HIV infection is characterized by a generalized immune activation which affects almost all 
cell types in the immune system, causing severe immune dysfunction especially in the B and 
T cell compartments (Figure 1.5). Along with the general CD4+ T cell depletion, HIV 
infection causes a disproportionate depletion of Till? cells in the gut and the peripheral blood 
of HIV-infected individuals (Brenchley and Douek 2008; Prendergast, Prado et al. 2010), 
which confer protection against extracellular and intracellular bacteria particularly at 
epithelial surfaces. There is also a preferential loss of resting naive T cells during chronic 
stage, elevated levels of activated T cells (Douek 2007) and the inability of T cells to 
simultaneously produce effector cytokines (Betts, Nason et al. 2006).
In HIV-mfected persons, HIV-specific CD4+ T cells are depleted before CD4+ T cells 
specific for other antigens (Douek, Brenchley et al. 2002; Yue, Kovacs et al. 2005). Studies 
suggest that preferential infection and preferential apoptosis may explain the preferential 
depletion of HIV-specific CD4 T cells in HIV-infected persons (Douek, Brenchley et al. 
2002; Yue, Kovacs et al. 2005). Douek et al showed that HIV-1 infects preferentially those 
CD4+T cells that are HIV-1 specific, rather than CD4+ T cells specific for unrelated (Douek, 
Brenchley et al. 2002), whileYue et al. showed that in HIV-1-infected individuals, a greater 
proportion of ex vivo HIV-1-specific CD4+T cells undergo apoptosis compared with 
cytomegalovirus (CMV)-specific CD4+ T cells (Yue, Kovacs et al. 2005).
Within HIV-infected individuals, different pathogen-specific CD4 T cells populations are 
differentially affected by HIV as well. A study looking at the depletion rates between CD4 T 
cells to two common opportunistic pathogens, CMV and Mycobacterium tuberculosis (MTB) 
revealed that CMV-specific CD4 T cells persisted after HIV infection, whereas MTS- 
specific CD4 T cells were depleted rapidly (Geldmacher, Ngwenyama et al. 2010). This is 
thought to be due to differences in function of the pathogen-specific CD4 T cells. CMV- 
specific CD4 T cells tended to produce MIP-1[3 but not IL-2, whereas MTS-specific CD4 T 
cells produced IL-2 but not MIP-1|3 (Geldmacher, Ngwenyama et al. 2010). In the same 
study, cells producing IL-2 in the absence of MIP-1(3 were more susceptible to productive 
HIV infection withm SEB-activated CD4 T cells in vitro.
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As stated above, HIV causes severe immune dysfunction in the B compartment. The precise 
mechanisms of HIV-mediated B-cell immunodeficiency are uncertain. As HIV is not known 
to directly infect B-cells, these defects could result from loss or dysfunction of CD4+ T cells 
or from high plasma viral loads resulting in immune activation and dysregulation (Mo ir, 
Malaspina et al. 2008). Direct B-cell dysfunction may result from the transfer of HIV 
negative factor (Nef) from HIV-infected macrophages to B-cells through long-range 
intercellular conduits (Xu, Santini et al. 2009). Hence while iso type-switched memory B cells 
may be sustained in HIV infection, then function is likely to be indirectly suppressed by HIV. 
Furthermore, B cells undergo phenotypic and functional changes, including depletion of 
memory B cell pools, which are responsible for the maintenance of serologic memory, 
hypergammaglobulinemia, impaired reactivity to immunization and loss of specific 
antibodies obtained as a result of normal vaccination (De Milito, Morch et al. 2001; De 
Milito 2004; De Milito, Nilsson et al. 2004; Titanji, De Milito et al. 2006; Cagigi, Nilsson et 
al. 2008)(Figure 1.5).
The memory B cell compartment is only partially restored by antiretroviral therapy 
(D'Orsogna, Krueger et al. 2007; Moir, Malaspina et al. 2008). HIV infection is also 
associated with numerous defects in the innate immune defences. Effector functions carried 
out by monocytes/macrophages are impaired by HIV infection, including phagocytosis, 
intracellular killing, chemotaxis and cytokine production (Kedzierska and Crowe 2002; 
Kedzierska, Azzam et al. 2003). The ability of macrophages to present antigens to T cells is 
also abnormal (Yoo, Chen et al. 1996) which may be due to decreased expression of MHC 
class II and B7 costimulatory molecules (Chougnet 2003). In addition, HIV infection is 
associated with depletion and impaired function of plasmacytoid and myeloid dendritic cells 
(DC) (Chougnet 2003; Reitano, Kottilil et al. 2009)
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Figure 1.5 | Direct and indirect effects of HIV on T, B cells and Antigen presenting cells
(macrophages/monocytes and dendritic cells).
1. (Guadalupe, Reay et al. 2003; Brenchley, Schacker et al. 2004; Mehandru, Poles et al. 2004), 2. (Chougnet and Gessani 2006),
3. (Subauste, Subauste et al. 2007), 4. (Prendergast, Prado et al. 2010), 5. (Chougnet 2003), 6. (Kedzierska and Crowe 2002; Chougnet 
2003; Kedzierska, Azzam et al. 2003; O'Brien KL 2008), 7. (Reitano, Kottili! et al. 2009), 8. (Donaghy, Pozniak et al. 2001; Pacanowski, Kahi 
et al. 2001), 9. (De Milito, Nilsson et al. 2004) 10. (De Milito 2004; Moir and Fauci 2008; Moir and Fauci 2009), 11. (Martinez-Maza and 
Breen 2002), 12. (Bekker, Scherpbier et al. 2006), 13. (De Milito, Morch et al. 2001; Titanji, De Milito et al. 2006). *HIV virion-
adapted from (Abbas and Lichtman 2007).
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1.10 Adaptive Immunity to extracellular pathogens
B cell-mediated (but not T cell-mediated) immune responses are the principal protective 
responses against extracellular bacteria as revealed by clinical observations of persons 
suffering fi'om Bruton’s agammaglobulinemia (Weiser and Nahm 2008). These individuals 
who have fairly normal T cell function but do not have mature B cells are particularly 
susceptible to bacterial infections caused by extracellular bacteria such as Streptococcus 
pneumoniae, a condition which can be effectively treated with passive administration of a 
broad spectrum of IgG antibodies (Lederman and Winkelstein 1985; Weiser and Nahm 
2008).
Dining an infection, a large number of antigens such as capsular polysaccharides and proteins 
are shed by the bacteria. These antigens or then antibodies are often used to diagnose 
infections (Scott, Hannington et al. 1999; Weiser and Nalnn 2008). Bacterial proteins elicit 
strong immune responses in a conventional T cell-dependent maimer while bacterial 
polysaccharides generally stimulate antibody production in the absence of MHC class II 
restricted T cell help hence they are classified as T cell-independent antigens. 
Polysaccharides are able to stimulate antibody production because they usually have 
numerous repeating units and many epitopes which enable them to efficiently cross-link B 
cell receptors and stimulate B cells (Weiser and Nahm 2008). Polysaccharide antigens 
however are poor immunogens and generally do not stimulate the formation of germinal 
centres and easily tolerize B cells (Weiser and Nahm 2008).
The polysaccharides mainly stimulate two subsets of B cells: B1 B cells and marginal zone 
(MZ) B cells (Guinamard, Okigaki et al. 2000; Martin, Oliver et al. 2001; Weiser and Nalnn 
2008). BIB cells, marginal zone B cells and follicular B cells are three subsets of mature B 
cells with preferential anatomic locations. BIB cells are associated with the peritoneum, MZ 
B cells are found in the splenic marginal zone and follicular B cells are in the splenic follicles 
(Figure 1.6). Not all bacterial antigens are shed during an infection or when the bacteria enter 
the blood circulation. Some antigens remain attached to the bacteria. When the bacteria enter 
the blood circulation, they generally accumulate in the marginal zone of the spleen (Figure 
1.6).
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Figure 1.6 | Schematic diagram of the spleen. Microanatomically, the spleen has two types of 
compartments, the white pulp and the red (erythrocyte-filled) pulp. The white pulp forms a sleeve, 
the periarteriolar lymphoid sheath (PALS), around the arterioles; this sheath contains numerous T 
cells. Closely associated with the PALS is the marginal zone, an area rich in B cells that contains 
lymphoid follicles that can develop into secondary follicles containing germinal centres . Antigens 
are brought into the spleen along with arterial blood (Adapted from: (Goldsby, Kindt et al. 2003).
The marginal zone is best suited for capturing particles in the blood: the zone is where the 
terminal arteriole terminates and empties into sinuses and is filled with macrophages, 
dendritic cells (DCs) and pre activated B cells (MZ B cells) (Pillai, Cariappa et al. 2005; 
Weiser and Nahm 2008). Within 2-3 days of exposure to invasive microbes and even in the 
absence of T cell, MZ B cells can be activated and mature into plasma cells secreting 
antibodies (mainly IgM antibodies) to bacterial polysaccharides (Martin, Oliver et al. 2001). 
The marginal zone B cells by their unique features (high complement receptor 2 expression 
and multireactivity) are best suited to initiate a quick and an efficient response against the 
poorly immunogenic polysaccharide antigens. Furthermore, MZ B cells may also aid the 
activation of follicular B cells because they can capture IgM immune complex and transport 
it to follicular dendritic cells (Ferguson, Youd et al. 2004; Lopes-Carvalho, Foote et al. 2005; 
Weiser and Nahm 2008). They can also present bacterial (protein) antigens to naive T cells 
(Lopes-Carvalho, Foote et al. 2005).
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The protein antigens of extracellular bacteria activate CD4+ helper T cells, to produce 
cytokines that stimulate B cell responses (antibody production).
Antibodies use a number of effector mechanisms to fight infection including neutralisation, 
opsonisation and phagocytosis and activation of complement by the classical pathway (Abbas 
and Lichtman 2007)(Figure 1.7). Neutralisation is mediated by high-affinity IgG and IgA 
isotypes. These antibodies inhibit infectivity of microorganisms by blocking the binding of 
the organisms to cellular receptor. Phagocytes express receptors for the Fc portions of IgG 
antibodies (FcRs are also expressed on B cells). IgG isotypes opsonise (coat) the pathogens 
and promote their phagocytosis by binding to the Fc receptors on phagocytes. The binding of 
natural antibodies (either IgG subclasses or IgM) to microbial surfaces not only opsonises 
invading microbes but also activates complement via the classical pathway, a major effector 
of the humoral immunity.
Once the classical pathway is initiated, a cascade of events (the ‘complement cascade’) 
follows. In this case, the central protein of the complement system, C3 is cleaved, generating 
C3a and C3b, and bringing about a cascade of further cleavage and activation events. C3b 
binds to the surface of microbes, leading to greater internalisation by phagocytic cells by 
opsonisation.
Although, immunity against extracellular bacteria is clearly centred on the B cell responses, 
recent studies suggest additional roles for T cells in responses to extracellular bacteria and 
their products. For instance, studies of Bacteroides fragilis induced abscess formation 
indicate that Bacteroides fragilis zwitterionic capsular PS can be ingested and processed by 
antigen presenting cells using a nitric oxide-dependent mechanism and present it in 
association with MHC class II molecules to stimulate CD4+ T cells to produce IL-17 
(Tzianabos, Finberg et al. 2000; Cobb and Kasper 2005; Weiser and Nalun 2008). Till7 CD4 
T cells appear to confer protection against extracellular bacteria particularly at epithelial 
surfaces (Curtis and Way 2009) and studies in mice have shown that IL-17 receptor 
deficiency or deficiency of IL-23 is associated with increased risk of infections by 
extracellular bacterial infections (Happel, Dubin et al. 2005; Weiser and Nalun 2008).
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Figure 1.7 | Adaptive Immunity to extracellular bacteria. Adaptive immunity against 
extracellular bacteria is mediated primarily by antibodies. Antibodies protect against infection 
through a number of mechanisms including opsonisation and phagocytosis and activation of 
complement by the classical pathway. Extracellular microbes also activate CD4 T helper T cells to 
produce cytokines that stimulate B cell responses, macrophage activation (IFN-y) and 
*neutrophil recruitment (IL-17). ARC -antigen-presenting cell; IFN-y- interferon-y; INF- tumor 
necrosis factor. Adapted from (Abbas and Lichtman 2007).
IL-17 has been shown to participate in host defence against extracellular pathogens, such as 
Klebsiella, Candida and S. pneumoniae in mice (Ye, Garvey et al. 2001; Huang, Na et al. 
2004; Malley, Srivastava et al. 2006). The role of Thl7 cells has been demonstrated in 
vaccine-induced immunity regardless of whether whole organisms, killed or live, were used. 
Animal studies showed that protection against Bordetella pertussis and S. pneumoniae 
(experimental pneumococcal colonization) with a whole cell vaccine induced Thl7- 
dependent protection (Higgins, Jamicki et al. 2006; Lu, Gross et al. 2008).
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It appears IL-17 mediates its protective effects against extracellular bacteria by activating 
early neutrophil recruitment into local sites of infection (Curtis and Way 2009). The protein 
antigens of extracellular bacteria also stimulate CD4+ helper T cells to produce cytokmes that 
enhance the phagocytic and microbicidal activities of macrophages (Figure 1.7). Interferon-y 
(IFN-y) is the T cell cytokine responsible for macrophage activation.
1.11 Innate immunity to S. pneumoniae.
There is a huge disconnect between frequent rates of asymptomatic nasopharyngeal 
colonisation in humans and the relatively lower prevalence rates of invasive pneumococcal 
diseases (Greenwood 1999; Mulholland, Ogunlesi et al. 1999; Obaro and Adegbola 2002), 
suggesting the existence of naturally acquired protective immunity against pneumococcal 
disease. The development of natural immune response to pneumococcal infection generally 
involves both innate and adaptive immunity working in concert, to bring about protection 
against pneumococcal infection.
Innate immunity represents the first non-specific step in host defence and covers a wide range 
of host defences, including mucociliary clearance, complement, neutrophils and macrophages 
(Paterson and Mitchell 2006). Through a diverse array of mechanisms, such as phagocytosis, 
intracellular killing and activation of pro-inflammatory or antiviral cytokine production, the 
cells of the innate immune system trigger and support the adaptive immunity.
Complement
The complement system (over 30 serum and membrane proteins) is a biochemical cascade 
activated by three biochemical pathways (Walport 2001; Walport 2001; Paterson and 
Mitchell 2006): the classical pathway activated by antibody-antigen complexes; the lectin 
pathway, which is set off by mannose-binding lectin recognition of carbohydrate on the 
microbial surface and the alternative pathway, which is constantly triggered at low levels, but 
only amplifies on the surfaces of foreign particles. The role played by complement in innate 
and adaptive responses to pneumococcal infection is long established in humans; humans 
with complement deficiency are known to be at increased risk of invasive disease (Hostetter 
2004). Studies in mouse models indicated that the classical pathway is the dominant pathway 
for innate immunity to the pneumococcus (Brown, Hussell et al. 2002).
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It has been suggested that natural IgM antibodies and possibly acute-phase proteins such as 
C-reactive protein and complement component Clq contribute to the activation of the 
classical pathway (Paterson and Mitchell 2006; Rupprecht, Angele et al. 2007). The 
alternative pathway also contributes to protective innate responses, though to lesser degree 
compared to the classical pathway while the role of the lectin pathway is somewhat small 
(Paterson and Mitchell 2006).
Irrespective of the activation pathway, the deposition and activation of the complement 
component C3 on the bacterial surface is a critical step in the biochemical cascade which 
facilitates pathogen elimination. In line with the key role complement play in innate 
immunity, S. pneumoniae has developed ways of evading its effects. For example, the 
pneumococcal capsule, not only restrict access to cell-bound complement but also reduces the 
amount of complement that can be deposited on the bacterial surface (Abeyta, Hardy et al. 
2003). Additionally, Pneumolysin activates the classical pathway by binding to the Fc region 
of immunoglobulin G (Paton 1996) and this interaction reduces C3 deposition on the 
pneumococcus, limiting opsonisation of pneumococci by the classical pathway (Yuste, Botto 
et al. 2005).
Innate immune cells
S. pneumoniae interacts with and activates phagocytic cells of the innate immune system 
including granulocytes, monocytes/macrophages and dendritic cells (DCs), thus indirectly 
stimulating the production and recruitment of T and B cell responses.
Pneumococcal colonisation of the murine upper respiratory tract triggers an acute 
inflammatory response characterized by the influx of neutrophils into the para-nasal spaces 
(Nelson, Roche et al. 2007) stimulating the production of inflammatory cytokines and 
chemokines. Pneumolysin stimulates neutrophil recruitment (van Rossum, Lysenko et al. 
2005) and in a mouse model of pneumococcal colonisation the interaction of pneumolysin 
and neutrophils promoted delivery and release of pneumococcal specific antigens to the 
nasal associated lymphoid tissues, enhancing adaptive immune responses against S. 
pneumoniae (Matthias, Roche et al. 2008; Jambo, Sepako et al. 2010).
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Vital components of the innate immune system are the so-called pathogen recognition 
receptors (PRRs). Their function is to detect microbes or pathogens and initiate the 
production of a variety of inflammatory mediators and cytokines and the phagocytosis of the 
invading pathogen (Henneke, Takeuchi et al. 2002). Among the key PRRs important in 
pneumococcal infection are members of the Toll-like receptor (TLR) family such as TLR-2 
and TLR4 (Srivastava, Henneke et al. 2005; Dessing, Florquin et al. 2008). Antigen 
presenting cells such as dendritic cells, as well as macrophages, detect microbial infections 
by recognition via TLRs enhancing the production of pro-inflammatory cytokines and the up- 
regulation of MHC and co-stimulatory molecules (Colino and Snapper 2003).
Pneumococcal components have been found to be recognised by Toll-like receptor 2 (TLR2) 
and 4 (TLR4). TLR2 has been reported to influence pneumococcal disease progression 
(Srivastava, Henneke et al. 2005; Dessing, Florquin et al. 2008) and TLR2 knock-out mice 
have been shown to exhibit impaired pneumococcal clearance (van Rossum, Lysenko et al. 
2005). Pneumolysin, a proven pneumococcal virulence factor interacts directly with TLR4 
(Malley, Henneke et al. 2003; Zhang, Bagrade et al. 2007). The pro-inflammatory effect of 
pneumolysin on macrophages has been shown to be TLR4 dependent (Malley, Henneke et al. 
2003), and macrophage apoptosis was found to regulate the clearance of bacteria in a murine 
model of pneumococcal pneumonia through the TLR4 Ugand (Dockrell, Maniott et al. 2003).
In a pneumococcal colonisation mouse model, TLR4-deficient mice were more heavily 
colonised and more susceptible to infection compared to control mice (Malley, Henneke et al. 
2003). In a human study, CD4+ T cell proliferation induced by pneumolysin was inhibited by 
neutralising antibody to TLR4 but not TLR2 (Zhang, Bagrade et al. 2007). Thus, 
pneumolysm-specific CD4+ T cell responses may be modulated by TLR4-dependent cellular 
activation probably of TLR4-expressing antigen presenting cells (APC) such as dendritic 
cells and macrophages (Beutler 2004).
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1.12 Naturally-acquired immunity to S. pneumoniae.
In HIV-unaffected persons, as with many mucosal pathogens, pneumococcal disease becomes 
less frequent with age, a process which is thought to be due to the acquisition of natural 
adaptive immunity. In most individuals, programming of the immune system occurs as a 
result of carriage of the pneumococcus and related bacteria in the nasopharynx (Rapola, Jantti 
et al. 2000; Sominen, Pursiainen et al. 2001; Zhang, Choo et al. 2002; Heyderman, Davenport 
et al. 2006; Zhang, Bernatoniene et al. 2006; Zhang, Bagrade et al. 2007). The characteristics 
of the immunity involved in this upper respimtory tract (URT) process are not well 
understood. Natural immunity to the pneumococcus had been thought to be largely mediated 
by anti-capsular antibodies (Lipsitch, Whitney et al. 2005). This assumption was based on a 
number of observations.
In unimmunised populations, the incidence of invasive disease follows a familiar age 
distribution pattern. It peaks in the first 2 years of life and drops by more than an order of 
magnitude by the second and third decades of life. Thereafter, the incidence goes up quickly, 
with incidence in individuals over 70 years nearly the same as that in infants (Robinson, 
Baughman et al. 2001; Lipsitch, Whitney et al. 2005)]. Although the reason for the decline 
has not been fully established, it is frequently proposed that anti-capsular antibodies are 
involved (Musher, Groover et al. 1993; Lipsitch, Whitney et al. 2005).
Furthermore, data from several surveys show that carriage rates decline from over 50% in 
infants to 5-10% in adults and this correlate with a rise in both mucosal and serum anti- 
capsular antibody level (Gwaltney, Sande et al. 1975; Syrjanen, Kilpi et al. 2001; Simell, 
Kilpi et al. 2002; Zhang, Arnaoutakis et al. 2004; van Rossum, Lysenko et al. 2005). In a 
longitudinal household study, Goldblatt et al. reported a significant increase in anti-capsular 
IgG levels after carnage of serotypes 9V, 14, 18C, 19F, and 23F by an individual or a family 
member. For serotype 14, a higher level of anti-capsular IgG at the beginning of the study 
correlated with diminished odds of carriage, suggesting that naturally induced anti-capsular 
IgG can prevent carriage (Goldblatt, Hussain et al. 2005).
Passive transfer of anti-capsular antibody and polysaccharide-based vaccine studies show that 
anti-capsular antibodies are clearly sufficient to protect against invasive pneumococcal 
disease and colonisation (Malley 2010).
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Immunisation with conjugate pneumococcal vaccine (7-valent and 9-valent vaccine), lead to 
a decrease in nasopharyngeal carriage of vaccine serotypes (Mbelle, Huebner et al. 1999; 
Huang, Hinrichsen et al. 2009) and the number of new acquisitions of nasopharyngeal 
pneumococcus (serotypes 14 and 19F) was inversely correlated with the serum serotype- 
specific pneumococcal anti-capsular IgG concentrations (Dagan, Givon-Lavi et al. 2005). An 
analysis of longitudinal carriage data from Israeli children in day care showed that some 
serotypes generate anti-capsular antibodies that can reduce the risk of carriage in 
unimmunised toddlers (Wemberger, Dagan et al. 2008; Malley 2010).
In addition to then serotype-specific polysaccharides, pneumococci express a range of sub- 
capsular antigens common among serotypes as described earlier in this chapter. Animal 
models and studies of human carriage have implicated some of these antigens in protection 
against both nasal colonization and invasive disease (Rapola, Jantti et al. 2000; Simell, 
Korkeila et al. 2001) (Balachandran, Brooks-Walter et al. 2002; Zhang, Choo et al. 2002; 
Zhang, Bernatoniene et al. 2006)(Table 1.5). Although, it is well established that anti- 
capsular and anti-subcapsular antibodies can protect against pneumococcal colonisation and 
disease it is less clear whether these antibodies are necessary for the natural development of 
protection against pneumococcal colonisation and disease (Malley 2010).
Data from sero-epidemiologic studies from the United States, Finland and Israel showed that 
unimmunised children were significantly less susceptible to pneumococcal invasive disease 
prior to the development of measurable systemic anticapsular antibodies. (Lipsitch, Whitney 
et al. 2005; Malley, Trzcinski et al. 2005). The age-specific decline in pneumococcal 
invasive disease was observed across serotype, arguing for a common and possibly a capsular 
serotype-independent mechanism of protection. Similarly, the reduction in the duration of 
carnage preceded by several years the detection of naturally-acquired anti-capsular antibodies 
in most children (Hogberg, Geli et al. 2007).
A longitudinal study in Bangladeshi children <1 year old, revealed that the rate of acquisition 
of colonisation declined in a manner consistent with the acquisition of immunity other than 
anti-capsular antibodies (Granat, Ollgren et al. 2009). In an experimental human carriage 
study, an increase in the antibody levels (serum and mucosal antibody response to capsular 
polysaccharide and PspA) did not correlate temporally with the loss of carriage, suggesting
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that antibodies may play a limited role in the clearance of a pre-established colonisation 
(McCool, Cate et al. 2002; McCool, Cate et al. 2003; van Rossum, Lysenko et al. 2005).
Table 1.5 | Antibody responses to pneumococcal non-capsular antigens
Human or
Year Antigen Response Murine Model Ref
2000 PsaA, PspA &
PdB
Serum IgG Human Natural carriage (Rapola, Jantti et
al. 2000)
2000 PsaA Serum IgG Human
(infants)
Natural carriage (Obaro, Adegbola
et al. 2000)
2002 PspA Serum IgG
Secretory IgA
Human Experimental carriage (McCool, Cate et 
al. 2002)
2003 PspA & CbpA Serum IgG Human Experimental carriage (McCool, Cate et 
al. 2003)
2005 PsaA, PspA & Ply Serum IgG Human Natural carriage
(Longitudinal study)
(Goldblatt,
Hussain et al.
2005)
2005 PsaA, PspA, PspC 
& PdB
Serum IgG
Nasal secretion IgA
Murine Experimental carriage (Palaniappan,
Singh et al. 2005)
2006 CbpA, PsaA, PspA 
& Pneumolysin
Serum & salivary IgG
Adenoidal IgA, IgG & 
IgM
Human
(children)
Natural carriage
in vitro cell 
stimulation
(Zhang,
Bernatoniene et
al. 2006)
Studies in mice suggest that T cells play a role in the development of natural immunity to the 
pneumococcus (Malley, Trzcinski et al. 2005; Trzcmski, Thompson et al. 2005; van Rossum, 
Lysenko et al. 2005; Basset, Thompson et al. 2007; Trzcinski, Thompson et al. 2008). Murine 
challenge models using B cell, T cell, f32-inicroglobulin and MHC Class II knockouts 
suggest that immunity to pneumococcal colonisation and infection is antibody independent 
but is dependent on the presence of CD4+ T cells at the time of challenge (Malley, Trzcmski 
et al. 2005; Trzcmski, Thompson et al. 2005; van Rossum, Lysenko et al. 2005). This CD4+ 
dependent immunity is mediated by interleukin-17A hi a neutrophil-dependent mamier (Lu, 
Gross et al. 2008). Pneumococcal specific-Thl7 cells have been detected in adults and 
children, but not hi newborn babies, suggesting that Till 7 may be a result of natural exposure 
to S. pneumoniae (Lu, Gross et al. 2008),
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Mucosal CD4+ T cellular immunity to pneumococcal protein antigens has been shown in 
children and seems to modulate nasopharyngeal carnage (Zhang, Bagrade et al. 2007). In the 
same study, systemic CD4+ T cellular immunity to pneumococcal protein antigens was 
demonstrated as well and this naturally acquhed immune memory persists into adulthood 
(Zhang, Bagrade et al. 2007; Mureithi, Finn et al. 2009). The induction of CD4 T cell 
responses was associated with Thl-type cytokine production (IFN-y, TNF-a, IL-12[p40]) and 
Thl7-type cytokine production (IL-17, IL-12[p40]) (Zhang, Bagrade et al. 2007; Mureithi, 
Finn et al. 2009).
1.13 Vaccine prevention of pneumococcal disease- current strategies.
The first pneumococcal vaccine was a killed whole pneumococci vaccine and was introduced 
in 1911 by Sir Almroth Wright. Unfortunately, this vaccine failed as only one of the two 
serotypes identified was included and maximal vaccine dosage was inadequate (Watson and 
Musher 1999). Subsequently, vaccines based on capsular polysaccharide have been the main 
focus of pneumococcal vaccine research and implementation for many years (French 2003; 
Whitney 2005; Tai 2006) Tai SS et al. 2006). There are two formulations of pneumococcal 
vaccines that have been licensed thus far: pneumococcal polysaccharide vaccines (PPV) was 
developed first, followed by pneumococcal capsular polysaccharide-protein conjugate 
vaccine.
1.13.1 Pneumococcal Polysaccharide Vaccines
Capsular polysaccharides vaccines are purified capsular polysaccharides made from a 
selection of pneumococcal serotypes based on the relative frequency of serotypes in 
naturally occurring pneumococcal infections, aiming at a worldwide coverage of >90% of 
isolates that cause invasive in disease (Bematoniene and Finn 2005). The first commercially 
available 14-valent polysaccharide vaccine was licensed in 1977 and by 1981 this was 
modified to a 23-valent vaccine (CDC[MMWR] 1984) (Figure 1.8). Polyvalent 
polysaccharides vaccines are efficacious in healthy adults. The 23-valent vaccine confers 60- 
80% protection against invasive pneumococcal disease in adults. However, it is poorly 
immunogenic in children <2 years of age, the age group which is most vulnerable to 
pneumococcal disease (Lynch and Zhanel 2009) and shows no protective effect against 
carriage (Obaro and Adegbola 2002). Additionally, it is less effective in HIV-infected adults 
and is not recommended for use in Africa (French, Nakiyingi et al. 2000; WHO 2008c).
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In parts of the world, where the 23-valent vaccine is used, it is recommended for use early in 
the course of HIV disease (Masur, Kaplan et al. 2002). Poor immunogenicity of 
polysaccharide vaccines may be due to lack of T cell involvement which is a requirement for 
an increased antibody response in infants, induction of memory cells, and a booster response 
on subsequent antigenic exposures (Regev-Yochay, Malley et al. 2008).
1.13.2 Pneumococcal Conjugate Vaccines
Failure of polysaccharide vaccines to provide protection to those at the greatest risk, 
demonstrated the need to develop vaccines with expanded coverage and immunogenicity. 
The success of Haemophilus influenza type b (Hib) conjugate vaccine (Adegbola, Mulholland 
et al. 1998; Adegbola, Usen et al. 1999) and the Neisseria meningitidis serogroup C (Men-C) 
conjugate vaccine (Lakshman, Jones et al 2001; Zhang, Lakshman et al. 2001; Lakshman 
and Finn 2002) led to the development of pneumococcal conjugate vaccines. In 
pneumococcal conjugate vaccines, a polysaccharide antigen is coupled to a protein carrier 
(e.g. diphtheria protein CRM197 or toxoid, tetanus toxoid or meningococcal outer-membrane 
protein) and the resulting conjugate acts as a typical T-cell-dependent antigen which is 
antigenic in infants.
T cells exposed to peptides derived from the protein carrier promote robust antigenic-specific 
B cell proliferation, affinity maturation and immunological memory (Mulholland, 
Hoestermann et al. 1994; Regev-Yochay, Malley et al. 2008). Several vaccine formulations 
incorporating between 4 to 13 pneumococcal capsular polysaccharides types have been 
investigated for safety and immunogenicity.
The seven-valent pneumococcal conjugate vaccine (PCV7) was licensed in the USA in the 
year 2000 and in Europe in 2001. The vaccine targets the seven serotypes that most often 
cause invasive pneumococcal disease (IPD) in children. (Figure 1.8) (Pavia, Bianco et al 
2009). Vaccination with PCV7 has resulted in a decrease in the incidence of IPD, pneumonia, 
bacteraemias and pneumococcal meningitis in adults and children (Table 1.6) (Adam 2009; 
Lynch and Zhanel 2010). In a meta-analysis of nine clinical trials of PCV7 in children < 2 
years old, IPD caused by vaccine-serotypes and all serotypes fell by 89% and 63-74% 
respectively (Pavia, Bianco et al. 2009).
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7-valent pneumococcal 
conjugate vaccine (diphtheria 
CRM19r protein - PCV7)
[4 6B9V14.18C.19F &23F]
13-valent pneumococcal conjugate 
vaccine (diphtheria CRMi97 protein- 
PCV13)
[1,3 4 6 6A,6B7F,9V,14,18C 19A.19F&23F]
14-valent polysaccharide 
vaccine (14PPV)
[17,3.4 6A 7F 8.9N 9V 12F 14 
18C 19F20 23F&25F]
23-valent polysaccharide vaccine (23PPV)
[1,2,3.4,5,68 7F.8 9N 9V,iaA11A12F,14,15B.17F, 
18C 19A 19F.20.22F23F &33F]
9-valent pneumococcal conjugate vaccine 
(diphtheria CRM197 protein - PCV9)
[1.4 6 6B 9V,14,18C,19F,&23F]
10-valent pneumococcal conjugate 
vaccine (Protein D from NTHi - 
PCV10)
[1 4 5 6B 7F 9V14 18C 19F &23F]
1977 2000'
Figure 1.8 | Timeline- Highlights of development of pneumococcal vaccines. a,b|CDC[MMWR] 
1984; c| Pavia, Bianco et al. 2009; d | Klugman, Madhi et al. 2003;
e,f\www.gsk.com/media/.../2009/2009_pressrelease_10039.htm & Reinert, Paradise et al. 2010. 
1-additional serotypes to PCV7. ??* - No date of licensure, withdrawn by manufacturer.
Table 1.6 | Outcomes of pneumococcal conjugate vaccines (PCV7 and PCV9)
Vaccine Outcomes References
Seven-valent 
pneumococcal 
conjugate 
vaccine (PCV7)
>!> vaccine-type IPD in children
mortality linked to invasive disease 
nasopharyngeal carriage in children
^vaccine-serotype carriage and IPD in 
unvaccinated children and 
adults (herd immunity)
4^ carriage & frequency of IPD cause by 
antibiotic -resistant pneumococci 
• Effective in HIV+ adults 
§ Replacement by non- vaccine serotypes 
(particularly 19A) & 'l' non-vaccine type 
disease
(Whitney, Pilishvili etal. 2006)
(Tsigrelis, Tleyjeh et al. 2008)
(Ghaffar, Barton et al. 2004; Millar, O'Brien et 
al. 2006)
(Flannery, Schrag et al. 2004; Lexau, Lynfield 
et al. 2005; Millar, Watt et al. 2008)
(Kyaw, Lynfield et al. 2006)
(French, Gordon et al. 2010)
(Pelton, Loughlin et al. 2004; Flicks, Flarrison 
et al. 2007; Moore, Gertz et al. 2008; Dagan 
2009)
Nine-valent 
pneumococcal 
conjugate 
vaccine (PCV9)
4* incidence of radiologically confirmed 
pneumonia
4^ vaccine-type & antibiotic-resistant IPD 
Among FHV-ve and HIV+ve children
§ No herd immunity
§ Replacement by non-vaccine serotypes
(Klugman, Madhi et al. 2003; Cutts, Zaman et 
al. 2005)
(Klugman, Madhi et al. 2003)
(Cheung, Zaman et al. 2009)
(Cheung, Zaman et al. 2009)
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Additionally, vaccination protects unvaccinated population including adults reflecting herd 
immunity (CDC(MMWR) 2005). Recently, the vaccine was shown to protect HIV-infected 
adults from recurrent pneumococcal infections caused by vaccine serotypes or serotype 6A 
(French, Gordon et al. 2010). Post-licensure epidemiologic surveillance however show a 
replacement of the vaccine-serotypes with the non-vaccine serotypes, resulting in an 
increased incidence of pneumococcal disease caused by non-PCV7 serotypes (particularly 
serotype 19A) (Dagan 2009). Furthermore, PCV7 does not induce immunity to serotype 1 or 
5, which are important causes of pneumococcal disease in many non-industrialised countries. 
Serogroup data from Malawi suggest that PCV7 would cover 41% of invasive isolates from 
children and 25% from adults (Gordon, Kanyanda et al. 2003). There are also indications that 
the vaccine may be less effective in overcrowded settings such as day care centres where 
pneumococcal infections are stubborn and persistent (Adam 2009).
A 9-valent conjugate vaccine which included serotypes 1 and 5 in addition to PCV7 (Figure 
1.8), was successfully trialled in the Gambia (Cutts, Zaman et al. 2005) and South Africa 
(Kingman, Madhi et al. 2003) but was subsequently withdrawn by the manufacturer. The 
vaccine was effective in reducing mortality in the two populations. However, there was no 
evidence of herd immunity in the Gambia, where pneumococcal carriage rates are very high 
(Cheung, Zaman et al. 2009). Two new vaccines were licensed hi Europe in 2009, the 10- 
valent and 13 valent pneumococcal conjugate vaccines (Figure 1.8). The 10 valent vaccine 
mcludes three additional serotypes (1, 5 and 7F) (Vesikari, Wysocki et al. 2009; Wysocki, 
Tejedor et al. 2009) which are highly invasive and increasingly prevalent (representing 5- 
25% of all IPD cases in children) (Munoz-Almagro, Jordan et al. 2008). The 13-valent 
vaccine is a response to the changing epidemiology of pneumococcal serotypes in countries 
where there is general or widespread use of PCV7 and to the increasing disease burden by 
serotype 19A. The vaccine includes additional six serotypes (mcluding 19A) to PCV7 
(Remert, Paradiso et al. 2010). It is predicted that PCV13 will increase the percentage of 
vaccine-preventable cases of IPD to up to 90% or more (based on serotype data available 
before wide or general use of PCV7) hi many parts of the world (Reinert, Paradiso et al. 
2010).
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1.13.3 Whole Cell Vaccine
Whole-cell vaccine (WCV) is usually made firam ethanol-killed (70% (vol/vol) ethanol at 
4°C) cells of a noncapsulated strain of Streptococcus pneumoniae. A noncapsulated S. 
pneumoniae is used to maximize the exposure of species-common sub capsular antigens. 
Killing the cells with 70% (vol/vol) ethanol at 4°C produces the most protective preparation 
than traditional methods of inactivation such as heat, formalin, or UV radiation (Lu, Yadav et 
al. 2010). Recently, it has been shown however that killing the cells with chloroform, 
trichloroethylene, or beta-propiolactone without postkilling wash procedure gave more 
immunogenic preparations than ethanol, expanding the range of agents that can be used to 
mactivate S. pneumoniae whole cells (Lu, Yadav et al. 2010). Intranasal application (thought 
to be effective for inducing both systemic and mucosal immunity ) of ethanol-killed whole 
cells with cholera toxin as a mucosal adjuvant reduced nasopharyngeal colonisation, middle 
ear infection and fatal pneumonia caused by encapsulated pneumococci of all tested serotypes 
in mice (Malley, Morse et al. 2004).
Nontoxic single and double mutants of Escherichia coli heat-labile toxin however have been 
tested as adjuvants and were shown to be as effective as mucosal adjuvants and with these 
adjuvants protection against colonisation could be induced by the sublingual and buccal 
routes (Lu, Yadav et al. 2010). Thus, an immunogenic whole-cell antigen can be generated 
and given in a variety of ways. Research has shown that WCV engages TLR2 and TLR4 in 
preventing colonisation (Malley, Srivastava et al. 2006). The vaccine also induces serum 
antibodies in mice when administered prior to challenge (Malley, Lipsitch et al. 2001). 
Induction of reduced colonisation is CD4+ T cell-dependent and interleukin 17A (IL-17A) 
mediated and can be antibody independent (Malley, Trzcinski et al. 2005; Lu, Gross et al. 
2008). Further in-depth research to demonstrate safety and efficacy in humans will be 
required in the development of WCV.
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1.13.4 Pneumococcal Protein Vaccines
Although capsular polysaccharide-protein conjugate vaccines have been shown to be 
effective in reducing invasive pneumococcal disease, they are less effective in preventing 
mucosal disease (20-39% efficacy compared to 77-85% efficacy for systemic disease)( 
(Cutts, Zaman et al. 2005; Qasi S 2007) and it is unclear whether their effects on carriage due 
to herd immunity are sufficiently long-lived for a setting such as sub-Saharan Africa where 
pneumococcal carriage rates are very high. Furthermore, then usefulness is limited by 
restricted capsular serotype distribution, serotype replacement, multiple -dose regimens and 
high cost. Even the newer generation of conjugates vaccines will partly cover serotypes in 
developing countries. For instance, a 9-valent conjugate vaccine, would cover 66% of 
invasive isolates from children and 55% from adults in Malawi (Gordon, Kanyanda et al. 
2003) while the 10-valent and 13-valent vaccines would could cover 50% and 60% of 
invasive isolates in Malawi, respectively (Everett, D, MLW, unpublished data). Several 
pneumococcal proteins have been identified as potential vaccines which could circumvent 
some of these drawbacks identified with PCVs and would be synergistic to the capsular 
polysaccharide approach (Tai SS et al. 2006). Candidate proteins under investigation include 
pneumolysin and its non-toxic derivatives, choline-binding proteins such as PspA and CbpA, 
metal-binding proteins, such as PsaA and PiaA and neuraminidase NaA (Table 1.7) and some 
of these proteins not only contribute to pneumococcal virulence but are produced by virtually 
by all clinical isolates.
Preliminary studies in mice showed that immunisation of these proteins can protect against 
infection with multiple serotypes of S. pneumoniae and /or prevent nasopharyngeal carriage 
(Briles, Hollingshead et al. 2000). Immunization with certain combinations of pneumococcal 
proteins such as a combination of Ply, PspA and CbpA have been shown to provides additive 
or even synergistic protection (Ogumiiyi, LeMessurier et al. 2007). The use of protein-based 
vaccines raises the possibility of mucosal vaccination which may be a more effective way to 
protect against mucosal carriage than parenteral immunisation (Jambo, Sepako et al. 2010) 
and also to induce herd immunity. Protein-based vaccine may also be easier and cheaper to 
manufacture than polysaccharide vaccines. Additionally, they may not require refrigerated 
storage and multiple-dose regimens, and hence may be cheaper and easier to administer in 
resource-poor countries.
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Table 1.7 | Mouse models of mucosal immunisation with pneumococcal protein antigens3 (Jambo, 
Sepako et al. 2010)
Antigen or 
vaccine
Route Immunogenicity Correlates of 
protection
Protection
against;
Refs
PspA Intranasal Mucosal and 
systemic
Antibodies in 
serum and saliva
Colonisation,
pneumonia,
sepsis
(Wu, Nahm et al. 1997; 
Yamamoto, McDaniel et al. 
1997; Campos, Darrieux et al. 
2008)
PspA/
attenuated
Salmonella
Oral Mucosal and 
systemic
Antibodies in 
serum and vaginal 
fluids
Pneumonia,
bacteraemia
(Nayak, Tinge et al. 1998;
Kang, Srinivasan et al. 2002; 
Park, Ko et al. 2008; Li, Wang 
et al. 2009; Xin, Li et al. 2009)
PsaA Oral Mucosal and 
systemic
Antibodies in 
serum, BAL and 
intestinal fluid
Pneumonia,
bacteraemia
(Seo, Seong et al. 2002;
Areas, Oliveira et al. 2004; 
Pimenta, Miyaji et al. 2006)
PsaA/lactic
acid
bacteria
Intranasal Mucosal and 
systemic
Antibodies in 
serum, saliva, 
nasal and 
bronchial washes
Colonisation (Oliveira, Areas et al. 2006)
PotD Intranasal Mucosal and 
systemic
Antibodies in 
serum and saliva
Colonisation,
pneumonia,
bacteraemia
(Shah, Briles et al. 2009)
PsaA and 
PspA
Intranasal Mucosal and 
systemic
Antibodies in 
serum and saliva
Colonisation (Briles, Ades et al. 2000)
PspA and 
PspC
Intranasal Mucosal and 
systemic
Antibodies in 
serum, vaginal 
washes, and
BAL; cytokine 
responses in
BAL, lung and 
splenic samples
Pneumonia,
bacteraemia
(Xin, Wanda et al. 2008;
Ferreira, Darrieux et al. 2009)
PsaA, PdT 
and CWPS
Intranasal Systemic Antibodies in 
serum; T cell 
response in whole 
blood
Colonisation,
pneumonia
(Lu, Gross et al. 2008;
Arevalo, Xu et al. 2009)
GEM with 
PpmA, Sir A 
and IgAlp
Intranasal Systemic Antibodies in
serum
Pneumonia (Audouy, van Roosmalen et 
al. 2006)
PCV Intranasal Mucosa] and 
systemic
Antibodies in 
serum and nasal 
washes
Colonisation, 
otitis media
(iakobsen, Saeland et al.
1999; Lynch, Briles et al.
2003; Sabirov and Metzger 
2006; Sabirov and Metzger 
2008)
Abbreviations: PspA, pneumococcal surface protein A; PsaA, 'pneumococcal surface adhesion A' protein; BAL, bronchoalveolar 
lavage; PotD, polyamine transport protein D; PspC, pneumococcal surface protein C; PdT, pneumolysin nontoxic derivative; CWPS, 
cell wall polysaccharide; GEM, Gram-positive enhancer matrix; PCV, pneumococcal conjugate vaccine.
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1.14 Current and new approaches for evaluating T cell Immunity
T lymphocytes play an important role in the regulation of immune responses and mediate 
many of the effector mechanisms of the immune system. Therefore, there has always been a 
need for assays that can measure accurately the function or activity of T cells in both humans 
and animal models. This section reviews some of the assays that are commonly used to 
assess T cell function and describes some new approaches for evaluating T cell immunity.
The available assays measure functions of the responding T cells that occur from relatively 
early time points (MHC-peptide binding, cytokine production, cytotoxicity) to later time 
points (proliferation) in the T cell activation process (Figure 1.9). The assays can be 
categorized according to whether their readout measures a function in bulk cultures (Enzyme 
Linked Immunoassay (ELISA), Cytometric Bead Array (CBA) and Luminex), or enumerates 
the responding T cells on a single cell basis (MHC-peptide tetramer staining, enzyme-linked 
immunospot (ELISpot), Intracellular cytokine staining (ICS), CD 107 staining and CFSE 
assay) (Table 1.8).
APC-T cell Cytokine Cytotoxicity Proliferation/
interactions expression Death
Figure 1.9 | Targets for immune evaluation. Available T cell assays measure functions of the 
responding T cells that occur from relatively early time points (MHC-peptide binding, cytokine 
production, cytotoxicity) to later time points (proliferation) in the T cell activation process.
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Measurement of proliferative capacity of T cells
Proliferation is a functional feature vital for the T cell control of several diseases (Horton, 
Frank et al. 2006). Classically, the proliferative capacity of T cells was determined by 
radioactive thymidine incorporation into the DNA of dividing cells. The assay requires the 
cells to be stimulated for 3-7 days, before addition of the radio labelled titrated thymidine (3H- 
Thy) for 6-8 hours. The total amount of radioactive thymidine incorporated into cells in that 
tune period is then measured, providing a measure of the rate of synthesis of DNA by the 
entire population of cells (Hickling 1998).
However, the development of non-radio active flow cytometric assays supplants the need to 
use radioactivity and provide additional detail about the proliferating antigen-responsive T 
cells (Bolton and Roederer 2009). An example of a nonradio active method is 
carboxyfluorescem succinimidyl ester (CFSE) lymphoprohferation assay. In this case, cells 
(usually PBMCs) are labelled with CFSE fluorescent dye, incubated with desired antigens 
and allowed to proliferate for 7-10 days. As the cells proliferate, CFSE is divided equally 
among daughter cells with each generation becoming half as intense in CFSE staining (Lyons 
2000; Wallace, Tario et al. 2008). Halving of cellular fluorescence intensity therefore marks 
each successive generation in a population of proliferating cells which can be easily 
identified and enumerated by flow cytometry (Mamiering, Morris et al. 2003). CFSE staining 
can be used in combination with phenotypic and intracellular cytokine stabling measurements 
to provide a detailed view of cell responsiveness.
Cytokine measurement
One of the ways T cells mediate effector mechanisms of the immune system is through the 
release of cytokmes, effector molecules that regulate many of the functions of the cells of 
innate and adaptive immunity (O'Shea, Ma et al. 2002). One of the mainstays for quantifying 
cytokines in many laboratories is the enzyme-linked nnmunosorbent assay (ELISA). The 
majority of ELISAs are a double antibody method, where a cytokine is sandwiched between 
two specific antibodies bound to two different, non-competing epitopes of the cytokme (de 
Jager and Rijkers 2006). One of the antibodies, the capture antibody is immobilised in a solid 
carrier. The second antibody is labelled either directly or mdirectly with a reporter. ELISA is 
commonly used due to its high specificity and sensitivity.
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Additionally, it is relatively cheap, require little instrumentation, is easy to automate and no 
radioactive ingredients are used. ELISA methods however generally analyse one cytokine at 
a time and therefore they are not well suited for high throughput multiplex analysis (de Jager 
and Rijkers 2006) and do not identify the cells producing the cytokines. Studies show that 
measurement of a single cytokine is often not sufficient to obtain a realistic idea of the 
complexity of biological interactions that occur at the cellular level and underestimates the 
magnitude of antigen-specific responses. Due to an increased need for more rapid, sensitive, 
robust and high throughput methods for getting a foil spectrum of cytokines from a single 
often-limited amounts of sample, fluorescent-labelled bead based assay have emerged similar 
to ELISA (Elshal and McCoy 2006).
Bead array assays may be carried out on either multi-use flow cytometry or on more 
specialised platforms such as Luminex 200 system. The two most widely used fluorescent 
bead based assays are the Cytometric bead array (BD Biosciences) and the xMAP technology 
(Luminex). In both assays, the bead set is coated with capture antibody specific for a 
particular cytokine. When a sample is combined with the antibody-coupled beads, the 
cytokine of interest is captured through a biochemical binding reaction. The amount of 
cytokine bound to each bead population is shown by staining intensity of the detection 
reagent (Bolton and Roederer 2009).
Multiple bead array methods (MBA) allow simultaneous measurements of many cytokines, 
cover a greater dynamic range (minimising the need to earned out multiple dilutions) and use 
far less specimen material. However, they do not identify the cells that elicit cytokine(s), nor 
the patterns of co-expression by cytokines at the level of an individual cell (Bolton and 
Roederer 2009).
Another commonly used method for assaying cytokine production is the intracellular 
cytokine staining (ICS) method. ICS is a method that permits simultaneous measurements of 
multiple cytokine production produced at the level of an individual cell. In the ICS method, 
cells are stimulated with desired antigens and in the presence of cytokine secretion inhibitor 
(Brefeldin A [BFA] or Monensin) for at least some of the stimulation period. The cells are 
then fixed and permeabilised to be stained intracellularly with anti-cytokine fluorescent 
antibodies. ICS offers several advantages: it allows identification of cells that elicit cytokines 
other than IFN-y (a cytokine commonly detected by ELISpot assay) expanding the range of 
antigen-responsive T cells that can be detected.
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It also allows simultaneous detennination of the phenotype of responding T cells, reducing 
the need to do multiple assays on often-limited amounts of sample.
Enzyme-linked immunospot (ELISpot)
The enzyme-linked immunospot (ELISpot) assay is an adaptation of the ELISA and is widely 
used for monitoring T cell immune responses and validating new T cell epitopes (Mashishi 
and Gray 2002; Karlsson, Martin et al. 2003). PBMCs are plated on a filter-bottom 96-well 
plate coated with anti-cytokine antibody. The cells are incubated with antigens for 18- 24 
hours to allow cytokine secretion and capture on the plate. Cells are washed off and detector 
antibody is added, followed by enzyme substrate. Cytokine-producing cells are identified as 
spots of secreted cytokine. This assay is 200 times more sensitive than ELISA, relatively 
inexpensive and non-radio active (Hickling 1998). However, the assay only quantifies a single 
function and as such may underestimate the number of antigen-specific T cells. Additionally, 
it provides no information on the cytokine-secreting cells (Bolton and Roederer 2009).
Helper function
CD4+ T cells provide essential helper function for antigen-presenting cells (e.g. dendritic 
cells, monocytes and B cells). This function is mediated partly by CD 154 (on the CD4 T cell) 
via binding to CD40 on the antigen-presenting cells (Miga, Masters et al. 2000; Straw, 
MacDonald et al. 2003). CD 154 is nearly globally expressed by T cells upon activation and 
therefore the measurement of CD 154 can serve as an global indicator of the capacity of 
CD4+ T cells to provide helper function (CD154-mediated help) and as a surrogate marker 
for antigen-responsive T cells. CD 154 synthesis is assessed by flow cytometry and can be 
coupled to multiplexed measurements of cytokine expression, providing more details on the 
function of antigen-specific CD4+ T cells. It has been shown that CD 154 marks a wide 
variety of antigen -specific CD4 T cells, including nearly all cells that express IFN-y, IL-2 
and/or TNF-a (Chattopadhyay, Yu et al. 2005). Since surface staining for CD154 is not 
lethal, it provides a means to isolate and purify viable antigen-responsive CD4+ T cells for 
further analysis.
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Table 1.8 | Assays for evaluating T cell immunity
Function Bulk Assay Single-cell Assay
Proliferation 3h -thymidine incorporation
Advantages
• relatively easy to do
Disadvantages
• Use of isotypes
• Identify proliferating cells unknown
• Functional properties unknown
CFSE labelling
Advantage
• Relatively easy to do
• Allows identification of cells
• No use of isotypes
Disadvantages
• Identifies proliferating cells only
Cytokine ELISA ELlSpot
Multiples bead assay Advantages
- Cytometric Bead Array • Sensitive, reliable and relatively
- Luminex-xMAP inexpensive
Advantages • Suitable for high through put testing
• Relatively simply & robust Disadvantages
• Suitable for high throughput • Identity of cytokine producing cells not
screening always known
Disadvantages • May underestimated the number of
• Identity of cytokine producing antigen-specific cells
cells not always known Intracellular Cytokine staining
• Patterns of coexpression of Advantages
cytokines from individual cells • Sensitive, reliable and relatively
unknown inexpensive
• Can be very expensive • Suitable for high throughput testing
T helper function CD154 expression
Advantages
• Ease to perform
• Compatible with ICS
• Allow purification of viable cells
T cell specificity MHC-peptide tetramer staining
Advantages
• Ease to perform
• Identifies all epitope specific! cells
• Simple detection by flow cytometry
• Can be performed ex vivo
• Depends on frequencies
Disadvantages
• Number of available MHC class 1 peptide 
complexes is limited
• Must know HLA background of study 
subjects
• For defined epitopes only
Cytotoxicity 51Chromium release assay CD107a expression
Disadvantages Advantages
• Use of isotopes • Ease to perform
* Effector cells identity unknown • Compatible with other assays e.g. tetramer
■ Relatively insensitive binding
• Expansion of T cells required Disadvantages
• May overestimate cytotoxicity
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MHC multimer staining
Antigen-responsive T cells can also be assessed by flow cytometric detection of cells stained 
with fluorescently labelled peptide-MHCs (tetramers), a technique known as ‘MHC tetramer 
staining’ (Altman, Moss et al. 1996). The technique allows detection of antigen-specific T 
cells based on the binding specificity of their cell surface receptors for specific MHC-peptide 
complexes. The main advantage of this assay is its ability to identify rare populations of 
antigen-specific T cells without in vitro activation. This is important for assessing cellular 
properties that correlate with antiviral and tumour immunity, for example memory phenotype 
(Wherry, Teichgraber et al. 2003; Klebanoff, Gattinoni et al. 2005; Bolton and Roederer 
2009). It can also identify T-cell epitopes important for controlling disease (Pahnowski, 
Salio et al. 2002). Flow cytometric analysis of MHC tetramer allows phenotypic analysis and 
isolation of antigen-responsive cells for further analysis (Vollers and Stern 2008). The major 
disadvantage of tetramer staining is that the tetramer can only be used on a subject with 
matching haplotype but the number of available MHC class I peptide complexes is limited 
and the development of CD4 T cell tetramers has been impeded by the folding constraints for 
recombinant class II MHC protems (Vollers and Stem 2008; Bolton and Roederer 2009). 
Furthermore, peptides to be loaded onto the MHC must be detennined for each disease.
CTL cytotoxicity assays
Cytotoxic CDS T cells (and the rarer cytotoxic CD4 T cells) play a critical role in the control 
of intracellular pathogens and malignant tumour cells. The gold standard assay for 
detennining the number of antigen-specific killer cells is the chromium (51 Cr) -release assay 
(Hickling 1998). In this assay, the ‘target cells’ are radiolabelled with sodium chromate 
(Na251Cr04) and then incubated with the test effector cell population for 4-6 hours. The 
amount of 51 Cr released into the supernatant is then quantified, to provide a measure of 
target-cell lysis. However, there are several nonradioactive flow cytometric assays that are 
often used to detect functional antigen-specific CTLs and one such assay is the flow 
cytometric assay for degranulation (Betts, Brenchley et al. 2003).
The granule-associated integral membrane proteins CD 107a and CD 107b are proteins found 
in cytotoxic granules of CTL. Upon degranulation, CD 107a and CD 107b are transiently 
transported to the cell surface.Using labelled antibodies to CD 107a and CD 107b during a 
short-term stimulation, the exocytosis of CD 107 is captured on degranulating cells.
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CD 107a staining correlates well with 51 Cr-release (Rubio, Stuge et al. 2003). Although 
degranulation is a requirement for cytotoxicity, not all degranulated cells are cytotoxic 
(Bolton and Roederer 2009). C107a/b staining has been found to be useful for determining 
the effectiveness of therapeutic vaccines (Betts, Brenchley et al. 2003; Rubio, Stuge et al. 
2003). It can also be used in combination with other assays such as tetramer binding.
1.15 Study Rationale
S. pneumoniae is an important HIV-related pathogen in sub-Saharan Africa. HIV-infected 
adults are 20 to 100 times more likely to suffer invasive pneumococcal disease (IPD) than 
age-matched HIV negative persons and are at increased risk of pneumococcal infection at all 
stages of HIV-1 infection. In Malawi, pneumococcal bloodstream infection is one of the 
common reasons for hospital admission amongst HIV-infected adults. Though some 
restoration of immunity has been reported following antiretroviral therapy (ART) coupled 
with reduction in HIV-1 related opportunistic infections and a reduction in the incidence and 
magnitude of IPD, HIV positive persons are still at a greater risk of IPD compared to 
uninfected individuals.
Questions remain as to how pneumococcal immunity changes with HIV-infection, immune 
reconstitution and vaccination. We hypothesize that immunity to S. pneumoniae (which is 
thought to rely on T and B cell memory) is considerably compromised in HIV-infected 
persons and is only partially restored by antiretroviral therapy. A better understanding of the 
influence of HIV infection on pneumococcal immunity in the adult population can inform 
design and implementation of both ant he tro viral therapy (ART) and protective vaccines.
This thesis proposes to:
1- Investigate the hnpact of HIV on naturally-acquired cellular to pneumococcal 
antigens. This will provide an in-depth mechanistic understanding of the impact of 
HIV on pneumococcal immunity.
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2- Investigate the impact of ART on naturally-acquired immunity to pneumococcal 
antigens, mapping out the kinetics and the degree of immune reconstitution. The 
kinetics and the degree of recovery of pneumococcal immunity with antiretroviral 
therapy will shed light as to what is the right time to immunise with existing and 
novel protein-based pneumococcal vaccines.
3- Provide preliminary data on the relationship between naturally-acquired immunity 
and carriage of Streptococcus pneumoniae in HIV-infected adults. The study will 
provide important insights into how S. pneumoniae carnage changes during immune 
reconstitution and will inform the likelihood of vaccine being able to achieve herd 
immunity through the eradication of pneumococcal caniage.
4- Evaluate immune responses elicited by PCV7 vaccination and to compare the 
differences in immune responses mounted by healthy HIV uninfected adults with 
HIV-mfected adults. The study seeks to determine whether HIV-1—infected patients 
are capable of mounting significant and sustained immune responses to the 
pneumococcal antigens and carrier protein after vaccination.
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2.1 Research Setting
2.1.1 Malawi
Malawi is a landlocked country in southeast Africa with a population of 13 571 000. Malawi 
is one of the poorest countries in the world with a per capita Gross National Income of 
US$160(~690 PPP international $) (Figure 2.1)(WorldVision 2008; WHO 2008a). The 
overall per capita expenditure on health is only US$14 (Inti $, 2005:- 64) and private 
financing accounts for 59% of the total expenditure. HIV seroprevalence in Malawi is around 
14% in adults (WHO 2008b), rising to 18-28% in Blantyre antenatal clinics. Highly active 
anti-retroviral therapy (HAART) became available in 2003 and as at the end of December 
2009, a total of 198 846 (73%) individuals were alive on therapy (Malawi ART Programme 
Report for Quarter 4 2009).
HIV/AIDS and lower respiratory infections were the top two causes of death in all ages in 
Malawi in 2002 (Figure 2.2a)(WHO 2006), both remain prominent causes of mortality. 
Additionally, S. pneumoniae (17.2%) and S. typhimurium (32.4%) accounted for nearly 50% 
of all cases of bacteraemia in Malawian adults in 2008 (Figure 2.2b) (Malawi-Liverpool 
Wellcome Trust Clinical Research Programme: Core Laboratory).
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Statistics:
Total population: 13,571,000
Gross national income per 
capita (PPP international $): 
690
Life expectancy at birth m/f 
(years): 49/51
Healthy life expectancy at 
birth m/f (years, 2003): 35/35
Probability of dying under five 
(perl 000 live births): 120
Probability of dying between 
15 and 60 years m/f (per 1 000 
population): 554/514
Total expenditure on health 
per capita (Inti $, 2005): 64
Total expenditure on health as 
% of GDP (2005): 12.2
Figures are for 200$ unless 
indicated.
Figure 2.1 | Malawi: Geographic location and country statistics (WorldVision 
2008; WHO 2008a)
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Figure 2.2 | Causes of death and bacteraemia in Malawi. a|Top ten causes 
of death in all ages in Malawi in 2002 (WHO 2006) b | Causes of bacteraemia 
in Malawian adults in 2008 (Malawi-Liverpool Wellcome Trust Clinical 
Research Programme: Core laboratory).
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2.1.2 The Malawi-Liverpool Wellcome Trust (MLW) Clinical Research Programme
The Malawi-Liverpool-Wellcome Trust (MLW) Clinical Research Programme 
(www.mlw.medcol.mw) is based in Blantyre, Malawi, at its Wellcome Trust-funded research 
laboratories. The laboratories were opened on 22 January 1999 and are located on the 
grounds of the Queen Elisabeth Central Hospital (QECH). The Programme is a research 
affiliate of the College of Medicine, University of Malawi and investigates health problems 
relevant to Malawi and the region. The research activities are focused under five large 
multidisciplinary research themes to develop multiple synergistic projects namely, malaria 
and brain diseases, therapeutics in the tropics, severe bacterial infection, mucosal and vaccine 
immunity and health in population (http://www.mlw.medcol.mw/research.html). The 
Programme has strong scientific and administrative links with the University of Liverpool 
and the Liveipool School of Tropical Medicine (LSTM), UK.
2.2 Study population
2.2.1 Cross-Sectional Pueumococcal immuuity-HIV infection Study in Malawian 
Adults (Chapter 4)
The aim of the study was to investigate the impact of HIV on naturally-acquired 
pneumococcal immunity. The study was conducted in compliance with relevant guidelines 
and institutional practices of LSTM, UK and the Malawi-Liverpool Wellcome Trust Clinical 
Research Programme, Blantyre, Malawi and was approved by the College of Medicine 
(University of Malawi) and LSTM research ethics committees (Protocols: P.03/08/626 and 
08.41 respectively). Recruitment followed informed consent.
Sample size
It was anticipated that >70% of control adults will have B cell and T cell immunity to the 
pneumococcus. At the time the proposal was written there were no data on cellular immune 
responses to the pneumococcus in HIV infected individuals, on which to base a sample size 
calculation. However, with 100 HIV-1 positive patients and 40 HIV-1 healthy volunteers, 
there was an 80% power to detect a difference in means of 0.53S, assuming responses are 
normally distributed with equal variability, using a two-sample t-test and a 5% significance 
level (S= standard deviation). At the end of the study, we had recraited 53 HIV-infected 
individuals and 31 HIV-uninfected persons.
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2.2.1a HIV-seronegative adults: Participants for the study were drawn from healthy 
uninfected adults visiting the voluntary counselling & testing (VCT) clinic, Queen Elisabeth 
Central Hospital, Blantyre, Malawi or recruited by advertisement in the hospital grounds. 
Persons visiting the VCT clinics for HIV testing are tested with 2 complimentary rapid tests; 
Unigold™ (Trinity biotech, Ireland) and determine (Abbot, Japan). Samples were collected 
from consenting adults who met the prescribed inclusion and exclusion criteria (see criteria 
below). To ensure that individuals in the non-HIV control group were HIV seronegative the 
samples were retested at the MLW Clinical diagnostic laboratory.
HIV testing was done using 2 complimentary rapid tests; Unigold™ (Trinity biotech, Ireland) 
and determine (Abbot, Japan) according to manufacturers’ instructions. In the case of 
disparate results, a 3rd test was done using the Bioline test kit (Standard Diagnostics Inc, 
Korea).
Inclusion criteria for HIV-seronegative adults
• Age >18 years and <5 5 years
• HIV negative
• In good health at the tune of entry into the study as determined by medical history, 
physical examination and clinical judgment of the investigator
• Not known to be pregnant
Exclusion criteria for HIV-seronegative adults
• HIV infection by serological test
• Febrile (>38.0°C axillary) or unwell
• Patients with previous or current TB
• Other immunocompromising ilhiess e.g. diabetes, cancer data
• Known or possible pregnancy
• Immunosuppressant drags e.g. steroids
• Any condition which, in the opinion of the investigator, might interfere with the 
evaluation of the study objectives
• Severe anaemia HB <8 g/dl
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2.2.1b HIV infected adults: Participants were recruited from healthy infected adults (WHO 
stage 1 [Appendix I]) attending anti-retroviral (ARV) out-patient clinics or visiting the VCT 
clinic of Queen Elisabeth Central Hospital, Blantyre, Malawi. Samples were collected from 
HIV-positive consenting adults who meet the prescribed inclusion and exclusion criteria (see 
below).
Inclusion criteria for HIV-1 infected cases
• HIV infection by serological test and clinical features of WHO stage 1 (asymptomatic 
or persistent generalized lymphadenopathy)
• Age >18 years and <5 5 year
• In good health at the time of entry into the study as determined by medical history, 
physical examination and clinical judgment of the investigator
• Not known to be pregnant
Exclusion criteria for HIV-1 infected cases
• Febrile (T >38.0°C axillary) or unwell
• Unexplained weight loss, recurrent respiratory infections, or Heipes zoster
• Patients with previous or current TB or cryptococcal disease
• Patients who are taking anth'etroviral treatment.
• Other immunocompromising illness e.g. diabetes, cancer data
• Known or possible pregnancy
• Iimnunosuppressant drugs e.g. steroids
• Any condition which, in the opinion of the investigator, might interfere with the 
evaluation of the study objectives
• Severe anaemia HB <8 g/dl
2.2.2 Longitudinal Anti-Retroviral Therapy Study in Malawian Adults (Chapter 5)
The aim of the study was to investigate the impact of antiretroviral therapy on naturally- 
acquired immunity to pneumococcal protein antigens, mapping out the kinetics and the 
degree of immune reconstitution.
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The study was conducted in compliance with relevant guidelines and institutional practices of 
LSTM, UK and the Malawi-Liverpool Wellcome Trust Clinical Research Programme, 
Blantyre and was approved by the College of Medicine (University of Malawi) and LSTM 
research ethics committees (Protocols: P.07/09/801 and 09.71 respectively). Recruitment 
followed informed consent.
Sample size
Based on our initial work on cellular immune responses to the pneumococcus in HIV infected 
adults (Chapter 4 of this thesis), we proposed that with 52 HIV-1 positive patients, there will 
be 85% power to detect a difference in means of 0.300, assuming responses are normally 
distributed with equal standard deviation of 0.5 using a two-sample t-test and 5% significance 
level. Allowing for subject tolerance of the sample correction procedures, we anticipated that 
we will recruit 60 HIV-1 positive adults 30 HIV uninfected healthy volunteers. At the time of 
writing this thesis, we had recruited 48 HIV-positive patients initiating ART and 14 healthy 
HIV-uninfected individuals.
2.2.2a HIV-seronegative adults: Participants for the study were drawn from healthy 
uninfected adults visiting the voluntary counselling & testing (VCT) Clinic, Queen Elisabeth 
Central Hospital, Blantyre, Malawi or recruited by advertisement in the hospital grounds. 
Samples (venous blood and nasopharyngeal swabs) were collected from consenting adults 
who met the prescribed inclusion and exclusion criteria (see criteria below).
Inclusion criteria for HIV-uninfected volunteers
• Age >18 years and <5 5 years
• HIV negative
• In good health at the time of entry into the study as determined by medical history, 
physical examination and clinical judgment of the investigator
• Not known to be pregnant
Exclusion criteria for HIV-uninfected volunteers
• HIV infection by serological test
• Febrile (>3 8.0° C axillary) or unwell
• Patients with previous or current TB
• Other immunocompromising illness e.g. diabetes, cancer data
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• Known or possible pregnancy
• Immunosuppressant drugs e.g. steroids
• Any condition which, in the opinion of the investigator, might interfere with the 
evaluation of the study objectives
• Severe anaemia HB <8 g/dl
2.2.2b HIV infected adults: Participants were recruited from HIV-mfected adults 
commencing on anti-retroviral therapy (ART) at the anti-retroviral out-patient clinics of 
Queen Elisabeth Central Hospital, Blantyre. Samples (venous blood and nasopharyngeal 
swabs) were collected from consenting adults who met the prescribed inclusion and exclusion 
criteria (see criteria below). Samples were collected at the tune of enrolment and the 
participants were followed up for a period of 12 months during which samples were collected 
at 3, 6 and 12 months.
Inclusion criteria for HIV-1 infected cases
• HIV infection by serological test and eligible for ART therapy (clinical stage III or 
IV, or CD4 count <250)
• Age >18 years and <55years
• In good health at the time of entry into the study as determined by medical history, 
physical examination and clinical judgment of the investigator
• Not known to be pregnant
Exclusion criteria for HIV-1 infected cases
• Febrile (T >3 8.0 ° C axillary) or unwell
• Unexplained weight loss, recurrent respiratory infections, or Herpes zoster
• TB or cryptococcal disease in the past six months
• Patients already on antiretroviral treatment.
• Other immunocompromising illness e.g. diabetes, cancer data
• Known or possible pregnancy
• Immunosuppressant drugs e.g. steroids
• Any condition which, in the opinion of the investigator, might interfere with the 
evaluation of the study objectives
• Severe anaemia HB <8 g/dl
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2.2.3 Longitudinal Pneumococcal Conjugate Vaccine Study in Malawian Adults 
(Chapter 6)
The aim of the study was to investigate inmiunological memory mounted in response to 
vaccine antigens in HIV-infected Malawian adults well established on ART. The study was 
considered and approved by the institutional review boards of the College of Medicine of 
University of Malawi (College of Medicine Research and Ethics Committee- COMREC) and 
Liveipool School of Tropical Medicine , UK (Protocols: P.05/08.665 and 08.64 respectively) 
and recruitment followed informed consent.
Sample size
The sample size was constrained by access to past PCV7 vaccine trial participants (placebo 
arm). The proposed numbers (40 HIV-infected and 15 HIV-uninfected persons) were a 
pragmatic number based on the follow-up rates of the clinical trial (137 HIV-infected and 19 
HIV uninfected subjects). With these numbers we anticipate to detect a moderate difference 
in immune response between 2 groups with 80% power. For example, if responses are 
normally distributed with standard deviation (s), then differences of 0.63s will be detectable 
for comparison of the groups(s = standard deviation). At the end of the study, we had 
recruited 32 HIV-infected individuals and 15 HIV-uninfected individuals into the study.
2.2.3a HIV-seronegative and HIV infected adults: Participants for the study were drawn from 
adults who were previously enrolled (as controls) in a double-blinded, randomized, placebo- 
controlled clinical efficacy trial of a 7-valent conjugate pneumococcal vaccine (PCV7) 
(French, Gordon et al. 2010). The recruitment was done at the Pneumovac clinic, Queen 
Elisabeth Central Hospital, Blantyre, Malawi. Samples (venous blood and nasopharyngeal 
swabs) were collected from consenting adults who met the prescribed inclusion and exclusion 
criteria (see criteria below). Samples were collected at the time of enrolment and the 
participants were folio wed-up for a period of six (6) months during which samples were 
collected at 8 weeks and 24 weeks post enrolment (Figure 2.3).
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Inclusion criteria for study participants
• Age >18 years <5 5 years
• In good health at the time of entry into the study as determined by medical history, 
physical examination and clinical judgment of the investigator
• Not known to be pregnant
• Never received PCV-7 vaccine ( but previously in PCV7 trial placebo group)
• Willing to have an HIV test if not known to be HIV positive (HIV-seronegative 
group)
Exclusion criteria for study participants
• Severe anaemia Hb <8 g/dl
• Febrile (>38.0°C axillary) or unwell
• Patients with known TB
• Other immunocompromising illness (apart from HIV) e.g. diabetes, cancer data
• Pregnant
• Immunosuppressant drugs e.g. steroids
• Any condition which, in the opinion of the investigator, might interfere with the 
evaluation of the study objectives.
Follow-up- 6 months per participant
1 2 4 6
I
•Enrollment 
•PCV7 1st dose • 
•Immunoanalysis 
•Pneumocarriage
!
PCV7 2nd dose
•Immunoanalysis
•Pneumocarriage
Months
•Immunoanalysis
•Pneumocarriage
Figure 2.3 | Vaccination Schedule and follow-up. Two doses of the 7-valent conjugate 
pneumococcal vaccine (PCV7) were given 4 weeks apart, after which patients were 
requested to come at 4 weeks and 20 weeks. Samples of venous blood and 
nasopharyngeal swabs were collected at these visits to assess vaccine-induced immunity 
and pneumococcal carriage.
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2.3 Sample Collection and Processing
2.3.1 Venous blood
Approximately 45 ml of blood was drawn by venipuncture into preservative free, sodium 
heparin vacutainer tubes (BD, UK) for PBMCs isolation and 5 ml into EDTA vacutainer 
tubes (BD) for diagnostic tests: malaria, differential haematology, CD4 T cell count and 
plasma for viral load quantification (performed by the MLW Core Laboratory).
2.3.2 Peripheral Blood Mononuclear Cells Isolation
Fresh PBMCs were isolated from whole blood by density-gradient centrifugation. Briefly, 
whole blood was diluted in BBSS (Gibco) (l:2[blood:HBSS]) and carefully layered on top 
of lymphoprep (Axis-Shield, UK) at a ratio of 1:2.5 (lymphoprep:diluted blood) in a 50 ml 
polypropylene conical tube and spun at 700 x g for 25 minutes at room temperature with the 
centrifuge break removed. After centrifugation, the erythrocytes and granulocytes settled at 
the bottom of the tube, while the mononuclear cells remained at the plasma-fico 11 interface 
appearing as an opaque layer. The mononuclear cells were carefully harvested into a clean 50 
ml polypropylene tube. The cells were washed twice with BBSS by spinning for 15 minutes 
at 650 x g. The cells were resuspended in RPMI medium (Gibco) containing 20 mM BEPES, 
2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (Sigma) and counted on a 
Bright line Baemocytometer (Bausser Scientific) using white blood cell (WBC) counting 
media [ 18ml dB^O, 380f.il 1M acetic acid and 180ul 0.4% weight/volume trypan blue (dye 
exclusion stain, Sigma)]. Trypan blue was used to assess cell viability. Cells with intact 
membranes exclude the dye while cells without intact membranes (dead cells) do not and 
hence their cytoplasm stain blue (Strober 2001).
2.3.3 T Lymphocytes Enumeration and Differential Haematology
Absolute counts of T lymphocytes were enumerated using BD FACSCount™ reagent kit 
(CD4/CD8/CD3) (BD, UK) on a BD FACSCount™ instrument (BD Biosciences). 
Differential haematology was done using COULTER® BmX Baematology Analyser 
(Beckman Coulter).
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2.3.4 Nasopharyngeal Swabs
Nasopharyngeal swabs were obtained using calcium alginate fibre tipped ultrafine alum 
applicate swab (MWE Medical Care, UK) (O'Brien and Nohynek 2003). Briefly, the swab 
was held by the shaft, and the tip of the swab inserted into the anterior nares. The medial wall 
was followed till a resistance was felt and then the swab was rotated through 180 on its axis 
to ensure good mucosal contact. The swab was carefully removed from the nose and 
immediately placed into a vial containing 3ml of skim milk-tryptone-glucose-glycerol 
(STGG) transport medium (avoiding contamination) and the handle cut. The swabs were 
transported to MLW Clinical diagnostic laboratory in a cool box within 2 hours of collection 
where the swabs were kept at room temperature overnight before processing.
2.3.5 Detection of upper respiratory carriage of Streptococcus pneumoniae
Pneumococcal carriage was evaluated usmg the World Health Organisation standard protocol 
for detecting nasopharyngeal pneumococcal colonisation (O'Brien and Nohynek 2003). The 
nasopharyngeal swab specimen in STGG media was mixed thoroughly and plated onto a 
gentamicin (2.5pg/ml) sheep blood agar (BA) for the isolation of S. pneumoniae. The plate 
was incubated at 37°C, 5% COa overnight and pneumococci identified by their morphology 
(alpha-haemolytic colonies). From the primary plate, two presumptive pneumococcal 
colonies were picked and streaked out on one half of a blood agar and an optochin 6-mm size 
disc placed in the centre of each streak. The plate was incubated at 37°C, 5% CO2 overnight. 
Susceptibility to optochin was defined as the diameter of inhibition zone and depended on the 
disc size. Zones of inhibition greater than 14 mm indicated susceptibility, 7 to 13 mm 
indicated indeterminate and less than 7 mm as resistant to optochin. Isolates that were 
susceptible to optochin were considered pneumococci and those that were resistant to 
optochin were considered to be a species other than pneumococcus (Figure 2.4).
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Figure 2.4 | Optochin sensitive pneumococci growing in Gentamicin 
blood agar (BA) plate - plate after incubation
2.3.6 Diagnosis of Malaria infection
Light microscopy of thick stained blood smears was used to exclude malaria infection (Lewis 
SM 2005). The slides were prepared at the study clinics in Queen Elisabeth Central Hospital 
and sent to MLW malaria diagnostic laboratory for staining and examination. To prepare the 
slides, a drop of blood (6 -12 ul) obtained by puncturing the ball of a finger was placed on a 
microscope slide and spread to make a 10 mm circle and the filmed was then air dried. The 
correct thickness of the film is the one through which newsprint is barely visible.
In the laboratory, the blood smears were stained using the Field’s stain method. The slides 
were dipped in acetone for 10 minutes and then in Field's Stain A (Merck, South Africa) for 
5 seconds. Next, the slides were gently rinsed in clear tap water for about 5 seconds and 
stained with Field’s Stain B (Associated Chemical Enterprises, South Africa) for 5 seconds 
and the stain removed by rinsing in clear tap water. The slides were drained vertically and left 
to dry.
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The films were examined under an Olympus Ch30 microscope (Olympus Optical Co. Ltd, 
Japan) for at least 10 minutes (100 to 200 high power fields) before the slide could be declared 
negative. In a well stained positive film the parasites are seen as deep red chromatin and pale 
blue cytoplasm.
2.4 Antigens and Antibodies
2.4.1 Pneumococcal Strains
The study used whole pneumococcal protein antigens prepared from culture supernatants of a 
standard encapsulated type 2 strain (D39), a pneumolysm deficient mutant encapsulated type 
2 (D39) isogenic pneumococci (Ply-) and a genetic toxoid derivative ofpneumolysin ( PdB).
(kindly provided by Dr James Paton, Adelaide, Australia)(Berry, Ogumiiyi et al. 1999). The 
culture supernatants were used at a final concentration of Spg/ml and PdB at a final 
concentration of 4pg/ml.
2.4.1.1 Preparation of Pneumococcal Culture Supernatants
Each pneumococcal strain (standard encapsulated type 2 (D39) and an isogenic pneumolysin- 
deficient mutant (D39Ply-) was grown on blood agar plates. A pure colony showing an a- 
haemolytic pneumococcal type growth and optochin (an antibiotic) sensitivity was seen. A 
few colonies were picked and cultured in Todd-Hewitt broth (Oxoid, UK) supplemented with 
0.5% yeast extract (THY) in 5% CO2 at 37°C to exponential phase (optical density of 0.4 to 
0.5 at 620 mn, approx 1 x 10s cfii mf1). Growth was terminated by centrifugation (300g; 30 
min) (Mureithi, Finn et al. 2009). Following centrifugation, the supernatant was collected and 
initially filtered through a 0.45 pM-pore-size sterile filter (Sigma), and then through a 0.2 
pM-pore-size sterile filter (Sigma). The filtered supernatant was concentrated (10-fold) by 
ultrafiltration using the Vivaspin 20 ml centrifugal concentrator (10 000 MWCO PES) 
(Sartorius Stedim biotech, UK). Briefly, the culture supernatant was placed in the 
concentrator chamber and centrifuged, according to manufacturer’s instructions. During 
centrifugation, solutes with low molecular weight as well as solvents pass through the 
membrane and into the filtrate vial whereas macrosolutes (i.e. concentrated sample) remains 
in the impermeable concentrate pocket.
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2.4.1.2 Determination of Colony Forming Units in pneumococcal cultures
The colony forming units in the pneumococcal cultures were determined using the Miles and 
Misra method (Heritage J 1996). Briefly, a blood agar plate was divided into six numbered 
sections (Figure 2.5). Serial dilutions of the pneumococcal culture were prepared as required 
using sterile PBS. Three drops (each 10 ul) of each dilution were deposited in three different 
areas of the corresponding section of the blood agar plate (Figure 2.5). The first and second 
dilutions were not used as they tend to have many colonies with confluence to make viable 
counts. The samples were left to dry on the plate before incubation overnight in 5% C(> at 
37°C.
The following day, colonies were counted in each section where more than 20 colonies were 
present without any confluence and divided by three. The colony forming units per ml were 
calculated as follows:
i. dilutions made x amount inoculated = ‘k plated dilution”
ii. dilution factor (inverse of plated dilution) x number of colonies = CFUs/ml (of the undiluted
culture)
"" Numbered sector
Inoculum
Figure 2.5 | Determination of pneumococcal colony forming units 
by the Miles & Misra method - plate after incubation
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2.4.1.3 Bradford Protein Assay
The protein concentrations of the pneumococcal concentrated culture supernatants 
(PneumoCCS) were determined using the Bradford protein assay (Bradford 1976; Stoscheck 
1990). The assay relies on the binding of the dye Coomassie Blue G-250 to protein. When 
Coomassie Blue G-250 dye binds to a protein, the absorbance maximum of the dye shifts 
from 465 nm (the reddish/brown form of the dye) to absorbance maximum of 610 mn (blue 
form of the dye). The difference between the two forms of the dye is greatest at 595 mn, 
hence it is the optimal wavelength to measure the blue colour from the Coomassie dye- 
protein complex.
Five standards of bovine serum albumin (BS A, Sigma-Aldrich) with protein concentrations 
ranging from 23 to 375 micrograms were used as assay standards. Where necessary the 
pneumoCCS were diluted with Todd-Hewitt broth plus 0.5% yeast extract (THY) to obtain 
protein concentrations that fall within the range of the assay standards. Bradford reagent 
(Sigma) was added to an equal volume of the aliquots of each standard and concentrated 
culture supernatants. They were then incubated at room temperature for 5 minutes and the 
Optical Density (O.D) read from the NanoDrop® ND-1000 spectrophotometer (Thermo 
Scientific) at absorbance of 595 mn. THY was used as a blank.
2.4.1.4 Discontinuous SDS-PAGE and Western Immunoblotting
Discontinuous sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western immunoblotting tests were carried out to confirm the presence of proteins of interest 
in the standard encapsulated type 2 (D39) and absence of specific proteins in the case of the 
mutant strain. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
method used to separate and/or identify proteins in a mixture according to their molecular 
size. SDS portion is a negatively charged detergent and is used to reduce proteins to then 
primary structure and coat them with uniform negative charges. When an electric field is 
applied across the gel, the proteins migrate toward the positive pole and depending on their 
size, each protein will move differently through the gel matrix: smaller proteins move 
through the matrix faster than large ones. Western immunoblotting is a method used to 
identify or detect a protein in a mixture of any number of proteins using an antibody that is 
specific to the protein while giving information about the size of the protein.
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Each pneumococcus concentrated culture supernatant (containing 20pg of protein) was 
mixed with 12.5 pi of loading buffer [ddfEO Ibpl, 0.5M Tris, pH 6.8 5 pi, 50% glycerol 8pl, 
10% SDS 8pl, 2-P mercaptoethanol 2ul and Bromophenolblue] and the volume made up to 
50ul with ddH20 in eppendorf tubes and heated for 5 minutes at 95°C to denature the proteins. 
The samples (20 pi) were then loaded onto a 12% Bio-Rad Read Precast gel (Bio-Rad, UK) 
together with a Bio-Rad pre-stained standard and ran at 180V constant voltage for 40 
minutes.
The proteins in the gel were then transferred to a nitrocellulose membrane (Bio-Rad) by 
electro blotting. Briefly, the electrophoresed gel was dipped in transfer buffer (IX 
Tris/Glycine/SDS buffer, Bio-Rad laboratories, GmbH, Munchen) and then laid flat on pre­
wetted 2 layers of filter papers supported by a fibre pad resting on the cathode. Nitrocellulose 
membrane was placed on top of the gel and overlaid with 2 filter papers and a fibre pad. Any 
ah bubbles that may have formed inside the sandwich were smoothed away with a pipette. 
The assembly was placed in the transfer cell with the black side facing the cathode (black 
electrode). The transfer was done at 0.3 A for 60 minutes.
The blots were blocked with 10ml of 3% BSA in PBST plus Sodium Azide (500ul 100X 
Sodium Azide+ 50 ml 3% BSA in PBST[PBST-250pl Tween 20 in 500ml IX PBS]) for 1 
hour at room temperature, followed by 4°C on a shaker overnight. The following day, the 
blocking solution was removed and the blot incubated with the mouse polyclonal antiserum 
to Ply (diluted 1 :4000[2ul anti-semm to Ply + 8 ml 1% BSA-PBST] gift from James Paton, 
Adelaide University, Adelaide, Australia) for 1 hour at room temperature with shaking. After 
washing with PBST, the blot were incubated with an anti-mouse IgG alkaline phosphatase 
conjugate (diluted 1 :1000[5ul conjugate + 5 ml 1% BSA-PBS]) for 1 hour at room 
temperature with gentle shaking on a rocker. The blots were washed as previously described 
and developed using an alkaline phosphatase substrate buffer containing NBT (Nitro-Blue 
Tetrazolium Chloride) and BCIP (5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt) at 
on a rocker at room temperature. NBT and BCIP yield an intense, insoluble black-purple 
precipitate when reacted with Alkaline Phosphatase. The colour reaction was stopped with 
deionised water once the protein bands had become clear.
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Recombinant pneumococcal proteins
Recombinant pneumococcal proteins CbpA, PspA, PsaA and the genetic toxoid derivative of 
pneumolysin ( PdB) were kindly provided by Dr James Paton, Adelaide, Austraha. They 
were used at a final concentration of: CbpA — 1.5 pg/ml, PspA - 2 pg/ml, PsaA - 2 pg/ml 
and PdB - 2 pg/ml.
2.4.2 Diphtheria Toxoid
Diphtheria toxoid (D52.2; Cone- 191 ILffnl; Purity- 2222 Lf/mg PN; Statens Seram Institut, 
Copenhagen, Denmark) was used at a final concentration of 2LfimL
2.4.3 Control Antigens and Mitogens
Positive antigen controls and mitogens used in this study were:
i) Mycobacterium tuberculosis purified-protein-derivative (PPD RT50; Statens Seram 
Institut, Copenhagen, Denmark) at final concentration of lOpg/ml (unless stated 
otherwise). It was used as a positive control in Malawian setting because of universal 
neonatal BCG vaccination.
ii) Inactivated influenza vaccine (Split Virion) BP (2009/2010 vaccine; Sanofi Pasteur 
MSD Limited UK). It contains 15 pg of haemagglutinin (HA) of each of the 
following strains: A/Brisbane/59/2007(HiNi) - like strain (A/Brisbane/59/2007(IVR- 
48), A/Brisbane/10/2007(H3N2) - like strain (A/Uruguay/716/2007[NYMC X-175C]), 
B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008).
iii) Phytohemaglutinin (PHA) (Sigma-Aldrich, St-Louis, MO) (an extract of red kidney 
beans that induces global activation of T cells) was also used as a positive control at 
5pg/ml (unless stated otherwise).
iv) Phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, St-Louis, MO) and 
lonomycin (ionophore produced by bacterium Streptomyces conglobatus) (Sigma- 
Aldrich, UK). PMA (lOng/ml) and lonomycin (500ug/ml) were used together to 
stimulate intracellular production of cytokines.
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v) Staphylococcus enterotoxin B (SEB) (Sigma-Aldricli) (exotoxin produced by S. 
aureus). It is a superantigen and causes non-specific activation of T cells resulting in 
polyclonal T cell activation and cytokine release (Krakauer 1999; Llewelyn and 
Cohen 2002). It was used at a final concentration of 1 jig/ml
vi) Purified Tetanus Toxoid (NIBSC,UK) was used at a final concentration of 5jig/ml
vii) Pokeweed mitogen (PWM) (1/1000; Sigma), Staphylococcus aureus Cowan (SAC) 
(1/100 000; Calbiochem, Merck Biosciences, UK) and CpG ODN-2006 (final 
concentration Ipg/ml; InvivoGen, San Diego, CA) combined were used as polyclonal 
B cell activators (Crotty, Aubert et al. 2004).
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2.4.4 Antibodies
Antibodies used in multicolour flow cytometry are summarised in Table 2.1(see below):
Table 2.1 | Staining panel for multicolour flow cytometry
Antibody Fluorochrome(s) Clone Company
CDS APC-H7 SK7 BD Pharmingen™
CDS FITC HITS 9 BD Pharmingen™
CDS PerCP SK7 BD Biosciences
CD4 APC RPA-T4 BD Pharmingen™
CD4 APC-H7 SKI BD Biosciences
CD4 BCD SFC112T4D11 Beckman Coulter
CD4 Pacific Blue™ RPA-T4 BD Pharmingen™
CD4 PerCP SK3 BD Biosciences
CDS APC-Cy7™ SKI BD Pharmingen™
CDS PerCP SKI BD Biosciences
CD25 FITC 2A3 BD Biosciences
CD28 PE CD28.2 BD Pharmingen™
CD45RA FITC L48 BD Biosclences
CD45RA PE HUGO BD Pharmingen™
CD57 APC HCD57 BioLegend
CD69 APC L78 BD Biosciences
CD69 PCS FN50 BD Pharmingen™
CD154 PE TRAP-1 BD Pharmingen™
CD197(CCR7) PE-Cy™7 3D12 BD Pharmingen™
CD197(CCR7) APC-AlexaFluor® 750 3D12 eBioscience
FoxpS PE 236A/E7 eBioscience
IFN-y FITC B27 BD Pharmingen™
IFN-v APC 25723.11 BD Fastlmmune
IgGl, K PE MOPC-21 BD Pharmingen™
IL-2 APC 5344.11 BD Biosciences
IL-2 PE MQ1-17H12 BD Pharmingen™
TNF-a Alexa Fluor® 488 MAbll BD Pharmingen™
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2.5 Lymphocytes Phenotyping
2.5.1 T Cell Phenotyping
Careful measure or characterization of different cell types of the immune system such as 
central memory and immunoregulatory cells in well-characterized patients provides useful 
information on the utility of these cell subsets in immunity, regulation of the immune 
responses and immune exhaustion. The proportions of naive and memory T cells in whole 
blood were determined by flow cytometry on the basis of surface expression of CD45RA and 
CCR7(Sallusto, Lenig et al. 1999; Harari, Vallelian et al. 2004). Regulatory T cells (Tregs) 
were identified using a phenotypic definition involving coexpression of surface CD3, CD4 
CD25 and intracellular Forkhead box p3 (Foxp3). Senescent cells were characterized by 
surface expression of either CD57 and CD28 or Programmed Death-1 (PD-1) (Brenchley, 
Karandikar et al 2003; Warrington, Vallejo et al. 2003; Day, Kaufinann et al. 2006).
Whole blood: 200 ul of peripheral blood was aliquoted into appropriately labelled 12 x 75 
nun FACS tubes (Naive/memory T cells, Tregs and Senescent T cells). The aliquots were 
stained extracellularly at room temperature in the dark for 10 minutes with a combination of 
antibodies specific to each of the three T cell phenotype groups. A combination of CD3 
PerCP, CD45RA PE, CDS APC-Cy7™, CD4 APC and CCR7 PE-Cy™7 antibodies all from 
BD Biosciences was used to stain for naive/memory T cells. CD3 PerCP, CD4 pacific blue, 
CD25 FITC antibodies (BD Biosciences) were used for Tregs, For analysis of senescent T 
cells, peripheral blood was stained with anti-CD3 FITC, anti-CD28 PE, anti-CD4 pacific 
blue, anti-CD57 APC and anti-CD8 PerCP or a combination of anti-CD4 PerCP, anti-CD38 
FITC, anti-PD-1 PE and anti-CD57 APC all antibodies ffomBD Biosciences.
After surface staining, red blood cells were lysed with 3 ml of IX BD FACS™ Lysing 
solution (BD Biosciences) for 20 minutes at room temperature in the dark. Next, the cells 
were washed with IX PBS at 700 x g for 7 minutes and the supernatant removed. The cell 
stained for naive/memory T cells and senescent T cells were resuspended in 2% 
paraformaldehyde (Sigma-Aldrich, UK) and kept at 4°C until acquisition. The cells were 
surface-stained for Tregs were fixed and permeabilised using 400pi of freshly prepared IX 
Foxp3 Fixation/Permeabilization working solution (ebiosciences, San Diego, CA) at 4°C for 
20 minutes. The cells were washed with IX Perm wash (ebiosciences, San Diego, CA) by 
centrifugation at 700 x g for 5 minutes and the supernatant removed.
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Thereafter, the cells were stained intracellularly with an anti-Foxp3 PE (ebiosciences) for 30 
minutes at 4°C and then washed with IX Penn wash and supernatant decanted. The cells 
were acquired on a Cyan™ ADP flow cytometer (Beckman Coulter), configured to detect 11 
parameters. Approximately 60 000 lymphocytes were acquired. Single stained cells and cells 
stained using all 5 fluorochromes were used to calculate the compensations. Automatic 
compensation was checked and adjusted manually where necessary. Data were analyzed 
with either Flow Jo software (TreeStar Inc, Stanford University, FlowJo Africa scheme) or 
Summit software version 4.3.2 (Beckman Coulter). Lymphocytes were gated based on 
forward scattering (FSC) and side scattering (SSC) and CD3+, CD8-, and CD4+ cells were 
considered to be CD4 T cells. These CD4 T cells were analysed for Foxp3+ CD25hlgh cells 
(Tregs), CD45RA and CCR7 expression [naive/memory cells: Tcm (CCR7+ CD45RA-), Tem 
(CD4+ CCR7-, CD45RA-) and naive CD4 T cells (CCR7+ CD45RA+)] and CD57+CD28- 
cells or PD-1+CD38+ cells (senescent cells).
PBMCs after antigen stimulation: After stimulation with appropriate antigens, the cells were 
harvested into 12 x 75 mm FACS tubes and washed with IX sterile PBS at 700 x g for 7 
minutes and the supernatant decanted. The cell pellet was resuspended in 100 ul of IX PBS 
(staining buffer) and stained with LIVE/DEAD® Fixable Violet stain (ViViD) (Invitrogen, 
UK) for dead cell discrimination at 4°C for 20 minutes. After washing as previously 
described, the cells were surface stained with CD4 ECD (Beckman Coulter), CD45RA FITC 
(BD Biosciences) and CCR7 Alexa Fluor® 750 (ebiosciences) for 15 minutes at 4°C. Next, 
the cells were washed with 2 mis of IX PBS at 700 x g for 7 minutes. The cells were 
acquired on a Cyan™ ADP flow cytometer (Beckman Coulter) and analysis performed with 
Summit software (version 4.3.2, Beckman Coulter). At least 100 000 lymphocytes were 
collected. Cell doublets were excluded using forward light scatter-area vs forward light 
scatter-height parameters. Lymphocytes stained positively for CD4 were analyzed for 
CD45RA and CCR7 expression.
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2.5.2 B Cell Phenotyping
200ul of peripheral blood was aliquoted into a 5 ml FACS tubes ( BD, UK) and stained with 
Fluorescein isothiocyanate (FITC)-, Phycoerythrin (PE)-, and Allophycocyanin (APC)- 
conjugated anti-human monoclonal antibodies binding to CD 19, CD27, surface IgD (BD 
Biosciences) respectively for 10 minutes at room temperature in the dark. The red blood cells 
were then lysed with 3 ml of IX BD FACS™ Lysing buffer for 20 minutes at room 
temperature in the dark. The cells were washed with 2 mis of IX PBS at 700 x g for 7 
minutes and the supernatant decanted. The cell pellet was resuspended in 200ul of 2% 
paraformaldehyde (Sigma-Aldrich, UK). Data were acquired using acquired the Cell Quest 
Pro software (Becton Dickinson, version 5.2.1) on a four colour FACSCalibur flow 
cytometer (Becton Dickinson) and analyzed with FlowJo software (TreeStar Inc, Stanford 
University, FlowJo Africa scheme). At least 60 000 lymphocytes were acquired. 
Lymphocytes were gated based on characteristic forward and side scatter profiles. Then the 
cells stained positively for CD 19 within the lymphocyte gate (B cells) were selected and 
analysed for CD27 and IgD expression [Marginal zone memory B cells (CD27+ IgD+-), 
Germinal centre memory B cells (CD27+ IgD-) and naive B cells (CD27- IgD+)].
2.6 CFSE Cellular Proliferation
Cellular proliferation is an essential feature of the adaptive immune response and a 5, 6- 
carboxylfluorescein diacetate succinimidyl ester (CFSE) flow cytometry based method 
provides a tool of assessing the proliferative activity of cells during an immune response. The 
assay relies on the ability of a highly fluorescent CFSE, to form highly stable bonds with 
intracellular and cell surface proteins by reaction with lysine side chains and other available 
amine groups. When cells divide, the fluorescent molecules are distributed equally to progeny 
cells resulting in a halving of the fluorescence of the daughter cells. Consequently, halving of 
the fluorescence intensity indicates each successive generation in a population of 
proliferating cells which can be easily tracked by flow cytometry (Mannering, Morris et al. 
2003; Quah, Warren et al. 2007).
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To identify dividing T lymphocytes following antigenic challenge, as previously optimised in 
this laboratory, 12 x 106 freshly isolated PBMCs were resuspended in 1 ml PBS and labelled 
with CFSE dye (final concentration 1.25 pM, Invitrogen) for 8 minutes at 37°C in the dark 
(kept free from excessive light to avoid photo bleaching). Next, 200ul of fetal bovine serum 
(Sigma-Aldrich, UK) was added to stop CFSE staining and the cells were washed at 700 x g 
for 5 minutes. The supernatant was discarded and the pellet was resuspended in 3 ml 
complete RPMI (RPMI 1640 supplemented with penicillin/streptomycin (concentration, 100 
U/mL), L-glutamine (4 mmol/L), HEPES, (10 mmol/L; Sigma-Aldrich) and 2% (vol/vol) of 
heat-mactivated human AB serum (National blood Services, Blantyre, Malawi).
The cells were recounted and complete RPMI added to make a final cell concentration of 0.8 
x 106 cells/ml. Thereafter, the cells (0.8 x 106/ml) were cultured in a 48-well flat bottom plate 
(Costar, Appleton Woods, UK) in the presence of appropriate antigens and controls for 8 
days at 37°C in a 5% CCB incubator. On day 8, the cells were harvested into labelled FACS 
tubes and washed twice with 1 ml IX PBS at 700 x g for 7 minutes. The cells were 
resuspended in 100 ul PBS (staining buffer), stained with anti-CD4-APC and anti-CD8-Percp 
(BD Biosciences), and incubated in the dark at 4°C for 15 minutes. After washing with 1 ml 
IX PBS, the cells were fixed with 200 ul of a 2% paraformaldehyde (Sigma) and acquired 
using the Cell Quest Pro software (version 5.2,1) on a four-colour flow cytometer (BD 
FACSCalibur, BD Biosciences). 60 000 events in the lymphocyte gate were acquired.
Single-stained PBMC samples were used to periodically adjust fluorescence compensation 
settings on the FACSCalibur. Data were analysed with FlowJo software (TreeStar Inc, 
Stanford University, FlowJo Africa scheme) by initially gating on lymphocytes (including 
blasts). This was followed by gating on CD4+ or CD8+ CFSElow and CFSEhlsh lymphocytes 
in a CD4+/CD8 versus CFSE plot.
2.7 Interferon-v Enzyme-linked Immunospot (ELIspot) Assay
Interferon gamma Enzyme-Linked Immunospot (ELISpot) assay provides a sensitive means 
for quantifying antigen-specific T cells at the single cell level by detection of antigen-induced 
cytokine secretion (Mashishi and Gray 2002; Karlsson, Martin et al. 2003). The cytokine 
(IFN-y) secreted by stimulated cells is captured locally by a monoclonal antibody that is 
immobilised on a nitrocellulose membrane.
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The ELISpot assay was performed in collaboration with Mi' David Mzinza as previously 
described by this laboratory (Mureithi, Finn et al. 2009). Briefly, Multiscreen HTS™ 96- 
Well Filtration plates (Millipore, Ireland) were coated with 15 ug/ml anti-human IFN-y 
mouse monoclonal antibody (1-D1K; Mabtech, Stockholm, Sweden) in sterile phosphate- 
buffered saline (PBS) for 4 hours at room temperature.
The plates were washed six times with IX sterile PBS to remove unbound coating antibody 
and blocked for 1 horn* with 200ul RPMI supplemented with 10% fetal calf serum (Sigma). 
PBMCs suspended in complete media were seeded at 0.5 x 106 cells/well in duplicate wells 
and were left unstimulated (negative control) or were stimulated with appropriate test 
antigens and controls for 18 hours at 37°C, 5% CO2. lOpg/ml PPD (Statens Serum Institute) 
and/or 0.9pg/ml influenza vaccine, split-virion inactivated (2009/2010 vaccine; Sanofi 
Pastern* MSD Limited UK) were used as positive antigen controls and 5pg/ml PHA-L 
(Sigma-Aldrich, St-Louis, MO) as a mitogenic control.
After 18 hours of incubation, the plates were washed six times with IX sterile PBS 
containing 0.05% TWEEN®20 (Sigma-Aldrich) followed by three times with sterile IX PBS. 
1 ug/mL of biotinylated anti-human IFNg antibody 7-B6-1 (MABTECH) diluted in 0.5% 
fetal calf serum plus IX PBS was added to each well and the plates were incubated for 2 hour 
at room temperature. Next the plates were washed as before and incubated with Ipg/ml of 
streptavidin-alkaline phosphatase conjugate (Mabtech) for 1 hour at room temperature. The 
plates were washed six times with IX PBS containing 0.05% TWEEN®20 followed by three 
times with sterile PBS and were developed using a chro mo genic alkaline phosphatase 
substrate kit (Bio-Rad) for 15 minutes at room temperature. The plates were washed three 
times with miming water to stop the reaction and then dried at room temperature in the dark. 
Spot forming cell numbers were counted using an ELISPOT plate reader 
(AutoImmuneDiagnostica, Vers. 4.0). The results were expressed as spot forming units 
(SFU) per million PBMC after subtraction of individual background values.
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2.8 B Cell ELISpot
The B-cell ELISpot is a highly sensitive assay that allows at the cellular level, detection and 
enumeration of the total number of antibody secreting cells in a sample as well as those 
secreting antibodies to a specific antigen. In an antigen-specific setting, the assay can be 
performed in either of two ways, one where the antigen is immobilized on the ELISpot plate 
and one where the same antigen is instead used for detection. In this work, the former was 
used.
The ELISpot was performed as previously described (Crotty, Aubert et al. 2004) with 
modifications devised by Dr Olowadamilola H. Unuigbe-Iwajomo (PhD thesis, 2011). 2 xlO6 
freshly isolated PBMCs were plated in a 24-well plate in 2ml RPMI 1640 medium 
supplemented with 10% fetal calf semm (Sigma-Aldrich, UK), 2 mM L-glutamine, 100 U/ml 
penicillin, 20 mM HEPES buffer and 100 ug/ml streptomycin (Sigma-Aldrich, UK) and 
polyclonally activated with a mix of the following: l|!g/ml phosphothiolated CpG 
oligodeoxynucleotide (CpG ODN 2006) (InvivoGen, San Diego, CA), 1/100,000 
standardized pansorbin cell (SAC) (Calbiochem, Merck Biosciences, Nottingham, UK), and 
1/1000 pokeweed mitogen extract (PWM) (Sigma). Cells were cultured for 6 days at 37°C, 
5% CG2. A negative control well was cultured with media alone. In preparation for the 
ELIspot (on day 5 of cultured PBMCs), multiscreen HTS™ 96-Well Filtration plates 
(Millipore) were coated with appropriate antigens overnight at 4°C. A pool of 10 ug/ml PPD 
(Statens Serum Institute, Copenhagen, Denmark), 5pg/ml purified tetanus toxoid (TT) 
(NIBSC,UK) and Ipg/ml influenza vaccine (2009/2010 vaccine; Sanofi Pasteur MSD 
Limited UK) was used as a positive control and PBS as a negative control.
To detect all IgG and IgA secreting cells (used as assay controls), some wells were coated 
with 2pi/ml goat anti-human IgG antibody or 1 pl/ml goat anti-human IgA antibody (Zymed, 
Invitrogen, Carlsbad, CA). Samples were run in triplicate for each test antigen. On day 6 of 
the cell culture, the coated plates were washed six times with 200ul wash buffer (IX PBS 
containing 0.05% TWEEN 20[PBST]) followed by three 3 times with IX PBS. The wells 
were blocked with RPMI-1640 plus 2% bovine serum albumin (BSA; Sigma) for 2 hours at 
37°C prior to use. Stimulated cells were harvested and washed with RPMI media and 4 x 105 
cells were added to the wells of the coated plate and incubated for 18 hours at 37°C, 5% CO?.
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After incubation overnight, the plates were washed as previously described. 1.6pg/ml 
biotinylated goat anti-human IgG detection antibody (A3188; Sigma-Aldrich, St Louis, 
Missouri) in lOOul of PBS/2% BSA was added to each well and the plate was incubated for 
18 hours at 37°C, 5% CCb. For total IgA, the wells were incubated in 0.5 pl/ml biotinylated 
goat anti-human IgA detection antibody (H140008; Caltag laboratories, Burklingame, 
CA)After incubation, the plates were washed six and 3 times with 200ul PBS-0.05% TWEEN 
20 wash buffer and PBS respectively and developed with an alkaline phosphatase substrate 
buffer containing NBT (Nitro-Blue Tetrazolium Chloride) and BCIP (5-Bromo-4-Chloro-3'- 
Indolyphosphate p-Toluidine Salt) (Bio-Rad, UK) in the dark at room temperature for 10- 
20 minutes. The development mix was washed off the plates with gently running tap water, 
and dried at room temperature. Developed spots were counted with an AID ELISpot reader 
(AID software version, Vers. 4.0).
2.9 Induction and Flow cytometric analysis of CD154 expression
Flow cytometric measurement of CD 154 provides the means of identifying CD4 T cells that 
may provide ‘help’ for the development of cell-mediated immune responses and T cell 
dependent antibody responses and identifying a wide array of antigen-responsive CD4 T cells 
(both cytokine -dependent and independent antigen-specific T cells)(Frentsch, Arbach et al. 
2005; Bolton and Roederer 2009).
Two different approaches were assessed to study CD 154 expression: conventional method 
(staining for cell-surface CD 154 after stimulation) and coculture method (addition of CD 154 
to stimulation culture) as described elsewhere (Chattopadhyay, Yu et al. 2005; Wang, Cao et 
al. 2010) . Briefly, a minimum of 1.5 xlO6 or a maximum of 2 xlO6 freshly isolated PBMCs 
(depending on availability) were plated in a 96-well plate (Costar, Appleton Woods, UK) in 
200 ul RPMI 1640 medium (Sigma-Aldrich, UK) supplemented with 2% heat inactivated AB 
human serum (National Blood Services, Blantyre, Malawi), 2 mM L-glutamine, 100 U/ml 
penicillin, 20 mM HEPES buffer and 100 ug/ml streptomycin (Sigma). For coculture method, 
an anti-CD 154-phycoerythi'in (PE) antibody was added to every well immediately before 
stimulation.
76
CHAPTER 2 SUBJECTS, MATERIALS AND METHODS
The cells (both conventional and coculture methods) were stimulated with appropriate test 
antigens and 4ug/ml PPD (Statens Seram Institute, Copenhagen, Denmark) as a positive 
antigen control and 0.5 pg/ml PHA-L ( Sigma, St Louis, MO) as a mitogenic control for 18 
hours at 37°C, 5% CO2 incubator. Negative control wells were left unstimulated in all 
experiments. No costimulatory molecules were added. After stimulation, cells were harvested 
into appropriately labelled FACS tubes and washed with 1 ml of staining buffer (IX sterile 
PBS) at 700 g for 7 minutes. For the conventional method, cells were surface-stained with 
anti-CD3 fluorescein isothiocyanate (FITC), anti-CD4 peridinin chlorophyll protein (PerCP), 
anti-CD69 allophycocyanm (APC) and anti-CD 154 phycoerythrin (PE) all from BD 
Biosciences for 15 minutes at 4°C in the dark.
For the coculture method, the cells were surface-stained with anti-CD3 fluorescein 
isothiocyanate (FITC), anti- CD4 peridinin chlorophyll protein (PerCP), anti-CD69 
allophycocyanin (APC). After staining, the cells were washed with 1ml IX sterile PBS at 700 
g for 7 minutes and resuspended in 2% paraformaldehyde. The cells were acquhed using the 
Cell Quest Pro software (version 5.2.1) on a four-colour flow cytometer (BD FACSCatibur, 
BD Biosciences). Single-stained samples were used to periodically check the settings on the 
FACSCalibur. Data were analyzed with FlowJo software (TreeStar Inc, Stanford University, 
FlowJo Africa scheme) by initially gating on lymphocytes followed by CD3 then CD4+ cells. 
CD 154 expression was examined on CD69+ CD4+ T cells.
2.10 CD4 ligation and CD154 expression
2 xlO6 freshly isolated PBMCs were plated in a 96-well plate in 200 ul IX sterile PBS. An 
anti-CD4 domain 1 antibody (final concentration lOug/ml [clone QS4120; Ancell, Bayport, 
MN]) was added to appropriate wells and the plate was incubated for Ih at 4°C as described 
elsewhere (Zhang, Fichtenbaum et al. 2004; Rutjens, Vermeulen et al. 2008). Thereafter, the 
cells were washed twice with 1ml sterile IX PBS at 700 g for 7 minutes and resuspended in 
RPMI 1640 medium supplemented with 2% heat inactivated AB human serum (National 
Blood Services, Blantyre, Malawi), 2 mM L-glutamine, 100 U/ml penicillin, 20 mM HEPES 
buffer and 100 ug/ml streptomycin (Sigma). An anti-CD 154-phycoerytlirin antibody and anti- 
CD28/CD49d costimulatory antibodies (Ipg/ml; BD Biosciences) were introduced into the 
cell culture immediately before stimulation.
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Appropriate antigens were then added to the cells and the cultures were incubated for 18 
hours at 37°C, 5% CCb. SEB (final concentration Ipg/ml) was used as a positive control and 
No antigen (costimulantory antibodies only) was used as negative control. Next, the cells 
were harvest in FACS tubes and after washing with IX sterile PBS, the cells were surface 
stained for 15 minutes at 4°C with anti-CD3 fluorescein isothiocyanate (FITC), anti- CDS 
peridinin chlorophyll protein (PerCP), anti-CD69 allophycocyanin (APC) all from BD 
Biosciences. The cells were washed with 1ml IX sterile PBS at 700 g for 7 minutes. Date 
were acquired on FACSCalibur flow cytometer (BD Biosciences) and analyzed with FlowJo 
software (TreeStar Inc, Stanford University, FlowJo Africa scheme).
2.11 Intracellular Cytokine Staining for IFN-y, IL-2 and TNF-a
Intracellular Cytokine Staining (ICS) assay (using flow cytometry) allows for detection of 
many different cytokines in T cells simultaneously following antigen challenge. The cells are 
stimulated with desired antigens in the presence of cytokine secretion inhibitor (Brefeldin A 
[BFA] or Monensin) and then fixed and permeabilised to be stained intracellularly with anti­
cytokine fluorescent antibodies.
Two different methods were used to assess expression of various cytokines: a Brefeldin A 
based method to assess coexpression of IFN-y, TNF-a and IL-2 and a Monensin based 
CD154 coculture method to assess coexpression of CD154 and IFN-y and IL-2 
(Chattopadhyay, Yu et al. 2006; Lamoreaux, Roederer et al. 2006). Briefly, a minimum of 1.5 
xlO6 or a maximum of 2 xlO6 freshly isolated PBMCs (depending on availability) were 
plated in a 96-well plate in 200 pi RPMI 1640 medium supplemented with 2% heat 
inactivated AB human serum (National Blood Services, Blantyre, Malawi), 2 mM L- 
glutamine, 100 U/ml penicillin, 20 mM HEPES buffer and 100 pg/ml streptomycin (Sigma). 
For CD154 co culture method, an anti-CD 15 4-phycoerythr in antibody was added to every 
well immediately before stimulation.
The cells were stimulated with appropriate test antigens and lOug/ml PPD (Statens Serum 
Institute, Copenhagen, Denmark) and/or influenza vaccine, split-virion inactivated 
(2009/2010 vaccine; Sanofi Pasteur MSD Limited UK) as a positive antigen control and 
PMA (lOng/ml) plus ionomycin (lpg/mI)(Sigma, St Louis, MO) and incubated at 37°C in the 
presence of 5% C02.
78
CHAPTER 2 SUBJECTS, MATERIALS AND METHODS
Brefeldin A (10 jig per ml) or Monensin (2 pM final concentration) all fi‘om BD Biosciences 
was added after 2 h of incubation and the plate was incubated for an additional 16 hr at 370C> 
5% CO2. Negative control wells were left unstimulated in all experiments. No costimulatory 
molecules were added. After stimulation, cells were harvested into appropriately labelled 
FACS tubes and washed with 1 ml of staining buffer (IX sterile PBS) at 700 g for 7 minutes 
and stained with ViViD (Invitrogen, UK) for dead cell discrimination (Figure 2.6) at 4°C for 
20 minutes. After washing as previously described, the cells were stained at 4°C for 15 
minutes with surface marker antibodies (BFA based method: CD4 APC-H7and CDS PerCP 
all from BD Biosciences; Co-culture method: CD4 BCD [Beckman Coulter], CD3 APC-H7, 
CD69 PECy5™ all from BD Biosciences).
After staining, the cells were washed with 1ml IX sterile PBS at 700 g for 7 minutes and 
permeabilised using 250 ml Cytofix/Cytoperm solution (BD Biosciences) for 20 minutes at 
4°C. After washing twice with BD wash buffer, the cells were incubated for 30 min at 4°C 
with a cocktail of anti-human monoclonal antibodies the antibodies for intracellular cytokine 
staining (BFA based method: IFN-y APC, TNF-a Alexa Fluor® 488 and IL-2 PE (BD 
Biosciences); Coculture method: IFN-y FITC and IL-2 APC all from BD Biosciences).
Cells were washed again, resuspended in 2% paraformaldehyde. The cells were acquired on 
a Cyan™ ADP flow cytometer (Beckman Coulter), configured to detect 11 parameters. At 
least 100 000 lymphocytes were acquired. Cell doublets were excluded using forward light 
scatter-area vs forward light scatter-height parameters and dead cells discriminated by ViViD 
(Figure 2.6). Single stamed cells and cells stamed with all the fluorochromes were used to 
calculate compensations. Automatic compensation was checked and adjusted manually where 
necessary. Data were analyzed with FlowJo software (TreeStar Inc, Stanford University, 
FlowJo Africa scheme) or Summit 4.3.2 software (Beckman Coulter). Unstimulated cells 
were used to set cut-off gates for cytokines.
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Figure 2.6 | Dead cell discrimination using Violet Viability dye (ViViD;LIVE/DEAD 
Fixable dead cell stain kit, Invitrogen). To exclude dead cells, PBMCs that have been 
stained with ViViD, were gated based on forward scatter height vs. Forward scatter area 
to identify singlets (single cells). Then lymphocytes were gated based on characteristic 
light-scatter properties. Live lymphocytes were gated based on forward scatter area 
without staining for the dead cell ViVID.
2.12 Multiplex analysis of cell culture supernatant cytokine concentration
Cytokines (IFN-y, TNF-a, IL-10 and IL-2) in cell culture supernatant were quantified using a 
Bio-Plex cytokine assay (Bio-Rad Laboratories, Inc. Hercules, CA, USA; Human Grp 1 Plex 
panel [171-A11100]) according to the manufacturer's instructions in collaboration with Dr 
Sarah Glennie. Bio-Plex cytokine assay is a multiplex bead-based assay for measuring the 
levels of multiple cytokines in a single well of a 96 well microplate using as little as 50 ul 
aliquot of cell culture supernatant. The assay is designed in a capture sandwich immunoassay 
format. Each colour-coded 5.6 pm polystyrene bead set is coated with capture antibody 
specific for a particular cytokine. When a sample is combined with the antibody-coupled 
beads, the cytokine of interest is captured through a biochemical binding reaction. Captured 
cytokine is detected using a biotinylated detection antibody and streptavidin-phycoerythrin 
(S-PE).
Assay results are detected using a flow-cytometry based dual laser analyzer, the Luminex 200 
(Bio-Rad, Hercules, CA). One laser is bead-specific and determines which cytokine is being 
detected. The other laser determines the magnitude of PE-derived signal, which is in direct 
proportion to the amount of cytokine bound [Bio-Plex1 M Cytokine Instruction Manual, BIO­
RAD].
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Prior to the assay, the premixed lyophilized cytokine standard was reconstituted with 500 pi 
of standard diluents (stock concentration 32 000 pg/ml) and incubated on ice for 30 minutes. 
The standard stock was serially diluted with the standard diluent to generate 8 points for the 
cytokine standard curve,
A 96 -well sterile filter plate (supplied with the assay kit) was pre-wetted with 100 p 1/well of 
assay buffer and removed the buffer by vacuum filtration (Bio-Rad Auram™ Vacuum 
Manifold). 50 pi of premixed multiplex antibody-coupled beads was pipetted into each well 
plate (5,000 beads per well per cytokine) followed by vacuum filtration. The plate was 
washed twice with lOOul/well of Bio-Plex wash buffer using vacuum filtration. 50 pi of 
premixed standards or cell culture supernatant samples were added to each well. Blank 
control wells contamed standard diluents. The plates was sealed with a plate sealing tape, 
covered with aluminium foil and shaken for 30 seconds at 1 100 rpm on a microplate 
shaker and incubated at reduced speed of 300 ipm for 30 minutes at room temperature.
After incubation, the buffer was removed by vacuum filtration and the plate washed 3 times 
as above. 25pl of IX Bio-Plex detection antibody working solution (detector antibody 
conjugated to biotin) was added to each well and incubated for 30min with shaking (as 
described above). The plate was washed three times with lOOpl/well with wash buffer using 
the vacuum fdtration. This was followed by an incubation of 10 minutes with 50pl/well of IX 
streptavidin Phycoerythrin (Streptavidin-PE) on a shaker as previously described at room 
temperature. After incubation, the plates were washed 3 times as previously described and the 
beads were resuspended in 125 pi of Bio-Plex assay buffer. The plate was read on the 
Luminex® 200™ analyzer (Bio-Rad Laboratories Inc, Hercules, CA). Raw data (mean 
fluorescence intensity, MFI) were analyzed using Bio-Plex Manager™ software (v 3.0). 
Unknown cytokine concentrations were calculated using a standard curve derived from 
recombinant cytokine standard supplied with the kit taking into account the supernatant 
dilution. All incubation steps were performed at room temperature and in the dark to protect 
the beads from light.
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2.13 Statistical Analysis
Analysis and graphical presentation were done using Graphpad Prism Version 5 (Graphpad 
Software). Non-normally distributed data were analysed using non-parametric tests; Mann- 
Whitney U test for non-paired data and Wilcoxon test for paired data. Results are given as 
means with standard deviations (for parametric tests) while non-parametrically distributed 
data are quoted as medians with ranges. Differences after comparisons were considered 
statistically significant if they yielded P values less than 0.05.
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3.1 Introduction
Epidemiological and experimental evidence suggests naturally-acquired antibodies to 
capsular and non-capsular components of S. pneumoniae (Rapola, Kilpi et al. 2001; Simell, 
Korkeila et al 2001; Goldblatt, Hussain et al. 2005; Weinberger, Dagan et al. 2008), and 
CD4+ T cell responses to pneumococcal proteins, may mediate protection against 
pneumococcal disease (Zhang, Bagrade et al. 2007; Lu, Gross et al. 2008; Mureithi, Finn et 
al. 2009). HIV- infected persons however have a dramatically increased risk of infections 
with pathogens such as Streptococccus pneumoniae, Mycobacterium tuberculosis or 
Pneumocystis jirovecii. For the pneumococcus, HIV infection confers a 50-fold increased risk 
of invasive pneumococcal disease (Dworkin, Ward et al. 2001). Dramatic increased 
susceptibility to pneumococcal disease suggests defects in both T and B cell immunity to the 
pneumococcus are likely.
To better understand how T cell immunity to S. pneumoniae may be compromised in HIV- 
infected adults, it was first essential to identify parameters and develop or optimise assays to 
investigate underlying mechanisms. Assays that are usually used to assess immunity were 
discussed in Chapter 1 Introduction (section 1.14). A number of assays were used in this 
research project. These are: CFSE proliferation, IFN-y ELISpot, IgG B cell ELISpot, 
Intracellular cytokine staining, Luminex cytokine analysis and CD154 expression assays. 
Except for the CD 154 expression assay, the assays mentioned above were developed and 
optimised by others in this laboratory. CFSE cellular proliferation, IFN-y ELISpot and B 
ELISpot assays were optimised or adapted for Malawi setting by Dr Sarah Glennie, Dr David 
Miles and Dr Oluwadamilola H. Unuigbe respectively. This chapter therefore describes the 
optimisation and adaptation of a novel assay for assessing surface expression of CD 154 on 
CD4+ T cells (Chattopadhyay, Yu et al. 2005).
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Flow cytometric measurement of surface CD 154
Direct assessment of T helper cell responses specific by CD 154 (a costimulatory cell surface 
protein that is expressed by activated CD4+ T cells) expression was first described 
independently by Frentsch M et aL (Frentsch, Arbach et al. 2005) and Chattopadhyay PK et 
al (Chattopadhyay, Yu et al. 2005). CD 154 is transiently expressed on activated CD4+ T 
cells as it is rapidly internalised (and degraded) after surface expression (Roy, Waldschmidt 
et al. 1993; Yellin, Sippel et al. 1994). The studies that have therefore relied on conventional 
staining methods for detecting surface CD 154 may overlook the dynamic nature of CD 154 
expression in the presence of CD40+ cells. Chattopadhyay PK et al however, described a co- 
culture method (where fluorescently labelled antibodies are added to stimulation culture) 
which allows immediate tagging of CD 154 upon expression on the surface; subsequent 
internalisation of CD 154 retains the conjugate rendering the cell fluorescent. The method was 
shown to identify a larger fraction of CD 154 expressing CD4+ T cells compared to either the 
intracellular or the conventional surface staining method. Additionally, the assay is said to be 
compatible with intracellular cytokine staining allowing combined quantitative and 
quahtative ex vivo assessment of CD4+ T cell innnunity for a defined antigen.
Recently, the co-culture assay was applied in a pulmonary tuberculosis study to understand 
the production and dynamics of memory T cell subsets during tuberculosis. (Wang, Cao et al. 
2010). This assay however has not been applied to study the human response to 
pneumococcal antigens or for longer in vitro stimulation tune without using co stimulatory 
antibodies. Previous studies have reported impairment of CD 154 expression in CD4+ T cells 
of HIV-infected individuals in response to polyclonal stimuli (Zhang, Fichtenbaum et al. 
2004; Zhang, Lifson et al. 2006; Subauste, Subauste et al. 2007) and some pathogens 
(Subauste, Wessendarp et al. 2004). In order to assess the effect of HIV on the ability of 
pneumococcal-specific T cells to provide CD154-mediated help, the co-culture method for 
detecting surface-expressed CD 154 molecues, was opthnised for use in an African setting.
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3.1.1 Rationale and Aims
This part of the research project aimed to develop, optimise and adapt appropriate assays to 
assess T helper cell responses. The main objective was to assess and compare different 
methods of assessing pathogen-specific induction of cell-surface CD154 in CD4+ T cells 
with the goal of identifying an assay that can be optimised and adapted for use in an African 
setting. Other objectives were to: i) batch test AB human sera to be used in cell culture 
assays in this research project; ii) characterise pneumococcal concentrated culture supernatant 
and iii) determine the tune course of CD 154 expression on CD4+ T cells following 
stimulation with pneumococcal protein antigens.
3.2 Materials and Methods
Samples collection and Processing (section 2.3)
• Venous Blood and PBMCs Isolation (sections 2.3.1 and 2.3.2)
Antigens used (section 2.4)
• Pneumococcal strains (section 2.4.1 )
• Preparation of pneumococcal culture supernatants (section 2.4,1.1.)
• Detennination of Colony Forming Units per ml (section 2.4.1.2)
• Bradford Protein Assay (section 2.4.1.3)
• Discontinuous SDS-PAGE and Western immunoblotting (section 
2.4.1.4)
Control antigen and Mitogen used (section 2.4.3)
• M. tuberculosis purified-protein-derivative (PPD) (section 2.4.3i)
• PMA and lonomycin (section 2.4.3ii)
Human AB sera batch testing using CFSE proliferation assay (section 2.6)
Induction and Flow cytometric analysis of CD154 expression (section 2.9)
Intracellular Cytokine Staining (IFN-y and IL-17) (section 2.11)
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3.3 Results
3.3.1 Human AB Sera batch testing
It is a well-established practice in this laboratory that where possible all cell culture assays 
should be carried out in media supplemented with AB human serum instead of foetal calf 
serum (PCS). In fact, previous work done by this group on T cell memory response to 
pneumococcal protein antigens in an area of high pneumococcal carnage and disease used 
AB human serum (Mureithi, Finn et al. 2009). Our experience with PCS is that it tends to 
give high background especially in assays involving long term culture. Therefore, all cell 
culture assays (except for T and B cell ELISpot assays) used in this project were carried out 
in media supplemented with heat inactivated AB human serum.
Three batches of AB human serum were donated to this research project by the National 
Blood Services of Malawi. The sera were screened by the National Blood Services for 
infectious agent such as HIV and hepatitis before they were given to the research project. 
Serum is an extremely complex mixture of plasma proteins, growth factors and hormones 
hence it is commonly used as a supplement in cell culture. The components of serum may 
vary according to origin, nutritive conditions and processing and because of these natural 
variations the thine sera obtained from the National Blood Services were batch tested using 
CFSE (Invitrogen) proliferation assay. PBMCs isolated from blood collected from willing 
and consenting HIV negative adults from MLW clinical research programme, were labelled 
with 1.25 pM CFSE and stimulated with tuberculin 10 pg/ml PPD (Statens Serum Institut, 
Copenhagen, Denmark) or left unstimulated for 8 days in media supplemented with AB 
human serum and CD4+ T cells analysed for proliferation by flow cytometry. M. tuberculosis 
PPD was used as stimulant because it was more likely to give a response in Malawian setting 
because of universal neonatal BCG vaccination.
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CD4+ T cells proliferated in all the three heat inactivated AB human sera (2%) in response to 
PPD (Figure 3.1). The cells proliferated slightly more in human serum S216 (12.18%, 
background removed) compared to sera S4383 and S5210 which recorded 11.17% and 
7.44%, respectively. Cells however proliferated slightly more when the cell culture was 
supplemented with 10% AB human serum (14.34%) (Figure 3.2). Since the difference 
between 2% AB human serum and 10% human serum was not substantial subsequent cell 
culture assays were carried out using 2% pooled supportive AB human sera.
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Figure 3.1 | CD4+ T cells proliferated in all AB human sera (2%). PBMCs were 
were labelled with 1.25 pM CFSE and stimulated with lOug/ml purified protein 
derivative (PPD) or left unstimulated for 8 days. The cells were then stained with anti- 
CD4 monoclonal antibody and proliferation of CD4+T cells measured by flow 
cytometry. Cells in the upper left quadrant in each plot are indicative of proliferation. 
CD4+ T cells proliferated in all the three sera: 5216-12.18%, 54383-11.17% and
55210- 7.44% (background subtracted). Results representative of three separate 
experiments.
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Figure 3.2 | CD4+ T cells proliferated in AB human sera; 2% 
versus 10% AB human serum. PBMCs were labelled with 1.25 uM 
CFSE and left unstimulated or stimulated with lOug/ml purified 
protein derivative (PPD) for 8 days. The cells were stained with anti- 
CD4 monoclonal antibody and proliferation of CD4+T cells measured 
by flow cytometry. Cells proliferated slightly more in cell culture 
supplemented with 10% AB human serum (14.34%) compared with 
2% AB human serum (11.17%), background subtracted. Results 
representative of three separate experiments.
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3.3.2 Optimization of CD154 (CD40L) detection
3.3.2.1 Detection of surface CD154 expression by CD4+ T cells by conventional and 
co-culture methods.
Two different methods (the conventional method [staining for cell-surface CD154 after 
stimulation] and the co-culture method were used to detect membrane CD 154 by flow 
cytometry (Chattopadhyay, Yu et al. 2005; Koguchi, Thauland et al. 2007). PBMCs from 
HIV negative subjects were stimulated with 10 ng/ml PMA (Sigma-Aldrich) plus Ipg/ml 
ionomycin (Sigma-Aldrich) or left unstimulated for 6 hours. For the co-culture method, a 
fluorescent antibody to CD154 was added before stimulation (Figure 3.3). After stimulation, 
the cells from the conventional method were stained with antibodies to CD3 (lymphocytes), 
CD4 and CD 154 while the cells from the co-culture method were stained with antibodies to 
CD3 and CD4 (Figure 3.3). The cells were then analysed by flow cytometry and the level of 
CD 154 staining was assessed on gated CD4+ T cells.
PBMCs Isolation
Conventional method
PBMCs+ Stimulus (PMA + Ionomycin ) 
Incubate for 6 hours
Co-culture method
PBMCs + Stimulus (PMA + Ionomycin) 
+ anti-CD!S4 antibody
Incubate for 6 hours
Harvest stimulated cells
, cm Stain with
and CD1M antibodies CD4 antibodies
u
Acquisition 
(Flow cytometer)
Figure 3.3 | Schematic summary of the methods used to detect membrane CD154 on 
CD4+T cells.
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As expected, the unstimulated cells from both methods did not express CD154 (Figure 3.4). 
The co-culture method identified a larger fraction of CD4+ T cells responding to PMA plus 
ionomycin stimulation (81.35% of CD4+ cells were CD154+, background subtracted) 
compared with the conventional surface staining method (64.94% of CD4+ T cells were 
CD154+).
+
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Conventional method
Coculture method
* CD154+
Figure 3.4 | Co-culture method identifies a larger fraction responding CD4+ T 
cells. PBMCs were stimulated with 10 ng/ml PMA plus lug/ml ionomycin or left 
unstimulated for 6 hours. For the co-culture method, an antibody to CD154 was 
included in the culture during stimulation. After stimulation, the cells for the 
conventional method were surface-stained with antibodies to CD3, CD4 and CD154 
while the cells for the co-culture method were surface-stained with antibodies to CDS 
and CD4. The level of CD154 staining was assessed on CD4+ T cells. The numbers 
inside the gates represent the percentage of CD4 T cells expressing CD154. The plots 
are representative of three separate experiments.
90
CHAPTER 3 ASSAY OPTIMISATION AND ADAPTATION
3.3.2.2 No uptake of the isotypic antibody in the co-culture method
CD 154 expression is highly transient. CD 154 is rapidly internalized after surface expression 
and so is the CD 154-antibody complexes formed during stimulation in co-culture method. It 
was important to confirm, however that there is no uptake of the unbound antibody in the co­
culture method. This was addressed by incubating cells with an isotopic antibody (PE- 
labelled anti-IgG mAb). The isotopic antibody was used at the same concentration as the 
antibody to CD 154 (0.25ug/test). No PE staining was detected in the stimulated cells 
incubated with the isotypic antibody (Figure 3.5) indicating that there was no nonspecific 
uptake of the isotypic antibody. Thus, in the co-culture method it is only the CD 154-antibody 
complex that is internalised. The co-culture method therefore was chosen as the method to 
use in subsequent experiments.
Figure 3.51 No nonspecific uptake of isotypic PE antibody in coculture method.
PBMCs were stimulated or left unstimulated with lOng/ml PMA plus lug/ml ionomycin 
for 6 hours. An equal concentration of anti-CD154 monoclonal antibody (mAb) and PE- 
labelled anti-IgG mAb (0.25ug/test-lgGl; k isotype control, BD Pharmingen) was included 
in the culture during stimulation. The plots show the levels of PE staining gated on CD4+ T 
cells. The plots are representative of three separate experiments.
91
CHAPTER 3 ASSAY OPTIMISATION AND ADAPTATION
3.3.2.3 Monensin failed to enhance detection of CD4+CD154+ T cells
It has been reported that CD 154-antibody complexes (in co-culture method) are unstable 
(unless monensin is added), leading to detection of fewer antigen responsive cells 
(Chattopadhyay, Yu et al. 2006). Therefore, we evaluated whether the presence of monensin 
in the culture during stimulation will lead to identification of more CD4+ CD 154+ T cells 
compared to when monensin is not included in the culture (Fig. 3.6). Contrary to previous 
reports, adding monensin to the cell culture did not lead to detection of more CD 154 
expressing CD4+ T cells: 81.29% CD4+ CD 154+ T cells (background subtracted) were 
detected in the absence of monensin and 80.85% CD4+CD154+ T cells were detected when 
the cells were incubated with monensin.
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Unstimulated PMA plus lonomycin
Coculture method
Coculture plus 
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---------------------------------------------------------------- ► CD154+
Figure 3.61 Monensin failed to stabilise CD154-antibody complexes. PBMCs 
were stimulated with PMA plus ionomycin or left unstimulated for 6 hours. An anti- 
CD154 monoclonal antibody (mAb) and monesin (2 pM) were included in the 
culture during stimulation. The levels of CD154 staining was gated on CD4+ T cells. 
The plot show the levels of CD154 staining gated on CD4+ T cells. The plots are 
representative of 3 separate experiments.
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3.3.2.4 Monensin inhibited extracellular secretion of IFN-y and IL-17
Monensin is usually used in intracellular cytokine staining assays to interrupt the maturation 
of cytokine processing and thus inhibit their extracellular secretion (Betts, Brenchley et al. 
2003; Lamoreaux, Roederer et al. 2006). This leads to accumulation of cytokine in the cell, 
therefore aiding antibody detection. Since including monensin in the cell culture did not 
enhance the detection of CD 154 expressing CD4+ T cells, we evaluated the ability of the 
monensin used in the previous experiment (section 3.3.2.3) to inhibit extracellular secretion 
of cytokines IFN-y and IL-17 following stimulation with PMA plus ionomycin for 6 hrs. 
Brefeldin A (BFA [10 pg/ml] cytokine secretion inhibitor) was used as a control. The 
secretion inhibitors were added after 1 hour of stimulation. There was inhibition of 
extracellular secretion of cytokines (Figure 3.7) in the presence of monensin as well as in the 
presence of BFA.
Unstim PMA+lon +MonensinPMA + Ion + BFA
19.34
* IL-17
Figure 3.7| Monension inhibited extracellular secretion of IFN-y and IL-17.
PBMCs were stimulated with PMA plus ionomycin or left unstimulated for 6 hours in the 
presence or abscence of secretion inhibitors (brefeldin A (10 pg/ml or monensin [2 uM]). 
Secretion inhibitors were added after 1 hour of stimulation. Intracellular IFN-y and IL-17 
expression was analysed among CD4+ T cells. In presence of BFA, 20.24% CD4+ T cells 
expressing IFN-y only were detected while in presence of monension 19.26% CD4+ T 
cells expressing IFN-y only expressing CD4+ T cells were detected. The plots are 
representative of 3 separate experiments.
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3.3.3 Characterisation of the pneumococcal concentrated culture supernatant
This project made use of pneumococcal culture supernatants prepared from a standard 
encapsulated type 2 (D39) wild type (WT), and an isogenic Ply-deficient mutant strain 
(Chapter 2: Materials and methods, section 2.4.1). Each strain was cultured in 5% CO2 at 
37°C to exponential phase (optical density of ~0.4 at 620nm; ~ 108 cfu/ml) (Figure 3.8). The 
culture supernatants were harvested by centrifugation (3000 x g for 30 minutes), filtered and 
the protein concentration of the pneumococcal concentrated culture supernatants 
(pneumoCCS) determined by the Bradford protein assay as described in Chapter 2 materials 
and methods (section 2.4.1).
Discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western 
immunoblotting were used to demonstrate that the pneumolysin mutant supernatant lacked 
pneumolysin. The western immunoblot was visualised using mouse anti-sera to pneumolysin 
(Ply). The Western immunoblot confirmed that the pneumococcal culture supernatants 
derived from a standard encapsulated type 2 (D39) S. pneumoniae strain contained Ply but 
Ply was missing in the mutant culture supernatant (Figure 3.9). The antiserum to Ply reacted 
with the wild type at -53 kDa (Figure 3.9, lane B). A cross-reacting band is also visible at 
-70 kDa on both blots.
Work done in this laboratory by Dr Marianne Mureithi (as part of her PhD, 2010) showed 
that heat-modification (56°C for 30 minutes) of pneumococcal concentrated culture 
supernatant enhances the magnitude of the pneumococcal T cell responses probably because 
at 56°C heat denatures toxic pneumococcal proteins (and in principle without affecting their 
immunogenicity) such as pneumolysin which was observed to be toxic to T cells in its native 
form but elicited a robust T cell response after heat-modification. Therefore, the 
pneumococcal concentrated culture supernatants were heat-treated at 56°C for 30 min before 
use.
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Figure 3.8(Growth profile of encapsulated type 2 (D39) wild type (WT) and an 
isogenic pneumolysin (Ply) -deficient pneumococcal mutant strain. Pneumococcal 
strains were cultured in Todd-Hewitt broth supplemented with 5% yeast extract in 5% C02 
at 37°C. a,c|Growth curves of encapsulated type 2 (D39) wild type and an isogenic 
pneumolysin (Ply) - deficient mutant strain respectively (at optical density of 620nm 
[OD620]])- b,d|Growth curves of encapsulated type 2 (D39) wild type and an isogenic 
pneumolysin (Ply) - deficient mutant strain respectively, based on colony-forming units 
(cfu/ml). -> indicates that growth termination was at the exponential phase of ~ 0.4 at 620 
nm; ~ 108 cfu/ml
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Figure 3.91 Western Immunoblot. Western immunoblot analysis of the concentrated 
culture supernatant of S. pneumoniae and visualised using mouse anti-serum to 
pneumolysin (Ply): Lane A| The molecular mass marker. Lane B| Pneumococcal culture 
supernatant derived from a standard encapsulated type 2 (D39[WT]) Lane C| 
Pneumococcal culture supernatant derived from an isogenic pneumolysin-deficient mutant 
(Ply-). 30 |il/20pg of protein was loaded into each well.
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3.3.4 Time course of pneumococcal antigen induced CD154 expression
Having prepared and characterised pneumococcal concentrated culture supernatant, we 
investigated the kinetics of CD 154 expression following stimulation with pneumococcal 
protein antigens using the co-culture method to determine the optimal time point for detection 
of CD 154. Work done in this laboratory by Dr Marianne Mureithi ( as part of her PhD work, 
2010) showed that T cell responses (as measured by Thymidine incorporation proliferation 
assay), observed following stimulation with pneumococcal concentrated supernatant were 
associated to pneumococcal antigens present in the culture supernatant, and not to the culture 
Todd-Hewitt broth supplemented with 0.5% yeast extract (THY). No T cell responses were 
detected in response to THY-broth above background (RPMI 1640 medium supplemented 
with penicillin, L-glutamine and heat-inactivated human AB serum). Therefore, unstimulated 
cells in this project, were cultured in RPMI 1640 medium supplemented with penicillin, L- 
glutamine and heat-inactivated human AB serum. This approach has been used extensively 
in the work published by this group (Zhang, Bernatoniene et al. 2006; Mureithi, Finn et al. 
2009).
To determine the optimal time point for detection of CD 154, PBMCs were incubated with a 
fluorescently conjugated CD 154 specific antibody and stimulated with 8pg/ml pneumoCCS 
(D39WT), or left unstimulated at 37°C, 5% CO2. No costimulatory molecules (e.g. anti- 
human CD28 and anti-human CD49d antibodies) were used. The cells were removed from 
culture at various time points (after 6, 12, 18 and 24 hours of stimulation) to assess CD 154 
expression. After stimulation, the cells were stained with antibodies to CD3 and CD4 and 
analysed by flow cytometry.
In accordance with previous reports which have noted high levels of background CD 154 
staining in the absence of antigens (Chattopadhyay, Yu et al. 2005; Koguchi, Thauland et al. 
2007), we observed some background CD 154 staining in unstimulated cells which levelled 
off by 24 hours (Figure 3.10). There was a sequential increase in CD154 expression in 
stimulated cells with peak expression of CD 154 detected with 18 hours of stimulation and 
maintained at 24 hours of stimulation (Figure 3.9; 6 hr- 0.040, 12 In* -1.733, 18 hr-3.207 and 
24 hr-3.165). Based on this observation, 18 hour stimulation was selected as the optimal time 
point for detection of CD 154 and there subsequent experiments used 18 hour stimulations.
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Figure 3.10[Time course for CD154 staining after stimulation with pneumoCCS 
(D39WT) as measured coculture method. PBMCs were stimulated with 8[!g/ml 
pneumoCCS (D39WT) or left unstimulated at 37°C, 5% C02 and removed from culture at 
various time points: 6 hr stimulation, 12 hr stimulation, 18 hr stimulation and 24 hr 
stimulation. Anti-CD154 antibody was introduced into the cell culture immediately before 
stimulation and CD154 expression analysed among CD4+ T cells. A plateau of CD154 
expression was reached 18 hours after stimulation. The numbers in blue represent the 
percentage of CD154 expressed on CD4+ T cells. The plot is representative of three (3) 
separate experiments.
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3.4 DISCUSSION
HIV-infected persons are at increased risk of IPD compared with HIV negative individuals, 
suggesting defects in both T and B cell immunity to S. pneumoniae are likely. To investigate 
the influence of HIV infection on pneumococcal T cell innnunity, there was need to optimise 
and adapt in vitro assays that would be used in this research project. Since it is common 
practice in this laboratory to use AB human serum in cell culture assays, AB human serum 
provided by the National Blood Services of Malawi was batched tested to determine whether 
it could be used in this research project and if so at what concentration. The testing was done 
using a CFSE proliferation assay optimised by others in this laboratory. We were able to 
show that PPD could elicit robust proliferative responses in PBMCs cultured in media 
supplemented with even 2% AB human serum. Therefore, subsequent experiments used 2% 
pooled supportive AB human sera.
Consistent with data from elsewhere (Chattopadhyay, Yu et al. 2005; Koguchi, Thauland et 
al. 2007), data herein show that the co-culture method identifies a larger fraction of CD4+ T 
cells expressing CD 154 compared to the conventional surface staining method. Although, 
Chattopadhyay et al have shown that the inclusion of monensin in the cell culture (co-culture 
method) leads to detection of more CD4+ T cells that express CD 154 compared to when 
monensin is not included (Chattopadhyay, Yu et al. 2006), we were unable to confirm this in 
our experiments..
Having identified the co-culture method as the appropriate method for measuring surface 
expression of CD 154 on CD4+ T cells, the method was used to determine i) whether 
pneumococcal concentrated culture supernatants (pneumococcal protein antigens) can induce 
expression of CD 154 on CD4+ T cells and ii) the optimal time point for detection of CD154 
in the CD4+ T cells. Data herein show that pneumococcal protein antigens induced CD 154 
expression. Little is known about the role CD 154 in cellular immunity to S. pneumoniae. 
Nonetheless, data from mouse and humanised mouse studies show that CD 154 plays a role in 
the generation of antibodies to pneumococcal proteins and even to capsular polysaccharides 
(Jeurissen, Billiau et al. 2006; Moens, Wuyts et al. 2008).
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Data presented in this chapter also showed peak expression of cell-surface CD 154 with 18 
hour of pneumococcal antigen stimulation. Therefore, subsequent experiments used 18 hour 
stimulations which was consistent with other studies which have reported 18 hour of antigen 
stimulation as the optimal time for detection of CD 154 (Subauste, Wessendarp et al. 2004).
In conclusion, this chapter has shown that robust T cell responses to specific antigens can be 
generated when the cells are cultured in media supplemented with 2% AB human serum. This 
study has also established that CD 154 can be efficiently detected by incubating cells with a 
fluorescent antibody to CD 154 during stimulation. Having accomplished this, the CD 154 co­
culture method and other appropriate assays developed in this laboratory were subsequently 
applied in prospective and longitudinal studies of human immunity in Malawi to investigate 
the impact of HIV on naturally acquired cellular immunity to pneumococcal antigens (chapter 
4), immune reconstitution of cellular and humoral immunity to pneumococcal antigens 
(Chapter 5) and vaccine induced immunity (chapter 6).
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CHAPTER 4 Cross-sectional study of pneumococcal immunity 
in HIV infected Malawian adults
4.1 Introduction
HIV infection, with or without progression to acquired immunodeficiency syndrome (AIDS), 
dramatically increases the risk of pneumococcal invasive disease (IPD) and probably 
pneumococcal colonisation (Klugman, Madhi et al. 2007; Gill, Mwanakasale et al. 2008) 
suggesting that natural unmunity to the pneumococcus (which is thought to rely on antigen- 
specific T and B cell memory) is susceptible to HIV-mediated immune dysregulation. In 
order to better understand the immunological basis for the high incidence of IPD in HIV- 
infected adults even in individuals with relatively good CD4 T cell counts, a study was 
designed to investigate pneumococcal-specific T cell mediated responses or T cell function in 
asymptomatic HIV infected Malawian adults.
4.1.1 T cell immunity
The pool of T cells found in the periphery consists of cells with diverse histories of 
engagement with antigens and distinct functional properties. After a fust encounter with 
cognate antigens, naive T cells proliferate and differentiate into effector cells (Tem) which 
can produce cytokines resulting in pathogen elimination (Bernasconi, Traggiai et al. 2002). 
Effector cells however have limited proliferative capacity and traffic to disease sites. 
Although the majority of the effector cells die, some survive to become long-lived memory T 
cells capable of offering both immune surveillance and proliferative capacity and 
consequently sustained protection (Bernasconi, Traggiai et al. 2002). Each population of 
immune cells has distinct cell surface markers and homing patterns (Sallusto, Lenig et al. 
1999). Naive cells express both CD45RA and chemokine receptor CCR7. Central memory 
cells (Tcm) which typically home to lymph nodes express CCR7, but not CD45RA, and 
effector memory cells (Tem) do not express CCR7. Absence of CCR7 expression allows 
migration to the site of infection (Sallusto, Lenig et al. 1999). Central memory cells are IL-2- 
secreting cells and this cytokine supports their expansion (Amyes, McMichael et al. 2005).
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4,1.2 T cell helper function
CD4 T cells provide essential helper function for antigen-presenting cells such as B cells, 
monocytes and dendritic cells [DCs]. This is mediated in part through the interaction of the 
CD40 on antigen-presenting cells and CD 154 (CD40-Ligand) onT cells (CD 154 is expressed 
primarily on activated CD4 T cells), providing a signal for B cell clonal expansion and 
differentiation of Ig-secretmg cells (van Kooten and Banchereau 2000; Ma and Clark 2009). 
For dendritic cells and monocytes/macrophages, this signal stimulates among other things the 
secretion of inflammatory cytokines including IL-12 that are central to the initiation of cell- 
mediated immune responses. The expression of CD 154 is therefore central to the ability of 
CD4 T cells to provide appropriate ‘help5 for the development of cell-mediated immune 
responses and T cell dependent antibody responses. The critical role CD 154 plays in 
controlling the fundamental aspects of the immune response has been demonstrated in 
individuals presenting with a genetic CD 154 deficiency (the X-linked hyper-IgM syndrome). 
These individuals are susceptible to opportunistic infections and cancer (Levy, Espanol- 
Boren et al. 1997; Jam, Atkinson et al. 1999; Subauste, Wessendarp et al. 1999). Several 
groups have shown that the induction of CD 154 in CD4+ T cells is decreased in HIV-1- 
infected persons (Zhang, Fichtenbaum et al. 2004; Subauste, Subauste et al. 2007).
In this study, we characterised naturally-acquired pneumococcal-specific T cell immunity 
(mcluding T cell help) in individuals with asymptomatic HIV infection (WHO stage 1) and 
compared it to that of HIV-uninfected healthy controls. Functional properties of 
pneumococcal-specific T cells were characterised by measuring their proliferative capacity, 
their ability to produce cytokines (ELISpot and intracellular cytokine staining) and ability to 
provide T cell help (induction of GDI 54). Additionally, we compared the absolute numbers 
and/or relative proportions of different T cell subsets (naive T cells, central memory (Tcm), 
effector memory (Tem), regulatory T cells (Tregs) and senescent T cells) in peripheral blood 
of healthy controls and HIV infected individuals. We tested the hypothesis that there is loss 
of function or specific subsets of CD4+ T cells that mediate protection against S. pneumoniae 
in HIV positive individuals, which could at least partially explain why this group is highly 
susceptible to invasive pneumococcal disease.
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4.1.3 Study Rationale and aims
Protein antigen-specific immunity to the pneumococcus in the context of HIV has not been 
extensively studied. A better understanding of the influence of HIV infection on 
pneumococcal T cell unmunity in the adult population can inform design and implementation 
of both antiretroviral therapy (ART) and protective vaccines. It is hypothesized that subtle 
functional defects in pneumococcal specific T cell immunity predispose those with HIV 
infection to IPD even before there is a numerical reduction in CD4 numbers. Therefore, the 
aim of this chapter was to investigate the effect of underlying HIV-1 infection on the function 
and phenotype of pneumococcal protein specific CD4+ T cells in Malawian adults 
(individuals with asymptomatic HIV infection [WHO stage 1]) even before the fall in CD4 
count.
4.1.4 Study design
The study focused on a prospectively recruited otherwise healthy HIV-infected and 
uninfected adults. Adults were recraited from the voluntary counselling and testing clinic 
(VCT) or anti-retroviral (ARV) out-patient clinic at Queen Elizabeth Central hospital in 
Blantyre Malawi (as described Chapter 2: Materials and Methods, section 2.2 - 2.2.1). HIV 
status was tested and confirmed by two HIV rapid antibody tests Uni-gold (Trinity Biotech 
pic) and Determine (Abbott Laboratories). Subjects recruited were either healthy controls or 
asymptomatic and HIV infected (WHO stage 1). After informed consent, samples (venous 
blood and nasopharyngeal swabs) were collected from individuals fulfilled the inclusion 
criteria (Chapter 2: Materials and Methods, section 2.2 — 2.2.1). The collection of samples 
and the research complied with relevant guidelines and institutional practices of the College 
of Medicine (University of Malawi) and Liveipool School of Tropical Medicine (LSTM) 
research ethics committees (Protocols: P.03/08/626 and 08.41 respectively).
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4.2 Materials and Methods
4.2.1 General materials and methods are as described in chapter 2.
Pneumococcal protein-specific T-cell immune responses were assessed using T cell CFSE 
proliferation assay, IFNy T-cell ELISPOT assay, intracellular cytokine staining, cytokine 
ELISA, bioplex cytokine profiles in culture supernatants and expression of CD154 (Figure 
4.1). Additionally, nasopharyngeal swabs were cultured to determine carriage rates. In this 
study we used whole pneumococcal protein antigens prepared from culture supernatants of a 
standard encapsulated type 2 strain (D39), a pneumolysin deficient mutant encapsulated type 
2 (D39) isogenic pneumococci (Ply-), positive antigen control M. tuberculosis PPD and PHA 
as mitogenic control as described in Chapter 2 materials and methods (section 2.4). This work 
was done in collaboration with Dr Sarah Glennie and Mr David Mzinza as described in 
Chapter 2 materials and methods (sections 2.7 and 2.12).
T cell Phenotyping
CD45RACCR7 CD25 FoxpB PD-1
Naive/Memory T regulatory Senescent
Central memory
CFSE proliferation assay
Effector memory
IFN-y ELI Spot
Intracellular cytokine staining 
Cytokine ELISA & Multiplex*
CD40-CD154
T cell help
CD154 (CD40L) Induction
Figure 4.1 | Assays used to assess pneumococcal protein T cell immune responses.
* Bioplex cytokine profiles in culture supernatants- cytokines assessed come from T cells and 
other cell types. PBMCs- peripheral mononuclear cells.
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4.3 Results
4.3.1 Demographic characteristics of the study population
A total of 53 asymptomatic WHO stage 1 HIV-infected adults (median age, 31 years [range, 
18-58 years]) and 31 HIV-uninfected healthy adults (median age, 33 years [range, 23-53 
years]) were recruited. The characteristics of the study cohort are shown in Table 4.1. 
Although, the HIV-infected subjects were asymptomatic and WHO stage 1, they presented 
with a wide range of CD4 T cell counts (median CD4 count, 252 cells/p I [range, 7-913 
cells/pi]). The median CD4 T cell count of healthy controls was 853 cells/pl (range, 444- 
1323cells/pl). HIV-infected participants were classified on the basis of then CD4+ T cell 
count (<350,350-500 and >500 cells/pl) to allow assessment of carriage and immunity at 
different CD4 T cell counts. The CD4+ T cell count of 350 cells per microlitre was selected 
because it is the WHO recommended cut-off for initiating antiretroviral therapy while CD4+ 
T cell count of 500 cells per micro litre or more compares well with the CD4+ T cell counts of 
the majority of the HIV uninfected healthy adults recruited into the study. There was no 
difference in the nasopharyngeal carriage rate between the HIV-infected and HIV-uninfected. 
S. pneumoniae was detected in 14% of HIV-infected (<350 cells/pl: -13 %, 350-500: 14% 
and >500: 13%) and in 16% of HIV-uninfected participants (P=0.2, by z test for proportions).
Table 4.11 Demographic characteristics of the study population
HIV-uninfected HIV-infected P*value
Overall CD4>500P CD4 350-500P CD4<350P
N 31 53 9 14 30
Male (%) 68 54 13 50 76
Female (%) 32 46 87 50 24
Age, median 
yr (range) 33 (23-53) 31(18-58) 29(21-47) 28(23-40) 32(18-58)
CD4, median 
(range)cells/pl 853(444-1323) 252(7-913) 695(549-913) 403(352-495) 192(7-292)
Pneumococcal 
carriage (%) 16 14 13 14 13 0.2*
♦HIV-uninfected versus HIV-infected (overall) 
If z test for proportions 
p CD4 T cell counts (cells/pl)
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4.3.2 Phenotypic assessment of T cells in HIV-uninfected and HIV-infected adults
CD4+ cell depletion is the hallmark of HIV infection (Brenchley, Schacker et al. 2004). 
However, observations based on total CD4+ cell counts alone may not accurately reflect the 
state of immunity in HIV infected individuals (Dunham, Cervasi et al. 2008; Prendergast, 
Prado et al. 2010). Therefore, a detailed assessment of immune cell subsets and the extent to 
which different subsets are impacted by HIV may not only be informative but accurately 
reflect the influence of HIV infection on T cell immunity or T cell responses to microbial 
antigens. To determine the changes that occur within the T cell subsets during the course of 
HIV infection the absolute numbers and/or relative proportions of CD4+ naive (Tn), central 
memory (Tcm) and effector memory (Tem), T regulatory cells and senescent cells in 
peripheral blood of healthy controls and HIV infected individuals were assessed and 
compared.
4,3.2a Differential depletion of peripheral blood CD4+ T cell subsets in HIV-infected adults
CD4+ T cell subsets were assessed by measuring the expression of CD45RA and CCR7 
which characterises the state of differentiation (i.e. naive vs. central memory vs. effector) of 
CD4+ T cell subsets (Figure 4.2a). Analysis of the phenotype of the CD4+ T cell subsets 
revealed some differences between HIV-infected and uninfected persons. There was a 
significant decline in the proportion of Tcm compared to controls (p=0.0043, 11=115,5) 
(Figure 4.2b) and a significant increase in the proportion of the TEM subset in HIV-infected 
participants (p=0.0226, U=141.5) compared to HIV-uninfected individuals (Figure 4.2b). The 
proportion of the Tn subset in HIV-infected participants was comparable to that of HIV- 
uninfected individuals (p=0.6501, U=224.0) (Figure 4.2b).
In terms of absolute numbers of cells per cubic millimetre of blood, naive (Tn) and central 
memory (Tcm) CD4 T cell subsets declined significantly in HIV-infected individuals 
(p=0.0009; U= 61.0 and pO.OOOl; U= 18.0 respectively), compared to HIV negative persons 
(Figure 4.2c). The absolute number of effector (TEm) CD4+ T cell was lower but not 
significantly decreased (p=0.0555, U=114.00) compared to controls. These data show that the 
increase in the proportion of the Tem subset observed in HIV positive persons is not due to an 
increased absolute number of the subset but rather to a selective loss of naive (Tn) and 
central (Tcm) CD4+ T cell subsets.
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Additionally, these observations are in agreement with previous observations that HIV drives 
immune activation which results in a constant recruitment of CD4+ T cells from the naive 
and central memory pools into the effector pool (Hazenberg, Hamatm et al. 2000; McCune 
2001; Grossman, Meier-Schellersheim et al. 2002; Silvestri and Feinberg 2003) inevitably 
creating a strain on the homeostatic mechanisms of CD4+ T cell maintenance.
When the absolute counts were examined on the basis of CD4+ T cell count, we observed 
that there was a significant decline of the naive (Tn) and central (Tcm) CD4+ T cell subsets in 
HIV positive individuals with CD4+ T cell counts of 350-500 cell per microlitre (HIV 
uninfected vs. HIV-infected: Tn *p = 0.02 and Tcm *p=0.0003) while effector (Tem) declined 
significantly in individuals with CD4+ T cell counts of <350 cells/ul (HIV uninfected vs. 
HIV-infected ^p^O.OOSXFigure 4.2d). The data indicate that effector memory CD4+ T cells 
decline at a slower rate compared with naive and central memory CD4+ T cell subsets.
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Figure 4.2 | Phenotype of CD4 T cells in PB of humans a | Representative flow 
cytometry dot plot showing naive and memory CD4 T-cell subsets gated on characteristic 
expression patterns of CD45RA and CCR7 (Upper left quadrant - central memory CD4+ T 
cells, lower left quadrant - effector memory CD4+ T cells and upper right quadrant - 
naive CD4+ T cells). b| Proportional representation of TN, TCm and TEm in HIV-infected 
and HIV-uninfected adults c| Absolute numbers of peripheral blood CD4+ TN, TCm and TEm 
in HIV-infected and HIV-uninfected adults and d| Absolute numbers of peripheral blood 
CD4+ TN/ TCm and TEM in HIV-uninfected and HIV-infected adults according to CD4+ T cell 
count (>500, 350-500 and <350 cells/pl blood). HIV uninfected vs. HIV-infected: CD4 
count 350-500 cells/ul TN *p = 0.02, TCm *p=0.0003 and CD4 count <350 TEM *p=0.003).
Naive
Central Memory 
Effector Memory
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4.3.2b Changes in regulatory T (Tregs) cells during HIV disease progression
Regulatory T (Tregs) cells have been implicated in the suppression of T cell activation and 
effector function (Weiss, Donkova-Petrini et al. 2004; Belkaid 2007; Keynan, Card et al. 
2008), HIV- associated immune hyperactivation therefore may drive expansion and 
activation of Tregs population which may inhibit the development of effective immunity 
against microbes including S. pneumoniae leading to increased susceptibility to invasive 
pneumococcal disease. To assess this possibility, we compared the proportion and absolute 
number of T regulatory cells in peripheral blood of HIV-infected and uninfected adults. 
CD4+ Tregs cells were identified by CD25hl [top 15% CD25+ cells] and FoxP3 co-expression 
(Kinter, Horak et al. 2007) (Figure 4.3a). The frequency and absolute number of CD4+ 
CD25hlFoxP3+T cells in the peripheral blood of HIV-positive adults were comparable to that 
of HIV uninfected individuals (p=0.6160, U=311.5 and p= 0.3525, U=100.0)(Figure 4.3b and 
c). Next, we assessed the relationship between the Tregs and CD4+ T cell counts, the latter 
being a predictor of HIV disease progression. There was a significant inverse correlation 
between absolute CD4 T cell count and Tregs (Figure 4.3d; p=0.0006, r = 06474.). The result 
is consistent with previous studies that have shown that HIV-infected individuals with low 
CD4+ T cell counts have, on average, an elevated percentage of Tregs compared to those 
with high CD4 level (Tsunemi, Iwasaki et al. 2005; Montes, Lewis et al. 2006; Cao, Jamieson 
et al. 2009).
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Figure 4.31 Phenotypic analysis of T regulatory cells in peripheral blood. a|
Representative phenotypic analysis of CD25 and FoxP3 expression in peripheral blood 
CD4+ T cells from an HIV negative person b| The frequency of CD25hlFoxP3+ Treg cells 
in HIV negative and infected persons c| Absolute numbers of CD4+ CD25hlFoxP3+ Treg 
cells in PB of HIV negative and infected persons. d| Relationship between Tregs and 
CD4 T cell counts. Black horizontal bars represent median values of CD4 subsets, r- 
correlation coefficient. Differences were calculated using the Mann Whitney U test.
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4,3.2c Relative expansion of CD4+PD-1+ senescent T cell in HIV-infected Adults
Previous studies have shown that programmed death-1 (PD-1) expression is upregulated on 
CD4+ T cells from people with chronic HIV infection, leading to decay of the CD4+ T cells 
and then function (Day, Kaufinann et al. 2006; D'Souza, Fontenot et al. 2007). This may 
have a negative impact on CD4+ T responses to microbial antigens including pneumococcal 
antigens, increasing susceptibility to microbial infections. PD-1 expression was higher in 
HIV-infected subjects than in HIV-negative subjects (Figure 4.4b, p =0.0003, U = 92.0). 
Assessment of the relationship between PD-1 expression and CD4 T cell counts, a predictor 
of HIV disease progression showed that there was no correlation between absolute CD4+ T 
cell count and PD-1 expression ( p=0.1139, r = 0.2511). However, there was an elevated 
percentage of PD-1+CD4+ T cells in individuals with low CD4+ T cell counts (<350 cells/ul) 
compared with those with high CD4 level (350-500 cells/ul)(Figure 4.4d; p=0.0100, U=27.0).
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Figure 4.4 | PD-1 is upregulated on CD4+ T cell during HIV-infection. a|
Representative plot PD-1 expression on peripheral blood CD4+ T cells (HIV-uninfected) 
b| Percentage of PD-1 expression on PB of HIV-uninfected and infected individuals c| 
Percentage of PD-1 expression on PB of HIV uninfected and infected individuals 
according to CD4+ T cell count d | Relationship between PD-1 expression and CD4 T cell 
counts. Black horizontal bars represent median values of CD4 subsets. r= correlation 
coefficient. Differences were calculated using the Mann Whitney U test.
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4.3.3 Memory T cell responses to pneumococcal antigens 
4.3.3a Impaired pneumococcal-specific CD4+ T cell proliferation
T cell proliferation has been shown to be important for T cell control of several diseases 
(Horton, Frank et al. 2006). Having established that circulating central memory T cells (Tcm) 
are depleted during HIV infection, we sought to establish whether the proliferative capacity 
of the remaining cells in response to pneumococcal antigens is compromised in HIV-infected 
individuals. PBMCs from healthy controls and HIV infected individuals were stimulated in 
vitro with pneumoCCS derived from either the WT pneumococcal strain (D39), Ply 
negative (-) D39 mutant, positive antigen control M. tuberculosis PPD and PHA as 
mitogenic control with unstimulated as background for 8 days, after which CD4 T cell 
proliferation was evaluated by CFSE dilution using flow cytometry (Figure 4.5).
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Figure 4.5 | Proliferative capacity of pneumococcal-specific CD4+ T cells.
Representaive plots showing proliferation of PB CD4+ T cell toward pneumococcal and 
control antigens over a period of 8 days (HIV-uninfected). The percentage indicated in 
the upper-left quadrant represents CD4+ T cells that proliferated. Media- cells in RPMI 
1640 supplemented with with penicillin/streptomycin, L-glutamine; HEPES and 2% 
heat-inactivated AB human serum.
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The ability of CD4+ T cells from HIV-infected persons to proliferate in response to a 
mitogenic stimulus phytohemagglutinin (PHA) was comparable to that of HIV-uninfected 
individuals (HIV-uninfected-78%, HIV-infected-76%)(Figure 4.6d), indicating that HIV 
infection does not affect the intrinsic capacity of CD4+ T cells to proliferate. However, the 
capacity of CD4+ T cells to proliferate in response to pneumoCCS derived from a WT 
pneumococcal strain (D39), pneumoCCS derived from a Ply negative (-) D39 mutant and 
positive control antigen (PPD) was significantly impaired in HIV-infected individuals 
(Figures 4.6a, b and c). Since the proliferative responses to a mitogenic stimulus (PHA) were 
not impaired in HIV positive persons, impaired antigen specific proliferative responses 
suggests a defective antigen-CD4+ T cell interaction required to activate or maintain the 
central memory population.
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Figure 4.6 | Impaired proliferative capacity of pneumococcal-specific CD4+ T cells.
Percentage of proliferating CD4+ T cells in response to a| pneumoCCS derived from a 
WT pneumococcal strain (D39) b| pneumoCCS derived from a Ply negative (-) D39 
mutant c| positive antigen control M. Tuberculosis PPD. Black horizontal bars represent 
median values of total responses minus background. Differences were calculated using 
the Mann Whitney U test. d| mitogenic stimulus phytohemagglutinin (PHA). Graph 
represents median values of CD4 T cell proliferation minus background.
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4.3.3b Reduced IFN-y ELISPOT responses to pneumococcal protein antigens in HIV infected 
individuals
Work from this laboratory has demonstrated that pneumococcal protein antigens induce 
effector responses in the healthy adults as measured by an ex vivo ELISpot analysis 
(Mureithi, Finn et al. 2009). To examine the possibility that in addition to a total CD4 T-cell 
and Tcm deficit and impaired Tcm pneumococcal-specific proliferative capacity, the function 
of effector T cells is impaired in HIV-1—infected persons, pneumococcal effector memory 
(Tem) IFN-y responses were evaluated using a short-term ELISpot assay as described in 
chapter 2 materials and methods (section 2.7). PBMCs were stimulated for 16 hours with 
pneumoCCS derived from a WT pneumococcal strain (D39), pneumoCCS derived from a Ply 
negative (-) D39 mutant and a positive control antigen M. tuberculosis PPD before 
identifying the IFN-y spot-forming cells by ELISpot assay.
Stimulation of PBMCs with WT pneumococcus generated a low number of effector memory 
IFN-y producing cells and the responses were not affected by HIV infection (Figure 4.7a). Ex 
vivo IFN-y ELISPOT responses to the pneumoCCS derived from a Ply negative (-) D39 
mutant for HIV negative individuals, were not significantly different from responses induced 
by the pneumoCCS derived from aWT pneumococcal strain (p=0.0682, U= 40.0)(Figure 
4.7d). However, the Ply negative responses were two times higher than those induced by the 
pneumoCCS derived from a WT pneumococcal strain (D39) (average 67.25 ± 61.82 spots/106 
cells versus 31.42 ± 30.41spots/106 cells), suggesting an immunomodulatory effect of 
pneumolysin (Marriott, Mitchell et al. 2008). In addition, ex vivo IFN-y ELISPOT responses 
to pneumoCCS derived from a Ply negative (-) D39 mutant decreased significantly in HIV 
positive persons (HIV-uninfected vs. HIV-infected CD4 count: >500: p=0,008, U=13.50; < 
350: p=0.02, LH39.0) (Figure 4.6b). Ex vivo IFN-y ELISPOT responses to PPD were 
reduced as well (HIV-uninfected vs. HIV-infected CD4 count >500: p=0.007; U=26.50) 
(Figure 4.7c).
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Figure 4.7 | Ex vivo interferon-g (IFN-g) ELISpot responses to pneumococcal protein 
antigens after overnight stimulation. IFN-y ELispot response to a| pneumoCCS 
derived from a WT pneumococcal strain (D39) b| pneumoCCS derived from a Ply 
negative (-) D39 mutant c| positive control antigen M. tuberculosis PPD. d|Comparison 
between D39WT and D39Ply- induced responses in HIV negative individuals. Black 
horizontal bars represent median values and IQRs minus background responses. 
Differences were calculated using the Mann Whitney U test.
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4.3.4 Defective induction of CD154(CD40L) on activated CD4T cells
CD4+ T cells play a key role in the generation of immunity by providing appropriate ‘help’ 
for the development of humoral and cell-mediated immune responses. This pivotal role of 
CD 154 (CD40L) in the regulation of numerous aspects of the immune response led us to 
examine whether the induction of this molecule in response to pneumococcal protein antigens 
is defective in HIV-1 infected persons. Impaired pneumococcal specific induction of CD 154 
in CD4+ T cells from HIV-infected individuals may contribute to poor T and B cell responses 
against S. pneumoniae. PBMCs from healthy controls and HIV infected individuals were 
stimulated in vitro with pneumoCCS derived from either the WT pneumococcal strain (D39), 
Ply negative (-) D39 mutant, a positive antigen control M Tuberculosis PPD and PHA as a 
mitogenic control for 18 hours and CD 154 expression evaluated on recently activated CD4+ 
T cells by flow cytometry (Figure 4.9a)
Activation of CD4+ T cells following stimulation was determined by the expression of the 
early activation marker CD69. The expression of CD69 after stimulation with pneumoCCS 
derived from a WT pneumococcal strain (D39) and pneumoCCS derived from a Ply negative 
(-) D39 mutant was similar between HIV infected and uninfected individuals (D39WT: 
p=0.0925, U=252.5 and D39Ply-: p=0.1024, U=287.5)(Figures 4.8a and b). Stimulation with 
PPD resulted in significantly lower expression of CD69 in HIV-infected persons compared to 
HIV negative persons (p=0.0056, U=216.5) (Figure 4.8c). This is consistent with the 
evidence from previous studies that have shown that for some pathogens HIV infection does 
not significantly change the expression of CD69 on CD4+ T cells following stimulation 
(Subauste CS, 2004) and that HIV infection does not alter the expression of the early 
activation marker CD69 (Card, McLaren et al. 2009). There were no differences between 
responses induced by the D39WT and D39Ply negative concentrated culture supernatants 
(p=0.8035, U=171.5)(Figure 4.8d).
The expression of CD154 on activated CD4+ T cells in response to pneumoCCS derived 
from a WT pneumococcal strain (D39) and pneumoCCS derived from a Ply negative (-) D39 
mutant was impaired in groups of HIV infected individuals with CD4+ T cell counts of 350- 
500 cells/ul (D39WT:p=0.02; D39Ply-:p=0.03) and CD4+ T cell counts < 350 cells/ul 
(D39WT: p=0.0001; D39Ply-:p=0.004)(Figures 4.9b and c).
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Figure 4.8 | CD69 expression in response to microbial antigens in CD4+ T cells of HIV- 
infected and uninfected. a| pneumoCCS derived from a WT pneumococcal strain 
(D39WT) b| pneumoCCS derived from a Ply negative (-) D39 mutant c| positive control 
antigen M. tuberculosis PPD d|Comparison between D39WT and D39Ply- induced 
responses in HIV negative individuals. Black horizontal bars represent median values of 
total responses minus background. Differences were calculated using the Mann Whitney
Induction of CD 154 in response to PPD was defective in all 3 groups of HIV infected persons 
(CD4 count >500: p=0.04; 350-500: p=0.04 and <350: p=0.001) (Figure 4.9d). The intrinsic 
capacity of CD4 T cells to express CD 154 was however not impaired as stimulation with 
mitogenic stimulus PH A showed no defect in CD 154 expression in HIV infected individuals 
(Figure 4.9e).
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Figure 4.9 | Defective induction of CD154 (CD40L) on activated CD4 T cells from HIV+ 
persons, a | Representative plots showing expression of CD154 on activated CD4+ T cells 
from HIV-infected and uninfected individuals. b| Expression of CD154 in activated CD4+ 
T cells following stimulation with pneumoCCS derived from a WT pneumococcal strain 
(D39WT) c|CD154 expression following stimulation with pneumoCCS derived from a Ply 
negative (-) D39 mutant d| positive antigen control M. tuberculosis PPD and e| PHA. 
Black horizontal bars represent median values and IQRs of total responses minus 
background. Differences were calculated using the Mann Whitney U test.
4.3.5 Functional analysis of CD4 T cells (on the basis of their ability to secrete IL-2 and 
IFN-y)
No single functional parameter can adequately quantify or identify the extent of an immune 
response. In addition to CD154, CD4 T cells are capable of expressing diverse cytokine 
profiles (De Rosa, 2004,). Therefore, we examined pneumococcal cytokine response, as 
defined by the number of CD4+ T cells expressing IFN-y and IL-2 in HIV infected and 
uninfected individuals. Representative flow cytometry dot plots showing IL-2 and IFN-y 
expression after pneumococcal antigen stimulation are shown in Figure 4.10a. No difference 
in the total cytokine response was seen between HIV infected and uninfected individuals in 
D39WT and D39Ply- stimulated PBMCs (Figures 4.10b & c). In HIV positive individuals, 
the D39WT and D39Ply-specific responses shifted from a predominantly IFN-y response to 
an IL-2 dominated response (Figures 4.1 la & b). PPD specific responses were dominated by 
IFN-y regardless of HIV status (Figure 4.11c) and the CD4+ T cell response showed a 
distinct IFN-y+IL-2+ double positive population (Figure 4.11c) which was not seen in 
pneumococcal-specific responses.
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Figure 4.10 | Functional analysis of CD4 T cells. a| Representative flow cytometry dot 
plots showing IL-2 and IFN-y expression after antigen stimulation of PBMCs from an 
HIV-negative person Cytokine (CD4+ T cells expressing IFN-y and IL-2) expression after 
stimulation of PBMCs from in HIV-uninfected (HIV-) and infected individual with b| 
pneumoCCS derived from a WT pneumococcal strain (D39WT) c|pneumoCCS derived 
from a Ply negative (-) D39 mutant d| M. tuberculosis PPD. The numbers in the 
quadrants represent the percentage of cytokine expressed. Differences were calculated
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Figure 4.11 | Functionality of antigen-specific CD4+ T cells in PB. Distribution of a| WT 
pneumococcal strain (D39WT) b| pneumococcal Ply negative (-) D39 mutant c| M. 
tuberculosis PPD-specific cytokine responses in HIV-uninfected (n= 9) and HIV-infected 
(n=9-ll). The pie charts represent mean frequencies of antigen-specific cytokine+ cells.
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4.3.6 Cytokine profile of the cellular immune responses to pneumococcal antigens
Work from this laboratory has shown that pneumoCCS derived from a WT pneumococcal 
strain (D39) and a Ply negative (-) D39 mutant induced IFN-y, IL-10, IL-12(p40), IL-13, 
and IL-17 and TNF-a production quantified hi culture supernatants obtained after 5 days of 
PBMC culture (Mureithi, Finn et al. 2009). IL-10 is a suppressive cytokine (Said, Dupuy et 
al.; Maynard, Harrington et al. 2007) while other cytokines have been shown to mediate 
clearance of pneumococcal colonisation (Lu, Gross et al. 2008; Zhang, Clarke et al. 2009) or 
control the multiplication of disseminated bacteria (Rubins and Pomeroy 1997; Sun, Salmon 
et al. 2007). We therefore investigated the dynamics of pro-mflammatoiy/regulatoiy 
responses to pneumococcal protein antigens during HIV- infection using cytokine IFN-y and 
IL-10. Cytokines (IFN-y and IL-10) were quantified in culture supernatants obtained after 7 
days of PBMCs culture. The concentrations of the cytokine were determined on Bio-Plex 200 
system. PBMCs from HIV-infected persons produced significantly less IFN-y in response to 
pneumoCCS derived from a WT pneumococcal strain (D39WT) compared to controls 
(p=0.007) (Figure 4.12a). pneumoCCS derived from a Ply negative (-) D39 mutant (p=0.07). 
IL-10 production was also reduced in response to pneumoCCS derived from a WT 
pneumococcal strain (D39WT) (p=0.003)) (Figure 4.12b). There was a severe reduction in 
the concentration of IFN-y compared to the relatively small change in IL-10 production 
(Figure 4.12c), which may create an enviromnent that suppresses T cell immune responses to 
antigens.
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Figure 4.12 | Collated secreted cytokine profiles in PBMC culture supernatants stimulated 
with WT pneumococcal strain (D39), pneumococcal Ply negative (-) D39 mutant and 
medium (Med), as determined by bioplex cytokine assay. HIV-uninfected (grey)(n= 6) and 
HIV-infected (white)(n=9). Data are mean values standard error of the mean. Differences 
were calculated using the Mann Whitney U test. IFN-y - interferon-y.
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4.4 Discussion
HIV-infected individuals are vulnerable to invasive pneumococcal disease and the role of 
protein antigen-specific immunity to the pneumococcus in this has not been extensively 
studied or is far from understood. In this chapter, we earned out a detailed assessment of 
CD4+ T cell subsets and characterised the functional properties of pneumococcal-specific 
CD4+ T cells in HIV infected and uninfected adults (in an area of relatively high HIV- 
infection and pneumococcal carriage rate). We show that in addition to the numeric loss of 
CD4+ T cell subsets during HIV infection, pneumococcal-specific CD4+ T cell responses are 
reduced or impaired. These observations may at least in part explain why HIV-infected 
individuals are at an increased risk of invasive pneumococcal disease.
Although other studies have shown an increase in pneumococcal carriage in HIV-infected 
adults (Rodriguez-Barradas, Tharapel et al. 1997; Madlii, Adrian et al. 2007; Gill, 
Mwanakasale et al. 2008), we found no increase of the nasopharyngeal carnage in our study 
population even in individuals with CD4 count less than 350 cells/ul (the WHO 
recommended cut-off for initiating therapy). HIV infection causes substantial depletion of 
CD4+ T cells in the gastrointestinal (GI) tract and vaginal mucosa (Brenchley, 2004, 
Guadalupe, M, 2003), however a similar depletion does not manifest at all mucosal sites, 
particularly the lung in human studies (Brenchley JM, 2008). Although it is still to be 
demonstrated, it is conceivable that the mucosal immunity (immunity in the upper respiratory 
tract) in our HIV positive participants is still relatively intact or robust enough to control 
pneumococcal colonisation (but not necessarily dissemination) and hence no change in the 
carriage rate. It follows then that the increased risk of invasive pneumococcal disease may be 
due to failure to control pneumococcal dissemination rather than colonisation.
In this study, we established that circulating central memory T cells (Tcm) are not only 
depleted during HIV infection but have a diminished capacity to proliferate in response to 
pneumococcal antigens (although not to mitogenic stimulus, PHA), implying that the antigen- 
T cell interaction required to activate and renew the central memory population is 
compromised.
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T cell proliferation has been shown to be important for T cell control of several diseases 
(Horton, Frank et al. 2006) and therefore impaired proliferative capacity may have an effect 
on the ability of T cells to effectively control invasive pneumococcal infection. There was an 
elevated percentage of CD4+CD25h,FoxP3+ regulatory T cells (Tregs) in HIV-infected 
persons with low CD4+ T cell counts. It is likely that overrepresentation of Tregs in this 
group may establish an increased suppressor-to helper ratio, which could lead to suppressed T 
cell immune responses to HIV and other pathogens including S. pneumoniae.
In mouse models of pneumococcal pneumonia and sepsis, IFN-y has been shown to play a 
crucial role in mobihsation of the cellular immune responses to facilitate bacterial elimination 
from the tissues and from the bloodstream (Rubins and Pomeroy 1997; Sun, Salmon et al. 
2007). In this study, the number of pneumococcal-specific T cells as determined by ELISpot 
was reduced during HIV infection, especially in the absence of pneumolysin, a potent TLR4 
agonist and cognate antigen (Bernatoniene, Zhang et al. 2008). The proportion of CD4+ T 
cells producing IFN-y in response to stimulation with pneumoCCS derived from a WT 
pneumococcal strain (D39WT), or pneumoCCS derived from a Ply negative (-) D39 mutant 
also declined. The amount of IFN-y secreted into culture supernatants was decreased as well. 
It is therefore likely that impaired IFN-y synthesis may lead to poor macrophage 
phagocytosis and microbial killing when recruited to the sites of infection and failure to 
control pneumococcal infection in HIV-infected persons. Severe reduction of IFN-y in 
comparison to the relatively small change in IL-10 (a suppressive cytokine (Said, Dupuy et 
al.; Maynard, Harrington et al. 2007) secreted in culture supernatants may lead to suppressed 
immune response to pneumococcal antigens in HIV-infected persons. However, it is still to 
be demonstrated that IL-10 suppresses pneumococcal-specific responses.
In HIV positive individuals, pneumococcal-specific responses shifted from a predominantly 
IFN-y response to an IL-2 dominated response. There are indications that IL-2 producing 
cells may be more susceptible to productive HIV infection than other cell types (Geldmacher, 
Ngwenyama et al. 2010). Therefore, a shift from cells producing predominatly IFN-y to IL-2 
producing cells may render the pmneumococcal-specific cells to HIV infection and depletion.
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In this study, the induction of CD 154 on activated CD4+ T cells in response to 
pneumococcal protein antigens was impaired during HEV-infection, even in individuals with 
CD4 cell counts above 350 cells/ul (presumably with relatively intact immunological 
features). This observation suggests a specific defect in the regulation of induction of CD 154, 
above and beyond the loss of CD4+ T cells which is a hallmark of HIV infection. Patients 
presenting with genetic CD 154 deficiency (the X-linked hyper-IgM syndrome) are 
susceptible to opportunistic infections and cancer (Levy, Espanol-Boren et al. 1997; Jain, 
Atkinson et al. 1999; Subauste, Wessendaip et al. 1999), and therefore it is likely that poor T 
cell CD 154 expression in response to pneumococcal antigens may contribute to increased 
susceptibility to invasive pneumococcal disease.
There are multiple ways that defective CD 154 signalling may increase susceptibility to 
infections including impaired humoral response, defective priming of T cells and poor 
macrophage activation. In mouse studies, CD 154 has been shown to be essential for the 
antibody response to pneumococcal proteins and contributed to the humoral response to 
capsular polysaccharides and neutralization of CD 154 suppressed the antibody response to 
PspA protein (Hwang, Nahm et al. 2000). Thus, impaired CD 154 expression may affect 
antibody responses to pneumococcal proteins, contributing to poor control of IPD in HIV- 
infected persons.
In conclusion, this study provides evidence that reduced or impaired pneumococcal -specific 
CD4+ T cell responses may partly explain why HIV-infected are at increased risk of invasive 
pneumococcal disease. The study revealed considerable immune dysfunction hi 
asymptomatic HIV infected Malawian adults. Pneumococcal specific memory T cells 
exhibited defective IFN-y production, proliferation and GDI54 expression. Additionally, 
there was an overrepresentation of regulatory T cells and a suppressive environment, because 
of a severe reduction in the concentration of IFN-y compared to the relatively small change in 
IL-10 production. Together these observations demonstrate at least in part why HIV 
infection, with or without progression to acquhed hnmunodeficiency syndrome (AIDS), 
dramatically increases the risk of pneumococcal invasive disease (IPD).
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Given that pneumococcal immunity is susceptible to HIV-mediated immune disruption and 
that initiation of antiretroviral therapy leads to some functional innnune reconstitution (Geng 
and Deeks 2009), the question therefore is: does pneumococcal specific immunity recover, or 
return, folio whig initiation of antiretroviral therapy? This is the question the next chapter of 
this thesis sought to answer.
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5.1 Introduction
Evidence presented in chapter 4 together with work done by Dr Oluwadamilola H Iwajomo 
(PhD thesis 2011) in this laboratory showed that there is considerable compromise of 
pneumococcal specific T cell and B cell immunity in HIV infected Malawian adults. 
Initiation of antiretroviral therapy leads (although not completely) to CD4+ T cell recovery 
and functional immune reconstitution (Geng and Deeks 2009), coupled with a reduction in 
HIV-1 related opportunistic infections (Kaplan, Hanson et al, 2000), and a reduction in the 
incidence and magnitude of IPD (Grau, Failures et al. 2005; Heffeman, Barrett et al. 2005; 
Klugman, Madhi et al. 2007). Questions remain, however, as to whether pneumococcal 
specific protective immunity returns or is re-constituted following initiation of therapy and 
how naturally-acquired pneumococcal immunity changes with ART immune reconstitution. 
Therefore, a study was designed to investigate the impact of ART on naturally-acquired 
immunity to pneumococcal protem antigens, mapping out the kinetics and the degree of 
immune reconstitution.
5.1.1 Immune Reconstitution during Highly Active Antiretroviral Therapy 
5.1.1 a Reconstitution of CD4 T ceils
Initiation of ART leads to reconstitution of CD4+ T cells in the blood and mucosal sites 
(Kaplan, Hanson et al. 2000; Macal, Sankaran et al. 2008; Knox, Vinton et al. 2010). A 
longitudinal study of 23 HIV-infected persons on ART, showed that broncho alveolar lavage 
(BAL) CD4 T cells (representing mucosal [pulmonary] CD4+ T cells), reconstituted after 
mitiation of ART (Knox, Vinton et al. 2010). Based on Ki67 (a cell proliferation marker) 
expression by memory T cells, this reconstitution appeared to occur via local proliferation of 
resident BAL CD4+ T cells rather than redistribution. Reconstitution of CD4+ T cells in the 
gut-associated lymphoid tissue (GALT) has been shown to be slow and is substantially 
delayed compared to peripheral blood (Guadalupe, Reay et al. 2003).
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Analysis of jejunal biopsy samples for Ki67 and integrin py (which plays an important role in 
lymphocyte homing to the intestinal mucosa), indicated that intestinal CD4 T cell restoration 
following ART involved primarily CD4 T cell trafficking to the GALT from the periphery, 
and not local proliferation (Guadalupe, Reay et al. 2003). However, not all individuals on 
ART reconstitute CD4+ T ceils at the same rate, or to the same extent (Gazzola, Tincati et al. 
2009). As many as 30% of patients who are on ART present misatisfactory CD4 T cell 
recovery despite suppression of HIV replication (Gazzola, Tincati et al. 2009; Kelley, 
Kitchen et al. 2009). Some of the most predictive factors for poor immune reconstitution are 
a lower CD4 nadir (Anthony, Yoder et al. 2003; Siddique, Hartman et al. 2006; McKinnon, 
Kimani et al. 2010; Negredo, Massanella et al. 2010), older age (Micheloud, Berenguer et al. 
2008), increased immune activation (Hunt, Deeks et al. 2003; Benito, Lopez et al. 2005), 
altered T cell homeostasis (Benveniste, Flahault et al. 2005; Goicoechea, Smith et al. 2006), 
markers of microbial translocation (Jiang, Lederman et al. 2009) and HIV co-receptor usage 
(Delobel, Nugeyre et al. 2006).
Robbins et al observed that individuals with a lower baseline CD4 count at the time therapy 
is initiated achieved less immune reconstitution than those in the higher CD4 strata (Robbins, 
Spritzler et al. 2009). Additionally, it has been shown that initiation of therapy before CD4 T 
cell coimt falls below 350 cells/pl improves survival or better reconstitution of CD4 T cells 
(Guadalupe, Reay et al. 2003; Kitahata, Gange et al. 2009).
Several studies have demonstrated that antigen-specific CD4+ T cell responses recover 
following initiation of therapy (Lange, Valdez et al. 2002; Keane, Price et al. 2004; Furco, 
Carmagnat et al. 2008; Wilkinson, Seldon et al. 2009; Sutherland, Young et al. 2010). The 
degree of recovery is influenced at least in part by the prevalence of the antigen and baseline 
CD4+ T cell count. Studies have shown that there is either poor restoration of antigen- 
specific immune responses in individuals who are severely inmiunodeficient prior to 
treatment (Lange, Valdez et al. 2002; Sieg, Mitchem et al. 2002; Lederman, Williams et al. 
2003; French, Keane et al. 2007) or the restoration is short-lived in this group (Keane, Price 
et al. 2004). Little is known however about the evolution of protein antigen-specific 
responses to the pneumococcus following initiation of ART.
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5.1.1b Reconstitution of B cells
HIV infection leads to loss of circulating memory (CD19+CD27+) B-cell percentage and 
numbers in individuals with chronic HIV infection (De Milito, Morch et al. 2001; Nagase, 
Agematsu et al. 2001), and to memory B cell apoptosis (Titanji, Nilsson et al 2003). 
Additionally, memory B cell responses and serological memory against both T cell dependent 
antigens (for example, influenza virus, measles virus and tetanus toxoid) and 
T^celhindependent antigens (pneumococcal polysaccharides) are decreased in HIV-infected 
individuals (De Milito, Nilsson et al. 2004; Malaspina, Moh et al. 2005; Titanji, De Milito et 
al. 2006; Hart, Steel et al. 2007; Tejiokem, Gouandjika et al. 2007). In a study of 28 patients 
with primary HIV infection and 40 with chronic HIV infection, there was a dramatic 
reduction in plasma levels of antibodies to measles and S. pneumoniae compared to controls 
and long-term non-progressors (Titanji, De Milito et al. 2006) and in a subset of this 
population (9 primary HIV infection[PHI] and 20 chronic HIV infection[CHI]), the number 
of measles-specific ASCs was significantly reduced in HIV-infected patients compared to 
controls. Additionally, the production of measles and pneumococcus-specific IgM and IgG 
antibodies in cell culture supernatants was impaired.
Studies show that the restoration of memory B cell numbers following initiation of therapy is 
slow and incomplete (De Milito, Morch et al. 2001; Chong, Ikematsu et al. 2004; D'Orsogna, 
Krueger et al. 2007; Moir, Malaspina et al. 2008), while restoration of B cell memory 
responses is either absent or incomplete (Malaspina, Moir et al. 2005; Bekker, Scherpbier et 
al. 2006; Titanji, De Milito et al. 2006; Hart, Steel et al. 2007). In a cross-sectional analysis 
of memory B cells in a cohort of 96 HIV-infected individuals De Milito et al. failed to detect 
any improvement in the proportion of memory B cells in patients undergoing antiretroviral 
therapy (De Milito, Morch et al. 2001). A study evaluating the effect of ART on serologic 
memory in patients with PHI treated for 6 months and in patients with CHI treated for 24 
months, anti-measles titres did not recover and remained low compared with controls (Titanji, 
De Milito et al. 2006). In another study, initiation of therapy did lead to a reduction of 
spontaneous memory B cell apoptosis (Mon, Malaspina et al. 2008).
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5.1.2 Study Rationale and aims
In the light of the findings presented in chapter 4 (and Dr Oluwadamilola H. Unuigbe- 
Iwajomo findings on B cell immunity, PhD thesis 2011), the literature showing variability in 
immune reconstitution following ART and the observation that adults and children on ART 
continue to have a higher incidence of invasive pneumococcal disease (IPD) than uninfected 
individuals, we hypothesized that the pneumococcal protein specific immunity may also be 
incomplete. This study aimed to provide a clearer understanding of the kinetics and the 
degree of reconstitution of pneumococcal immunity following initiation of ART in Malawian 
adults (over a period of 12 months). We also sought to determine whether therapy has any 
effect on nasopharyngeal carriage of S. pneumoniae, which provides an insight into immune 
reconstitution at the mucosal level and the impact of ART on herd immunity.
5.1.3 Study design
After informed consent, peripheral blood was collected Irom all individuals who fulfilled the 
inclusion criteria (chapter 2: section 2.2.3b). Additionally, nasopharyngeal swabs were 
collected and cultured for S. pneumoniae to monitor pneumococcal carriage. The participants 
were followed up for a period of 12 months during which samples were collected before 
initiation of therapy and at 3, 6 and 12 months ART. The data presented in this chapter 
however are for the first 6 months of ART (the final samples collection will be completed 
after submission of this thesis and will be collated with this data for publication). Samples 
were also collected from HIV-uninfected healthy controls at month six (6) of the study 
(Chapter 2: section 2.2.3a) to assess the degree of reconstitution at 6 months ART. In line 
with previously published reports (Wilkinson, Seldon et al. 2009), controls used in this study 
were HIV-uninfected individuals and therefore not on ART. Although the perfect controls for 
the study would have been HIV-uninfected individuals given antiretroviral drugs, there is no 
published evidence that antiretroviral drugs have sufficient effects on T or B cell function 
directly, to account for the differences seen. In addition, in view of the numerous 
haematological, neurological and metabolic side effects of the drugs it would have been 
ethically unacceptable to administer ART to otherwise healthy over even a short time 
period.The immune responses obtained from controls used in the study, serve as a ‘goal post’ 
or an indicator of where the immune responses ought to be if immune reconstitution is 
complete.
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As described in section 2.2.3 (materials and methods chapter), this study was approved by 
the College of Medicine (University of Malawi) and Liveipool School of Tropical Medicine 
(LSTM) research ethics committees (Protocols: P.07/09/801 and 09.71 respectively).
5.2 Materials and Methods
5.2.1 General materials and methods are as described in chapter 2.
Antigen specific T and B cell immune responses were assessed using T cell proliferation 
assay, T (IFN-y) and B cell ELISpot assays, intracellular cytokine staining and expression of 
CD154 (Figure 5.1). Peripheral blood T and B cell immunophenotypes were evaluated as 
described in chapter 2 materials and methods (section 2.5). Additionally, nasopharyngeal 
swabs were cultured to determine carriage rates.
In this study we used whole pneumococcal protein antigens prepared from culture 
supernatants of a standard encapsulated type 2 strain (D39), a pneumolysin deficient mutant 
encapsulated type 2 (D39) isogenic pneumococci (Ply-), positive antigens control M. 
tuberculosis PPD and Inactivated influenza vaccine (Split Virion) BP (2009/2010 vaccine 
(Chapter 2: materials and methods; section 2.4) for T cell assays. To assess B cell immune 
responses we used pneumococcal recombinant proteins: CbpA, PspA, PsaA, and a 
combination of tetanus toxoid, PPD and Flu as a positive control (Chapter 2 materials and 
methods [section 2.4]). This work was done with the assistance of Mi* David Mzinza.
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Figure 5.1 | Flow chart for immunonological analysis. T cell immune responses were 
assessed by T cell proliferation, IFNy T cell ELISpot, intracellular cytokine staining assays 
and expression of CD154 using pneumoCCS D39WT and D39Ply- and positive antigen 
controls M. tuberculosis PPD and Flu. B cell immune responses assessed by B cell ELISpot 
assay using recombinant proteins: CbpA, PspA, PsaA, PdB and a combination of tetanus 
toxoid, PPD and Flu as a positive control.
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5.3 Results
5.3.1: Characteristics of the HIV-1 infected subjects commencing on ART
A total of forty eight HIV-positive patients initiating ART were enrolled to the study (median 
age 37; range of 25-55 years: 21 (44%) males and 27 (56%) females). 46 patients were 
initiated on Trio mime (stavudine, lamivudine and nevirapine), one patients received 
stavudine, lamivudine and efavirenz while the other received Zedolum N (zidovudine, 
lamivudine and nevirapine). During the follow up period (6 months ART), 2 participants died 
and 4 were lost to follow up. The median nadir absolute CD4+ T cell count was 159 cells/p 1 
(range 3-573 cells/p 1) increasing to 249 cells/pl (range: 63-760) at 6 months of antiretroviral 
therapy (Table 5.1) (see section 5.3.2). Baseline CD4+ cell counts were as follows: 15 
patients had CD4+ cell counts <100 cells/pl; 18 had CD4+ cell counts between 101 and 200 
cells/pl, 8 had CD4 cell counts between 201 and 350 cells/pl and 6 had CD4-I- cell counts 
>350 cells/pl (commencement of ART was based on WHO clinical staging as per national 
guidelines as opposed to CD4 counts).
As shown in table 5.1 at the start of the study, S. pneumoniae was detected in 27% (13/48) of 
study participants which increased to 33% (14/43) at 3 months on ART and to 40% (17/40) at 
6 months on ART. The carriages rates were not statistically different (p=0.189, Fischer’s 
exact). To assess whether there is viral suppression in the study participants, plasma viral 
load was detennined for 27 participants (27/43) at 6 months ART. All participants had viral 
load less than 5000 copies/ml. 11 had undetectable viral load, 9 had 100 - 1000 copies/ml, 4 
had 1000 -2000 copies/ml and 2 had viral load between 2000 and 4000 copies/ml.
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Table 5.1 | Baseline characteristics of the HIV-1 infected subjects commencing on ART
Time on ART
Baseline 3 months 6 months p*
No. Subjects 48 44 43
Male [No.%] 21 (44) NA NA
Female [No. %] 27(56) NA NA
Mean age [years(range)] 37(25-55) NA NA
CD4+ counts
median (range), cells/(rl 159(3-573)* 264(17-737)* 249(63 - 760) <0.0001*
median A, cells/^l NA 111.5(-50 -378) 114{-178 - 335)11
S. pneumoniae carriage [No. %] 13/48 (27)# 14/43(33) 17/42(40)* 0.189*
''Baseline versus 6 mths on antiretroviral therapy (ART), # baseline versus 6 mths on ART, * ft baseline versus 3 mths on ART
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5.3.2 Phenotypic Analysis of T Cells
5.3.2a Recovery ofCD4 T cell counts in adults during HAART
To examine immune recovery upon initiation of therapy, CD4 counts were measured in HIV- 
infected patients at months 0 (baseline/pre-therapy), 3 and 6 on antiretroviral therapy (ART). 
For comparison, measurements of CD4 counts were done in controls at the time of the 6 
months sampling of the ART patients. All HIV-infected subjects showed evidence of a 
CD4+ T cell increase after initiation of antiretroviral therapy. The CD4+ T cell count 
increased rapidly during the first 3 months (Figure 5.2; pO.OOOl) and then remained 
relatively unchanged for the next 3 months. The median change from baseline was 111.5 
cells/pl at 3 months ART (Table 5.1). This is consistent with previous reports which showed 
a biphasic reconstitution of CD4+ T cells: a steep increase during the first 8-12 weeks 
followed by a more gradual increase of CD4+ T cells (Lederman 2001; Gandhi, Spritzler et 
al. 2006; Robbins, Spritzler et al. 2009). CD4+ cell counts of the HIV infected were still 
significantly lower at 6 months ART compared to the controls (Figure 5.2; p=0.0001, 
U=29.0).
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Figure 5.21 Recovery of peripheral blood CD4 T cell counts in adults on antiretroviral 
therapy a| CD4 T cell counts were measured at baseline (pre-therapy), 3, 6 months 
ART and in controls at month 6 of the study. Red horizontal bars represent median 
values of CD4 subsets. Statistical significance was analysed using the Wilcoxon 
matched pairs when comparing CD4+ T cell counts of HIV-infected persons on ART, and 
the Mann Whitney U test in the HIV-infected and HIV-uninfected comparison.
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5.3.2b CD4+ naive and memory cells in adults during HAART
Naive, memory and effector T cell subsets were assessed based on the expression of 
CD45RA and CCR7 (as described in Chapter 4 section 4.3.2). Naive T cells (Tn) were 
defined as CD45RA+CCR7+, central memory (Tcm) as CD45RA-CCR7-I- and effector 
memory (Tem) as CD45+CCR7-. Consistent with the data shown in chapter 4 (section 
4.3.2a), we found that the relative size of the population of naive CD4+ T cells is not affected 
by HIV infection (Figure 5.3a). There were no changes in the proportion of central and 
effector memory T cells in HIV positive participants over the six months of ART (Figures 
5.3c and e). The proportion of central memory T cell remained significantly lower compared 
to controls at 6 months ART (Figure 5.3c, pO.OOOl) while the effector memory cells 
remained significantly elevated at 6 months ART (Figure 5.3e, p=0.0087, U=99.00). As 
expected there was an increase in the absolute counts of naive, central and Tem over the six 
months of ART (Figures 5.3 b, d and f; Tn: p=0.0007; Tcm: p=0.0002; Tem: p=0.0003 at 3 
months ART) but far from achieving the levels seen in the controls at 6 months ART (p= 
0.0413, U=76.00; pO.OOOl, U=8.00; p=0.0105, U=60.00 respectively).
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Figure 5.31 Incomplete reconstitution of CD4+ T subsets in peripheral blood of adults on 
antiretroviral therapy a, c and e| The frequency of naive CD4+ T cells (TN: CD45RA+CCR7+), 
central memory CD4+ T cells (TCm: CD45RA-CCR7+) and effector memory CD4+ T cells (TEM: 
CD45RA-CCR7-) in PB of HIV negative and infected persons on ART b, d and f | The frequency 
of Tn TCm and TEM CD4+ T cells in PB of HIV negative and infected persons on ART. Red
horizontal bars represent median values. Differences were calculated using the Wilcoxon 
matched pairs (HIV+ versus HIV+) and the Mann Whitney U tests (HIV+vs HIV-).
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5.3.2c Changes in Tregs and Senescent CD4+ T cells during HAART
In chapter 4, we showed that Tregs expand as HIV disease progresses and therefore we 
sought to determine whether Tregs level changes during therapy. To determine Treg levels in 
HIV-infected patients on ART, CD4+CD25high+FoxP3 cells (as percentages of CD4+ cells) 
were measured at baseline, month 3, and month 6. Controls were assessed at month 6 of the 
study. At baseline, median percentage of Tregs in HIV-infected patients was 2-45% (0-95- 
7-5%) of CD4+ cells. The median percentages decreased following initiation of therapy (1.13 
[0.30-3.73] at 3 months ART, p<0.0001(W=403.0) and 1.32% [0.61-4.65%] at 6 months 
ART, pO.OOOl). The median percentage of Tregs of the patients was still significantly 
higher compared to the controls [0-65% (0.27-1-47%), p=0.0002, U=51.00] at 6 months ART 
(Figure 5.4).
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Figure 5.41 Phenotypic analysis of T regulatory cells in peripheral blood of adults on 
antiretroviral therapy. a| The frequency of CD4+CD25hlFoxP3+ Tregs cells in HIV 
negative (controls) and infected persons on ART at baseline, month 3 and 6. Red 
horizontal bars represent median values of CD4 subsets. Statistical significance was 
analysed using the Wilcoxon matched pairs when comparing Tregs of HIV-infected 
persons on ART, and the Mann Whitney U test in the HIV-infected and HIV-uninfected 
comparison.
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Chronic immune activation and persistent infections in HIV-1 infected individuals provide an 
environment that favours accelerated replicative senescence of T cells (Cao, Jamieson et al. 
2009; Desai and Landay 2010). One characteristic feature of senescent T cells is the loss of 
CD28 costimulatory molecule (Merino, Martinez-Gonzalez et al 1998) and increase in the 
proportion of CDS7+ T cells (Brenchley, Karandikar et al. 2003). These markers were used 
to assess the effect of antiretroviral therapy on T cell aging. Whole blood was incubated with 
anti-human antibodies CD3/CD4/CD28/CD57 and analysed for replicative senescence by 
determining the frequency of CD4+CD28-CD57+ T cells (Figure 5,5a).
In patients, median percentages of CD4+ CD28-CD57+ decreased after initiation of ART 
(Figure 5.5b; baseline: 1.87% [0-17-59*34%], 3 month ART: 1*02% [0*02 - 26*26%, 
p=0.0005, W:=407.0] and 6 month ART: 1.21% [0*08- 36*91%]), The median percentage of 
senescent cells in controls was 0.42% (0.12-2.85%) and significantly lower compared to 
baseline (p = 0*0242, U=89.0) but not statistically different to either 3 or 6 months ART.
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Figure 5.51 Phenotypic analysis of Senescent T cells in peripheral blood of adults on 
antiretroviral therapy a| Representative phenotypic analysis of CD28 and CD57 
expression in peripheral blood CD4+ T cells b| The frequency of CD28-CD57+ 
senescent cells in PB of HIV negative and infected persons on ART. Red horizontal bars 
represent median values of senescent T cells. Statistical significance was analysed using 
the Wilcoxon matched pairs when comparing CD4+ T cell counts of HIV-infected 
persons on ART, and the Mann Whitney U test in the HIV-infected and HIV-uninfected 
comparison.
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5.3.3 Functional analysis of CD4 T cells in peripheral blood of adults on antiretroviral therapy
Having established that the numbers of circulating effector memory and central memory 
(Tcm) T cells were recovering during antiretroviral therapy, we sought to establish whether 
the functions of these cells were recovering as well. The function of the effector T cells was 
assessed using the T cell ELISpot assay while the function of central memory T cells was 
determined by assessing their proliferative capacity using the CFSE proliferation assay. In 
addition, we also assess the ability of CD4 T cells to express the CD 154 molecule and 
produce cytokines using an intracellular cytokine assay.
5.3.3a Regeneration of pneumococcal-specific T cell ELISpot responses during antiretroviral therapy
In chapter 4 we demonstrated that pneumococcal-specific effector function measured by T 
cell ELISpot was compromised especially in individuals with CD4 count <350 cells/pl. 
Following initiation of therapy, the median number of pneumococcal (D39WT)-specific IFN- 
Y SFC/106 PBMC increased significantly in the first three months of therapy (Figure 5.6a; 
p=0.0388, W=222.0). This effector function did not increase further at six months of ART. 
The ELISpot responses were significantly lower compared to controls (median for controls: 
24 SFC) at 6 months ART (p=0.0244, 11=57.00). Although, there was an increase in the 
median number of responding cells following stimulation with pneumolysin deficient mutant 
(D39Ply~)(Figure 5.6b; median: 3 months 3 SFC, 6 months 3.5 SFC and controls 41 SFC), 
the difference was not statistically significant even at 6 months ART (p=0.1304, W—82.00). 
The ELISpot responses were still significantly lower compared with controls at 6 months 
ART (p=0.0006, U=26.00). There was no recovery in the ELISpot responses to the positive 
control antigens PPD or influenza vaccine (Figures 5.6c and d).
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Figure 5.6 | Ex vivo interferon-gamma (IFN-y) ELISpot responses to pneumococcal 
protein antigens after overnight stimulation of PBMCs of adults on antiretroviral 
therapy. IFN-y ELispot response to a| pneumoCCS derived from a WT pneumococcal 
strain (D39) b| pneumoCCS derived from a Ply negative (-) D39 mutant c and d| positive 
control antigens M. tuberculosis PPD and influenza vaccine respectively. Black horizontal 
bars represent median values of total responses minus background. Statistical 
significance was analysed using the Wilcoxon matched pairs when comparing CD4+ T cell 
counts of HIV-infected persons on ART, and the Mann Whitney U test in the HIV-infected 
and HIV-uninfected comparison. Graph represents median values of CD4 T cell responses 
minus background.
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5.3.3b CD4+ T cell proliferative responses to pneumococcal antigens during antiretroviral therapy
Following the initiation of ART, the median proportion of proliferating CD4+ T cells in 
response to the pneumoCCS derived from a WT pneumococcal strain (D39WT) increased 
from 2.197% (IQR, 0.1898-5.118) at baseline to 5.950% (3.109-7.652) at 6 month ART 
(Figure 5.7a, p=0.0384, W=-61.00). No significant differences between 6 months ART and 
HIV negative controls were observed (p=0.6606, U=62.00). We observed no significant 
differences between HIV-infected patients on ART and HIV-uninfected control subjects 
following stimulation with the pneumoCCS derived from a Ply negative (-) D39 mutant 
(Figure 5.7b). There was no significant increase in the proliferative capacity of the cells from 
HIV-infected patients in response to the positive control antigen influenza after 6 months of 
therapy (Figure 5.7c, median: 2.418% [IQR, 0-10.42] at baseline and 3.304% [0.5475-8.340] 
p=0.3399) at 6 months ART. The proliferative capacity of the CD4+ T cells (in response to 
Flu antigen) remained significantly lower than that of HIV-uninfected control subjects 
(pK).0346, U=33.50).
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Figure 5.7 | Proliferative capacity of pneumococcal-specific CD4+ T cells during 
antiretroviral therapy. Percentage of proliferating CD4+ T cells in response to a| 
pneumoCCS derived from a WT pneumococcal strain (D39) b| pneumoCCS derived from 
a Ply negative (-) D39 mutant c| positive antigen control Influenza vaccine at baseline, 
month 3, 6 and controls. Red horizontal bars represent median values. Statistical 
significance was analysed using the Wilcoxon matched pairs when comparing CD4+ T 
cell counts of HIV-infected persons on ART, and the Mann Whitney U test in the HIV- 
infected and HIV-uninfected comparison. Graph represents median values of CD4 T cell 
proliferation minus background.
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5.3.3c Restoration of the induction ofCD154 (CD40L) on activated CD4 T cells in response to pneumococcal 
antigens during antiretroviral therapy
Having shown that the expression of CD 154 on activated CD4+ T cells in response to 
pneumococcal protein antigens is impaired in asymptomatic HIV infected individuals 
(chapter 4 section 4.3.4), we sought to ascertain whether antiretroviral therapy can restore this 
function. Frequencies of activated CD4+ T cells expressing CD 154 tended to be higher at 6 
month ART compared baseline following stimulation with pneumoCCS derived from a WT 
pneumococcal strain (D39WT) (Figure 5.8a; p=0.05). No significant differences were 
observed between 6 month ART and the control group (p=0,57). The proportions of CD154 
expressing cells was similar between HIV-infected persons on ART and controls in response 
to the pneumoCCS derived Rom a Ply negative (-) D39 mutant (Figure 5.8b; p=0.2838[ 6 
months ART versus control group]). There was no recovery in CD 154 expression with regard 
to the control antigens M. tuberculosis PPD (Figure 5.8c, p=0.3643, W—46.00). However, 
there was recovery of Influenza responses after 6 months of ART (Figure d; p=0.0379, W=- 
160.0). CD154 expression in response to PPD and influenza after 6 months of ART remained 
significantly lower compared with controls (p^0.0114, U=80.50 and 0.0042, 11=67.50 
respectively).
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Figure 5.8 | Induction of CD154 (CD40L) on activated CD4 T cells from adults on ART.
Induction of CD154 in response to a| pneumoCCS derived from a WT pneumococcal 
strain (D39WT) b| pneumoCCS derived from a Ply negative (-) D39 mutant c an d| 
positive antigen control M. tuberculosis PPD and influenza respectively. Red horizontal 
bars represent median values of total responses minus background. Statistical 
significance was analysed using the Wilcoxon matched pairs when comparing CD4+ T 
cell counts of HIV-infected persons on ART, and the Mann Whitney U test in the HIV- 
infected and HIV-uninfected comparison.
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5.3.3d Cytokine-producing CD4+ T cells during antiretroviral therapy
Percentage cytokine secreting T cells (IFN-y, IL-2 and TNF-ct) in peripheral blood before and after 6 
mouths ART compared to HIV-uninfected adults
The percentage of cytokine-producing CD4+ T cells (IFN-y, IL-2 and TNF-a) was used to 
assess the frequency of antigen-specific cells before and after 6 months ART. There was no 
difference in the total percentage of D39WT-specific peripheral blood CD4+ T cells between 
pre-therapy and 6 months ART (median, 0.0990 vs. 0.0790%; p=0.4210, W=35.00; Figure 
5.9a) and there was no difference between 6 months ART and controls (median, 0.0790 vs. 
0.0740%; p=0.5136; Figure 5.9a). Similar results were observed for D39 pneumolysm mutant 
(median, 0.0610 vs. 0.1120 vs. 0.0550, p=0.4212, W=-40.00 [baseline vs. 6 months ART]; 
p=0.0644 [6 months ART vs. controls]) (Figure 5.9b). Frequencies of Flu-specific CD4 T 
cells were similar between baseline and 6 months ART (median, 0.0495 vs. 0.0610; 
p=0.3786, W—32.00) but was lower compared to controls at 6 months ART (median, 0.0610 
vs. 0.1700%; p=0.0432, U=38.50); Figure 5.9c).
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Figure 5.9 | No change in the frequency of antigen-specific CD4+ T cells before and after ART
Percentage of cytokine-producing CD4+ T cells (IFN-yJNF-a and IL-2) in response to a| 
pneumoCCS derived from a WT pneumococcal strain (D39WT) b| pneumoCCS derived 
from a Ply negative (-) D39 mutant c| positive antigen control influenza vacciine. Red 
horizontal bars represent median values of total responses minus background. Statistical 
significance was analysed using the Wilcoxon matched pairs when comparing CD4+ T 
cell counts of HIV-infected persons on ART, and the Mann Whitney U test in the HIV- 
infected and HIV-uninfected comparison. Analysis was done using data analysis 
programs PESTLE and SPICE (Simplified Presentation of Incredibly Complex Evaluations)
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Analysis of multifunctional profile of CD4+ T cells before and at 6 months ART
Based upon the inability to simultaneously produce effector cytokmes, dysfunction of T cells 
is a hallmark of the chronic phase of HIV infection (Betts, Nason et al. 2006). With the 
reduction of the viral load and increase in CD4+ T cell levels after initiation of antiretroviral 
therapy, it was hypothesized that there would be a change in the ability of CD4+ T cells to 
simultaneously produce effector cytokmes. The relative proportions of pneumococcal- 
specific mo no functional (cells producing one cytokine), bifunctional (two cytokines), and 
polyfimctional CD4 T cells (three cytokines) were evaluated at baseline, 6 months ART and 
in HIV-uninfected controls. At baseline, D39WT- and D39Ply-specific responses were either 
mono or bifunctional with more than 75% of these cells mono functional (Figure 5.10). At six 
months ART over 25% of the cells were bifimctional with about 2% of cells coexpressing 
three cytokines. The cells from HIV-negative persons coexpressed two or three cytokines. 
For the control antigen Flu, nearly all cells expressed a single cytokine at baseline. At six 
months ART about 25% of the cells were producing two cytokines (Figure 5.10).
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Figure 5.10 | Polyfunctional CD4+ T cell profile pre-ART, 6 months ART and HIV- 
uninfected controls. Cytokine positive CD4+ T cells were analyzed for different 
combinations of IFN-y TNF-a, and IL-2. Pie charts represents the median proportions of 
D39WT, D39Ply- and Flu-specific polyfunctional (cells producing three cytokines, red), 
bifunctional (cells producing two cytokines, blue) and monofunctional (cells producing 
one cytokine, green) out of the total cytokine CD4T-cell response. Graphical 
representations of T-cell responses (using background-deducted flow cytometric data) 
was generated using data analysis programs PESTLE and SPICE (Simplified Presentation 
of Incredibly Complex Evaluations).
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5.3.4 Phenotypic Analysis of B Cells 
5.3.4a Memory B cells
Memory B cells are central to the swift amplified immune response observed following re­
exposure to an antigen (Crotty, Aubert et al. 2004; Pollard, Perrett et al 2009). This is 
demonstrated by a significant increase in antigen-specific B cells in the bone marrow and 
spleen following immunisation or exposure to a pathogen. They are involved in the 
maintenance of the supply of long-lived plasma cells to maintain long-term antibody levels 
even when there is no re-exposure to antigen (Slifka, Antia et al. 1998; Bernasconi, Traggiai 
et al. 2002). Memory B cells are generated in histological structures called the germinal 
centres (Vinuesa, Sze et al. 2003). In the germinal centres, naiVe B cells mature into 
antibody-secreting plasma cells or memory B cells after activation, proliferation, somatic 
hypermutation of rearranged V region genes, isotype switching of immunoglobulin, and 
antigen selection (Rajewsky 1998; Vinuesa, Sze et al. 2003).
Memory B cells co-express cell surface receptors; CD 19 and CD27. Additionally, they 
express somatically mutated IgG, IgA, IgM or IgD receptors (Maurer, Fischer et al. 1992; 
Klein, Rajewsky et al. 1998; Tangye, Liu et al. 1998; Agematsu, Hokibara et al. 2000). 
Memory B cells can be divided into two subsets, namely iso type-switched and IgM memory 
B cells. Iso type-switched memory B cells (CD19+, CD27+ IgM' IgD"), express IgG or IgA 
receptors and differentiate into plasma cells secreting IgG, IgE or IgA. The other subset, IgM 
memory B cells (CD 19', CD27+, IgM+ IgD+) express IgM somatically mutated variable 
region genes.
IgM memory B cells have a prediversified IgM antigen receptor and are capable of 
responding immediately to the antigens of encapsulated bacteria (such as S. pneumoniae) in a 
T-cell-independent fashion (Kruetzmann, Rosado et al. 2003; Weller, Braun et al 2004; Shi, 
Yamazaki et al. 2005). On the other hand, switched memory B cells require T-cell co­
stimulation to produce IgG and other isotypes of antibody and are known to promote long­
term serological memory. (Klein, Rajewsky et al. 1998; Shi, Agematsu et al. 2003; Hart, 
Steel et al. 2007). Peripheral IgM memory B cells appear to be the circulating correlate of 
marginal zone B cells in the spleen (Moir and Fauci 2009).
155
CHAPTER 5 PIMEUMOCOCCAL IMMUNITY IN HIV-INFECTED ADULTS COMMENCING ON 
HAART-WHEN DOES IMMUNE RECONSTITUTION OCCUR?
IgM memory B cells are thought to be important in immunity against pneumococcal infection 
as they have been shown to produce high-affinity IgM antibodies early in the course of 
pneumococcal infection which may restrict the replication of the bacteria in circulation (Shi, 
Yamazaki et al. 2005; Hart, Steel et al. 2007). Enumerating the numbers of antigen-specific 
memory B cells may serve as a surrogate of immune memory, since immune responses 
following vaccination are evident even when antigen-specific antibodies are no longer 
evident (Nanan, Heinrich et al. 2001).
5.3.4b Memory B cells in adults during ART
As stated in the introduction of this chapter, HIV infection is associated with a wide range of 
B cell defects including reduction of CD19+CD27+ memory B cells. To evaluate the effects 
of ART on memory B cells, absolute counts and percentages of memory B cells defined as 
CD19+CD27+ lymphocytes were determined at baseline, month 3 and 6 of therapy and in 
control subjects at month 6 of the study. Additionally, IgM memory B cells (CD27+IgD+) 
and switched memory B cells (CD27+IgD-) as percentages of CD19+CD27+ cells were 
evaluated. During the 6 months of antiretroviral therapy, the percentages of memory B cells 
(CD19+CD27+) in the patients remained relatively unchanged and significantly lower than in 
the controls (Figure 5.11b; baseline median(range) 27.29% [2.82-46-42], 3 months 23-09% 
[5-95 - 43*19] and 6 months 20.65% [13.71- 41-80%], pO.0001, U=19.00]. The absolute 
numbers of memory B cells remained relatively unchanged during the six months of ART 
and tended to be lower compared with HIV negative subjects (Figure 5.11c p=0.05).
A similar analysis was performed for isotype switched and IgM memory B cells (Figures 
5.1 ld,e,f and g). Consistent with the data generated in the laboratory by Dr Oluwadamilola H 
Unuigbe-Iwajomo (PhD thesis 2011), we found that the relative size and the absolute 
numbers of the isotype switched memory B cells remain unchanged during HIV infection 
(FigureS. lid and e). The proportion and absolute numbers of the IgM memory B cells in the 
patients remained relatively unchanged during the 6 months of ART and remained 
significantly lower compared to HIV negative subjects (Figures 5.1 If and g; p<0.0001, 
U=18.00 and p=0.0003, U=22.00].
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Figure 5.111 Phenotypic analysis of memory B cells in peripheral blood of adults on 
antiretroviral therapy a| Representative phenotypic analysis of memory B cells in 
peripheral blood B (CD19+) cells, b and c| The frequency and absolute numbers of 
total memory B cells in PB of HIV negative and infected persons on ART, d and e| The 
frequency and absolute numbers of isotype-switched memory B cells in PB of HIV 
negative and infected persons on ART, f and g| The frequency and absolute numbers 
of IgM memory B cells in PB of HIV negative and infected persons on ART. Red 
horizontal bars represent median values of B subsets. Statistical significance was 
analysed using the Wilcoxon matched pairs when comparing CD4+ T cell counts of HIV- 
infected persons on ART, and the Mann Whitney U test in the HIV-infected and HIV- 
uninfected comparison
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5.3.5 Functional analysis of B cells in peripheral blood of adults on antiretroviral therapy 
5.3.5a Pneumococcal specific B cell responses in HIV-l-infected Adults on ART
Work in this laboratory established that memory B cell responses to some pneumococcal 
protein antigens (e.g. CbpA) are compromised in HIV-infected individuals (JID 2011, In 
Press). We therefore sought to determine whether memory B cell responses to pneumococcal 
protein antigens recover upon starting antiretroviral treatment. The pneumococcal protein - 
specific antibody-secreting cells were enumerated by B cell enzyme-linked immunosorbent 
spot (ELISpot) as described in Chapter 2 materials and methods (section 2.8). The cells were 
stimulated with pneumococcal proteins: CbpA, PspA, PsaA and PdB. The median numbers of 
IgG producing memory B cells to CbpA, PspA and PsaA remain relatively changed following 
initiation of antiretroviral therapy. At 6 months ART, the median number of IgG producing 
memory B cells to CbpA (1 SFC/106 PBMC[IQR, 0-6]) was still significantly lower 
compared with controls (5 SFC/106 PBMC[IQR, 1-19], p=0.0408, U=68.00)(Figure 5.12a), 
No significant differences between memory B cell responses to PspA in HIV-infected 
patients at 6 months ART and HIV negative subjects (Figure 5.11b, p= 0.6599, U=89.00). 
The memory B cell responses to PsaA and PdB were significantly lower at 6 months ART 
compared to healthy controls (Figures 5.12c and d, p=0.0224, U=56.50 and p=0.0366, 
U=51.50 respectively). It should, however, be emphasised that the PsaA data must be treated 
with caution because of the low numbers of responding memory B cells.
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Figure 5.12 | Memory B cell responses to pneumococcal protein antigens during 
antiretroviral therapy. Memory B cell response to a | CbpA b | PspA c| PsaA d | PdB. Red 
horizontal bars represent median values of total responses minus background. Statistical 
significance was analysed using the Wilcoxon matched pairs when comparing CD4+ T 
cell counts of HIV-infected persons on ART, and the Mann Whitney U test in the HIV- 
infected and HIV-uninfected comparison.
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5.4 Discussion
Initiation of antiretroviral therapy leads to a reduction in HIV-1 related opportunistic 
infections and a reduction in the incidence and magnitude of IPD (Kaplan, Hanson et al. 
2000; Grau, Pallares et al. 2005). Whether pneumococcal- specific protective immunity 
returns and how naturally-acquired pneumococcal immunity changes with ART immune 
reconstitution is unknown. To examine the dynamics of immune reconstitution (in the context 
of pneumococcal immunity), we carried out a detailed assessment of CD4 and memory B 
cells subsets in peripheral blood of HIV-infected adults initiated on antiretroviral therapy and 
examined their functional capacity when stimulated with pneumococcal protein antigens and 
compared them with uninfected adults. We show that in addition to the recovery of CD4+ T 
cells and to a limited extent, memory B cells, there is some restoration of pneumococcal- 
specific CD4+ T cell responses by 6 months ART but not pneumococcal-specific B cell 
memory.
Contrary to our expectations, pneumococcal carriage rates did not decrease during the 6 
months of ART but were not significantly increased at both 3 and 6 months ART, although 
no. These results are unlikely to be due to how the samples were collected or processed. The 
nasopharyngeal swabs were taken by the same and well experienced individuals over the six 
months study period. The apparent increase in the carnage rates may be due to seasonal 
variation. Baseline samples were taken in December and January (summer months) while the 
six month follow-up samples were taken in June and July (winter months). There is an 
increased chance of person-to-person spread of the pneumococcus during winter because of 
colds and influenza. However, the pneumococcal carriage rate of the HIV negative subjects at 
6 month (taken in winter months) of the study was 10% which was comparable to the rate 
observed in chapter 4 where the samples were taken (mainly) during the summer months. 
The serotypes of the S. pneumoniae isolates have not been identified yet and as such we have 
not been able to determine whether ART affect the serotype(s) of the colonising S. 
pneumoniae.
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Following the initiation of antiretroviral therapy and as expected we observed a rapid 
increase in the CD4 T cell counts in the fust three months of therapy. This is consistent with 
previous observations that showed that during the first 8-12 weeks of therapy, there is a steep 
increase in circulating CD4+ T cells. The studies further showed that reconstitution of 
circulating CD4+ T cells occurs in two phases: a rapid increase in the first 8 to 12 weeks 
followed by a more gradual increase in CD4 T cell counts (Lederman 2001; Gandhi, Spritzler 
et al. 2006; Robbins, Spritzler et al. 2009). The rapid first phase of CD4+ T cell recovery 
coincides with the rapid reduction in activated CD4+ cell populations (Robbins, Spritzler et 
al. 2009). The increase in the CD4+T cell counts was observed in nearly all patients 
regardless of their baseline CD4 T cell counts. Several other studies have shown that the net 
yearly increases in CD4 T cell counts are independent of baseline CD4 T cell counts (Hunt, 
Decks et al. 2003) and ART regimen assignment (Robbins, Spritzler et al. 2009).
As stated in the introduction of this chapter, data from a number of studies suggest that 
patients who start therapy with low nadir CD4 T cells are less likely to adequately repopulate 
CD4 T cells even if they achieve long-term viral suppression. In this study, 68% of the 
patients started therapy with CD4 T cell count less than 200 cells/ul and the data suggest that 
most of them may have achieved viral suppression by six months ART. It remains to be seen 
therefore whether these individuals will adequately repopulate CD4 T cells after long-term 
viral suppression and also experience fewer episodes of opportunistic infections (French, 
Keane et al. 2007). Only one study has reported normalization of total CD4 T cell numbers 
in adults who started therapy with low baseline CD4 T cell counts (<200 cells/pi) and this 
was after at least 7 years of therapy (Vrisekoop, van Gent et al. 2008).
162
CHAPTER 5 PNEUMOCOCCAL IMMUNITY IN HIV-INFECTED ADULTS COMMENCING ON 
HAART-WHEN DOES IMMUNE RECONSTITUTION OCCUR?
The relative size of naive, central and effector memory CD4+ T cells remained unchanged 
after 6 months of therapy. There were however modest increases in the absolute counts of 
naive, central and effector memory cells over the 6 months of therapy. Studies done in the 
last decade have demonstrated reconstitution of CD4+ T cell subsets within weeks of 
initiation of therapy. Using data from 978 patients (621 with comprehensive immunological 
assessments) fi’om the AIDS [Acquired Immunodeficiency Syndrome] Clinical Trials Group 
protocol 384, a randomized international trial of initial ART, Robbins et al. showed that ART 
reconstitutes T cell subsets (naive and memory T cells) regardless of baseline CD4+ T cell 
count (Robbins, Spritzler et al. 2009). However, the degree of reconstitution of was 
dependent on baseline CD4+ cell counts.
Although, we did not determine which subset of CD4 T cells reconstitute first, studies have 
shown that the reconstitution occurs in two phases. During first phase of CD4 T cell 
reconstitution (~8-12 weeks), the increase in CD4+ T cells is primarily an increase in the 
cells of the memory phenotype (Lederman 2001; Moore and Keraly 2007; Robbins, Spritzler 
et al. 2009) and the naive CD4 reconstitute mainly in the second phase of the cellular 
increase. Thus CD4 T cells of the memory phenotype generally reconstitute earlier than naive 
T cells. Additionally, in chapter 4 of this thesis we demonstrated that effector memory T cells 
decline at a slower rate compared to central memory CD4+ T cells during HIV infection, it is 
not clear from the data obtained in this study as to which subset of memory T cells 
reconstitutes first during ART.
As stated earlier, patients with low baseline CD4 T cell count (some studies used CD4< 200 
cells/pl as a definition of low baseline CD4 T cell count while others used < 350 cells/pl) at 
the start of therapy tend to have smaller increases in naive T cells and greater increases in 
memory T cells resulting in persistently abnormal absolute cell counts and CD4+ naive- 
memory cell ratios (Vrisekoop, van Gent et al. 2008; Robbins, Spritzler et al. 2009). With 
regard to our study, it is too soon to assess whether there are greater increases in the memory 
T cells compared to naive T cells. The study participants are probably in a transition phase: 
from the first phase (which is characterised mainly by reconstitution of memory CD4+ T 
cells) moving into the second phase of reconstitution (which is characterised mainly by 
reconstitution of naive CD4+ T cells).
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In chapter 4 we showed that Tregs expand as disease progresses. Data here show that the 
Tregs (measured as CD4+CD25hlFoxP3+) contracted during the first 6 months of ART. This 
may be due to a decrease in immune activation (Robbins, Spritzler et al. 2009) which in 
advanced disease probably causes the expansion of the Treg population as an attempt to slow 
down disease progression. Others however have shown (using different phenotypic 
identification methods of Tregs such as CD25CD127lowCD4 and CD4CD25hl) that ART has 
little influence on the proportion of Tregs (Lim, Tan et al. 2007; Gaardbo, Nielsen et al. 
2008).
In addition to CD4 T cell recovery and reduction in the relative size of Tregs, there was a 
reduction in the senescence levels of CD4 T cells. Chronic antigenic stimulation and immune 
activation during HIV infection are thought to accelerate T cell differentiation resulting in 
cells that eventually lose expression of CD28 and increase the expression of CD57 (Appay 
and Sauce 2008; Cao, Jamieson et al. 2009; Desai and Landay 2010). Since antiretroviral 
therapy reduces the antigen load (by extension antigenic stimulation) and immune activation 
this may partly explain reduction in the senescence levels of CD4+ T cells.
Our study indicates that by 6 months ART there are signs of regeneration of pneumococcal 
specific CD4+ T cell responses including effector memory responses (ex vivo IFN-y ELISpot 
responses), ability to proliferate (central memory responses), ability to express the 
costimulatory molecule CD 154 and ability to produce simultaneously multiple cytokines 
(polyfunctional capacity). Several studies have demonstrated that antigen specific CD4+ T 
cell responses to prevalent antigens (e.g. Candida, cytomegalovirus and mycobacterial 
antigens) are readily restored following initiation of therapy and suppression of viral 
replication (Lange, Valdez et al. 2002; Keane, Price et al. 2004; Furco, Carmagnat et al. 
2008; Sutherland, Young et al. 2010). Because of the high rates of nasopharyngeal carriage in 
Malawi, pneumococcal antigens can be considered prevalent antigens. Therefore, it is not 
surprising that by 6 months ART there is some restoration of immune responses to S. 
pneumoniae. It would be interesting however, to determine whether this restoration is 
sustained in the long-term.
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Studies have also shown that for some antigens (e.g. CMV) restoration of CD4 T cell 
responses may be short-lived and least effective in severely immunodeficient patients (Lange, 
Valdez et al. 2002; Sieg, Mitchem et al, 2002; Lederman, Williams et al. 2003; Keane, Price 
et al. 2004; French, Keane et al. 2007). The data to be obtained at 12 months ART may shed 
some light on the robustness and durability of the regenerated immunity against pneumcoccal 
T-cell dependent antigens.
HIV infection leads to loss of memory B cells. In our study, the relative size and the absolute 
numbers of memory B cells remained unchanged after six months of therapy and remained 
lower compared to controls. Studies elsewhere have also shown that the increase in the 
percentage and number of CD27-expressing resting B cells (classic resting memory B cells) 
following initiation of therapy occurs slowly and fail to normalise (De Milito, Morch et al. 
2001; Chong, Ikematsu et al. 2004; D’Orsogna, Krueger et al. 2007). Consistent with the 
work done in this laboratory by Dr Oluwadamilola H. Iwajomo, the relative size of the 
population of switched-memory B cells was not affected by HIV infection but there was loss 
of IgM memory B cells in HIV-infected individuals (Iwajomo, In press). At 6 months ART 
the proportion and absolute numbers of the marginal memory B cells remained significantly 
lower compared with HIV negative subjects. Marginal zone B cells are thought to play a 
protective role against infection with encapsulated bacteria including S. pneumoniae (Martin, 
Oliver et al. 2001) (Martin and Kearney 2002; Rruetzmann, Rosado et al. 2003). Failure of 
the marginal zone memory B cells to expand may partly explain why HIV-infected persons 
on treatment are still at a higher risk of pneumococcal infections compared to HIV-uninfected 
individuals (Heffeman, Barrett et al. 2005),
In contrast to CD4+ T cell responses, there was no regeneration of memory B cell responses 
to T-cell dependent pneumococcal antigens at 6 months ART. Recent studies on 
reconstitution of immunity to some T-cell-dependent antigens (for example, influenza virus, 
measles and tetanus toxoid) indicated that restoration of memory B cell responses during 
anthetroviral therapy is either absent or incomplete (Malaspina, Moir et al. 2005; Titanji, De 
Milito et al. 2006; Hart, Steel et al. 2007).
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Failure to detect restoration (poor restoration) of B cell responses in our study may be due to 
the fact that at six months of therapy it is still early to observe any regeneration of antigen- 
specific memory B cell pools since at this stage memory B cells have not started recovering. 
In some cases, the number of antigen-specific memory B cells may be very low to detect any 
restoration. Furthermore, lack of restoration of antigen-specific memory B cells may be due 
to defects in the CD4+ T cell compartment which have not been fully restored at 6 months 
ART. For instance, CD4+ T-cell help given to B cells has been shown to be defective in 
HlV-viremic individuals as a result of an impaired interaction between the CD154(CD40L) 
on the T cells and CD40 on the B cells (Mon, Ogwaro et al. 2003). Patients in this study 
however will be follow-up for another six months to assess whether there is any regeneration 
of B cell responses to pneumococcal T cell dependent antigens at 12 months ART.
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6.1 Introduction
Evidence presented in previous chapters showed that HIV infection causes a range of 
immune defects which do not entirely resolve with ART. This may be reason why HIV- 
infected individuals on ART are still at an increased risk of invasive pneumococcal disease 
(IPD) compared to HIV-uninfected individuals. A recently completed study however showed 
that PCV7 vaccination prevented recurrent invasive pneumococcal disease in a cohort of 
HIV-infected Malawian adults (French, Gordon et al. 2010) suggesting that vaccines may 
offer a further option for protection against IPD in HIV-infected individuals. Having 
demonstrated (in previous chapters) that natural immunity to the pneumococcus is impaired 
we wondered whether this will be true of vaccine antigens. A study [capitalising on a 
recently completed vaccine trial in Malawian adults (French, Gordon et al. 2010)] was 
therefore designed to assess the effect of HIV infection on the immune memory mounted in 
response to vaccine antigens.
6.1.1 Rationale and Aims
In the light of the findings in chapter 4 and 5, the aim of this study was to define the 
robustness and disability of immune memory conferred by a vaccine antigen hi the context of 
HIV infection and antiretroviral therapy. In the absence of pneumococcal protein vaccines, 
diphtheria toxoid (DT) [the carrier protein in the 7-valent pneumococcal conjugate vaccine 
[PCV7]) was used as a model vaccine antigen. Additionally, the study sought to determine 
whether there are any surrogate markers of long term memory conferred by vaccine antigens. 
In a population where carriage rates are high, naturally-induced pneumococcal T cell 
responses were used as a positive control.
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The use of pneumococcal T cell responses as a positive control in this study offered an 
opportunity to: i) compare naturally-induced and vaccine induced surrogate markers, ii) 
assess the effects of vaccination on nasopharyngeal carriage rates and iii) study individuals 
well established on ART. M. tuberculosis PPD was also used as a another positive. PPD 
represents a model of T cell responses induced by vaccination with bacillus Calmette-Guerin 
live vaccine or presumably by sub-clinical infection with environmental mycobacteria­
expressing antigens that cross-react with PPD (Oftung, Borka et al. 1998; Mustafa, Oftung et 
al. 2000). For B cell memory responses tetanus toxoid was used as a positive control.
6.1.2 Study design
Study participants were drawn from the placebo arm of a recently completed double-blind, 
randomised, placebo-controlled 7-valent pneumococcal conjugate vaccine trial in HIV- 
infected and uninfected Malawian adults (French, Gordon et al. 2010). All study participants 
had recovered from a previous episode of invasive pneumococcal disease, either bacteraemia 
or meningitis (a criterion for enrolment into the original vaccine trial). Additionally, all HIV- 
infected individuals were on antiretroviral therapy (as the national roll-out of ART 
commenced during the course of the vaccine trial). 15 HIV-uninfected and 32 HIV-infected 
previous placebo recipients were recruited into the study. Two doses of PCV7 were given 
intramuscularly in the left deltoid one month apart. The vaccinees were followed up for 5 
months after the administration of the second dose of the vaccine.
As described in chapter 2 materials and methods (section 2.2,2) samples were collected at the 
time of enrolment (prior to administration of the vaccine), 1 month after the second dose and 
5 months after the completion of a two dose vaccination schedule. The study was approved 
by the College of Medicine (University of Malawi) and Liverpool School of Tropical 
Medicine (LSTM) research ethics committees (Protocols: P.05/08.665 and 08.64 
respectively).
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6.2 Materials and Methods
6.2.1 General materials and methods are as described in chapter 2.
Antigen-specific T-cell immune responses were assessed using intracellular cytokine staining 
and expression of GDI 54 (chapter 2 materials and methods [sections 2.9 and 2.11]). Memory 
B cell responses to protein antigens were assessed using IgG B cell ELISpot (section 2.8). 
Peripheral blood T and B cell immunophenotypes were evaluated as described in chapter 2 
materials and methods (section 2.5). Additionally, nasopharyngeal swabs were cultured to 
determine carriage rates. In this study we used whole pneumococcal protein antigens 
prepared from culture supernatants of a standard encapsulated type 2 strain (D39), diphtheria 
toxoid, positive antigen control M. tuberculosis PPD and tetanus toxoid as described in 
Chapter 2 materials and methods (section 2.4).
Whilst PCV7 is conjugated to diphtheria-derived earner protein CRM197, all measurements in 
this chapter were made to purified diphtheria toxoid which differs from CRM197 by one 
amino acid substitution. This work was done in collaboration with Dr Oluwadamilola H 
Unuigbe-Iwajomo (PhD Thesis 2011), who performed the B cell part of this study.
6.3 Results
6.3.1 Baseline characteristics of new PCV7 recipients
A total of forty-seven adults were recruited into the study: 15 HIV-uninfected median age 40 
years (range 32-50), 13% of them were females and 32 HIV-infected individuals median age 
40(range 34-47), 66% of them females (Table 6.1). All were clinically well at the time of the 
study without clinical evidence of ART failure. The median CD4 count for HIV-infected 
individuals was 382 (range 187-1043 cells/pl) which was significantly lower compared with 
HIV negative group (HIV negative: 719 [range 472-1410] p=0.0002). S. pneumoniae carnage 
was not detected in HIV-uninfected but was detected in 28% of HIV-infected participants 
(p=0.04 Fisher’s exact test). As previously observed (in chapter 5), it appears that ART has 
no effect on pneumococcal carnage rates. All previously HIV negative study participants 
were tested for HIV to ensure they remained HIV seronegative.
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Table 6.1 j Baseline characteristics of new PCV7 recipients
HIV-uninfected HIV-infected P*value
N 15 32 n/a
Female (%) 2/15(13) 21/32(66} 0.001
CD4, median (range)cells/pl 719(472-1410) 382(187-1043) 0.0002
Pneumococcal carriage (%) 0/15(0) 9/32(28) 0.04
*Statistical significance of differences between the HIV and HIV+ adults was tested using 
Fisher’s exact test (for sex and carriage) or Mann Whitney U test (for all others).
6.3.2 Pneumococcal nasopharyngeal rates in the study population during the 
study period
Nasopharyngeal carriage rates of S. pneumoniae in HIV-infected study participants remained 
relatively unchanged over the study period (Figure 6.1): baseline 28% (9/32), 2 months post 
vaccination 31% (9/29) and 6 months post vaccination 33% (9/27) suggesting that at this 
early tune point, vaccination may not have any effect in the overall nasopharyngeal carriage 
rates in HIV-infected persons. However, it is not known whether the serotype of the 
colonising pneumococcus changed following administration of the vaccine as has been 
shown previously. Studies from the USA and the Gambia have shown that the introduction of 
PCV7 led to significant decrease in the carnage of vaccine serotypes (Whitney, Farley et al. 
2003; Flannery, Schrag et al. 2004; Talbot, Poehling et al. 2004; Lexau, Lynfield et al. 2005; 
Millar, Watt et al. 2008) and an increase in disease incidence by non-vaccine serotypes 
(Eskola, Kilpi et al. 2001; Pai, Moore et al. 2005). Therefore, the high carriage rates in the 
HIV-mfected group may be a result of increase carriage of non-vaccine serotypes following a 
decrease in vaccine serotypes. Unlike in the HIV-infected individuals, there was a transient 
increase in the carriage rate in HIV-negative persons: baseline 0% (0/15), 2 months post 
vaccination 23% (3/13) and 6 months post vaccination 7% (1/14). As before, without 
serotype information it is difficult to hilly interpret this apparent change.
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Figure 6.11 Characteristics of pneumococcal carriage in Malawian 
adults. % pneumococcal nasopharyngeal carriage rates following 
administration of 7-valent pneumococcal conjugate vaccine (PCV7)
6.3.3 Characteristics of CD4 T ceils and CD4 T cell subpopulations in vaccinees
6.3.3a Peripheral blood CD4 T cell counts maintained throughout the study period
The CD4 T cell counts of the HIV positive participants were measured at every study visit to 
be sure that the HIV-infected participants are immunologically stable during the period of 
observation and to confirm that the counts are different from those of HIV-uninfected 
individuals, as shown in previous chapters. At baseline the median CD4 T cell count in HIV- 
infected individuals (well established on ART) was 376 cells/pl (67-1043). The CD4 T cell 
counts remained relatively unchanged for the entire period of the study (355 cells/p 1 [67-992] 
at 2 months post-vaccination, p=0.6069, W=37.00 and 386 cells/pl [78-848] at 6 months 
post-vaccination, p=0.1579, W=-88.00) (Figure 6.2). Thus there was little or no reconstitution 
of CD4 T cells in this group during the study period. As expected, the CD4 T cell counts of 
HIV-infected study participants were significantly lower compared with non-HIV study 
participants (p=0.0001, U=43.00, 6 months post-vaccination).
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Figure 6.21Stable peripheral blood CD4 T cell counts in HIV-infected patients (well- 
established on ART) during the study period a| CD4 T cell counts were measured at 
baseline (pre-vaccination), 2, 6 months post-vaccination and in HIV-uninfected adults . 
Red horizontal bars represent median values of CD4 subsets. Statistical significance 
was analysed using the Wilcoxon matched pairs when comparing CD4+ T cell counts of 
HIV-infected persons on ART, and the Mann Whitney U test in the HIV-infected and 
HIV-uninfected comparison.
172
CHAPTER 6 IMMUNE RESPONSES TO PROTEIN ANTIGENS FOLLOWING PCV7
VACCINATION AMONG HIV-UNINFECTED AND INFECTED MALAWIAN 
ADULTS ON ART
6.3.3b CD4+ naive and memory cells in study participants
The CD4 T cell subsets (naive, central and effector memory) were assessed at the beginning 
of the study and end of the study to: i) assess the effect of vaccination on CD4+ T cell subsets 
in HIV-infected individuals on ART and ii) to assess the profile of CD4 T cell subsets in 
HIV-infected individuals well established on ART and establish whether it is different from 
that of HIV negative individuals. The proportion of naive and memory (central and effector) 
in HIV-infected individuals did not change during the study period (Figure 6.3a; naive: 
p=0.2977, W=-45,00; central memory: p=0,0976, W:=-7L00; effector memory: p=0.3438, 
W=41.00). Similar results were obtained for the proportions of central and effector memory T 
cells in HIV negative individuals (Figure 6.3b; p=0.3591, W=34.00 and p=0.6257, W=17.00 
respectively). The relative size of naive T cells in the non-HIV group was however 
significantly elevated at 6 months (Figure 6.3b; p=0.0067, W=-92.00). There was no 
difference in the proportions of naive, central and effector memory T cells between HIV 
positive and HIV negative participants at 6 months after immunisation (Figure 6.3c; naive: 
p=0.8808, U=145.0; central memory: p=0.2237, U=113,0; effector memory: p=0.4533, 
U=127.0). As expected, the absolute comits were significantly lower in HIV positive 
participants compared to HIV negative study participants (Figure 6.3d; naive: p=0.0251, 
U=71.00; central memory: pcO.OOOl, U=18.00; effector memory p=0.0013, U=44.00),
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Figure 6.3 | Phenotypic analysis of CD4+T subsets in peripheral blood. a| Proportions 
of naive, central and effector memory CD4 T cells in peripheral blood of HIV-infected; 
baseline versus 6 months post-vaccination b| Proportions of naive, central and effector 
memory CD4 T cells in peripheral blood of HIV-uninfected; baseline versus 6 months 
post-vaccination c| Proportions of naive, central and effector memory CD4 T cells in 
peripheral blood of HIV negative and infected persons 6 months post vaccination (red- 
HlV-infected and black HIV negative) d | Absolute numbers of naive, central and effector 
memory CD4 T cells in peripheral blood of HIV negative and infected persons 6 months 
post vaccination. Black horizontal bars represent median values. Differences were 
calculated using the Wilcoxon matched pairs and the Mann Whitney U test. TCm- central 
memory, TEf - effector memory.
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6.3.4 Functional analysis of protein antigen-specific CD4 T cells after vaccination
6.3.4a Cytokine responses primed by immunization or natural exposure
To characterise cytokine responses primed by immunization or natural exposure, PBMCs 
from the same human subjects (before and after vaccination) were stimulated overnight with 
diphtheria (DT), pneumococcal concentrated culture supernatant (D39), and M. tuberculosis 
PPD. The cells were stamed intracellularly for IL-2 and IFN-y. At 0 month point (before 
vaccination), PBMCs samples from HIV negative study participants stimulated with 
diphtheria toxoid had few, if any cytokine-producing cells (Figure 6.4a). In comparison, cells 
treated with pneumococcal proteins (to assess naturally induced immunity), produced IL-2 
and IFN-y individually (Figure 6.4c), while the cells stimulated with PPD produced IL-2 or 
IFN-y individually or in combination (Figure 6.4e). Both pneumococcal and PPD-specific 
responses were maintained throughout the study period.
2 months after the administration the PCV7, cells stimulated with DT were predominantly 
IL-2 producing (median response 0.05%[interquartile range, 0.00-0.08]) and this response 
tended to be lower at 6 months after vaccination (median response 0.03%[interquartile range, 
0.00-0.0575])(Figure 6.4a). We also observed cells making IFN-y at the 6 month point. In 
HIV-infected study participants DT responses were not seen before or after vaccination 
(Figure 6.4b [median response at 2 month point 0.00% (interquartile range, 0,00-0,0075)]. 
There was little or no difference in the median responses for both pneumococcal proteins and 
PPD between HIV positive individuals and HIV negative persons.
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Figure 6.41 Cytokine responses primed by immunization or natural exposure.
Cytokine responses to a| diphtheria toxoid (DT)-HIV negative vaccinees b| DT-HIV 
positive vaccinees c| pneumococcal proteins - HIV negative vaccinees d| 
pneumococcal proteins-HIV positive vaccinees e| positive control PPD- HIV negative 
vaccines f|PPD-HIV positive vaccinees. Red horizontal bars represent median values 
CD4+ T cell responses. Differences were calculated using the Wilcoxon matched pair. 0 
-0 mth point (pre-vaccination). HIV negative (n=9) and HIV positive (n=9-10). 2- 2 mths 
post-vaccination, 6- 6 mths post-vaccination. IL-2- cells producing IL-2 only, IL-2/IFN-y- 
cells producing both IL-2 and IFN-y and IFN-y- cells producing IFN-y only
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6.3.4b Poor vaccine (DT)-induced CD154 expression
Activated CD4+ T cells express CD 154, providing costimulatory signals to B cells and 
antigen-presenting cells. CD 154 is therefore a central molecule in immune responses. 
Additionally, CD 154 marks a wide array of antigen-responsive CD4 T cells including nearly 
all cells that express IFN-y, IL-2 and TNF-a (Chattopadhyay, Yu et al. 2005; Bolton and 
Roederer 2009). Thus CD 154 alone can be used as global indicator of antigen specific CD4+ 
T cell responses. We therefore tested whether diphtheria toxoid presented to the immune 
system in the context of a vaccine (PCV7) induces expression of CD154 in CD4+ T cells in 
HIV negative vaccinees. Additionally, we wanted to assess whether CD 154 can be used as a 
surrogate marker of vaccine-induced responses. DT-specific responses were compared to 
those induced by natural exposure to the pneumococcus orM tuberculosis PPD. As expected 
CD4+ T cells stimulated with pneumococcal protein antigens expressed CD 154. The 
proportion of CD4+ T cells expressing CD 154 following stimulation with pneumococcal 
proteins remained unchanged throughout the study period (Figure 6.5b, 0 (pre-vaccination) 
versus 2 months post vaccination p=0.5807; 2 months versus 6 months post vaccination 
p=0.7525).
There was poor induction of CD154 on CD4+ T cells in response to diphtheria toxoid 
following PCV7 vaccination (Figure 6.5c, 0 [pre-vaccination] versus 2 months post 
vaccination p=0.0863; 2 months versus 6 months post-vaccination p=0.2837), suggesting that 
at this early time point of vaccination, the vaccine-elicited cells may not provide CD 154- 
mediated costimulation. As previously observed, M tuberculosis PPD also induced CD 154 
expression. There was a non-significant increase in PPD specific responses after 2 months of 
vaccination (Figure 6.5d, p=0.0515) but these dropped back to the pre-vaccination levels at 6 
months post-vaccination (p=0.0313).
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Figure 6.5 | Induction of CD154 (CD40L) on CD4 T cells from HIV negative vaccinees a |
Representative plots.The numbers in the gated represent the percentage CD154 
expressed on CD4 T cells. Induction of CD154 in response to b | pneumoCCS derived from 
a WT pneumococcal strain (D39WT) c|diphtheria toxoid d| positive antigen control M. 
tuberculosis PPD. Red horizontal bars represent median values of total responses minus 
background. Differences were calculated using the Wilcoxon matched pairs.
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6.3.5 Characteristics of memory B cells in vaccinees
Memory B cells and memory B cell subsets were assessed at the beginning and end of the 
study to be sure that the HIV-infected participants are immunologically stable (in the context 
of memory B cells) during the study period and to confirm that HIV-uninfected and infected 
are different as described in previous chapters. The percentage of circulating memory B 
cells in HIV positive individuals at the beginning of the study and at 6 months after 
vaccination were similar (Figure 6.6a, median 30.13% [11.03-59.80%] and 26.52% [9.660- 
52.38%], respectively; p=0.7795, W=-16.00). The proportion of memory B cells was slightly 
lower at the beghming of the study in HIV negative persons (Figure 6.6b, median 53.80% 
[33.9-70.70%] and 52.00% [37.2-75.00%] respectively; p=0.0195, W=-39.00). At both time 
points, the percentages of memory B cell were also significantly higher in the HIV negative 
group than the HIV positive group (Figure 6.6c, 0 months: p=0.0018, U=34.00 and 6 months 
post immunization: p=0.0004, 0=14.00). There was no significant change in the proportion 
of switched memory B cells during the 6 month period in both HIV positive and HIV 
negative individuals (p=0-3786, W=-32.00 and 0T289, W=-27.00 respectively. Figure 
6,7a,b). The median frequency of switched memory B cells tended to be lower in HIV 
positive vaccinees compared to HIV negative vaccines although not statistically significant 
during the 6 month period(p=0.1068, 0=43.00 and p=0.2458, 0=51.00 respectively. Figure 
6.6c).
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Figure 6.61 Phenotypic analysis of memory B cells in peripheral blood of vaccinees
The frequency memory B cells in PB of a| HIV positive vaccines b| HIV negative 
vaccinees before and after vaccination and c| The frequency total memory B cells in 
PB of HIV positive and negative vaccinees: a comparison. Black horizontal bars 
represent median values of memory B cells. Differences were calculated using the 
Wilcoxon matched pairs and the Mann Whitney U tests.
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Figure 6.71 Phenotypic analysis of switched memory B cells in peripheral blood of 
vaccines. Frequency of memory B cells in PB of a| HIV positive vaccines b| HIV 
negative vaccinees before and after vaccination and c| frequency of switched 
memory B cells in PB of HIV positive and negative vaccinees: a comparison. Black 
horizontal bars represent median values of memory B cells. Statistical significance was 
analysed using the Wilcoxon matched pairs when comparing B cells within a group 
(HIV-infected persons on their own or HIV-uninfected on their own), and the Mann 
Whitney U test in the HIV-infected and HIV-uninfected comparison
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6.3.6 Functional analysis of memory B cells following vaccination
The function of memory B cells in both HIV negative and positive following administration 
of the vaccination was assessed by IgG B cell ELISpot. The median number of IgG 
producing memory B cells to diphtheria toxoid was significantly higher after 2 months of 
administration of the vaccine compared to baseline levels in both HIV negative and HIV 
positive vaccinees (Figure 6.8a,b, HIV negative: p^O.0002; HIV positive: p=0.0096). 
However, 6 months after vaccination, the frequency of diphtheria toxoid specific memory B 
cells in the HIV positive vaccinees decreased significantly compared to 2 months after 
vaccination (p=0.0090) and compared well with levels seen at baseline (p=0.4333)(Figure 
6.8b), As expected, no post vaccine effect was observed to tetanus toxoid (Figure 6.8c, 2 
months post-vaccination: p=0.5934). The median numbers of IgG producing memory B cells 
to both diphtheria and tetanus toxoid remained consistently higher at all time points in HIV 
negative vaccinees compared to HIV positive ones (Figure 6.8c,d).
An arbitrary cut-off of 10 antibody secreting cells (ASC) was used to distinguish ‘high 
responders’ from Tow responders’. The number or percentage of ‘high responders’ in 
response to diphtheria toxoid increased in both HIV negative and HIV positive vaccines 
following vaccination (Figure 6.9a,b. HIV negative: Baseline 7%, 2 mths 73% and 6 mths 
67%; HIV positive: Baseline 3%, 2 mths 21% and 6 mths 12%). There were more ‘high 
responders’ in the HIV negative group compared to the HIV positive group. The percentage 
of ‘high responders’ was somewhat maintained in the HIV negative group while in the HIV 
positive group it decreased by nearly 50% 6 months after administration of the vaccine but 
remained higher than baseline (3%[baseline] versus 12%[6 months post vaccination]).
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Figure 6.81 PCV7 induces diphtheria toxoid specific IgG memory B cells in the 
circulation of recently vaccinated adults. Memory B cell responses were expressed as 
numbers of ASC per million cultured PBMC seeded on the ELISPOT well. a| diphtheria 
toxoid specific responses in HIV negative vaccinees b| diphtheria toxoid specific 
responses in HIV positive vaccinees c| tetanus toxoid specific responses in HIV 
negative vaccinees d| tetanus toxoid specific responses in HIV positive vaccines.
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Figure 6.91 PCV7 induces an increased frequency of high responders to diphtheria 
toxoid. Memory B cell responses were expressed as numbers of ASC per million 
cultured PBMC seeded on the ELISPOT well. a| diphtheria toxoid specific responses in 
HIV negative vaccinees b| diphtheria toxoid specific responses in HIV positive vaccines 
c| tetanus toxoid specific responses in HIV negative vaccinees d| tetanus toxoid 
specific responses in HIV positive vaccines. An arbitrary cut-off (brown dotted line) of 
10 ASC was set for antigen specific responses to distinguish 'high responders' from 
'low responders'.
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6.4 Discussion
Having established in previous chapters that naturally-induced immunity is compromised in 
HIV-mfected adults, this study investigated the impact of HIV infection on immune 
responses mounted in response to vaccine antigens. Cellular and humoral immune responses 
to diphtheria toxoid were assessed following PCV7 vaccination in HIV negative and HIV 
positive Malawian adults well established on ART.
Comparing vaccine elicited and naturally-induced CD4 T cell cytokine responses within the 
same HIV negative human subjects, we found that CD4 T cell responses to diphtheria toxoid 
were dominated by IL-2 production. CD4 T cells responses primed by natural exposure 
(responses to pneumococcal proteins) or a combination of natural and immunization 
(responses to M tuberculosis PPD) comprised IL-2 or IFN-y individually or a combination of 
the two. These observations are consistent with studies done elsewhere. A study 
investigating immune responses to immunization with two well-established licensed 
vaccines, hepatitis B vims and tetanus, showed that IL-2 was the dominant response (De 
Rosa, Lu et al. 2004). A similar observation was made by Divekar et al. They found that 
human CD4 T cells pruned by diphtheria, tetanus and hepatitis B mostly secreted IL-2 
whereas in the same individuals most CD4 T cells initially primed with live pathogens 
secreted IFN-y (Divekar, Zaiss et al. 2006). Thus IL-2 may be good surrogate marker of 
vaccine-induced immune responses.
In HIV-infected vaccinees, DT induced poor cytokine responses while responses to 
pneumococcal protems were fairly comparable to those in HIV negative persons. Cytokine 
responses to PPD were generally lower in HIV-infected vaccinees. Poor responses to the 
vaccine antigen observed in HIV-infected persons may be partly due to relatively low CD4 T 
cells counts in this group compared to the non-HIV groups and may also be a reflection of 
intrinsic defects in the CD4 T cell compartment such as T cell anergy (Hardy, Imami et al. 
2003). The fact that responses to vaccine may be poor in HIV “infected including those on 
ART, brings to the fore the need for the development of efficient vaccination strategies for 
use in HIV-mfected persons.
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We also investigated the ability of vaccine (DT) - elicited CD4 T cells to provide T cell help 
and compared this to responses induced by natural exposure. The expression of the 
costimulatory molecule CD 154 was used as a measure of T cell help. Data presented herein 
show that CD4 T cells generated naturally can offer CD 154 mediated help. This differs from 
vaccine (DT)-induced responses where CD 154 upregulation did not take place, suggesting 
that CD4 T cells generated immediately after vaccination may not provide CD154-mediated 
costimulation. Furthermore, this observation suggests CD 154 may not be a good early 
surrogate marker of vaccine-induced responses.
A similar profile of CD154 expression was observed by Chattopadhyay et al after analysis of 
CD4 T cell responses from 3 individuals with natural CMV infection and 4 individuals who 
had received a DNA vaccine encoding HIV-envA (Chattopadhyay, Yu et al. 2005). Our 
results need further investigation with pneumococcal protein-based vaccines (as they become 
available) and a larger sample size but suggest that there may be heterogeneity in the way 
protein antigens elicit T-cell help when presented to the immune system in the context of a 
vaccine and during natural exposure. In our study, we were unable to explore the relationship 
between CD 154 and cytokine expression. However, studies done elsewhere have shown that 
most of the naturally-elicited cytokine producing cells were capable of CD154-mediated help 
while cytokine producing CD4 T cells generated immediately after vaccination (and 
producing only IL-2) were unable to provide CD154-mediated costimulation 
(Chattopadhyay, Yu et al. 2005).
Analysis of memory B cell to diphtheria toxoid revealed significant differences in numbers of 
memory B cells to diphtheria toxoid, between pre- and post-vaccination samples and between 
HIV-infected and HIV-uninfected individuals. Both HIV negative and HIV positive adults 
had higher frequencies of diphtheria toxoid specific memory B cells detectable 1 month after 
complete dose of PCV7 vaccination but dropped by 6 months (almost to baseline levels in 
HIV positive adults).
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Diphtheria memory B cell frequencies were generally more robust in HIV negative vaccinees 
compared to HIV positive vaccinees, consistent with observations made by Malaspina et 
aL that memory B cell responses to T cell dependent antigens are impaired during HIV 
infection (Malaspina, Mon et al. 2005). Whereas others have shown that immunologic 
responses to vaccination with T cell dependent antigens are impaired in HIV —infected adults 
with low CD4+ T cells (Kroon, van Dissel et al 1995), our data suggest that this impairment 
is somewhat maintained in individuals well established on ART. Since the CD4 T cell count 
in the HIV-infected person has not frilly recovered, retarded memory B cell DT-specific 
responses in HIV positive adult on ART may be due to inadequate CD4+ T cell help, or 
simply low numbers of DT-specific B cell clones. The number of tetanus toxoid (a non­
vaccine related control) specific memory B cells was also higher in the HIV negative group 
compared with the HIV positive group. In this study, we observed DT response (though at 
minimal levels) before the administration of the vaccine. Natural immunity to diphtheria is 
however rather unlikely (Nanan, Heinrich et al. 2001) and the responses detected to it were 
probably residual immunity to previous vaccination. Serology (antibody titres in serum) for 
the samples obtained during the study is yet to be performed.
In summary, we have shown that IL-2 may be good early indicator or surrogate marker of 
vaccine-induced immune response and that there may be some heterogeneity in the way 
protein antigens elicit T-cell help. Data presented in this chapter also show that cellular and 
humoral responses to protein vaccine antigens are compromised and most likely short-lived 
in HIV-infected persons including those stable on ART. This calls for development of 
efficient vaccination strategies for use in HIV-infected persons. It will also be important to 
evaluate the longevity of T and B cell immunity to novel pneumococcal protein vaccines in 
both HIV positive and negative as they become available.
187
CHAPTER 7 Final Discussion
7.1 Introduction
Streptococcus pneumoniae (the pneumococcus) is a bacterial commensal that colonizes the 
mucosal surface of the human nasopharynx and only rarely causes disease in healthy adults 
(Obaro and Adegbola 2002). Pneumococcal proteins are major determinants of this 
adaptation, facilitating both colonisation and invasion through host cell attachment, toxicity 
and inflammation (Ogunniyi, Lemessurier et al 2007; Giefing, Meinke et al. 2008). Our 
research group has previously demonstrated the acquisition of natural T cell memory 
responses to pneumococcal protein antigens in an adult population in an area of high 
pneumococcal carriage and disease (Mureithi, Finn et al. 2009). The study revealed that 
memory T-cell immunity to pneumococcal protein antigens consisted of both effector 
memory phenotypes (TEm) marked by CD4+CD45RO+CCR7' T-cells which are implicated in 
pathogen clearance and long term resting central memory T-cells (Tcm), marked by the 
expression of CD4+ CD45RO+CCR7+ thought to be responsible for immune surveillance 
(Sallusto, Lenig et al. 1999; Geginat, Sallusto et al. 2001).
Although it is well established that HIV infection significantly increases the risk of invasive 
pneumococcal disease, little is known about the effect of HIV infection on the pneumococcal 
antigen-specific immunity described above. This is the first study to extensively assess the 
influence of HIV on natural- induced pneumococcal immunity in an area of high 
pneumococcal carriage, invasive disease and HIV infection. This thesis provides evidence 
that: (i) naturally induced pneumococcal-specific CD4+ T cell responses and the GDI54 
pathway are compromised in asymptomatic HIV-infected adults; (ii) in the context of 
persistent carnage, ART results in some regeneration of T cell responses to the 
pneumococcus by 6 months; and (iii) immune responses against protein antigens presented 
to the immune system in the context of a vaccine may be compromised in HIV-infected 
adults including those well-established on ART.
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These findings have raised several interesting questions about natural immunity to this 
commonly carried commensal and its reconstitution, the timing of ART, the possibility of 
using vaccines to provide additional protection to individuals starting ART with low CD4 T 
cell count and the durability and robustness of vaccine-induced immune memory in HIV- 
infected individuals including those on ART. These questions will be addressed in this 
chapter.
7.1.1 Impaired CD4 T cell functional responses to Streptococcus pneumoniae 
in asymptomatic HIV-infected Malawian adults
7.1.1.1 Phenotypic changes in asymptomatic HIV infected adults
In chapter 4, we carried out a detailed assessment of CD4 T cell subsets in both HIV-infected 
and uninfected individuals. In addition to loss of CD4 T cells in HIV infection (i) circulating 
central memory (Tcm) and naive (Tn) CD4+ T cells were preferentially lost in asymptomatic 
HIV infection; and (ii) there was overrepresentation of senescent and regulatory T cells in 
HIV-mfected individuals
There is now extensive literature to indicate that loss of CD4+ T cell subsets during HIV 
infection may be due to selective infection and killing of CD4+ T cells and constant 
recruitment of cells from one pool to another pool (Hazenberg, Hamann et al. 2000; McCune 
2001; Grossman, Meier-Schellersheim et al. 2002; Silvestri and Feinberg 2003; Stevenson 
2003). HIV replicates preferentially in memory CD4+ T cells expressing CCR5 (a co­
receptor used by HIV to infect CD4+ T cells), leading to a depletion of these cells, something 
that is particularly rapid and pronounced in the gut (Brenchley, Schacker et al. 2004). 
Conversely, HIV infection is characterised by chronic immune activation and because of this 
activation there is constant recruitment of CD4 T cells from the naive and central memory 
pools into the effector pool, creating a strain on the CD4 T cell homeostasis (Hazenberg, 
Hamann et al. 2000; McCune 2001; Grossman, Meier-Schellersheim et al. 2002).
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Early loss of naive T cells in HIV infection is partly due to abnormal thymic function. 
Maintenance of CD4 T cell homeostasis depends partly on the ability of the thymus to 
continuously export new naive T cells,- because naive T cells cannot be regenerated by 
peripheral mechanisms (Mackall and Gress 1997; Berzins, Uldrich et al. 2002; Ge, Hu et al. 
2002). HIV infection however compromises thymic export which results in poor 
replenishment of naive T cells in the periphery (Douek, McFarland et al. 1998; Hazra and 
Mackall 2005; Sempowski, Hicks et al. 2005). It is not clear what impact early depletion of 
naive T cells (mostly as a result of abrogated thymic export) has on the control of infections 
or pathogens. Nonetheless, studies done using animal models suggest that continued 
replenishment with cells from the thymus is required to maintain efficient gut mucosal 
defence (Bourgeois, Hao et al, 2008). Furthermore, naive CD4+ T cells are very sensitive to 
activation and for that reason HIV-associated chronic immune activation may cripple 
activated CD4 T cell responses against pathogens, such that only export of new naive T cells 
by the thymus can ensure sustained control of infections (Bourgeois, Hao et al. 2008).
As observed in chapter 4, there was an increase in the proportion of effector memory T cells 
in asymptomatic HIV-infected individuals. In contrast, the absolute number was not 
significantly changed. The expansion of effector memory cells was however accompanied by 
a decrease in the fraction and absolute number of central memory CD4 T cells, suggesting 
that the expansion of effector memory T cells was due to a selective absolute loss of the 
central memory cells. Using a different phenotypic classification of CD4+ T cell subsets 
based on the expression of CD127 and CD25 (receptors for IL-7 and IL-2 respectively), 
Dunham et al found that the relative expansion of the CD4+ CD127-CD25- subset (effector 
memory CD4+ T cells), was due to a selective absolute loss of the CD127-CD25low/- subset 
(naive and central memory) (Dunham, Cervasi et al. 2008). Consistent with our observation, 
they noted that the proportional expansion of effector memory CD4+ T cells correlated with 
decreased CD4+ T cell levels and the levels of immune activation (marker of disease 
progression). Dunham et al therefore concluded that the expansion of effector memory T 
cells reflected both as a determinant and as a consequence, the HIV-associated chronic 
immune activation.
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As noted in the data presented in chapter 4 and other studies done elsewhere, regulatory T 
cells expand as HIV disease progresses. A number of explanations have been given in an 
attempt to explain Tregs expansion among HIV-infected persons. Among these are: either the 
Tregs are not depleted during HIV infection or that they are expanded as an attempt by the 
immune system to slow down disease progression. Studies show that Tregs are just as 
susceptible to HIV infection as memory T cells (Oswald-Richter, Grill et al 2004). However, 
it has been proposed that immune activation drives non Tregs (CD4+CD25-FOXP3-) (upon 
activation) to convert to Tregs (CD4+CD25+FoxP3+) (Chen, Jin et al. 2003; Walker, 
Kasprowicz et al. 2003). A chronic state of activation (as seen during HIV infection) thus 
changes the rate at which Tregs are produced while providing a new avenue of cell loss of 
other T cell subsets.
An important and unanswered question is whether Tregs play a protective role or detrimental 
role during HIV infection. Tregs have been implicated in the suppression of HIV-specific T 
cell responses such that Tregs cell depletion enhances cytokine production and proliferation 
by T cells in vitro (Aandahl, Michaelsson et al. 2004; Kinter, Hennessey et al. 2004; Weiss, 
Donkova-Petrini et al. 2004; Kinter, Horak et al. 2007). For this reason, some argue that an 
increase of Tregs may impair the immune control of HIV-1 infection. Our observations and 
also those from elsewhere (Cao, Jamieson et al. 2009), show that expansion of Tregs is 
associated with HIV disease progression suggesting that the expansion of Tregs relative to 
other CD4+ T cell subsets may result in an increased suppressor-to helper ratio, leading to 
suppressed T cell immune responses to HIV-1 and other pathogens including S, pneumoniae 
and rapid progression to AIDS.
Recently, an analyses of in vitro suppressive capacity of CD25+ regulatory T cells isolated 
during chronic SIVmac 251 infection in cynomolgus macaques showed that the suppressive 
capacity of Tregs was associated with high CD4 T cell comits (Karlsson, Malleret et al. 2011) 
suggesting that in advanced HIV/SIV disease/infection (i.e. in cases of low CD4 T cell 
counts), the suppressive capacity of the Tregs may be impaired. Thus, in advanced HIV 
disease, Tregs may have little to do with suppressed T cell immune responses to pathogens. 
This however will have to be confirmed in human studies.
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One way of to investigate the suppressive capacity of Tregs at different stages of HIV disease 
would be to recruit HIV-infected individuals at different stages of HIV infection and collect 
peripheral blood. PBMCs would be isolated and split into two portions. Then Tregs would be 
depleted from one portion of the PBMCs. Thereafter, the cells whether depleted of Tregs or 
not will be stimulated with antigens to determine whether depletion of Tregs results in 
increased antigen-specific responses.
7.1.1.2 Compromised pneumococcal antigen-specific CD4 T cell responses in asymptomatic HIV 
infected adults
Characterisation of the functional properties of pneumococcal antigen-specific CD4+ T cells 
in HIV-infected Malawian adults revealed that CD4+ T cell responses were either 
compromised (IFN-y effector responses, proliferative capacity and CD 154 pathway) or 
altered (IFN-y/IL-10) in HIV infection (chapter 5).
Several mechanisms may explain the relatively poor effector memory responses to 
pneumococcal protems in HIV-infected persons. A simplistic explanation would be that the 
poor effector responses are due to low numbers of pneumococcal-specific T cell clones, a 
result of declining CD4 T cell counts. But poor pathogen-specific responses were observed 
even in individuals with relatively good CD4 T cell count (CD4 T cell count >500 cells/pl). 
Therefore, poor effector memory responses may in part be caused by poor sustenance of the 
effector memory T cell population during HIV infection. The effector memory T cell 
population is normally sustained through antigen-dependent and antigen-independent 
pathways (Geginat, Sallusto et al. 2001). It is unlikely however that poor pneumococcal- 
specific CD4 T cell responses observed in HIV-infected persons was caused by a lack of 
antigen-dependent stimulation because of the high pneumococcal carriage rates in our study 
population. High pneumococcal carnage rates should help maintain the frequencies of 
effector memory T cells.
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Central memory T cells can under the influence of cytokines derived from dendritic cells 
(antigen-independent pathway) proliferate leading to the generation of effector memory T 
cells. Among the cytokines involved in tills pathway are IL-15 (Geginat, Sallusto et al. 2001) 
and IL-23 (Brombacher, Kastelein et al. 2003). It has been shown that the generation of IL- 
23 by adherent cell fraction of PBMC (monocytes) is impaired in HIV-infected persons and 
that this was associated with decreased production of IFN-y by T cells (Lee, French et al. 
2004). The authors speculate that these poor IFN-y effector responses reflect a failure of the 
antigen-independent pathway to generate effector T cells from a pool of central memory T 
cells. Similarly, impaired proliferative capacity may be due to lack of sustained antigen- 
independent maintenance of central memory T cells. In the study described in chapter 4, 
culture supernatants were not analysed for IL-15 and IL-23. Therefore we were not in 
position to confirm whether secretion of IL-15 and IL-23 in response to pathogens is 
impaired in HIV-infected persons and by extension whether poor IFN-y responses (in 
response to pathogens) reflect a failure of the antigen-independent pathway in HIV positive 
persons.
Poor proliferative capacity may also be a reflection of T cell functional impairment in the 
form of T cell anergy (Beverly, Kang et al. 1992; Hardy, Imami et al. 2003) . Studies have 
shown that in HIV-infected persons where proliferative responses are impaired, the 
proliferative responses could be induced with high concentration of IL-2 (Hardy, Imami et al. 
2003). On the other hand, IL-2 has been shown to reverse anergic phenotype (Beverly, Kang 
et al. 1992). Taken together, these observations suggest that the poor proliferative responses 
observed in chapter 4 may be a result of T cell anergy.
In this thesis, we were able to optimise and adapt a novel assay to assess the CD 154 pathway 
in CD4+ T cells and subsequently used the assay to assess the effect of HIV-infection in 
pneumococcal antigen- induced CD 154 expression. Activated CD4+ T cells express CD 154, 
providing costimulatory signals to B cells and antigen-presenting cells (van Kooten and 
Banchereau 2000; Ma and Clark 2009). CD 154 is therefore a central molecule in immune 
responses. As noted in chapter 4, pneumococcal -specific induction of CD 154 on activated 
CD4-!- T cells was impaired during HIV-infection.
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It could be hypothesised that the impaired induction of CD 154 is caused by a selective loss of 
a CD4+ T subset capable of expressing of CD 154 upon activation since HIV infection is 
associated with a progressive decline of CD4+ T cells and subsets. However data presented 
here and elsewhere (Subauste, Wessendaip et al. 2004) suggest a specific defect in the 
regulation of the induction of CD 154.
The data presented in chapter 4 show that CD 154 expression was impaired even in 
individuals with relatively good CD4 T cell counts (CD4 cell counts above 350 cells/p 1) and 
by extension relatively intact immunity. Using concentrations of CD4+ T cells and 
monocytes that are similar to those of HIV negative persons( i.e. same ratio of CD4 to 
monocytes as in HIV-uninfected individuals), Subauste et al, observed that the expression of 
CD 154 in response to C. albicans (an extracellular pathogen) was impaired in HIV-infected 
patients (Subauste, Wessendaip et al. 2004) clearly indicating that the defective induction of 
CD154 on activated CD4+ T cells goes beyond numeric loss of CD4+ T cells.
As for the mechanism(s) underlying CD 154 dysregulation in HIV, in vitro studies suggest 
that interactions between HIV envelope glycoproteins and the CD4 receptor may play a role. 
Studies show that HIV-1 envelope proteins can cross-link CD4 molecules on the surface of 
the cell, and inhibit up-regulation of CD 154 (Chirmule, McCloskey et al. 1995; Marschner, 
Hunig et al. 2002; Zhang, Fichtenbaum et al. 2004; Rutjens, Vermeulen et al. 2008). 
Consistent with data from elsewhere, preliminary data from this laboratory showed that 
cross-linking of CD4 with mAb inhibit up-regulation of CD 154 in CD4-I- T cells (Appendix 
II).
There are several ways defective CD 154 signalling could increase susceptibility to infections. 
These mclude: decreased production of IL-12 and IFN-y (CD154 is cracial for optimal in 
vitro production of IL-12 and/or IFN-y in response to a number of pathogens), impaired 
macrophage activation, defective priming of CD4+ and CD8+ T cells and an impaired 
humoral response. Analysis of cytokmes in culture supernatants in this laboratory showed no 
difference in IL-12 concentration between HIV-positive and negative individuals (results not 
shown).
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A number of studies done in mice and humanised mice, however, have shown that CD 154 
plays a role in the generation of antibodies to pneumococcal proteins and capsular 
polysaccharides (Hwang, Nahm et al. 2000; Jeurissen, Billiau et al. 2006; Moens, Wuyts et 
al. 2008). Additionally, neutralization of CD154 has been shown to suppress antibody 
responses to pneumococcal protein (PspA) (Hwang, Nahm et al. 2000). This suggests that 
impaired CD154 expression may affect antibody response to pneumococcal proteins and 
results in poor control of IPD in HIV-infected persons.
7.1.1.3 Implications for clinical management
WHO recommends that ART should be initiated before CD4 T cell count falls below 350 
cells/p 1 regardless of symptoms (WHO 2009). Interestingly, our data show that some antigen- 
specific CD4 T cell responses are impaired even at CD4 T cell count much higher than 350 
cells/p 1. Therefore, our findings support WHO recommendations and further suggest use of 
an even higher CD4 T cell count as a threshold for initiation of therapy. This is consistent 
with suggestions made elsewhere (Robbins, Spritzler et al. 2009) that ART should be 
initiated at a threshold of 350 cells/pl or higher CD4+ T cell count at which the CD4+ naive 
cell populations and naive-memory cell ratios are more likely to be intact. In their study, 
Robbins et al. obseived that CD4+ naive-memory cell ratios were lower among patients with 
CD4 T cell count <350 cells/pl and this deficit persisted even after nearly 3 years of ART 
((Robbins, Spritzler et al. 2009). It is however doubtful if WHO recommendations can be 
fully implemented in resource poor setting (at least in the short term) for a variety of social 
and infrastructural reasons such as poorly resourced health centres especially in rural areas 
and shortage of well-trained health personnel (Van Damme 2006; Libamba, Makombe et al. 
2007; USAID 2010).
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Having demonstrated that pneumococcal-specific immune responses are compromised in 
asymptomatic HIV-infected adults, it was important to determine whether pneumococcal 
immunity can be regenerated dining ART.
7.1.2 Immune responses to Streptococcus pneumoniae following initiation of 
antiretroviral therapy
7.1.2.1 Regeneration of T cell responses to S. pneumoniae
Data presented in chapter 5 showed that by 6 months ART and in addition to increases in 
CD4 T cell counts and viral load suppression there was some regeneration of pneumococcal 
antigen-specific CD4+ T cell responses. These include effector memory responses (ex vivo 
IFN-y ELISpot responses), ability to proliferate (central memory responses) and ability to 
produce simultaneously multiple cytokines (polyfimctional capacity) (illustrated in Figure 
7.1). However, there was little or no regeneration of either PPD or Flu-specific CD4 T cell 
responses after 6 months of ART.
There are several hypothetical explanations for the reconstitution of pneumococcal antigen- 
specific CD4+ T cell responses. As stated above, diminished proliferative responses observed 
in treatment naive HIV infected individuals may have been due either to very low antigen- 
specific clone numbers or T cell anergy. The recovery of proliferative responses folio whig 
weeks of antiretroviral therapy may be a result of reversed T cell anergy (Beverly, Kang et al. 
1992; Meyaard, Schuitemaker et al. 1993; Hardy, Imami et al. 2003), Additionally, the 
reconstitution of central and effector memory responses may reflect the regeneration of the 
antigen-independent pathway and consequently the capacity to maintain a pool of central 
memory T cells (Geginat, Sallusto et al. 2001; Lee, French et al. 2004). However, the 
responses in HIV positive individuals were still lower compared to HIV-negative persons at 6 
months ART, suggesting that the regeneration of antigen-mdependent pathway was 
incomplete in this group. Another possible explanation for the rejuvenation of an immune 
response in the periphery in early stages of therapy may be redistribution of sequestered cells 
(from lymphoid tissues) rather than de novo synthesis (Evans, Bonnez et al. 1998; Bucy, 
Hockett et al. 1999).
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Figure 7.1 | Schematic summary of the influence of HIV infection and ART on 
antigen-specific responses and immunity in general (peripheral blood) a| On
encounter with antigen, T cells proliferate and acquire effector function. Activated cells 
also acquire ability to provide T cell help (by expressing CD154) to antigen presenting 
cells and B cells b| HIV infection leads to poor antigen-specific CD4 T cell responses 
(e.g. poor proliferation and cytokine responses), CD4+ T cell help (CD154 expression) to 
antigen-presenting cells and B cells and B cell responses. HIV infection also leads to 
premature aging, persistent activation and high proportion of Tregs c| Initiation ART 
leads to some regeneration of antigen-specific CD4 T cell responses, CD4 T cell help, 
viral load suppression, reduced premature aging and activation.
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The fact that T cell responses to pneumococcal antigens, recovered quicker than PPD or flu 
specific responses may be a reflection of ongoing or persistent encounter of the immune 
system with pneumococcal antigens (because of high pneumococcal carnage) which help 
preserve and then regenerate a pool of pneumococcal specific T cell clones dining chronic 
HIV infection and then upon initiation of therapy. It will be difficult to prove this in a setting 
like Malawi, where carriage rates are very high and as such there is a high prevalence of 
pneumococcal antigens. Thus, there is a persistent encounter of the immune system with 
pneumococcal antigens. However, this could possibly be tested in a setting of low 
nasopharyngeal carriage rate and low antigen prevalence.
As noted in the data presented in chapter 5, there is also some restoration of CD 154 
expression on CD4+ T cells in response to pneumococcal antigen following initiation of 
ART. As indicated above, studies on CD 154 expression during HIV infection implicated 
cross-linking of CD4 by HIV envelope glycoproteins in impairment of CD 154 expression in 
HIV-infected individuals (Zhang, Fichtenbaum et al. 2004). Additionally, studies also 
showed that impaired defective CD 154 expression was more prevalent in subjects with 
detectable plasma viral load (Zhang, Fichtenbaum et al. 2004; Subauste, Subauste et al. 
2007). These observations provide a potential explanation for improved CD154 expression 
following initiation of ART, In our study and at 6 months ART, the participants exhibited 
viral suppression. Suppression of viral replication means less viral proteins are released into 
circulation to cross-link CD4 receptors, leading to improved CD 154 expression in individuals 
on ART.
7.1.2.2 No restoration of B cell responses to 5. pneumoniae
As shown in chapter 5, ART did not restore IgM memory B cell percentages or numbers. 
This may partly explain why HIV-infected individuals on ART are still at an increased risk of 
invasive pneumococcal disease compared to HIV-uninfected persons. In fact, patients with 
reduced IgM memory B cells counts have been shown to have impaired pneumococcal IgM 
antibody responses (IgM memory B cell responses are more directed to polysaccharide) post 
vaccination compared with controls (Hart, Steel et al. 2007).
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The importance of IgM memory B cells in host protection against pneumococcal infection 
have been demonstrated in several patient groups such as children under 2 years of age, the 
elderly or patients with congenital asplenia. Reduced or absence of IgM memory B cells in 
these patient groups is associated with increased risk of invasive pneumococcal infection 
(Kmetzmann, Rosado et al. 2003; Shi, Yamazaki et al. 2005).
Additionally, lack of IgM memory B cells in patients with common variable 
immunodeficiency (CVID) and asplenic individuals has been associated with increased 
susceptibility to pneumococcal infections (Kruetzmann, Rosado et al. 2003; Carsetti, Rosado 
et al. 2004). In a study by Hart et al the reduction in IgM memory B cells in individuals on 
ART was similar to that seen in patients with CVID (Hart, Steel et al. 2007), Reduced IgM 
memory B cells in HIV-infected individuals probably explains why the 23-valent 
pneumococcal polysaccharide vaccine has suboptimal activity in HIV-infected adults and is 
not recommended for use in Africa (WHO 2008c; French, Gordon et al. 2010).
Although the difference in switched memory B cells between HIV-mfected individuals on 
ART and HIV-uninfected persons was not pronounced, responses to pneumococcal protein 
CbpA were significantly lower in the HIV-infected on ART. This suggests that HIV- 
associated immune dysfunction goes beyond the numeric loss of memory B cells. Possible 
explanations for persistently impaired CbpA-specific responses are that at 6 months ART, 
therapy had not fully reversed either the intrinsic defects in the B cell response and/ or that 
persistent defects in the CD4 T cell compartment compromised the ability of CD4 T cells to 
provide adequate help to B cells (Moir, Ogwaro et al. 2003; Subauste, Subauste et al. 2007).
The fact that IgM memory B cells (whose responses are directed towards polysaccharides) 
are reduced and antibody responses to pneumococcal proteins are unpaired suggests poor 
responses from both IgM and switched memory B cells contribute to increased risk of 
invasive pneumococcal infection observed in HIV-infected individuals ART.
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7.1.2.3 Implications for clinical management
Although, there was some regeneration of T cell responses, the responses in HIV-infected on 
ART were still significantly lower compared to controls at 6 months ART, indicating that 
additional protection may be required perhaps in the form of vaccination. The World Health 
Organisation guidelines recommend ART initiation when CD4 counts drop below 350 
cells/p 1 regardless of symptoms (WHO 2009). Our data suggest that this may be crucial in the 
context of retaining adequate response to pneumococcal protein antigens and reduce the risk 
of IPD in HIV-infected persons on ART.
7.1.3 Immune responses to protein vaccine antigens in HIV-infected Malawian 
adults on antiretroviral therapy
This part of the thesis investigated immunological memory mounted in response to vaccine 
antigens in HIV-infected Malawian adults well established on ART. Study participants were 
drawn from the placebo arm of a recently completed double-blind, randomised, placebo- 
controlled 7-valent pneumococcal conjugate vaccine trial in HIV-infected and uninfected 
Malawian adults (French, Gordon et al. 2010). The vaccine trial showed a 74% clinical 
efficacy for PCV7 in preventing pneumococcal disease caused by one of the vaccine 
serotypes and a vaccine related serotype 6A in HIV-infected Malawian adults. For the study 
described in chapter 6, diphtheria toxoid (DT) [earner protein in the 7-valent pneumococcal 
conjugate vaccine (PCV7)] was used as a model vaccine antigen.
7.1.3.1 Poor CD4 T cell responses to diphtheria toxoid in HIV-infected adults on ART
In HIV-uninfected, CD4 T cells primed by vaccination with diphtheria toxoid mostly secreted 
IL-2 hi response to diphtheria toxoid whereas in the same individuals most CD4 T cells 
pruned by natural exposure to S. pneumoniae secreted IL-2 or IFN-y individually or in 
combination in response to M. tuberculosis PPD. The fact that IL-2 producing CD4 T cell 
dominated the vaccine-mduced responses suggests that IL-2 may be an early indicator of 
vaccine-induced responses. Little or no DT responses were detected in HIV-infected 
individuals on ART. Thus even in individuals well established on ART vaccine T cell 
responses are compromised. Naturally-induced responses were detected in HIV-infected 
persons on ART but these were relatively lower than those of HIV negative individuals.
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It is not clear why IL-2 is a dominant response for ‘diphtheria toxoid’ immunization. 
However, studies done in mice have shown that CD4 T cells that produce IFN-y are short­
lived in vitro and in vivo and only cells that do not produce IFN-y efficiently developed into 
long term memory cells (Wu, Kirman et al. 2002; De Rosa, Lu et al. 2004). Therefore, the 
fact that it is the IL-2 producing cells that become memory cells may explain the dominance 
of CD4 T cells that produce IL-2 after ‘DT’ vaccination.
Studies suggest that vaccine-induced IL-2 only producing cells are uncommitted and under 
the right polarizing conditions can differentiate into Thl or Tli2 phenotypes (Divekar, Zaiss 
et al. 2006). This may have implications for pneumococcal protein vaccines especially in 
HIV-mfected persons. If pneumococcal protein vaccines are to induce strong effector T 
responses additional signals (probably in the form of potent adjuvant) may be required to 
push the pruned but uncommitted CD4 T cells into efficient effectors.
The fact that DT responses were less robust in HIV-infected group emphasises the need to 
develop efficient vaccination strategies for use in HIV-infected persons including those on 
ART. This observation also raises the possibility that although current vaccination strategies 
may offer short-term protection, additional booster doses may be required to achieve long 
lasting immune responses.
While pneumococcal proteins and PPD induced expression of CD 154 in CD4+ T cells, 
diphtheria toxoid did not induce CD 154 expression, even in healthy individuals, suggesting 
that CD 154 may not be good early correlate of vaccine efficacy or an early indicator of 
vaccine-induced responses. This observation also suggests heterogeneity in the way protein 
antigens elicit T-cell help when presented to the immune system in the context of a vaccine 
and during natural exposure.
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7.13.2 Poor B cell responses to diphtheria toxoid in HIV-infected adults on ART
Memory B cells are central to the swift amplified immune response observed following re- 
exposure to an antigen (Crotty, Aubert et al. 2004; Pollard, Perrett et al. 2009). Enumerating 
the numbers of antigen-specific memory B cells may be used as a surrogate of immune 
memory, as immune response following vaccination is evident even when antigen-specific 
antibodies are no longer evident (Nanan, Heinrich et al. 2001). Data presented in chapter 6 
showed that DT-specific memory B cells in HIV positive vaccinees were lower than in HIV 
negative vaccinees. The impaired DT-specific memory B cell responses cannot be explained 
simply by the differences in the levels of memory B cells between the two groups because 
there were no significant differences between HIV-mfected and uninfected individuals was 
seen. Impaired DT-specific memory B cell responses therefore may be a reflection of the fact 
that: 1) ART has not folly reversed intrinsic defects in the B cell response (Moir, Ogwaro et 
al. 2003), and/or 2) ART has not fully restored the ability of CD4 T cell to provide help to B 
cells leading to less optimal antibody responses. Poor and short-lived vaccine-induced 
memory B cell responses observed in HIV-infected person on ART indicates the need for 
booster doses of vaccines in HIV-infected persons to maintain a pool of antibody secreting 
cells necessary for sustained protection.
7.1.4 Impact of HIV infection, ART and PCV-7 vaccination on S. pneumoniae 
nasopharyngeal colonisation
HIV infection with or without progression to AIDS, significantly increases the risk of 
invasive disease due to the pneumococcus (Gilks OF, 1996, Dworkin MS, 2001). 
Nasopharyngeal colonization with Streptococcus pneumoniae precedes invasive 
pneumococcal disease (Bogaert, De Groot et al. 2004)). There has been conflicting data as to 
whether HIV infection increases the risk of pneumococcal nasopharyngeal colonisation. 
Recent literature however suggest that HIV infection increases the prevalence of colonisation 
in African adults (Gill, Mwanakasale et al. 2008) and children (Madhi, Adrian et al. 2007).
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Data presented in this thesis show that HIV infection increases the frequency of 
pneumococcal nasopharyngeal colonization in HIV-infected Malawian adults with advanced 
disease but not in asymptomatic HIV-mfected individuals (Table 7.1). 6 months ART or 
PCV7 vaccination of HIV-infected persons well established on ART did not reduce the 
nasopharyngeal carriage rates in HIV-infected adults (Table 7.1).
Table 7.11 Pneumococcal nasopharyngeal carriage rates in Malawian adults during 
HIV infection, ART and following PCV-7 vaccination.
HIV-ve HIV+ve
(asymptomatic)
HIV+ve
(Pre-ART)
HIV+ve 
(6 mths 
ART)
HIV+ve
(6mths Post-Vac 
& >lyr ART)
N 31 50 48 42 27
Carriage (%) 5/31(16) 7/50(14) 13/48(27) 17/42(40) 9/27(33)
Pre-ART - individuals about to start ART; 6 mths post-vaccination — PCV7 vaccination
The observation that HIV infection increases the prevalence of colonisation may partly 
explain the increased rates of invasive pneumococcal disease in patients with HIV/AIDS. It 
may also be a reflection of compromised epithelial layer in the upper respiratory tract, innate 
and adaptive immunity.
7.2 Study limitations
Streptococcus pneumoniae is primarily a mucosal commensal colonising the nasopharynx. 
Natural carriage of pneumococcus and related bacteria in the nasopharynx leads to the 
development of ‘protective’ T cell immunity both at the mucosal surface and in the 
circulation (Zhang, Bagrade et al. 2007; Mureithi, Finn et al. 2009; Richards, Ferreira et al. 
2010). This study mainly looked at the influence of HIV on pneumococcal responses in the 
periphery and as such they may not entirely reflect the effect of HIV on mucosal upper 
respiratory tract immunity. Recently, we investigated immune responses generated at 
mucosal pulmonary site which is an immune effector site (as compared to upper respiratory 
tract which is an inductive site).
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We observed that the percentage frequencies of S. pneinnoniae-antigen specific CD4+ T cells 
were higher in BAL than peripheral blood in HIV-uninfected (immunity is 
compartmentalized) (Jambo, Sepako et al. 2011). The data clearly indicated that solely 
investigating peripheral immune responses does not necessarily reflect responses generated at 
mucosal sites. Future studies would benefit if both and local mucosal responses to 
pneumococcal proteins were assessed. At the time the study (described and discussed in 
chapter 4) was undertaken, upper respiratory mucosal T cell sampling at Queen Elizabeth 
Central Hospital, Blantyre was not feasible. Such studies are now underway.
In this thesis, concentrated culture supernatants (CCS) derived from a standard strain D39 
wild-type and isogenic mutant strains lacking pneumolysin (Ply-) were to measure antigen- 
specific CD4+ T cell responses. The limitation with using concentrated culture supernatant is 
that the native pneumococcal proteins in the CCS may be complex compared to the purified 
recombinant proteins, which may affect their uptake, processing and presentation. 
Additionally, concentrated culture supernatants may contain proteins also expressed by other 
similar bacteria. Nevertheless, using concentrated culture supernatant guaranteed that 
potentially the totality of pneumococcal-specific CD4+ T cell response was captured. The use 
of pneumoCCS in our in vitro stimulation most probably mimicked the in-vivo process of 
pneumococcal antigen presentation. In addition, some purified pneumococcal proteins such 
as pneumolysin are highly toxic to T cells in then native form.
For the study done in Chapter 6, the HIV negative study group (just like the HIV study 
participants) was drawn from individuals who have had a previous episode of invasive 
pneumococcal disease. Since pneumococcus rarely causes diseases in adults, our HIV 
negative group consisted of individuals with potentially compromised immune systems 
(subtle not gross defects) and therefore they were not a true representative of an HIV negative 
control group.
In some studies described in this thesis, especially where both T and B cell assays were done, 
it not always possible to do all the assays because of insufficient PBMCs. This was 
particularly true in Chapter 6. In such cases, assays had to be prioritised. Thus in some cases 
(for example cytokine responses to diphtheria toxoid), the sample size was small. However, 
the data collected could form the basis for future studies.
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7.3 Future Studies
The data presented in this thesis raise a number of important mechanistic and clinical 
questions warranting further investigation. If addressed they would lead to a better 
understanding of the effects of HIV infection on pneumococcal immunity and reconstitution 
following antiretroviral therapy and could help in clinical care of HIV-infected persons.
7.3.1 Effects of HIV infection on pneumococcal immunity at the upper respiratory 
tract mucosal site
Studies show that HIV affects mucosal immunity and much earlier than systemic immunity 
(Guadalupe, Reay et al. 2003; Brenchley, Schacker et al. 2004; Mehandru, Poles et al. 2004). 
So far studies have focussed mainly on systemic immunity and immunity at the gut and 
pulmonary mucosal sites. Little is known about the effects of HIV on immunity at the upper 
respiratory tract. Taking into account that the pneumococcus is primarily a mucosal 
commensal colonising the nasopharynx and mucosal surface plays a significant role in the 
development of naturally acquired immunity to S. pneumoniae, understanding the effects of 
HIV on the upper respiratory tract and mucosal responses to pneumococcus may help explain 
why HIV -infected individuals have an increased risk of IPD.
7.3.2 Pneumococcal immunity following concurrent administration of ART 
and vaccine
WHO recommends that ART should be initiated before CD4 T cell count falls below 350 
ceils/p I regardless of symptoms (WHO 2009). As stated earlier, it is doubtful if this 
recommendation will be implemented in resource poor setting (at least in the short term), as 
for a variety of social and infrastructural reasons (Van Damme 2006; USAID 2010), people 
continue to access HIV testing and ART care at a late stage in their disease. Therefore, many 
HIV-infected individuals will still start ART with CD4 count <350 cells/pl. Data presented 
hi chapter 5 demonstrated that there is some regeneration of pneumococcal immunity in 
HIV-mfected persons on ART, the immunity is not as robust as seen in HIV negative persons 
suggesting that individuals on ART (especially in early stages of therapy) may need 
additional protection probably in the form of vaccination.
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There are no WHO recommendations with regard to the use of conjugate vaccines in HIV 
positive adults yet and because of suboptimal activity of the 23-valent pneumococcal 
polysaccharide vaccine in HIV-infected adults, routine PPV23 vaccination of HIV-infected 
adults not recommended for use in resource poor countries (WHO 2008d). However, WHO 
recommends the use of other measures that directly or indirectly may help prevent 
pneumococcal disease such as trimethoprim-sulfamethoxazole chemoprophylaxis (WHO 
2008d), Nonetheless, a recent study done in Malawi, the 7-valent pneumococcal conjugate 
vaccine protected HIV-infected adults from recurrent pneumococcal infection caused by 
vaccine serotypes or serotype 6A supporting a possible role for the 7-valent or similarly 
constructed vaccine among HIV-positive adults. Further studies should aim to understand 
whether there are any benefits in vaccinating individuals (perhaps with pneumococcal 
conjugate vaccines) starting antiretroviral therapy especially those with CD4 count <350 
cells/pl. The studies should also help define the optimal time, frequency and clinical 
effectiveness of additional doses.
7.3.3 Longevity of regenerated immune responses against pneumococcal 
protein antigens
Data presented in chapter 5 indicated that there is some restoration of pneumococcal CD4+ T 
cell immunity in HIV-infected persons by 6 months ART. Further data will be generated on 
this cohort by the MLW study team at 12 months ART. Studies have shown that there is 
either poor restoration of antigen-specific immune responses in individuals who are severely 
immunodeficient prior to treatment (Lange, Valdez et al. 2002; Sieg, Mitchem et al. 2002; 
Lederman, Williams et al. 2003; French, Keane et al. 2007) or the restoration is short-lived in 
this group (Keane, Price et al. 2004). An important and unanswered question is whether the 
reconstituted pneumococcal immunity observed in chapter 5 is preserved long-term 
especially in a setting like Malawi where pneumococcal carriage rates are very high. Future 
studies should therefore aim to assess the robustness and protective efficacy of immunity 
against pneumococcal protein antigens following long-term ART. A proposed study design 
would include following individuals on ART beyond 12 months and collect samples during 
their routine clinical visits and assess pneumococcal immunity.
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7.3.4 Effects of HIV and ART on nasopharyngeal flora and pneumococcal 
Serotypes
Our data show that individuals commencing on ART have higher pneumococcal carriage 
rates compared to HIV-uninfected and these rates remained relatively unchanged in the first 6 
months of ART. Questions remain as to whether HIIV infection alters: (i) the 
nasopharyngeal flora; (ii) the serotypes of the colonising S. pneumoniae (iii) the number of 
colonising pneumococcus and if so does ART in the long-term restore the nasopharyngeal 
flora and colonising pneumococcal serotypes. Until recently, it was almost possible to answer 
these questions. Serotyping methodologies were limited in the coverage of serotypes or 
detection of multiple serotype carriage. A microarray-based molecular serotyping method 
has now been developed (Hinds and Turner 2010). The method provided the ability to detect 
and identify multiple serotype carnage, co-colonization by other pathogens and also 
determine the relative abundance of each serotype present. The presence of multiple 
serotypes is detected in DNA extracted from a plate sweep of bacterial colonies grown from a 
nasopharyngeal swab. In the study described in chapter 5, nasopharyngeal swabs were 
collected before initiation of ART and at month 3, 6 and will be collected at 12 months after 
initiation of therapy. Therefore, these swabs can be used to answer the questions raised 
above.
7.4 Concluding Remarks
The findings of this thesis show that HIV compromises systemic pneumococcal immunity at 
an early stage in disease progression. This immunity is regenerated to some extent following 
initiation of ART. It remains to be seen however whether the reconstituted immunity is long­
term and protective. S. pneumoniae is a highly adapted commensal and so the challenge 
particularly in an immunocompromised population is to generate robust long lasting 
protective immunity. In fact, data presented in this thesis suggest that immune responses that 
may be elicited by vaccines based on pneumococcal proteins may be unpaired and possibly 
short-lived in HIV-infected even those on ART.
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Since S. pneumoniae is a mucosal commensal and mucosal surface plays a significant role in 
the development of naturally acquired immunity to the pneumococcus, solely investigating 
the influence of HIV on pneumococcal immunity in the periphery may not fully explain why 
HIV-infected individuals are at an increased risk of IPD. There is a need for research on 
pneumococcal immunity at the upper respiratory tract mucosal sites. Nonetheless, the 
findings of this thesis have important implications for clinical care of HIV-infected persons 
on ART and future studies on pneumococcal immunity in the context of HIV infection and 
therapy.
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APPENDIX I
WHO CLINICAL STAGING OF HIV/AIDS FOR ADULTS AND ADOLESCENTS
Primary HIV infection
• Asymptomatic
• Acute retroviral syndrome
Clinical stage 1
• Asymptomatic
• Persistent generalized lymphadenopathy (PGL)
Clinical stage 2
• Moderate unexplained weight loss {<10% of presumed or measured body weight)
• Recurrent respiratory tract infections (RTis, sinusitis, bronchitis, otitis media, pharyngitis)
• Herpes zoster
• Angular cheilitis
• Recurrent oral ulcerations
• Papular pruritic eruptions
• Seborrhoeic dermatitis
• Fungal nail infections of fingers
Clinical stage 3
Conditions where a presumptive diagnosis can be made on the basis of clinical signs or simple 
investigations
• Severe weight loss (>10% of presumed or measured body weight)
• Unexplained chronic diarrhoea for longer than one month
• Unexplained persistent fever (intermittent or constant for longer than one month)
• Oral candidiasis
• Oral hairy leukoplakia
• Pulmonary tuberculosis (IB) diagnosed in last two years
• Severe presumed bacterial infections (e.g. pneumonia, empyema, pyomyositis, bone or
• joint infection, meningitis, bacteraemia)
• Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Conditions where confirmatory diagnostic testing is necessary
• Unexplained anaemia (< 8 g/dl), and or neutropenia (<500/mm3) and or
• thrombocytopenia (<50 000/ mm3) for more than one month
Clinical stage 4
Conditions where a presumptive diagnosis can be made on the basis of clinical signs or simple 
investigations
• HIV wasting syndrome
• Pneumocystis pneumonia
• Recurrent severe or radiological bacterial pneumonia
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• Chronic herpes simplex infection (orolabial, genital or anorectal of more than one month's 
duration}
• Oesophageal candidiasis
• Extrapulmonary TB
• Kaposi's sarcoma
• Central nervous system (CNS) toxoplasmosis!
• HIV encephalopathy
Conditions where confirmatory diagnostic testing is necessary
• Extrapulmonary cryptococcosis including meningitis
• Disseminated non-tuberculous mycobacteria infection
• Progressive multifocal leukoencephalopathy (PML)
• Candida of trachea, bronchi or lungs
• Cryptosporidiosis
• Isosporiasis
• Visceral herpes simplex infection
• Cytomegalovirus (CMV) infection (retinitis or of an organ other than liver, spleen or lymph 
nodes)
• Any disseminated mycosis (e.g. histoplasmosis, coccidiomycosis, penicilliosis)
• Recurrent non-typhoidal salmonella septicaemia
• Lymphoma (cerebral or B cell non-Hodgkin)
• Invasive cervical carcinoma
• Visceral leishmaniasis
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Appendix II | CD4 ligation and CD154 expression. 2 xl0(1 freshly isolated PBMCs were 
plated in a 96-well plate in 200 ul IX sterile PBS. An anti-CD4 domain l blocking 
antibody (final concentration lOug/ml [clone QS4120; Ancell, Bayport, MN]) was added 
to appropriate wells and the plate was incubated for Ih at 4°C as described elsewhere 
(Zhang, Fichtenbaum et al. 2004; Rutjens, Vermeulen et al. 2008). Thereafter, the cells 
were washed twice with l ml sterile IX PBS at 700 g for 7 minutes and resuspended in 
RPMI 1640 medium supplemented with 2% heat inactivated AB human serum (National 
Blood Services, Blantyre, Malawi), 2 mM L-glutamine, 100 U/ml penicillin, 20 mM 
HEPES buffer and 100 ug/ml streptomycin (Sigma). An anti-CDl54 antibody was 
introduced into the cell culture immediately before stimulation and cells cultured for 18 
hours.
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Potential role for mucosally active 
vaccines against pneumococcal 
pneumonia
Kondwani C. Jambo1,2*, Enoch Sepako1'3*, Robert S. Heyderman1 and 
Stephen B. Gordon2
1 Malawi-Liverpool-Wellcome Trust Clinical Research Programme, P.O. Box 30096, Chichiri, Blantyre, Malawi
2 Respiratory Infection Group, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK 
3School of Clinical Sciences, University of Liverpool, Daulby Street, Liverpool, L69 3GA, UK
Pneumococcal pneumonia is a life-threatening disease 
with high mortality and morbidity among children under 
5 years of age, the elderly and immunocompromised 
individuals worldwide. Protection against pneumococ­
cal pneumonia relies on successful regulation of coloni­
sation in the nasopharynx and a brisk alveolar 
macrophage-mediated immune response in the lung. 
Therefore, enhancing pulmonary mucosal immunity 
(which includes a combination of innate, humoral and 
cell-mediated immunity) through mucosal vaccination 
might be the key to prevention of pneumococcal infec­
tion. Current challenges include a lack of information in 
humans on mucosal immunity against pneumococci and 
a lack of suitable adjuvants for new vaccines. Data from 
mouse models, however, suggest that mucosally active 
vaccines will enhance mucosal and systemic immunity 
for protection against pneumococcal infection.
Prevention of pneumococcal pneumonia: current 
strategies
Streptococcus pneumoniae (the pneumococcus) is a Gram­
positive aerobic commensal bacterium which forms part of 
the normal flora in the nasopharynx [1]. The pneumococcus 
can evade the immune system through a combination of 
surface expressed and secreted virulence factors to cause 
mucosal diseases such as otitis media, sinusitis and pneu­
monia, as well as systemic diseases such as bacteraemia and 
meningitis [1,2]. These diseases, collectively termed pneu­
mococcal disease, can be classified as invasive or non-inva- 
sive disease. Otitis media, sinusitis and non-bacteraemic 
pneumococcal pneumonia are examples of non-invasive 
disease which are confined to the mucosal surface, whereas 
bacteraemic pneumonia, bacteraemia and meningitis are 
examples of invasive disease. Bacteraemic pneumococcal 
pneumonia, defined as having pneumonia and a positive 
blood culture [3], is more common in HIV-infected patients. 
Invasive pneumococcal disease is thought to progress from 
colonisation to bacteraemia, with or without pneumonia, 
only a minority of cases developing meningitis (Figure 1).
Pneumonia accounts for 19% of all under 5 year old 
deaths worldwide, which makes it the most deadly infec-
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tious illness for this age group [4]. The pneumococcus is the 
leading cause of pneumonia in children and it has been 
reported to cause over 50% of severe pneumonia cases in 
Africa [4]. Pneumococcal disease is most prevalent in the 
young and the elderly, but is also very common among 
HIV-infected individuals, who are 20-40 times more likely 
than uninfected adults to suffer from this illness [5].
Pneumococcal pneumonia is treatable using antibiotic 
therapy. However, where treatment is delayed or unavail­
able mortality is high [5]. Previously, the developing world 
had focused on treating pneumococcal disease rather than 
preventing it, but with the current increase in antibiotic 
resistance and the HIV pandemic, it is widely accepted that 
prevention is the key to minimising the disease burden [5].
Vaccination offers the most efficient and cost-effective 
method of preventing this disease. However, there are more 
than 90 pneumococcal serotypes which make development 
of a vaccine to provide universal protection a big challenge. 
There are two formulations of pneumococcal vaccines that 
have been licensed thus far: polysaccharide vaccines (PPVs) 
and protein conjugate vaccines (PCVs). The 23-valent pneu­
mococcal polysaccharide vaccine, which contains purified 
capsular polysaccharide antigens from 23 serotypes, offers 
some protection against invasive pneumococcal disease in 
adults but is not effective in either children less than 2 years
Glossary
Colonisation: establishment of bacteria in the upper respiratory tract without 
causing overt disease.
Compartmentalisation: in the context of this article, the regional sequestration 
of a specific function within the immune system. Local immune responses 
within the body (site of infection) are often functionally independent from 
systemic immunity.
Complement system: a cascade of plasma proteins that act together in defence 
against extracellular bacteria by coating bacteria (opsonisation) or killing 
pathogens directly.
Mucosal immunity: part of the immune system that is responsible for 
protection against pathogens, commensals and other non-microbial antigens 
restricted to the mucous membranes of the gastrointestinal, respiratory and 
urinogenital tracts, i.e. the major sites of antigen/pathogen entry into the body. 
Opsonisation: alteration of surfaces of pathogens by immune molecules in 
such a manner that the pathogens are more easily recognised by immune cells. 
Opsonophagocytosis: the process whereby bacteria are altered for optimal 
interaction with phagocytes and then engulfed.
Systemic immunity: the general immune system responsible for protection 
against pathogens, commensals and other non-microbial antigens; it is not 
confined to the site of infection or antigen entry.
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Figure 1. Diseases caused by Streptococcus pneumoniae. Pneumococci colonise the nasopharynx, evade host immunity and spread to the middle ear, sinus, lower 
respiratory tract, blood and meninges. Pneumococci cause otitis media in the middle ear, sinusitis in the sinus, pneumonia in the lower respiratory tract, bacteraemia in 
blood and meningitis in the meninges. The incidences of different types of pneumococcal infection are inversely related to the severity of disease: otitis media is the most 
common but the least severe. Redrawn and redesigned with permission from Ref. [21.
of age or immunocompromised adults [6]. PCVs, which 
contain purified capsular polysaccharides conjugated to a 
carrier protein, offer protection against both pneumonia and 
invasive disease in children [7] and immunocompromised 
adults (French et al. unpublished). The currently licensed 7- 
valent conjugate vaccine (containing 7 capsular polysac­
charides conjugated to a diphtheria CRM197 protein) is 
being used as part of childhood immunisation programmes 
in several countries but others are waiting for the licensing 
of 10-valent and 13-valent vaccines. The disadvantages of 
PCVs are that they are expensive, have limited serotype 
coverage, can be associated with an increase in disease 
caused by serotypes not included in the vaccine and are less 
effective against radiological pneumonia (20-37% efficacy) 
[7,8] than against invasive disease (77-83% efficacy) [7], In 
African children, PCVs appear to provide no protection to 
unvaccinated children (herd immunity) and is not very 
effective against colonisation (39% against vaccine sero­
types, 0% against all serotypes) [9],
There are several key developments that would result in 
a breakthrough in the global control of pneumococcal dis­
ease. Use of the PCV is an important landmark [8] but the 
use of conserved proteins in a universal vaccine would 
allow a single vaccine to be deployed in all geographical 
regions without regard to the prevalent serotype patterns. 
In addition, the development of mucosally active vaccines 
might reduce mucosal disease including pneumonia and
otitis media, but this will require the identification of safe 
and effective mucosal adjuvants for successful vaccine 
delivery.
This review will focus on recent advances in our un­
derstanding of mucosal immunity relevant to pneumococ­
cal infection and, in particular, the critical immune 
responses that must be augmented by new vaccines.
Mucosal immunity against Streptococcus pneumonia
Host response against pneumococcal colonisation 
Pneumococcal colonisation of the upper respiratory tract 
precedes infection of the lower respiratory tract, but is 
normally asymptomatic and not usually followed by dis­
ease [2]. The local host immune response plays an import­
ant role in regulating the containment of pathogens within 
the nasopharyngeal cavity [2]. A brisk local host immune 
response to S. pneumoniae involving phagocytes (neutro­
phils and macrophages), B cells (antibodies against pneu­
mococcal polysaccharides and proteins) and T cells rapidly 
eliminates colonisation, whereas a poor mucosal immune 
response results in protracted colonisation [2]. Both innate 
and adaptive immunity play a role in these host defence 
responses against S. pneumoniae.
Innate immune response during colonisation
Innate factors (including C-reactive protein, CRP) play a
crucial role in the host defence against colonisation with S.
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pneumoniae. CRP is an acute-phase protein which is 
mainly found in serum and elevated during inflammation 
[10]. It has also been detected in the upper respiratory tract 
of healthy individuals and is also elevated during inflam­
mation [11]. The concentration of CRP is lower in the 
respiratory tract than in serum but is sufficient to contrib­
ute to innate immunity, and is locally produced by epi­
thelial cells [11,12]. CRP has several functions in relation 
to cell-surface phosphorylcholine-expressing bacteria 
(such as S. pneumoniae and Haemophilus influenzae), 
which includes activation of complement by the classical 
pathway, enhancing opsonisation and inhibition of the 
attachment of bacteria to epithelial cells [12]. These func­
tions help in clearance of colonising pneumococci from the 
upper respiratory tract, which if not cleared might trans­
migrate across endothelial and epithelial monolayers in a 
process called pericellular tissue invasion [13].
It is known that complement plays a role in protection 
against pneumococcal infection through the promotion of 
opsonophagocytosis [14,15]. However, there are still con­
flicting data on the role of complement in protection 
against colonisation. Data from a co-colonisation mice 
model (of S. pneumoniae and H. influenzae) suggest that 
successful clearance of pneumococci in the nasopharynx 
resulted from opsonisation by complement, followed by 
phagocytosis by neutrophils which were recruited to the 
mucosal surface [16]. In a different model, C3 (a protein 
that plays a central role in activation of the complement 
system) was essential within the lungs for an optimal 
immune response against S. pneumoniae and sub­
sequently played an important role systemically [17]. In 
contrast, another murine colonisation model showed that 
C3-deficient mice lacking functional complement system 
cleared pneumococcal colonisation at the same rate as wild 
type mice [18]. It is important to take note that murine 
models vary according to the genetic background of the 
mouse and the serotype of pneumococcus used, and hence 
they might not always produce similar results.
The innate response includes cellular responses from 
neutrophils and macrophages. It has been demonstrated in 
murine models that pneumococcal colonisation of the 
upper respiratory tract triggers an acute inflammatory 
response characterised by a robust influx of neutrophils 
into the lumen of the paranasal spaces [18,19] and release 
of cytokines (tumour necrosis factor alpha, TNF-a) and 
chemokines (interleukin 8, IL-8) [20]. This acute inflam­
matory response is ineffective at controlling initial mucosal 
colonisation [19], but it enhances the adaptive immune 
response and subsequent bacterial clearance [21].
Adaptive immune response during colonisation 
Nasopharyngeal colonisation stimulates the production of 
secretory IgA antibodies (the predominant immunoglobu­
lin class in human external secretions) and serum IgG [22]. 
However, it is unclear whether these antibodies are pro­
tective against colonisation. Many isolates of S. pneumo­
niae secrete a zinc metalloprotease which inactivates IgAl 
(a subclass of IgA). Furthermore, the cleaved IgAl frag­
ment might assist translocation of the opsonised bacteria 
across the host respiratory epithelium [23]. By contrast, 
increased concentrations of serotype-specific antibodies
Box 1. The role of pneumolysin in pneumonia and 
bacteraemia
Pneumolysin is a potent pore-forming cytotoxin produced by almost 
all pneumococcal isolates, and a proven virulence factor. Animal 
studies show that this protein is required for the development of 
pneumonia and bacteraemia. Data suggests that S. pneumoniae 
requires pneumolysin to successfully survive in both the upper and 
lower respiratory tracts [1,78,79]. The cytotoxin is essential for 
pneumococcus to translocate from the lungs to the bloodstream 
[1,78-80]. It is also required for bacterial survival in blood: 
pneumolysin-expressing pneumococci are associated with high 
bacteraemia and severe infection [79,80]. By contrast, pneumoly- 
sin-deficient pneumococci result in low bacteraemia (often chronic) 
with minimal severity in animal models [81].
against pneumococcal polysaccharides [24,25] and anti­
bodies against pneumococcal proteins in serum and saliva 
[26] have been correlated with increased protection against 
carriage. These antibodies opsonise pneumococci, making 
it easier for phagocytes to recognise, ingest and clear 
bacteria from the respiratory tract [27]. This has long been 
thought to be the primary main mechanism for protection 
against pneumococcal colonisation.
Several recent studies suggest that other mechanisms of 
protection against pneumococcal carriage are required, in 
addition to antibody-mediated immunity. Firstly, the 
course of an experimental colonisation is not affected in 
mice that are unable to produce pneumococcal-specific 
antibody [28]. Secondly, the adaptive immune response 
is enhanced in the presence of pneumolysin and neutro­
phils. Pneumolysin, a pore-forming cytotoxin is a critical 
pathogenic factor ofS. pneumoniae (Box 1). The interaction 
of pneumolysin and neutrophils promotes delivery and 
release of pneumococcal-specific antigens to the nasal 
associated lymphoid tissues, a process that is impaired 
in either neutrophil- or pneumolysin-deficient conditions 
[21]. Impaired antigen delivery is associated with pro­
longed nasopharyngeal colonisation [21]. Finally, mice 
lacking the ability to induce a cell-mediated immunity 
owing to the absence of appropriate molecules to present 
antigens to CD4+ T cells (MHC-II knockout mice) show 
prolonged carriage, suggesting an important role for CD4+ 
T cells rather than antibody-mediated immunity [29] (for 
the antigen presentation process, see Figure 2).
Studies have shown that immunity to pneumococcal 
colonisation is mediated by a specific subset of CD4+ T 
cells (Thl7) which produce IL-17A [30-34]. Malley et al. 
showed that blocking IL-17A in mice models reduced 
immunity to pneumococcal colonisation following intrana­
sal immunisation with cell wall polysaccharide [33]. In 
another study by the same group, they showed that IL- 
17A expression in peripheral blood samples from immu­
nised mice was associated with protection in vivo against 
pneumococcal carriage [32],
IL-17A-mediated protection against pneumococcal colo­
nisation results in recruitment of neutrophils into the 
upper airway lumen to clear bacterium [32,34]. Recently, 
Zhang et al. showed that primary challenge with pneumo­
cocci in mice generates CD4+ T cell memory, resulting in 
enhanced Thl7-mediated recruitment of neutrophils after 
secondary pneumococcal challenge [34]. These neutrophils 
were shown to contribute to early bacterial clearance
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Figure 2. Induction of cell-mediated immune response by CD4* T cells. There are three signals that are important during T cell activation: antigen presentation 
(TCR:Peptide-MHC class II ligation), co-stimulation (CD40:CD40L and CD80/CD86:CD28) and polarising signals (cytokine milieu). Professional antigen-presenting cells 
(dendritic cells, B cells and macrophages) present antigens to T cells in the context of MHC class II via the TCR (T cell receptor). This induces upregulation of CD40L and 
CD28 on the T cells, which bind to their receptors CD40 and CD80/CD86, respectively, on APCs, in a process called co-stimulation. These events lead to the production of 
polarising cytokines by APCs which include IL-12 from macrophages and dendritic cells, and IL-23 from dendritic cells. The polarising cytokines are important because they 
dictate the fate of T cells on whether to differentiate into Thl, Th2 or Th17.
following secondary challenge [34], However, it is still not 
clear whether Thl7 cells are involved in immunity against 
human pneumococcal colonisation.
Host response against pneumococcal pneumonia
Post colonisation events leading to pneumonia 
If pneumococci colonising the human nasopharynx are 
aspirated into the distal airways and alveolar air spaces, 
they will interact with pulmonary defence mechanisms. 
The bacteria will either be cleared or cause disease. Exces­
sive replication of the bacteria in the alveoli triggers 
infiltration of immune cells which - if not properly 
regulated - impairs gas exchange resulting in the clinical 
syndrome of pneumonia.
The process of bacterial clearance in the lung is a highly 
regulated process - an excessive response might potentially 
lead to tissue damage, whereas a weak response leads to 
exponential growth of the pathogens. The primary host 
immune defence against small numbers of pneumococci 
during early infection is phagocytosis [27] which is enhanced 
through opsonisation by immunoglobulin and complement 
[19], in a process called opsonophagocytosis. The mechanism 
of host defence against pneumococci during late infection is 
different. It involves multiple immune cells and combi­
nation of innate and adaptive immunity.
population that mediates mucosal responses in the lower 
airways [36,37], Approximately 90% of cells found in 
bronchoalveolar lavage fluid of healthy volunteers are 
macrophages [37]. It has been suggested that during early 
infection (where the bacterial load is low), resident alveolar 
macrophages are capable of multiple episodes of phagocy­
tosis and killing [38]. This helps to clear the bacteria 
without recruitment of inflammatory cells such as neutro­
phils, and hence maintaining a low inflammatory state in 
the lung [38]. Early clearance of pneumococci through 
alveolar macrophage phagocytosis probably prevents bac- 
teria-dendritic cell interaction, which in turn limits the 
initiation of T cell-mediated inflammatory responses in the 
lymph node [37].
It is still unclear whether antigen presentation occurs in 
the lung, in the draining lymph nodes, or both, and 
whether alveolar macrophages are part of this antigen 
presentation process. There is data in vitro to suggest that 
alveolar macrophages are able to present antigens to T 
cells, although less effectively than other antigen-present­
ing cells (APCs) [39]. Alveolar macrophages might induce 
antigen-specific unresponsiveness in CD4+ T cells as a 
result of antigen recognition in the absence of co-stimu­
lation [39] (for the antigen presentation process, see 
Figure 2).
Early infection in the lung
Alveolar macrophages are the first cells that combat pneu­
mococci during early infection [35] and the main cell
Late infection in the lung
When the alveolar bacterial load rises above a critical 
threshold, alveolar macrophages cease to perform effective
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opsonophagocytosis and produce an increased proinflam- 
matory cytokine response dominated by TNF-a and IL-8 
[38]. The presence of TNF-a is not a prerequisite for 
pulmonary anti-pneumococcal responses, because success­
ful clearance of the bacteria can occur independent of this 
cytokine - but it is beneficial during systemic infection [40]. 
Inflamed epithelial cells enhance neutrophil recruitment 
into the lung by secretion of IL-8 [41], both as a direct result 
of pneumococcal binding to epithelial receptors and in 
response to macrophage proinflammatory signalling.
When a proinflammatory signal (TNF-a and/or IL-8) is 
produced in the alveolus, there is upregulation of adher­
ence molecules on endothelial cells which bind to their 
receptors on neutrophils. This results in rolling of neutro­
phils along the endothelial wall and transmigration into 
the alveolar space in a process called chemotaxis [42]. 
Neutrophils then become the major immune cell popu­
lation responsible for pneumococcal clearance in the lung 
[43].
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T cells are also recruited in high numbers to the lung in 
late infection - the peak of T cell infiltration in the lung 
during intranasal pneumococcal infection in mice in vivo 
coincided with the phase when bacterial growth ceased 
[44]. The recruited T cells are predominantly of the effector 
memory phenotype and potentially secrete interferon 
gamma IFN-y to activate alveolar macrophages. The 
actual mechanisms on the role played by T cells are still 
not clear, but we have hypothesised some of the possible 
pathways in Figure 3. In addition, it has been shown that T 
cells expressing the gammadelta receptor (y& T cells) act as 
regulators of alveolar macrophages and pulmonary den­
dritic cells during the resolution of pneumococcus- 
mediated lung inflammation [45]. Cytoxicity mediated 
by yS T cells helps restore mononuclear phagocyte num­
bers to homeostatic levels, and hence preventing excessive 
inflammation in the lung [45].
Following clearance of pneumococci from the lungs, 
neutrophils, some macrophages and T cells undergo rapid
Figure 3. Pneumococcal clearance in the lung. Host defence in the lower respiratory tract is mediated by alveolar macrophages, (i) During early infection where the bacterial 
load is low, resident alveolar macrophages efficiently kill and phagocytise opsonised pneumococci in a quiescent manner, effectively preventing bacteria-dendritic cell 
interaction, and hence inhibiting initiation of T cell-mediated inflammatory responses, (ii) In situations where bacterial load exceeds the capability for macrophages to 
perform effective opsonophagocytosis, neutrophils are recruited following secretion of TNF-a by alveolar macrophages and/or IL-8 by epithelial cells, (iii) T cells are 
recruited following successful antigen presentation in the draining lymph nodes by pulmonary dendritic cells. These cells secrete IFN-y which activates macrophages to kill 
internalised pneumococci and also promotes further TNF-a production by alveolar macrophages, (iv) Following clearance of pneumococci from the lungs, neutrophils, 
some macrophages and T cells undergo rapid apoptosis. Surviving T cells remain in the alveoli as resident effector memory cells.
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apoptosis. Macrophage apoptosis leads to reduced TNF-a 
expression, which in turn results in reduced neutrophil 
recruitment and enhanced neutrophil apoptosis [46]. Dead 
cells are then cleared through phagocytosis, efferocytosis 
(clearance of apoptotic cells by phagocytes) and the normal 
function of the mucociliary escalator, whereas the surviv­
ing T cells remain in the alveoli as resident effector mem­
ory cells.
In summary, mucosal responses are critical in regulat­
ing pneumococcal carriage and defence against infection. 
Therefore, enhancing pulmonary mucosal immunity might 
be an effective strategy in the prevention of pneumococcal 
disease.
Evidence for vaccine-induced mucosal immunity 
against pneumococcus
Mucosal exposure to S. pneumoniae induces both mucosal 
and systemic humoral and cellular immune responses 
[25,26]. Enhancing these responses by mucosal vaccination 
is an attractive immunisation approach against pneumo­
coccus as it mimics the natural route of infection. The 
success of other mucosal vaccines such as the trivalent 
oral poliovirus vaccine shows that this approach is a viable 
alternative of delivering vaccines [47]. There is evidence 
from mouse models, employing a similar route of vaccine 
delivery, showing that oral immunisation of PspA family 
fusion proteins delivered by attenuated Salmonella enter- 
ica serovar Typhimurium enhances protection against S. 
pneumoniae [48-51]. An important difference is that polio 
virus can replicate in the respiratory mucosa but pneumo­
coccal antigens cannot. Nevertheless, there are several 
studies which have shown that mucosal immunisation 
can elicit protection against pneumococcal colonisation 
and infection (Table 1).
Protection against pneumococcal colonisation 
Mucosal immunisation of experimental animals has been 
shown to elicit protection against carriage [29,52]. Intra­
nasal immunisation of mice with killed, unencapsulated,
whole cell pneumococci and cholera toxin adjuvant elicited 
protection against experimental colonisation. The protec­
tion was dependent on CD4+ T cells and independent of 
antibody and bacterial serotype [29]. Furthermore, intra­
nasal immunisation with a cholera toxin B subunit fused to 
the pneumococcal surface adhesin A (PsaA) also protected 
mice against colonisation with S. pneumoniae [52],
An ideal mucosal vaccine would include several pneu­
mococcal proteins such as pneumolysin, PspA, PsaA or 
PspC [53]. Many of these proteins play a role in S. pneu­
moniae pathogenesis, and several are particularly relevant 
to protection against carriage [54]. Recently, Lu et al. 
demonstrated that a fusion conjugate, including cell wall 
polysaccharide coupled to pneumolysin and PsaA, deliv­
ered intranasally with cholera toxin, protected mice 
against experimental pneumococcal colonisation [31]. 
Mucosal vaccines based on protein combinations are more 
likely to exhibit coverage of all pneumococcal serotypes.
Protection against pneumococcal pneumonia 
Pneumococcal conjugate vaccine is less effective against 
pneumonia than against invasive pneumococcal disease 
[7,8]. This observation might be as a result of difficulty 
either in the diagnosis of non-bacteraemic pneumococcal 
pneumonia or in distinguishing this diagnosis from other 
infective causes of pneumonia. Consequently, the chances 
of underreporting non-bacteraemic pneumococcal pneumo­
nia as an endpoint in determining efficacy of the pneumo­
coccal conjugate vaccine are high. By contrast, the 
intramuscular administration of the vaccine might result 
in a compartmentalisation of the immune response and a 
suboptimal lymphocyte trafficking to the pulmonary 
mucosa.
Mucosal vaccination has shown promising results in 
protection against pneumococcal lung infection [31,55- 
57]. Nasal administration of Lactococcus lactis increased 
the clearance rate of S. pneumoniae from the lung and 
prevented invasion of pneumococci into blood [57]. In these 
experiments, L. laetis increased phagocyte activation in
Table 1. Mouse models of mucosal immunisation with pneumococcal protein antigens”
Antigen or vaccine Route Immunogenicity Correlates of protection Protection against:Refs
PspA Intranasal Mucosal and systemic Antibodies in serum and saliva Colonisation, pneumonia, sepsis [60-62]
PspA/attenuated
Salmonella
Oral Mucosal and systemic Antibodies in serum and 
vaginal fluids
Pneumonia, bacteraemia [48-51,63]
PsaA Oral Mucosal and systemic Antibodies in serum, BAL and 
intestinal fluid
Pneumonia, bacteraemia [52,64,65]
PsaA/lactic acid 
bacteria
Intranasal Mucosal and systemic Antibodies in serum, saliva, 
nasal and bronchial washes
Colonisation [66]
PotD Intranasal Mucosal and systemic Antibodies in serum and saliva Colonisation, pneumonia, 
bacteraemia
[67]
PsaA and PspA Intranasal Mucosal and systemic Antibodies in serum and saliva Colonisation [68]
PspA and PspC Intranasal Mucosal and systemic Antibodies in serum, vaginal 
washes, and BAL; cytokine 
responses in BAL, 
lung and splenic samples
Pneumonia, bacteraemia [69,70]
PsaA, PdT and 
CWPS
Intranasal Systemic Antibodies in serum; T cell 
response in whole blood
Colonisation, pneumonia [31,71]
GEM with PpmA, 
SlrA and IgAlp
Intranasal Systemic Antibodies in serum Pneumonia [72,73]
PCV Intranasal Mucosal and systemic Antibodies in serum and 
nasal washes
Colonisation, otitis media 174-77]
"Abbreviations: PspA, pneumococcal surface protein A; PsaA, 'pneumococcal surface adhesion A' protein; BAL, bronchoalveolar lavage; PotD, polyamine transport protein D; 
PspC, pneumococcal surface protein C; PdT, pneumolysin nontoxic derivative; CWPS, cell wall polysaccharide; GEM, Gram-positive enhancer matrix; PCV, pneumococcal 
conjugate vaccine.
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lung, blood and bone marrow of the vaccinated mice [57], 
Moreover, mucosal immunisation with caseinolytic pro­
tease, a conserved pneumococcal protein, induced the pro­
duction of both systemic and mucosal antibodies and 
resulted in reduced lung bacterial load in a pneumococcal 
pneumonia model and prevented death in an intraperito- 
neal sepsis model [58]. Lastly, a mucosal vaccine made of 
recombinant PspA elicited protection against invasive 
pneumococcal challenge, characterised by increased 
secretion of IL-17 and IFN-y by lung and spleen cells, 
respectively [55]. These data support the concept that 
mucosal immunisation might protect against both mucosal 
and systemic infection. However, the duration of protection 
afforded by these mucosal vaccines is not clear.
There are also some data to suggest that mucosally 
administered vaccines might actually provide better pro­
tection against both mucosal and systemic disease than 
conventional parenteral (systemic) vaccines. Immunis­
ation of mice with lactococcal PspA vaccine elicited better 
protection against respiratory pneumococcal challenge 
than conventional parenteral PspA vaccine in intraperito- 
neal sepsis and intranasal respiratory infection models 
[56].
In summary, there are encouraging data to support the 
role of mucosal vaccination in protection against both 
mucosal and systemic pneumococcal disease. However, 
lack of a suitable adjuvant is a major obstacle to success, 
but cytokine adjuvants might be useful [59].
Concluding remarks and future directions
We have discussed the role of mucosal immunity and 
reviewed available data on mucosal immunisation against 
pneumococcal disease. There is evidence from murine 
studies to suggest that mucosal immunisation against 
pneumococci induces mucosal and systemic immunity 
more effectively than parenteral vaccination. The data 
from humans, however, are insufficient to draw firm con­
clusions. Further studies using lung, nasal and other 
mucosal samples from humans are needed.
Immediate priorities include the need to address the role 
of T cell-mediated immunity against pneumococcal coloni­
sation and infection in humans. Such data might clarify the 
human correlates of protection or immunity to S. pneumo­
niae. These correlates of protection might then help in 
predicting efficacy to future vaccines. Research questions 
for future work in the field are outlined in Box 2.
Strategic decisions regarding future pneumococcal 
vaccines need to determine whether to focus on improving 
the current conjugate vaccines (by including more sero-
Box 2. Questions for future research
• What are the correlates of protection (measurable signs of 
immunity) against carriage and disease as a result of S. 
pneumoniae in human mucosa?
• Which is the most effective mode of vaccine delivery to enhance 
both mucosal and systemic immunity to S. pneumoniae?
• What adjuvants are most effective for mucosal pneumococcal 
vaccine delivery?
• How does HIV infection affect mucosal immunity against S. 
pneumoniae in the respiratory tract?
types or replacing the carrier with a pneumococcal 
protein) or developing new pneumococcal protein based 
vaccines. Pneumococcal conjugate vaccines are currently 
being used in several developed countries because they 
provide good protection against systemic disease. Their 
main disadvantage is that they have limited serotype 
coverage and are less effective against mucosal disease. 
By contrast, pneumococcal protein based vaccines have 
the potential to offer universal coverage as well as offer 
protection against both mucosal and systemic disease if 
delivered through the mucosal route. Vaccination still 
remains the key to minimising the high burden of pneu­
mococcal disease worldwide. We believe that alternative 
routes of immunisation (with conjugate vaccines or pneu­
mococcal proteins) might help in improving the efficacy of 
pneumococcal vaccines to both mucosal and systemic 
disease.
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ABSTRACT
Rationale HIV-infected adults are at an increased risk of 
lower respiratory tract infections. HIV infection impairs 
systemic acquired immunity, but there is limited 
information in humans on HIV-related cell-mediated 
immune defects in the lung.
Objective To investigate antigen-specific CD4+ T cell 
responses to influenza virus, Streptococcus pneumoniae 
and Mycobacterium tuberculosis antigens in 
bronchoalveolar lavage (BAL) and peripheral blood 
between HIV-infected individuals and HIV-uninfected 
Malawian adults.
Methods We obtained BAL fluid and blood from 
HIV-infected individuals (n=21) and HIV-uninfected 
adults (n=24). We determined the proportion of T cell 
subsets including naive, memory and regulatory T cells 
using flow cytometry, and used intracellular cytokine 
staining to identify CD4+ T cells recognising influenza 
virus-, S' pneumoniae- and M tuberculosis-antigens.
Main results CD41 T cells in BAL were predominantly 
of effector memory phenotype compared to blood, 
irrespective of HIV status (pcO.OOl). There was immune 
compartmentalisation with a higher frequency of antigen- 
specific CD4+ T cells against influenza virus,
S pneumoniae and M tuberculosis retained in BAL 
compared to blood in HIV-uninfected adults (p<0.001 in 
each case). Influenza virus- and M fube/rufos/s-specific 
CD4+ T cell responses in BAL were impaired in 
HIV-infected individuals: proportions of total 
antigen-specific CD4+ T cells and of polyfunctional IFN-y 
and TNF-a-secreting cells were lower in HIV-infected 
individuals than in HIV-uninfected adults (p<0.05 in each 
case).
Conclusions BAL antigen-specific CD4+ T cell 
responses against important viral and bacterial 
respiratory pathogens are impaired in HIV-infected 
adults. This might contribute to the susceptibility of 
HIV-infected adults to lower respiratory tract infections 
such as pneumonia and tuberculosis.
This paper is freely available 
online under the BMJ Journals 
unlocked scheme, see http:// 
thorax.bmj.com/site/about/ 
unlocked.xhtml
INTRODUCTION
Respiratory infections are a leading cause of death 
in lower income countries, accounting for approx­
imately three million deaths a year.1 Infants, the 
elderly and immunocompromised individuals are 
particularly susceptible to these infections. In 
particular, HIV-infected individuals are 30 times 
more likely than uninfected adults to suffer from 
bacterial pneumonia or active tuberculosis.2 3 
Southern Africa is the region with the world’s 
highest burden of HIV infection, with over nine 
countries, including Malawi, having an estimated 
HIV prevalence that is greater than 10%.4
Defence against respiratory infection involves 
mucosal and systemic immunity.5 Antigen-specific 
CD4+ T cells are important as they protect against 
respiratory infections.6-8 Cytokines secreted by 
CD4+ T cells, such as IFN-y, TNF-a, IL-2,1L-17 and 
IL-22,9-12 are critical to the activation of macro­
phages9 and the recruitment of neutrophils,10 and 
enhance the magnitude and quality of CDS + T cell 
responses.12 Immune protection against common 
viral and bacterial respiratory pathogens depends 
on the integrity of these effector responses. There is 
limited information about the phenotype and 
function of these CD4+ T cells within the human 
lung.
Studies of the human lung suggest that mecha­
nisms of local intrapulmonary immunity may differ 
from those mediating systemic immunity. Influ­
enza virus antigen-specific memory CD4+ T cells 
from lung tissue were present at higher frequencies 
and produced more IFN-y than those from periph­
eral blood in patients undergoing lobectomy for 
a localised solitary peripheral lung carcinoma who 
had no symptoms of upper respiratory infection.1" 
In patients with tuberculosis, IFN-y and TNF- 
a responses to Purified Protein Derivative (PPD) 
were stronger by CD4 1 T cells from BAL fluid than 
by CD4+ Tcells from peripheral blood.14
The decline in immunity caused by HIV is not 
equally distributed among immunological sites. In 
particular, the depletion of CD4+ T cells primarily 
occurs at sites of ‘persistent inflammation’ such as 
the mucosa, which may leave individuals vulner­
able to acute infections. Brenchley et al showed 
that there was a rapid depletion of mucosal gut T 
cells during early HIV infection while pulmonary 
CD4+ T cell depletion was less acute.10 Clinical 
evidence indicates that there is a high burden of 
pneumococcal pneumonia and tuberculosis early on 
in HIV infection when peripheral CD4f T cell 
counts are relatively stable.16 1 We hypothesised 
that HIV infection preferentially depletes antigen- 
specific T cells against common respiratory patho­
gens within the lung compartment, which 
predisposes individuals to respiratory infections.
The authors have compared baseline T cell 
phenotypes and antigen-specific CD4+ T cells in 
BAL and peripheral blood, between HIV-infected 
individuals and HIV-uninfected adults. The aim 
of the authors was to compare T cell phenotypes in 
BAL and peripheral blood between the two 
groups of subjects; to assess antigen-specific CD4 + 
T cell responses to common respiratory antigens; 
and to investigate whether HIV infection differen­
tially affects the lung and peripheral blood 
compartments.
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METHODS
Participants
Adult volunteers with no recent history of severe respiratory 
diseases and a normal chest x-ray were recruited by advertise­
ment in the Queen Elizabeth Central Hospital, Blantyre, 
Malawi. All participants gave written-informed-consent to HIV 
testing, venesection and bronchoscopy. The authors enrolled 
HIV-uninfected adults and asymptomatic anti-retroviral therapy 
naive HIV-infected individuals (WHO stage 1) into the study. 
The exclusion criteria for the study were as follows: the presence 
of other immunocompromising illnesses such as diabetes and 
cancer, the use of immunosuppressive drugs, cigarette smoking, 
moderate or severe anaemia (HB<8 g/dl), and known or possible 
pregnancy. This study complies with local institutional guide­
lines and was approved by the College of Medicine Research 
Ethics Committee of the University of Malawi (COMREC P.01/ 
09/717) and the Liverpool School of Tropical Medicine Research 
Ethics Committee (LSTM REC 08.61).
Sample collection and processing
Peripheral blood samples were collected on all subjects. Periph­
eral blood mononuclear cells (PBMCs) were isolated from blood 
by density centrifugation using Lymphoprep (Axis-shield, 
Norway) according to the manufacturer’s instructions. Bron­
choscopy and BAL collection was carried out as previously 
described.15 The BAL samples were filtered and spun to obtain 
a cell pellet. The cells were counted and re-suspended in 
complete cell culture media (containing RPMI, L-glutamine, 
penicillin/streptomycin and HEPES (all from Sigma-Aldrich, 
UK) with 2% (vol/vol) heat-inactivated human AB serum 
(National Blood Services, Blantyre)).
Phenotyping of T cell subsets
PBMCs and BAL cells were stained with fluorochrome conjugate 
antibodies when cell numbers were sufficient. Anti-CD3 fluo­
rescein isothiocyanate (FITC), anti-CD4 Pacific blue, anti-CD8 
allophycocyanin-H7 (APC-H7), anti-CD45RA phycoerythrin 
(PE), and anti-CCR7 allophycocyanin (APC) (all antibodies from 
BD Bioscience, UK) were used to characterise: naive 
(CD45RA+CCR7+), central memory (CD45RA CCR7+), 
effector memory (CD45RA~CCR7-) and terminal effector T 
cells (CD45RA+CCR7-).19 Anti-CD4 pacific blue, anti-CD25 
FITC (all antibodies from BD Bioscience, UK) and anti-FoxP3 PE 
(eBioscience, UK) were used to characterise regulatory T cells 
(CD4f CD25hlFoxP3+).20 The samples were acquired on CyAn 
ADP 9 Colour flow cytometer (Beckman Coulter, USA) and 
analysed using Flowjo (TreeStar, USA).
Intracellular cytokine staining
PBMCs and BAL cells re-suspended in complete cell culture 
media were cultured in a volume of 200 pi in a 96 well plate and 
stimulated with influenza vaccine (0.45 pg/ml), pneumococcal 
cell culture supernatant (8 pg/ml) or Purified Protein Derivative 
(PPD, 10 pg/ml) for 2 h. Brefeldin A (1 pi) (BD Bioscience, UK) 
was added at 2 h and the cells were cultured for a further 16 h. 
Cells were harvested and stained with Violet Viability dye 
(LIVE/DEAD® Fixable Dead Cell Stain kit, Invitrogen, UK) as 
per manufacturer’s instructions. Cells were then surface stained 
with anti-CD4 FITC and CDS PerCP (all BD Bioscience, UK). 
Next, cells were permeabilised and fixed using Cytofix/Cyto- 
perm (BD Bioscience, UK) as per manufacturer’s instructions. 
The cells were then stained with anti-interferon-gamma (IFN-y) 
APC and anti-tumour necrosis factor-alpha (TNF-a) Alexa flour 
488 antibodies (all BD Bioscience, UK) to detect intracellular
cytokines. Lastly, cells were washed with lx Perm Wash (BD 
Bioscience, UK), re-suspended in FACS flow and acquired on 
a flow on CyAn ADP 9 Colour flow cytometer (Beckman 
Coulter, USA). Flow cytometry analysis was done using Flowjo 
(TreeStar, USA).
Statistical analysis
Statistical analyses and graphical presentation were carried out 
using Graphpad Prism 5 (GraphPad Software, USA). Student t 
tests were used for the volunteer demographic data with the 
exception of gender, where a y} test was used instead. For the 
experimental data, Mann—Whitney U test was used for non- 
paired data and Wilcoxon sign ranked test for paired data. 
Results are given as mean with ranges or medians with IQRs. 
Differences were considered statistically significant if p values 
were less than 0.05.
RESULTS
Demographic characteristics of study population
Basic demographics are shown in table 1. HIV-uninfected 
Malawian adults ((n=24, females 11) mean age 38 years)) and 
asymptomatic HIV-infected adults ((n=21, females 11) mean 
age 40 years)) participated in the study. The mean CD4 count 
for HIV-infected individuals was 375 cells/pl. All participants 
were asymptomatic and had no recent history of respiratory 
infection or tuberculosis. The mean BAL cell concentration was 
comparable between HIV-infected individuals and HIV-unin­
fected adults (16.2xl06cells/100 ml vs 20.5xl06cells/100 ml 
respectively; p=0.1134), but the proportion of lymphocytes in 
the BAL cells was higher in HIV-infected individuals than HIV- 
uninfected adults (17.8% vs 9.0%; p—0.0106).
Proportions of naive, memory and regulatory T cells in BAL and 
peripheral blood
CD4 and CDS T cells
There was a lower proportion of CD4+ T cells in the total CD3+ 
T cell population in HIV-infected individuals compared to HIV- 
uninfected adults in both BAL (median 35.0% vs 65.5%, 
p<0.001) and peripheral blood (median 38.5% vs 61.2%, 
pcO.OOl). The proportion of CD8+ T cells in the total CD3+ T 
cell population was higher in HIV-infected individuals compared 
to HIV-uninfected adults in both BAL (median 59.7% vs 34.5%, 
p<0.05) and peripheral blood (median 61.5% vs 38.8%, p<0.05) 
(figure 1A).
Naive and memory T cells
To examine whether the proportion of T cell subsets was similar 
between compartments and whether they were altered by 
HIV infection, the authors measured expression of CD45RA
Table 1 Characteristics of subjects enrolled in the study
HIV-uninfected 
adults n = 24
HIV-infected 
adults n = 21 p Value
Sex: female/male 11/13 11/10 0.6611
Age, mean yr±SD 382:17 40± 18 0.7733
Systemic mean CDA’- 
cells/nl±SD
767 ±208 375±172 <0.0001
BAL cells/100ml BALF, 
mean±SD
16.2X10S±8.2X106 20.5X106±9.5X106 0.1134
BAL lymphocyte %, 
mean±SD
9.0±7.3 17.8±14.1 0.0106
WHO Stage NA Stage 1
BAL, bronchoalveolar lavage; BALF, BAL fluid; N/A, not applicable.
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Figure 1 Lower proportion of CD4+ T 
cells in BAL and peripheral blood of HIV- 
infected individuals compared to HIV- 
uninfected adults. T lymphocytes 
obtained from BAL and peripheral blood 
were stained with anti-CD3 FITC, anti- 
CD4 Pacific blue and anti-CD8 APC-H7 
fluorochrome conjugated antibodies. (A) 
The data shows a lower proportion of 
CD4+ T cells in BAL and peripheral 
blood of HIV-infected individuals 
compared to HIV-uninfected adults. (B) 
The data shows a higher proportion of 
CD8+ T cells in BAL and peripheral 
blood of HIV-infected individuals 
compared to HIV-uninfected adults. 
Significance was assessed using 
Mann—Whitney U test. Black horizontal 
bars represent median and IQRs.
pcO.OOl pcO.OOl
Blood
100-. p=0.002 PcO.OOl
Blood
and CCR7 on CD4+ and CD8+ T cells—as described in the 
materials and methods section. BAL CD4+ and CD8+ T cells 
were predominantly of effector memory phenotype 
(CD4+CD45RA~CCR7median 98%; CD8+CD45RA“CCR7‘, 
median 90%) compared to peripheral blood CD4+ and 
CD8+ T cells which were distributed among naive 
(CD4+CD45RA+CCR7+, median 25%; CD8+CD45RA+CCR7+, 
median 30%), central memory (CD4+CD45RA~CCR7+, median 
37%; CD8+CD45RA~CCR7+, median 5%), effector memory 
(CD4+ CD45RAXCR7-, median 37%; CD8+ CD45RAXCR7', 
median 20%) and terminal effector phenotypes 
(CD4+CD45RA+CCR7~, median 6%; CD8+ CD45RA+CCR7 , 
median 45%) (figure 2). In BAL, there was a higher proportion
of effector memory cells in HIV-infected individuals 
compared to HIV-uninfected adults (CD4, median 98.9% vs 
98.1% p=0.03; CDS, median 96.3% vs 90.3% p=0.03) and 
a lower proportion of central memory T cells (CD4, median 
0.37% vs 1.42% p=0.003; CDS, median 0.44% vs 1.88% 
p=0.007) (figure 2A,B). In peripheral blood, there was no 
difference in peripheral blood CD4f T cell subsets between 
HIV-infected and HIV-uninfected groups. However, the HIV- 
infected group had a higher proportion of CD8+ effector 
memory T cells (median 29.6% vs 17.8%, p=0.007) and 
a lower proportion of CD8+ terminal effector T cells (median 
22.2% vs 45.0%, p=0.01) than the HIV-uninfected group 
(figure 2C,D).
Figure 2 The proportions of naive and A p*o.oo3
memory T cell subsets are different 
between BAL and peripheral blood, and 
are altered during HIV infection. T 
lymphocytes obtained from BAL and 
peripheral blood were stained with anti- 
CD3 FITC, anti-CD4 Pacific blue, anti- 
CD8 APC-H7, anti-CD45RA PE and anti- 
CCR7 APC fluorochrome conjugated 
antibodies. The proportion of 
naive (CD45RA+CCR7+), central 
memory (CD45RA“CCR7+), effector 
memory (CD45RA CCR7~) and terminal 
effector (CD45RA' CCR7-) were 
defined. (A, B, C, D) The data shows 
that BAL T cells (upper) were 
predominantly of effector memory 
phenotype compared to peripheral blood 
(lower), in which T cells were 
distributed among naive, central 
memory, effector memory and terminal 
effector phenotypes. (A, B) The data 
shows a higher proportion of effector 
memory and lower proportion of central 
memory BAL CD4+ (left) and CD8+
(right) T cells in HIV-infected individuals 
compared to HIV-uninfected adults. (C,
D) The data shows no difference in 
peripheral blood CD4+ T cell subsets 
between HIV-infected individuals 
compared to HIV-uninfected adults (left), 
but there was a higher proportion of CDS + effector memory and a lower 
HIV-uninfected adults (right). Black horizontal bars represent median and 
value <0.05 was used to determine statistical significance.
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Regulatory T cells (Tregs)
We investigated the hypothesis that in HIV-infected individuals, 
persistent immune activation by HIV results in a higher 
frequency of regulatory T cells. Blood and BAL Tregs were 
defined as CD4+CD25h‘FoxP3+ as described in the materials and 
methods (figure 3A). The proportions of Tregs in HIV-infected 
individuals were similar in BAL and peripheral blood (median 
3.7% vs 3%, p>0.01), but were higher in BAL compared to 
peripheral blood in HIV-uninfected adults (median 4.3% vs 1.5%, 
p<0.001) (figure 3B). There was a higher proportion of Tregs in 
the peripheral blood of HIV-infected individuals than in the 
HIV-uninfected adults (median 3% vs 1.5%, p<0.001). However, 
in BAL the proportions were similar between the groups 
(median 3.7% vs 4.3%, p>0.01) (figure 3B). Absolute counts, 
however, of Tregs in peripheral blood were similar between HIV- 
uninfected adults and HIV-infected individuals (median 11 cells/ 
pi vs 9 cells/pl, p>0.01) (figure 3C).
Antigen-specific CD4* T cells against influenza virus,
5 pneumoniae and M tuberculosis in BAL and peripheral blood
To investigate respiratory pathogen antigen-specific T cell 
responses in BAL and peripheral blood, we measured the quality 
and magnitude of the CD4+ T cell response to influenza virus, 
S pneumoniae and M tuberculosis antigens using intracellular 
cytokine staining. We detected antigen-specific CD4+ T cells 
against influenza virus, S pneumoniae and Af tuberculosis in BAL 
and peripheral blood (figure 4).
Differences between BAL and peripheral blood compartments 
There was a higher percentage frequency of antigen-specific 
CD4+ T cells against influenza virus (median 0.51% vs 0.13%, 
pcO.OOl), S pneumoniae (median 0.59% vs 0.11%, p<0.001) and 
M tuberculosis (median 5.53% vs 0.20%, pcO.OOl) in BAL 
compared to peripheral blood (figure 5A—C). The proportion of 
antigen-specific CD4+ T cells against influenza virus, S pneumo­
niae and M tuberculosis producing either IFN-y alone, TNF- 
a alone or both cytokines were different between BAL and 
peripheral blood (figure 6A—C). Background responses were 
subtracted from all the antigen-specific CD4+ T cell responses.
Differences between HIV-infected and HIV-uninfected adults 
The percentage frequency of antigen-specific CD4+ T cells 
against influenza virus (median 0.15% vs 0.51%, p<0.05) and 
M tuberculosis (median 0.5% vs 5.53%, p<0.05) antigens were 
lower in HIV-infected individuals compared to HIV-uninfected 
adults in BAL (figure 5A,C). However, this was not the case in 
peripheral blood where the percentage frequencies were 
comparable (Influenza virus, median 0.3% vs 0.13%, p>0.05; 
M tuberculosis, median 0.12% vs 0.19% p>0.05)(figure 5A,C). The 
percentage frequency of antigen-specific CD4+ T cells against S 
pneumoniae were similar in HIV-infected compared to HIV- 
uninfected adults in BAL (median 0.84% vs 0.59%, p>0.05). 
However, in peripheral blood the percentage frequency was 
higher in HIV-infected compared to HIV-uninfected adults 
(median 0.2% vs 0.1%, p=0.02) (figure 5B). Background
Figure 3 Higher frequency of 
regulatory I cells in BAL compared to 
peripheral blood, but altered in HIV- 
infected individuals. T lymphocytes 
obtained from BAL and peripheral blood 
were stained with anti-CD4 Pacific blue, 
anti-CD25 FITC and anti-Foxp3 PE 
fluorochrome conjugated antibodies. 
Regulatory I cells (Tregs) were defined 
as CD4+ T cells expressing CD25hl and 
FoxP3+. (A) A flow cytometry 
representative dot plot showing Tregs in 
BAL and peripheral blood from a healthy 
control. (B) The data shows a higher 
frequency of Tregs in BAL than 
peripheral blood in HIV-uninfected 
adults. It also shows a higher frequency 
of peripheral blood Tregs in HIV-infected 
individuals compared to HIV-uninfected 
adults. (C) The data shows no difference 
in the absolute counts of Tregs in 
peripheral blood between HIV-infected 
individuals and HIV-uninfected adults. 
Black horizontal bars represent median 
and IQRs. Statistical significance was 
analysed by the Mann—Whitney U test 
in the HIV-uninfected versus HIV- 
infected comparison, and Wilcoxon 
Signed rank test in the BAL versus 
peripheral blood comparison, p value 
<0.05 was used to determine statistical 
significance.
A
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Figure 4 Representative flow cytometry dot flow from an HIV-uninfected adult showing multiple subsets of antigen-specific CD4+ T cells in BAL and 
peripheral blood. BAL and peripheral blood lymphocytes were stimulated with antigens and T cell responses were measured by intracellular cytokine 
staining. Representative flow cytometry dot plots from an HIV-uninfected adult showing interferon-y (IFN-y) and TNF-alpha (TNF-a) responses in BAL 
(top) and peripheral blood (bottom) cells, in an unstimulated negative control and cells stimulated with influenza virus, S. pneumoniae and M 
tuberculosis antigens.
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p<0.001
p«0.011
5. pneumoniae C Mycobacterium (PPD)
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Figure 5 Lower frequency of antigen-specific BAL CD4+ T cells in HIV-infected individuals compared to HIV-uninfected adults. BAL and peripheral 
blood lymphocytes were stimulated with antigens and the magnitude of the antigen-specific T cell response was measured by intracellular cytokine 
staining. The total of all cytokine-secreting CD4+ T cells was used to represent the percentage frequency of antigen-specific cells. (A) The data shows 
a higher percentage frequency of influenza virus antigen-specific CD4+ T cells in BAL compared to peripheral blood in HIV-uninfected adults. It also 
shows a lower percentage frequency of BAL influenza virus antigen-specific CD4+ T cells in HIV-infected individuals compared to HIV-uninfected 
adults. (B) The data shows a higher percentage frequency of Spneumoniae antigen-specific CD4+ T cells in BAL compared to peripheral blood in HIV- 
uninfected adults. It also shows a higher percentage frequency of 5 pneumoniae antigen-specific peripheral blood CD4+ T cells in HIV-infected 
individuals compared to HIV-uninfected adults. (C) The data shows a higher percentage frequency of M tuberculosis antigen-specific CD4+ T cells in 
BAL compared to peripheral blood in HIV-uninfected adults. It also shows a lower percentage frequency of BAL M tuberculosis antigen-specific CD4+ T 
cells in HIV-infected individuals compared to HIV-uninfected adults. Black horizontal bars represent median and IQRs after background responses were 
subtracted from all the antigen-specific CD4 T cell responses. Statistical significance was analysed by the Mann—Whitney U test in the HIV-uninfected 
versus HIV-infected comparison, and Wilcoxon Signed rank test in the BAL versus peripheral blood comparison, p value <0.05 was used to determine 
statistical significance.
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Figure 6 Lower proportion of polyfunctional antigen-specific CD4+ T cells in BAL and peripheral blood of HIV-infected individuals compared to HIV- 
uninfected adults. BAL and peripheral blood lymphocytes were stimulated with antigens and the quality of the antigen-specific T cell response was 
measured by intracellular cytokine staining. The proportion of single producers (IFN-y alone or TNF-a alone) and double producers (IFN-y and TNF-a) 
in the antigen-specific CD4+ T cell population was defined. (A) The data shows that in both BAL (upper) and peripheral blood (lower), the proportion of 
double producers (green) in the influenza virus antigen-specific CD4+ T cell population was lower in HIV-infected individuals (right) than HIV-uninfected 
adults (left). It also shows that the proportion of subsets of antigen-specific CD4+ T cells against influenza virus including IFN-y single producers (blue), 
TNF-a single producers (red), and IFN-y/TNF-a double producers (green) were different between BAL (upper) and peripheral blood (lower) in HIV- 
uninfected adults. (B) The data shows that the proportion of subsets of antigen-specific CD4+ T cells against S pneumoniae (including single producers 
and double producers), were different between BAL (upper) and peripheral blood (lower) in HIV-uninfected adults. (C) The data shows that in BAL 
(upper) and peripheral blood (lower) the proportion of double producers (green) in the M tuberculosis antigen-specific CD4 T cell population was lower 
in HIV-infected individuals (right) than HIV-uninfected adults (left). It also shows that the proportion of subsets of antigen-specific CD4+ T cells against 
M tuberculosis (including single producers, and double producers), were different between BAL (upper) and peripheral blood (lower) in HIV-uninfected 
adults.
responses were subtracted from all the antigen-specific CD4+ T 
cell responses.
Further, in BAL and peripheral blood, there was a lower 
proportion of multiple cytokine-producing (polyfunctional) 
antigen-specific CD4+ T cells against influenza virus (BAL, 59% 
vs 27%; Blood, 41% vs 34%) and M tuberculosis (BAL, median 
77% vs 41%; Blood, median 57% vs 26%) in HIV-infected 
individuals compared to HIV-uninfected adults (figure 6A,C).
DISCUSSION
The authors have demonstrated compartment differences 
between T cell immunity in the bronchoalveolar space and the 
periphery. These include a predominant presence of effector 
memory T cells and regulatory CD4+ T cells in BAL, and a higher 
percentage frequency of antigen-specific CD4+ T cells against 
influenza virus, S pneumoniae and M tuberculosis in BAL compared 
to peripheral blood. Our data has also demonstrated that HIV- 
infected individuals have impaired pulmonary CD4+ T cell 
immunity, which is characterised by lower proportions of total 
CD4+ T cells and impaired antigen-specific BAL CD4+ T cell 
response to influenza virus and At tuberculosis antigens.
Consistent with previous observations,21 we noticed that BAL 
CD4+ and CD8+ T cells were predominantly of effector memory 
phenotype irrespective of HIV status, while peripheral blood T 
cell phenotypes were distributed among naive, central memory, 
effector memory and terminal effector. Effector memory T cells 
migrate to the lung following antigen presentation by antigen 
presenting cells in the local draining lymph nodes.22 In the lung, 
effector memory T cells may be involved in mediating host 
defence against pathogens through macrophage activation and 
neutrophil recruitment9 10 Formulation of vaccines which can 
induce effector memory T cells in the lung, mimicking the 
natural route of exposure, might improve the efficacy of future
vaccines against pulmonary mucosal infections such as pneu­
mococcal pneumonia.
The authors observed a higher proportion of regulatory T cells 
in BAL fluid compared to peripheral blood in HIV-uninfected 
adults. Immunity in the lung is well regulated. A high degree of 
regulation is necessary because an excessive response may lead to 
destructive immunopathology, while a weak response may lead 
to prolonged infection. The higher proportion of Tregs in BAL, 
compared to peripheral blood in HIV-uninfected adults, may 
reflect the capacity for highly regulated immunity in the lung. 
While beneficial to the host, this sophisticated level of pulmo­
nary immunocompetence poses a challenge to the potential 
success of mucosally-administered vaccines against respiratory 
pathogens.
In addition to the overall phenotypic differences between BAL 
and peripheral blood T cells seen in this study, the authors 
observed a higher percentage frequency of antigen-specific CD4 l' 
T cells against influenza virus, S pneumoniae and M tuberculosis in 
BAL, when compared to the peripheral blood of HIV-uninfected 
adults. The authors investigated a variety of respiratory antigens 
in this study and demonstrated that each pathogen has its 
unique cytokine secreting profile. The influenza virus antigen- 
specific CD4+ T cells were likely induced through previous 
infection or exposure. The pneumococcal antigen-specific CD4'h 
T cells were probably induced through previous exposure 
following contact, colonisation in the nasopharynx or disease. 
The Af tuberculosis antigen-specific CD4+ T cells may have been 
induced by previous BCG vaccination, latent infection or expo­
sure. Despite differences in kinetics of exposure, our data suggest 
that antigen-specific CD4+ T cell responses against common 
respiratory pathogens are compartmentalised in the lung, where 
they may confer protection at the site of antigen entry. There­
fore, the induction of pulmonary antigen-specific CD4+ T cells
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through vaccination may provide a useful strategy for 
preventing respiratory infections in the lung.
In the context of HIV, first, the authors observed a higher 
proportion of BAL and peripheral blood effector memory CD4 + 
and CD8+ T cells in HIV-infected individuals than in HIV- 
uninfected adults. This may be attributed to the high level of 
hyper-activation associated with HIV infection,2n whereby naive 
T cells are driven along their differentiation pathway to become 
effector memory T cells.
Second, the authors observed a higher proportion of Tregs in 
the blood of HIV-infected individuals compared to HIV-unin­
fected adults. This observation is consistent with other studies 
on Tregs in peripheral blood during HIV infection.24 Expressing 
Tregs as absolute counts, however, showed that there was no 
difference between HIV-uninfected adults and HIV-infected 
individuals. This suggests that, during HIV infection, non-Tregs 
are preferentially depleted compared to Tregs. In contrast, the 
authors did not observe a difference in proportion of BAL Tregs 
between HIV-infected individuals and HIV-uninfected adults. 
However, the proportion of BAL CD8+ T cells was higher in 
HIV-infected compared to HIV-uninfected adults, suggesting 
that there is either a depletion of CD4+ T cells or an infiltration 
of CD8+ T cells. Taking these observations together, there is 
likely to be an altered ratio of Tregs to effector CD4+ and CD8+ 
T cells in BAL. This factor may either tip the balance to over­
regulation of CD4 responses or lack of control of CDS infiltrates 
in HIV-infected adults.
Third, consistent with the earlier observation on altered 
proportions of pulmonary T cell subsets in HIV-infected indi­
viduals, the percentage frequencies of influenza virus and 
M. tuberculosis antigen-specific BAL CD44' T cells were lower in 
HIV-infected individuals compared to HIV-uninfected adults. 
This is in line with a recent observation that there was depletion 
of BAL M tuberculosis antigen-specific CD4+ T cells in HIV- 
infected individuals."1 Recent work from other investigators has 
shown a preferential depletion of peripheral blood M tuberculosis 
antigen-specific but not cytomegalovirus (CMV) antigen-specific 
CD4+ T cells in HIV-infected adults.25 They concluded that 
M tuberculosis antigen-specific adaptive immunity is particularly 
vulnerable to HIV-associated immune damage. This study has 
shown that adaptive immunity to other respiratory antigens 
such influenza virus and not only M tuberculosis is also impaired 
in HIV-infected individuals. The impaired antigen-specific BAL 
CD4' T cell response observed in this study might help to 
explain the increased susceptibility of HIV-infected individuals 
to influenza virus and M tuberculosis infections.1 26 The 
impaired BAL CD4+ T cell immunity to influenza virus in HIV- 
infected adults may result in increased risk to secondary bacte­
rial infection such as pneumococcal pneumonia. The authors 
observation that there were detectable antigen-specific CD4+ T 
cell defects in BAL, but not in peripheral blood, has implications 
for clinical practice and for vaccine development. Most available 
assays, being based on peripheral blood, do not detect local 
responses in the lung and may therefore give misleading results 
when used for diagnosis or for estimations of vaccine efficacy.
Lastly, the authors demonstrated that there was a lower 
proportion of polyfunctional CD4 + T cells in BAL and peripheral 
blood of HIV-infected individuals compared to HIV-uninfected 
adults. This observation is consistent with others that have 
showed impaired polyfunctionality in M tuberculosis antigen- 
specific CD4+ T cells in BAL from HIV-infected adults.21 
Recently, it has been shown that during HIV infection, 
M tuberculosis antigen-specific T cells in blood change from poly­
functional CD4+ T cells to a more predominant monofunctional
CD8+ T cell phenotype.27 The authors speculate that owing to 
hyperactivation induced by HIV,2 ' Tcells are driven towards the 
terminal differentiation stages of their life cycle, where there is 
loss of the ability to secrete more than one cytokine.20 It has been 
reported that polyfunctional T cells may be functionally superior 
to monofunctional T cells and may provide a correlate of 
protection against parasitic,24 bacterial'"0 and viral pathogens.'"1 
This finding provides supporting evidence to the suggestion that 
an impaired repertoire of multifunctionality, as well as lower 
absolute numbers of respiratory antigen-specific CD4+ T cell 
immunity, may contribute to the high burden of respiratory 
diseases in HIV-infected individuals.
In conclusion, the authors have demonstrated that HIV 
infection is associated with impaired pulmonary antigen-specific 
CD4+ T cell immunity against viral and bacterial respiratory 
pathogens. These defects in pulmonary immunity may help to 
explain the observed increased risk of acute lower respiratory 
tract infections in HIV-infected adults at any point during the 
fall in their systemic CD4 count. A greater understanding of 
antigen-specific T cell responses that occur in the lungs of HIV- 
infected individuals will potentially enable better planning of 
clinical care for these individuals — in terms of prophylactic 
treatments against common infectious pathogens and the 
timing of anti-retroviral medication. In addition, it will also 
provide appropriate markers of efficacy in future vaccine trials 
for common respiratory pathogens such as S pneumoniae, 
M tuberculosis and influenza virus.
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MRSA colonisation may lead to increased mortality in 
patients with cystic fibrosis
The long-term impact of respiratory tract methicillin-resistant Staphylococcus aureus (MRSA) 
on cystic fibrosis (CF) outcomes is unclear. This cohort study used longitudinal data from the 
US CF registry between 1996 and 2008. The aim of the study was to assess whether 
acquisition of MRSA influenced mortality.
A total of 19 833 MRSA negative patients aged 6—45 years were included in the study. Over 
the study period 5759 patients developed positive cultures for MRSA and there were 2537 
deaths. The mortality rate was 27.7 deaths (95% Cl 25.3 to 30.4) per 1000 patient-years in 
patients with MRSA and 18.3 deaths (95% Cl 17.5 to 19.1) per 1000 patient-years in those 
without MRSA. After adjusting for variables associated with disease severity, the risk of death 
in patients positive for MRSA was higher than in patients who never cultured MRSA, with 
the greatest risk in patients chronically colonised with MRSA. Interestingly, patients who 
cleared MRSA within a year did not have an increased risk of death. No treatment or 
eradication data were described in the study.
This study provides convincing evidence that MRSA is an important pathogen in the CF 
airway. Questions remain about both the pathogenesis of MRSA infection and the optimal 
medical management in chronically infected patients. For now it is essential that strict 
infection control is in place to minimise transmission, and that eradication protocols are 
followed after a new identification.
► Dasenbrook EC, Checkley W, Merit) CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus 
aureus and survival in cystic fibrosis. JAMA 2010;303:2386-92.
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